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Abstract 
This Thesis details the development of a series of rhodium catalysed asymmetric additions to 
activated aldimines to give enantioenriched protected secondary amines. A particular focus has 
been the choice of activating group to allow deprotection of the protected amines under mild 
conditions, which would tolerate a wide substrate scope. 
 Initially methyl addition to give enantioenriched arylethanamines was studied, using 
diphenylphosphinoyl imines, dimethylzinc as the methyl source with rhodium catalysis in the 
presence of a bidentate phosphine ligand. Reduction of the starting material was identified as 
VLGH UHDFWLRQ ZLWK D 0HHUZHLQޤ9HUOH\ޤ3RQQGRUI W\SH PHFKDQLVP IRU WKH UHGXFWLRQ EHLQJ
proposed. Addition of the imine to the reaction mixture via a syringe pump was found to 
minimise this by-product. The imine scope was tested with yields ranging from 34-73% and 
enantiomeric excesses from 75-93%. 
 Subsequently, aryl additions were concentrated on using aryl boroxines and boronic 
acids to give enantioenriched diarylmethylamine products. BisޤVXOIDP\O DOGLPLQHV ZHUH
identified as an overlooked substrate class for asymmetric aryl additions, which gave addition 
products that could be converted to free amines using mild basic aqueous conditions. The 
rhodium catalysed aryl boroxine addition using a chiral diene ligand was optimised after which 
D VWXG\ LQWR WKH UHDFWLRQ¶V VFRSH ZDV FDUULHG RXW <LHOGV UDQJHG IURP ޤ ZLWK
GLDVWHUHRPHULFUDWLRVRIޤ!DQGHQDQWLRPHULFH[FHVVHVRIޤ!8QIRUWXQDWHO\WKH
unwanted meso-diastereoisomer could not be removed, leading to a lowering of enantiomeric 
excess after deprotection, nevertheless the free diarylmethylamine were isolated in yields of 
31-99% and enantiomeric excesses of 82-97%. 
 Leading on from this work, a novel class of N-sulfamyl aldimines were developed 
which could be deprotected under the same mild conditions, and would avoid the problem of 
the undesired meso-diastereoisomer. A scalable synthesis of these substrates was developed. 
However, aryl addition proved more problematic with imine hydrolysis being a major side 
reaction. Eventually a set of conditions were settled on and the scope investigated briefly. The 
yields were found to depend on the electronic character of the substrates and the ligand 
employed. 
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 Finally, a brief investigation into the iridium catalysed reductive coupling of these 
activated aldimines and alkynes to give allylic amines was carried out. However, useful 
conversions were not achieved, with imine and alkyne hydrogenation being competing 
reactions. 
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Abbreviations 
app.   Apparent 
BINAP   2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
BINOL   1,1-Binaphthol 
BIPHEP   2,2'-Bis(diphenylphosphino)-1,1'-biphenyl 
CBS   Corey-Bakshi-Shibata 
coe   Cyclooctene 
CSI   Chlorosulfonyl isocyanate 
dec.   Decomposed 
DPP   N-Diphenylphosphinoyl 
dppb   1,4-Bis(diphenylphosphino)butane 
dppbenz   1,2-Bis(diphenylphosphino)benzene 
dppf   1,1'-Bis(diphenylphosphino)ferrocene 
eV   Electron volt 
FGI   Functional group interconversion 
HMDS   Hexamethyldisilazane 
m-CPBA  meta-Chloroperbenzoic acid 
M.S.   Molecular sieves 
MVP   Meerwein-Varley-Ponndorf 
n.d.   Not determined 
Ns   4-Nitrobenzenesulfonyl 
Pet. ether  Petroleum ether 
PG   Protecting group 
PMP   p-Methoxyphenyl 
psi   Pound per square inch 
quant.   Quantitative 
QUINAP  1-(2-Diphenylphosphino-1-naphthyl)isoquinoline 
RAMP   (R)-1-Amino-2-(methoxymethyl)pyrrolidine 
SAMP   (S)-1-Amino-2-(methoxymethyl)pyrrolidine 
sat.   Saturated 
TFE   Trifluoroethanol 
Tol   Tolyl 
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Chapter 1 Introduction 
1.1 8VHVRIĮ-Chiral Amines 
Į-Chiral amines are ubiquitous chemical motifs occurring in pharmaceutical and agrochemical 
targets,[1] and used in the synthesis of enantioenriched compounds as chiral ligands, chiral 
auxiliaries and chiral bases.[2] This class of compounds is of interest in the areas of synthetic 
methodology, natural product synthesis, bioorganic and medicinal chemistry.[3] Scheme 1 
shows a range of pharmaceutical and agrochemical active species containing optically active 
amines. 
 
Scheme 1 
 10 
1.1.1 5RXWHVWRĮ-Chiral Amines 
7KH HIILFLHQW V\QWKHVLV RIĮ-chiral amines has been a significant goal for both academic and 
industrial research groups and is a current active area of research efforts. 
 
Scheme 2 
Various rouWHVWRVHFRQGDU\Į-chiral amines are shown in Scheme 2 above, these include: 
x Chemical or enzymatic resolution of a racemic amine (Route A).[4] 
x Reduction of a ketimine or its enamine tautomer (Route B).[5] 
x Nucleophilic displacement of a suitable leaving group (Route C), for 
example an azide or an activated alcohol (Mitsunobu reaction). 
x Carbon-carbon bond formation between an aldimine, oxime or hydrazine and 
nucleophile (Route D).[6,7] 
x C-H activation of a methylene unit (Route E).[8] 
x Hydroamination of an olefin (Route F). 
The research in this Thesis will focus on nucleophilic additions to aldimines (Route D), 
although other areas will be discussed. 
 
1.2 Activated Aldimines 
Imines are inherently less electrophilic than the aldehydes or ketones from which they are 
GHULYHGGXH WRQLWURJHQ¶VGHFUHDVHGHOHFWURQHJDWLYLW\DQGDVD UHVXOW UHVHDUFK LQ WKLVDUHDKDV
lagged behind additions to aldehydes.[9] The electrophilicity of the imine can be increased by 
substituting the nitrogen with an activating, electron withdrawing group. Examples of such 
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activating groups are shown in Scheme 3. Forming oximes and iminium ions are other 
strategies for increasing reactivity; however, these will not be discussed in this Thesis. 
 
Scheme 3 
The LUMO energies (in eV) of various activated imines and benzaldehyde 1.10 for 
comparison, relative to N-methyl imine 1.12, are shown below in Scheme 4.[10,1] Alkyl and aryl 
substituted imines 1.12 and 1.11 are both less electrophilic than benzaldehyde. However, 
addition of electron-withdrawing groups such as tosyl 1.8, diphenylphosphinoyl 1.9 and 
benzoyl 1.7 create increasing electrophilic species. The lower energy LUMO and increased 
electrophilicity of the azomethine carbon makes transition metal catalysed nucleophilic 
additions possible to these activated imines. 
 
Scheme 4 
Other issues encountered when working with imines are polymerisation, hydrolysis and 
enamine tautomerisation. Polymerisation is prevented by adding a substituent to the nitrogen 
atom. The stability of the imine is dependent on the substituent on the azomethine carbon, 
aromatic groups lead to much more stable imines than alkyl groups, which more readily 
decompose. However, this problem has been worked around in some cases by forming the 
imines in situ from a sulfinate adduct (see Sections 2.2 and 3.2). ImineVZLWKĮޤK\GURJHQVDUH
prone to deprotonation resulting in tautomerisation to the enamine form; for these reasons most 
research in this area has been carried out on aryl aldimines. 
 
Scheme 5 
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Imines 1.15 are accessed from aldehyde precursors 1.13 typically by condensation with the 
appropriate amine 1.14 (Scheme 5). Nucleophilic addition gives a chiral protected amine 1.16. 
The amine 1.14 is ideally inexpensive and readily available. Finally, the activating/protecting 
group must be easily removed from the resultant protected amine 1.16 to give the free chiral 
amine 1.17. 
Strategies for making enantioenriched amines fall into two groups. The first of these is 
addition to imines bearing chiral auxiliaries incorporated (asymmetric diastereoselective 
synthesis). The second of these is external chiral ligand controlled addition to an achiral imine 
(asymmetric enantioselective synthesis); the ligand may be present in stoichiometric or ideally 
catalytic quantities. As already discussed, it is necessary to add an activating substituent to the 
nitrogen atom; by having this as a chirally pure auxiliary this allows the possibility of 
diastereofacial selectivity when the nucleophile is added. No extra steps will be added to the 
synthesis provided the optically pure amine precursor is readily available in stoichiometric 
quantities; ideally, both enantiomers will be available. Non-racemic imines derived from 
enantiopure aldehydes and addition of chiral organometallic reagents fall outside the scope of 
this Thesis. Separation of the diastereoisomers prior to deprotection may give very good 
optical purities compared to resolution of enantiomers after asymmetric catalysis.[3] 
External chiral ligands can be used alone or in conjunction with a transition metal 
catalyst. In both cases, the presence of the ligand creates a pair of diastereomeric transition 
states; the favoured, lower energy transition state will lead to the enantioenriched product. 
Catalysis with enantiopure ligands is the most efficient approach to enantioenrichment, with 
the enantiopure ligand only required in catalytic quantities. 
A short review of the most frequently used activating and protecting groups (both 
achiral and enantiopure) will follow. The availability of the amine precursor 1.14, the reactivity 
of the activated imine and the removal of the activating group from the addition product 1.16 
will be considered. 
 
Scheme 6 
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N-acylimines 1.1 (Scheme 6) are the most reactive of these activated imines,[11] however, this 
high reactivity is detrimental to catalytic asymmetric strategies as there can be significant 
uncatalysed background reactions.[12] Both 1.18 and 1.19 are synthesised in situ from their 
sulfinate adducts (see Scheme 22, Section 2.2.3). Some acylamines can be troublesome to 
deprotect needing forcing acidic conditions, addition products from N-formyl imine 1.19 can 
be deprotected using mildly acidic conditions.[13] 
 
Scheme 7 
N-Sulfonylimines 1.3 (Scheme 7) are one of the most commonly used activated aldimines. 
They are less reactive than N-acylimines however; they have the advantage of long-term 
stability. N-Tosylimines 1.20 are the most frequently cited N-sulfonylimines. Condensation of 
the readily available p-toluenesulfonamide and an arylaldehyde gives 1.20; other synthesis 
routes are discussed in Section 3.4.2. The stability of the subsequent sulfonamide product can 
be a problem; to deprotect the tosyl group requires harsh conditions for example dissolving 
metal reduction or strong acids. An alternative is the nosyl group 1.21, which can be removed 
by treatment with a thiol and base (Scheme 8).[14,15] 
 
Scheme 8 
 
Scheme 9 
N-Phosphinoylimines 1.5 (Scheme 9) are less reactive than N-sulfonylimines 1.3 and are also 
stable enough to be isolated and stored.[12] P,P-Diphenyl- and P,P-diethoxy- are the most 
common substituents.[16,17] They can be made by the condensation of P,P-diphenyl 
phosphinamide with arylaldehyde or by other methods discussed in Section 2.4.4. The resulting 
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phosphinamides are easily deprotected using mild acidic conditions. Recently a series of 
enantiopure N-phosphinoylimines imines have been developed 1.24,[18] 1.25[19] and 1.26[20] 
amongst others.[21,22] See Section 2.4.4 for a further discussion of 
NޤGLSKHQ\OSKRVSKLQR\OLPLQHV 
 
Scheme 10 
N-Sulfinylimines 1.4 (Scheme 10) are stable with both alkyl and aryl substituents from the 
aldehyde and undergo diastereoselective additions which, if the substrates are non-racemic, can 
lead to enantioenriched products. N-p-Toluenesulfinyl imines 1.27,[23,24] N-tert-butyl imines 
1.28[25] and iso-propylimines 1.29[26,27] have been developed. Imine 1.28 is the most widely 
used, with the required chiral amine being commercially available as both enantiomers. The 
resulting sulfinamides are deprotected using mild acidic conditions. 
Further specific examples of enantioenriched amine synthesis will be reviewed at the 
beginning of the following chapters. This Thesis will discuss the asymmetric synthesis of 
arylethanamines (Chapter 2), diarylmethylamines (Chapters 3 and 4) and briefly, 
1ޤDU\OޤޤSURSHQ\ODPLQHV&KDSWHU 
 
1.3 Rhodium Catalysed Carbon-Carbon Bond Formation 
Another area that should be reviewed herein as it forms a major part of this Thesis is the use of 
rhodium to catalyse the formation of carbon-carbon bonds. The formation of carbon-carbon 
bonds using transition metal catalysis has been a major development in modern organic 
chemistry. Palladium has dominated this field of transition metal catalysis, with key 
FURVVޤFRXSOLQJreactions such as Suzuki-Miyaura,[28] Mirozoki-Heck[29] and Stille couplings.[30] 
However, rhodium catalysis has been a growing area recently as its use allows for alternative 
reactivity not possible with palladium. As well as its novel and often complimentary reactivity, 
another advantage of the use of rhodium is the reactions often withstand or require the presence 
of water which can possibly be used as a co-solvent.[31] 
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To understand the differences in their reactivity the catalytic cycles of palladium and 
rhodium must be compared. In a palladium cross-coupling catalytic cycle, the oxidation state 
of palladium shuttles between (0) and (II), with transmetallation only occurring at (II) 
oxidation level (Scheme 11). 
 
Scheme 11 
Rhodium, on the other hand, typically enters the catalytic cycle at an oxidation state of (I) 
allowing for transmetallation to occur as the first stage without the need for an oxidative 
addition (Scheme 12). Oxidative addition to give a Rh(III) species can then occur (left hand 
cycle, Scheme 12), followed by reductive elimination to give the equivalent product to the 
palladium cycle but with the step order reversed. Alternatively (right hand cycle, Scheme 12), 
an XQVDWXUDWHG ERQG FDQ LQVHUW LQWR WKH RUJDQRޤUKRGLXP FRPSOH[ WR JLYH DGGLWLRQ RI 51-H 
across an unsaturated bond.[31] It is this mode of reactivity that is taken advantage of in this 
Thesis and that this review will focus on. 
 
Scheme 12 
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Conjugate additions of organometallics to alkenes bearing electron-withdrawing groups have 
become a key reaction for rhodium catalysed carbon-carbon bond formation. Although 
excellent systems using alkylzinc compounds with copper asymmetric catalysis have been 
developed, there has been little success with aryl addition with this metal combination. Using 
rhodium catalysis 1,4-DU\ODWLRQV RI Įȕ-unsaturated carbonyl compounds have been made 
possible.[32] 
In 1997, Miyaura et al. reported the first rhodium catalysed 1,4-additions of aryl- and 
alkenyl boronic acids to Įȕ-unsaturated ketones (Entry 1, Table 1).[33] An asymmetric reaction 
using (S)-BINAP (S)-1.34 as a ligand soon followed in a collaboration between Miyaura and 
Hayashi using both linear and cyclic enones as substrates (Entry 2).[34] Amengual and 
FRޤZRUNHUV KDYH XVHG D%,1$3GHULYHG OLJDQG (R)-1.35 to give good enantiomeric excesses 
(Entry 3).[35] 
Table 1 
 
Entry Conditions 1.32 [%] ee [%] 
1 ArB(OH)2 (2 eq), Rh(acac)(CO)2 (3 mol/%), 1.33 (3 
mol/%), MeOH:H2O 6:1, 50 °C, 16 h 
84-99 
6 examples[33] - 
2 ArB(OH)2 (1.4-5 eq), Rh(acac)(C2H4)2 (3 mol/%), (S)-1.34 (3 mol/%), dioxane:H2O 10:1, 100 °C, 5 h 
51->99 
9 examples 
92-99 
(S)[34] 
3 
ArB(OH)2 (2.5 eq), Rh(acac)(C2H4)2 (1 mol/%), 
(R)-1.35 (1.2 mol/%), Na2CO3 (2 eq), ethylene 
glycol, 100 °C 
44-100 81-98[35] 
 
The mechanism of these conjugate additions is shown in Scheme 13, using cyclohexenone as 
an example substrate. The mechanism was probed by the group of Hayashi using 31P NMR 
spectroscopy to study the coordinated phosphine ligands of the species present, with 
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hydroxyrhodium species 1.36 found to be the catalytic species.[36] Other unsaturated systems 
that have been studied in the rhodium catalysed aryl boronic acid addition are Įȕ-unsaturated 
esters,[37] Įȕ-unsaturated amides,[38] Įȕ-unsaturated phosphonates[39] and nitroalkenes[40] 
(Table 2). 
 
Scheme 13 
Table 2 
 
Entry X Conditions 1.38 [%] ee [%] 
1 C(O)OR 
ArB(OH)2 (2-5 eq), Rh(acac)(C2H4)2 (3 
mol/%), (S)-1.34 (4.5 mol/%), 
dioxane:H2O 6:1, 100 °C, 16 h 
26-98 
10 examples 77-92
[37] 
2 C(O)NHR 
ArB(OH)2 (2 eq), Rh(acac)(C2H4)2 (3 
mol/%), (S)-1.34 (4.5 mol/%), K2CO3 (0.5 
eq), dioxane:H2O 6:1, 100 °C, 16 h 
19-90 
11examples 77-95
[38] 
3 P(O)OR2 
(ArBO)3 (3.3 eq), Rh(acac)(C2H4)2 (3 
mol/%), (S)-1.34 (3.3 mol/%), H2O (10 
eq), dioxane, 100 °C, 3 h 
39-96 
10 examples 91-99
[39] 
4 NO2 
ArB(OH)2 (5-10 eq), Rh(acac)(C2H4)2 (3 
mol/%), (S)-1.34 (3.3 mol/%), 
dioxane:H2O 10:1, 100 °C, 3 h 
33-89 
9 examples 38-99
[40] 
 
Other nucleophiles that have been employed in rhodium catalysed 1,4-arylations include aryl 
stannanes (Entry 1, Table 3),[41] various aryl silicon reagents (Entries 2, 3, 4 and 5)[42-45] 
triphenyl bismuth (Entry 6),[46] aryl titanium reagents (Entry 7)[47] and aryl lead compounds 
(Entry 8).[48] Almost all these reactions use water as a co-solvent with two examples (Entries 5 
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and 8) being run solely in water. However, there are fewer examples of asymmetric 
ޤDGGLWLRQXVing these nucleophiles rather than organoboron nucleophiles. 
Table 3 
 
Entry ArM Eq Conditions 1.32 [%] ee [%] 
1 ArSnMe3 1.2 
[Rh(cod)(MeCN)2]BF4 (2 
mol/%), H2O (1 eq), THF, 60 
°C, 2-20 h 
60-98 
10 examples[41] - 
2 ArSiEt(OH)2 0.3 [Rh(OH)(cod)]2 (3 mol/%), THF, 70 °C, 24 h 
61-99 
9 examples[42] - 
3 ArSi(OMe)3  
[Rh(cod)(MeCN)2]BF4 (2 
mol/%), dioxane:H2O 10:1, 90 
°C, 20 h 
73-93 
5 examples[43] - 
4 ArSi(OR)3 2 
[Rh(cod)(MeCN)2]BF4 (4 
mol/%), (S)-1.34 (6 mol/%), 
dioxane:H2O 10:1, 90 °C, 20 h 
56-90 
8 examples 75-98
[44] 
5 ArSiPhCl2 4 
[Rh(cod)2]BF4 (5.2 mol/%), 
NaF (20 eq), H2O, 100 °C, 12 h 
34-97 
11 examples[45]  
6 ArBiPh2 1.1 
[Rh(cod)Cl]2 (5 mol/%), 
H2O:THF 7:3, 50 °C, 12 h 
40-84 
4 examples[46]  
7[a] ArTi(OiPr)3 1.6 [Rh(OH)((S)-1.34)]2 (1.5 mol/%), THF, 20 °C, 1 h 
62-89 
8 examples 94->99
[47] 
8 ArPbMe3 1.4 
[Rh(cod)2]BF4 (10 mol/%), 
H2O, 70 °C, 15 h 
66-68 
2 examples[48] - 
[a] Isolated as silyl enol ether. 
 
Addition of organometallic nucleophiles to carbonyl compounds in a 1,2-fashion to give 
secondary alcohols, is another area of research for rhodium catalysis. Although additions of 
Grignard reagents are possible, rhodium catalysis allows for milder conditions to be used and 
more sensitive functional groups present in the reactant. As with 1,4-conjugate additions, boron 
nucleophiles have been the organometallic reagent of choice. Again, Miyaura et al. reported 
the first example of 1,2-addition of aryl boronic acids to aldehydes in excellent yield (Entry 1, 
Table 4).[49] Fürstner and co-workers used rhodium catalysis with a N-heterocyclic carbene 
ligand derived from 1.38 to give good conversions, including excellent chemoselectivity with a 
ketone containing substrate (Entry 2).[50] However, achieving enantioselectivity with these 
additions has proved more elusive than with 1,4-additions; Miyaura found only a 41% 
enantiomeric excess after a small ligand screen (Entry 3).[49] 
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Table 4 
 
Entry Conditions 1.39 [%] ee [%] 
1 ArB(OH)2 (2 eq), Rh(acac)(CO)2 (3 mol/%), dppf (3 mol/%), DME:H2O 1:1, 80 °C, 16 h 
31-97 
15 examples[49] - 
2 
ArB(OH)2 (2 eq), RhCl3.H2O (1 mol/%), 1.40 (1 
mol/%), NaOMe (1 eq), DME H2O 4:1,  
80 °C, 30 min 
52-99 
13 examples[50]  
3 ArB(OH)2 (2 eq), [Rh(acac)(C2H4)2] (3 mol/%), (Sޤ (3 mol/%), DME:H2O 1:1, 60 °C, 36 h 
78% 
1 example 41% (R)
[49] 
 
Again additions are not limited to organoboron compounds, with trimethylphenyl stannane 
(Entry 1, Table 5),[51] and aryl silicon reagents also being used (Entries 2 and 3).[52,53] 
Table 5 
 
Entry ArM Eq Conditions 1.39 [%] 
1 ArSnMe3 1 
[Rh(cod)2]BF4 (5 mol/%), NaF (5 eq), 
H2O, 110 °C, 12 h 
52-92 
11 examples[51] 
2 ArSiMeF2 2 
[Rh(cod)(MeCN)2]BF4 (2 mol/%), KF 
(3 eq), THF, 60 °C, 18-20 h 
70-100 
12 examples[52] 
3 ArSiEt(OH)2 2 [Rh(OH)(cod)]2 (3 mol/%), dioxane, 70 
°C, 24 h 
47-87 
4 examples[53] 
 
These are just two examples of the types of unsaturated substrates which can be used for 
rhodium catalysed carbon-carbon bond formation. Over the next three chapters, many 
examples of rhodium catalysed additions to imines substrates will be reviewed. 
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Chapter 2 
2.1 Chiral Arylethanamines 
$ SDUWLFXODU FODVV RI Į-chiral amines of interest are chiral arylethanamines. Chiral 
arylethanamines are present as single enantiomers in pharmaceutical products such as 
Rivastigmine[54] and Cinacalcet[55] (Scheme 14Į-Methylbenzylamine 2.1a is one of the most 
widely used resolving agents for resolving racemic acids via formation of diastereomeric 
salts.[56] Į-Methylbenzylamine 2.1a can itself be simply resolved with tartaric acid.[57,58] 
However, resolution is often not an efficient or particularly general method, so research has 
been ongoing towards a catalytic asymmetric synthesis of enantioenriched arylethanamines. 
The main points of this research will now be discussed. 
 
Scheme 14 
 
2.2 Methyl Addition to Aldimines 
2.2.1 Methyllithium 
Methyllithium is both a highly nucleophilic and highly basic reagent and this limits the range 
of functional groups that can be present in the substrates with which it is reacted in 
enantioselective fashion owing to achiral background or side reactions. It is commercially 
available as an ethereal solution, although it can also be made by treating methyl bromide with 
lithium. Initial studies into the addition of methyllithium to imines used a chiral auxiliary as the 
source of chirality. 
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Scheme 15 
Enders and co-workers reported the first synthesis of an enantioenriched amine (R)-2.1a using 
a chiral auxiliary approach (Scheme 15).[59] Diastereoselective addition of methyllithium to 
SAMP hydrazone (S)-2.2 followed by cleavage of the auxiliary (which can be recycled) using 
hydrogenolysis gave (R)-phenylethylamine (R)-2.1a in moderate yield and good 
enantioselectivity. Using the equivalent RAMP hydrazone allows access to (S)-2.1a. 
 
Scheme 16 
Similarly, Denmark et al. added organocerium reagents to SAMP hydrazone (S)-2.2 (Scheme 
16).[60] The methylcerium reagent was formed in situ from methyllithium and anhydrous 
cerium(III) chloride and is less basic than its precursor allowing hydrazones with enolisable 
protons to be used.[61] The carbamate (S,R)-2.3 was formed to prevent oxidation of the 
resulting hydrazine and the free amine could be obtained by hydrogenolysis as before. 
The breakthrough first methyl addition to an achiral imine using a chiral ligand was 
reported by Tomioka et al. in 1990.[62] The addition of methyllithium to a p-methoxyphenyl 
imine 2.4 in the presence of chiral amino-ether (S)-2.6 in stoichiometric quantities gave 
enantioenriched amine 2.5 in good enantiomeric excess (Entry 1, Table 6). Substoichiometric 
quantities of the ligand (S)-2.6 can be used, however, the enantiomeric excess is lowered 
(Entry 2).[63-66] The ligand-methyllithium complex is more reactive than the uncoordinated 
methyllithium reagent and in the absence of the ligand the conversion is lower. Denmark et al. 
used a C2-symmetric bis-oxazoline ligand (S,S)-2.7 for this addition in good yield and 
enantioselectivity (Entry 3).[67] The group of Alexakis used 1,2-diamine ligands in 
substoichiometric quantities with variable results (Entry 4).[68] The utility of this method was 
demonstrated in the synthesis of (R)-salsolidine (R)-2.11 in four steps from imine 2.9 (Scheme 
17).[69] 
 22 
Table 6 
 
Entry Ligand Eq T [°C] Time [h] 2.5 [%] ee [%] 
1 (S)-2.6 2.6 í 1 52-98 70-74 (R) 3 examples[62] 
2 (S)-2.6 0.5 í 3 96 62 (R)[63] 
3 (S,S)-2.7 1 í 1 77 89 (R)[67] 
4 (R,R)-2.8 0.2 í 15 35-98 48-74 (R) 6 examples[68] 
 
 
Scheme 17 
 
2.2.2 Methyl Grignard Reagent 
Methyl Grignard reagents are, like methyllithium, both highly nucleophilic and basic. They 
cannot be used with imines bearing enolisable protons as enolisation will be the dominant 
reaction and their reactivity will limit the substrate scope. Solutions of methylmagnesium 
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bromide in ethereal solvents are commercially available or the reagent can be freshly prepared 
from methyl bromide and magnesium turnings. 
Table 7 
 
Entry PG MeMgX [Eq] X (±)-2.13 [%] 
1 P(O)Ph2 3 I 63[17] 
2 Ts 3 Br 84[b][70] 
3 PO(OEt)2 2 Br 47[a][71] 
[a] Imine prepared in situ; [b] yield of amine following deprotection with HCl. 
 
Addition of methyl Grignard reagents to various activated imines 2.12 gives the racemic 
secondary amines (±)-2.13 in good yields (Table 7).[17,70,71] The first asymmetric methyl 
Grignard reagent addition was carried out by the group of Takahashi in 1979 using a chiral 
auxiliary approach employing N-methyl ephedrine (Scheme 18).[72] 
 
Scheme 18 
 
Scheme 19 
Pridgen et al. used a chiral oxazolidine (R)-2.16a for diastereomeric methyl Grignard reagent 
additions (Scheme 19).[73] Colobert et al.[20,74] have developed a P-chirogenic 
NޤSKRVSKLQR\OLPLQH (R)-2.18 (Scheme 20) and have achieved some encouraging 
diastereoselectivity with the addition of methyl Grignard reagent to give amine (R,R)-2.19. 
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Scheme 20 
 
2.2.3 Dimethylzinc 
Dialkylzinc reagents have a lower nucleophilicity than alkyllithium or alkyl Grignard reagents 
as the carbon-metal bond is far less polarised. This gives dialkylzinc reagents the advantage of 
wider range of functional group tolerance in both the substrate and any ligands used. However, 
as they are less nucleophilic, the imines used need to be more electrophilic. Coordination of the 
dialkylzinc with a Lewis basic ligand causes deviation from the normal linear geometry at zinc 
and increases the nucleophilicity of the alkyl groups. There are many examples of additions of 
diethylzinc to activated imines, however, due to its lower reactivity, there are fewer examples 
using dimethylzinc and often more equivalents are needed in comparison with diethylzinc. 
 
Scheme 21 
Soai et al. reported the first addition of dimethylzinc to imine 2.20a in their landmark paper of 
1992 (Scheme 21).[75] The chiral amino-alcohol (S,R)-2.22 was used in stoichiometric amounts 
to activate the zinc reagent and give good enantioselectivities. An example using an external 
[2.2]paracyclophane based N,O-ligand (RP,S)-2.26 in catalytic quantities was reported by the 
group of Bräse (Scheme 22).[13] The N-acyl imine 2.25 was formed in situ from sulfinate 
precursor 2.23. 
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Scheme 22 
Transmetallation with a transition metal is another strategy for increasing the nucleophilicity of 
the alkyl groups of dialkylzinc reagents. Copper has been the most extensively used transition 
metal.[76] Tomioka et al. investigated a chiral amidophosphine ligand (S)-2.29 and a copper 
catalyst system for the alkylation of N-sulfonyl imines 2.27 (Scheme 23). Methylation occurred 
in excellent yield and enantiomeric excess, however, eight equivalents of dimethylzinc were 
required.[77] 
 
Scheme 23 
The Charette group have developed a copper catalysed system for the catalytic asymmetric 
addition of dimethylzinc to diphenylphospinoyl protected aryl imines 2.20, initially using 
(R,R)-Me-DuPHOS (R,R)-2.30 (Entry 1, Table 8).[78] Subsequently, it was found that using the 
novel (R,R)-Me-DuPHOS monoxide (BozPHOS) ligand (R,R)-2.31 allowed the number of 
equivalents of dimethylzinc to be greatly reduced whilst the yield of (R)-2.21 increased (Entry 
2).[79] The BozPHOS ligand (R,R)-2.31 can be prepared from (R,R)-Me-DuPHOS in three steps 
with a 90% overall yield.[79] 
 26 
Table 8 
 
Entry Ligand Ligand [mol/%] 
ZnMe2 
[Eq] 
Cu(OTf)23K0H
[mol/%] 
(R)-2.21 
[%] ee [%] 
1 (R,R)-2.30 10 10 10 51 90[78] 
2 (R,R)-2.31 5 5 5 80-90% 89-97% 3 examples[79] 
 
Charette has also reported ethyl addition to N-phosphinoylalkylimines (Scheme 24).[80] The 
DGGLWLRQWRDON\OLPLQHVLVQRUPDOO\SUREOHPDWLFGXHWKHĮ-enolisable protons. Charette avoids 
these problems by generating the imine in situ from a sulfinate adduct 2.32 and an extra 
equivalent of the organozinc reagent. 
 
Scheme 24 
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Scheme 25 
Hoveyda et al. described a zirconium-catalysed imine alkylation (Scheme 25) using a peptide 
based chiral ligand (S,S)-2.36 to afford enantioenriched arylimines (S)-2.35 in good yields and 
enantioexcesses although again high dimethylzinc loadings were need to give these yields.[81] 
+D\DVKL¶VJURXSIRXQGUKRGLXPFRPSOH[HVFRRUGLQDWHGZLWKFKLUDOGLHQHOLJDQGVWREHHIILFLHQW
in the asymmetric addition of aryl boronic acids to imines (see Section 3.2.6.1). Initial attempts 
at methylation with methyl boronic acid failed, but it was found that dimethylzinc gave 
excellent results in the system using chiral diene ligand (R,R)-2.39 (Scheme 26);[82] this was 
the first example of a rhodium catalysed methylation. A variety of substituted 
NޤWRV\ODU\OLPLQHVZDVORRNHGDWDQGLWZDVIRXQGWKDWHOHFWURQ-donating or ortho-substituents 
required longer reaction times. The protecting tosyl group was removed by treatment with 
lithium in liquid ammonia to give the amine in 79% yield with no racemisation.[82] 
 
Scheme 26 
 
2.2.4 Trimethylaluminium 
Feringa et al. found that dimethylzinc was not effective under the conditions they had 
developed for diethylzinc addition to N-formyl imines. However, a little optimisation lead to 
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conditions under which trimethylaluminium could be used as the methyl source (Scheme 
27).[83] 
 
Scheme 27 
 
2.3 Other Routes to Chiral Arylethanamines 
2.3.1 Resolution 
2.3.1.1 Classical Resolution 
The crystallisation of diastereomeric salts (classical resolution) is a important method for the 
resolution of arylethanamines, for example (±)-2.1a can be resolved using (R,R)-tartaric acid 
(R,R)-2.43 (Scheme 28).[57] However, the choice of the resolving agent is substrate specific and 
typically found by trial and error. The effectiveness of a particular acid for a range of 
structurally similar amines can vary dramatically.[84,85] 
 
Scheme 28 
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2.3.1.2 Chemocatalytic Kinetic Resolution 
Another method for resolving enantiomers is kinetic resolution, which takes advantage of the 
different reaction rates of enantiomers with an enantiopure reagent via diastereomeric 
transition states. Fu et al. have used a chiral acylating agent í-2.45 formed by N-acylation of 
planar chiral DMAP derivative í-2.46 to give acetamides 2.44 in good enantiomeric excess 
(Entry 1, Table 9),[86] however, a high ratio of racemic amine to acylating agent is needed. A 
much lower ratio was used by the group of Blackmond with their acylating agent (S,S)-2.47 
(Entry 2),[87] but improvements need to be made for chemocatalytic kinetic resolution to be a 
practical route to enantioenriched arylethanamines. 
Table 9 
 
Entry Conditions 2.44 ee [%] 
1 (±)-2.1 (8 eq), í-2.45 (1 eq), CH2Cl2í& 81-91 (R) 5 examples[86] 
2 (±)-2.1 (1 eq), (S,S)-2.47 (0.5 eq), 
nOct3NMeCl (12.5 eq), 7+)í& 94 (S)
[87]
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2.3.1.3 Enzymatic Kinetic Resolutions 
 
Scheme 29 
A biocatalytic resolution method used for the industrial preparation (> 1000 tonnes yr-1) of 
enantioenriched amines is shown in Scheme 29.[4] A bacterial lipase was found to efficiently 
FDWDO\VH WKH HQDQWLRVHOHFWLYH DF\ODWLRQ RI Į-methylbenzylamine (±)-2.1a. Hydrolysis of the 
amide (R)-2.48 with base (with no racemisation in certain solvents) allows both enantiomers to 
be isolated and the acylating agent to be recovered. This method was found to be applicable to 
a range of arylalkylamines.[88] 
 
2.3.2 Reduction of Ketimines 
The synthesis of enantioenriched amines can also be achieved by the addition of hydride to a 
ketimine. The chirality can be induced by a chiral auxiliary incorporated into the imine 
substrate or an external chiral ligand, ideally in catalytic quantities. Enantioselective transition 
metal catalysed hydrogenation of enamine or enamide substrates is another strategy to access 
arylmethylamines[5] which will not be discussed here. 
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Scheme 30 
The N-tert-butylsulfinyl chiral auxiliary developed by Ellman has been utilised in reductive 
approaches to enantioenriched amines. It was found that the diastereoselectivity of the 
reduction of N-tert-butylsulfinyl ketimine (RS)-2.49 could be switched by changing the 
UHGXFLQJ DJHQW IURP VRGLXP ERURK\GULGH WR ݱ-selectride (Scheme 30).[89] Ellman and 
FRޤZRUNHUV DOVR IRXQG WKDW WKH DPLQH 2.50 could be made in one-pot from the ketone 2.51 
using a diastereoselective reductive amination (Scheme 30), and again the diastereoselectivity 
was dependent on the reductant.[90,91] 
 
Scheme 31 
Another approach is the asymmetric hydrogenation of prochiral ketimines with transition metal 
catalysis. In 1994 Burk et al. investigated the rhodium catalysed asymmetric hydrogenation of 
N-benzoylhydrazones 2.53 (Scheme 31).[92] The high enantioselectivities are explained by the 
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presence of the carbonyl group which can chelate to the metal centre. The free amine can be 
obtained by treatment of (S)-2.54 with samarium(II) iodide. 
Table 10 
 
Entry PG Conditions 2.57 [%] ee [%] 
1 4-MeOC6H4 
H2 (20 bar), [Ir(cod)Cl]2 (0.5 mol/%), 
(S)-2.58 (1.1 mol/%), I2 (2 mol/%), 
toluene, rt, 4-6 h 
Quant 
10 examples 69-98
[a][93]
 
2 Ts 
H2 (75 atm), Pd(OCOCF3)2 (1 mol/%), 
(S,S,R,R)-2.59 (1.2 mol/%), CH2Cl2, 
40 °C, 24 h 
Quant 
9 examples 
96->99 
(R)[94] 
3 Ts 
H2 (1000 psi), Pd(OCOCF3)2 (2 mol/%), 
(S)-2.61 (2.4 mol/%), 4 Å M.S., 
TFE, rt, 8 h 
70-98 
8 examples 
93-99 
(S)[95] 
4 P(O)Ph2 
H2 (1000 psi), Pd(OCOCF3)2 (2 mol/%), 
(S)-2.61 (2.4 mol/%), 4 Å M.S., 
TFE, rt, 8-12 h 
70-98 
6 examples 
93-99 
(S)[96] 
5 P(O)Ph2 
H2 (600 psi), [Et3NH][HFe3(CO)11] 
(0.33-1.33 mol/%), (S,S)-2.60 (1-5 
mol/%), KOH (5 mol/%), iPrOH, 
45 °C, 0.5 h 
85-98 
10 examples 
94-98 
(R)[97] 
[a] Absolute stereochemistry not determined. 
 
0RUHUHFHQWH[DPSOHVRIDV\PPHWULFFDWDO\WLFK\GURJHQDWLRQLQFOXGHWKH%ROPJURXS¶VLULGLXP
catalysed reduction of N-p-methoxyphenylimines (Entry 1, Table 10).[93] =KDQJ DQG =KRX¶V
groups have developed palladium catalysed systems (Entries 2-4).[94-96] Beller et al. have used 
an iron complex to good effect.[97] 
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Scheme 32 
An enantioselective reductive amination has been reported by the group of Zhang using 
pޤDQLVLGLQH DV WKH QLWURJHQ VRXUFH (Scheme 32).[98] The iridium complex used does not 
hydrogenate the starting acetophenone under the reaction conditions. 
 
Scheme 33 
An interesting development has been made by the group of Gosselin using unprotected 
acetophenone imines 2.63 (Scheme 33).[99] The imines are prepared by methyl Grignard 
reagent addition to benzonitriles. Ferrocene-based ligand (S,S)-2.62 with iridium as a catalyst 
was found to give excellent conversions and enantioselectivities across a wide range of aryl 
substitution. 
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Scheme 34 
An enantioselective Meerwein-Schmidt-Ponndorf-Varley reaction using N-diphenylphospinoyl 
ketimines 2.20 was reported Scheidt (Scheme 34).[100] The hydride source is 2-propanol which 
forms a chiral complex with (S)-BINOL (S)-2.65 and trimethylaluminium. A disadvantage of 
this approach is the stoichiometric quantity of ligand required. 
 
Scheme 35 
Rueping et al. have developed the first enantioselective Brønsted acid catalysed imine 
reduction (Scheme 35).[101] The chiral acid (R)-2.68 is the derived from BINOL and the 
hydride source is Hantzsch dihydropyridine 2.67. 
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2.3.3 Hydroamination 
 
Scheme 36 
Brown et al. have developed a one-pot synthesis of enantioenriched amines (S)-2.1 from 
styrene derivatives 2.69 via trialkyl boranes (S)-2.70 (Scheme 36).[102] Initially the 
catacholboronate is formed by asymmetric rhodium catalysed hydroboration, this is then 
converted to the trialkyl borane (S)-2.70 before a reaction with the aminating agent, 
hydroxylamine-O-sulfonic acid. The palladium catalysed hydroamination of substituted 
styrenes 2.69 with anilines has be reported by the group of Hartwig (Scheme 37).[103] The was 
no report of the anti-Markovnikov product and an initial trial with a chiral ligand suggests that 
this could be developed into an asymmetric process. 
 
Scheme 37 
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2.3.4 C-H Activation 
 
Scheme 38 
An intermolecular C-H amination is an active area of current research, to this end Müller et al. 
have developed the above process (Scheme 38).[104,105] Chiral sulfonimidamides (S)-2.75 react 
with the hypervalent iodine component to give a iminoiodane species, this forms a rhodium-nitrene 
complex which inserts into the C-H bond. The sulfonimidoyl group can be removed from (S,S)-2.74 
to give the free amine, with no epimerisation, by reaction with sodium naphthalenide, or Boc 
protection followed by magnesium in methanol. 
 
2.4 Results and Discussion 
2.4.1 Aims and Objectives 
The aim of the research discussed in this Chapter was to develop a catalytic asymmetric 
ޤDGGLWLRQ RI PHWK\O QXFOHRSKLOHV WR DU\ODOGLPLQHV 7KH UHTXLUHPHQWV RI WKH UHDFWLRQ ZHUH
defined as having a conveniently short reaction time, using commercially available ligands, 
catalyst precursors and reagents, utilising an activating group that could be mildly removed to 
give the free amine and being compatible with a range of substituted arylaldimines. 
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2.4.2 Background Work[106] 
 
Scheme 39 
Initially a range of protected imines (Scheme 39) was prepared from benzaldehyde 
and screened by Samir El Hajjaji.[106] From these N-diphenylphospinoyl imine 2.20a was found 
to be the most reactive and gave the highest conversions in various methyl addition systems. 
Initially trimethylaluminium was used as the methylating agent and an iridium species as the 
catalyst, this systeP JDYH JRRG FRQYHUVLRQ EXW D YHU\ ORZ HQDQWLRVHOHFWLYLW\ ZLWK )HULQJD¶V
ligand (S,S,S)-2.42 (Entry 1, Table 11). When a ligand screen was carried out, the highest 
enantioselectivity achieved was only 36% (Entry 2). A screen of iridium and rhodium catalysts 
with various methyl sources and a range of phosphine ligands was undertaken. The 
enantioselectivities were screened in a high throughput fashion using 31P NMR in the presence 
of (1S)-10-camphorsulfonic acid and verified by chiral HPLC, chiral supercritical fluid 
chromatography or chiral gas chromatography of an amide derivative. From this screen, an 
alternative system was discovered using rhodium as the catalytic species and dimethylzinc as 
the methyl source. This system gave a much improved enantioexcess of 92% with 
(R,Rޤ0Hޤ'X3+26 (R,R)-2.30 as the ligand (Entry 3). From here, the scope of the reaction 
was to be investigated. 
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Table 11 
 
Entry Methyl Source Conditions 
2.21a 
[%][a] ee [%]
[b] 
1 AlMe3 (2 eq) [Ir(cod)Cl]2 (2.5 mol/%), (S,S,S)-2.42 (5 mol/%), THF, rt, 24 h 96 <10
 
2 AlMe3 (2 eq) [Ir(cod)Cl]2 (2.5 mol/%), (R)-2.79 (5 mol/%), THF, reflux, 3 h 100 36
 
3 ZnMe2 (2 eq)  [Rh(C2H4)Cl]2 (2.9 mol/%), (R,R)-2.30 (10.4 mol/%),THF, reflux, 2 h 96 93
 
[a] From crude 1H NMR spectrum; [b] measured by chiral HPLC or SFC. 
 
2.4.3 DuPHOS Ligand 
The DuPHOS family of ligands were developed by Burk in the early 1990s.[107,108] These 
ligands have proved to be efficient catalysts for asymmetric hydrogenation[109] and 
hydrosilylation. The ligands are prepared in three steps (Scheme 40), the 1,4-diol (S,S)-2.80 
(produced by enzymatic reduction of 2,5-hexanedione) is treated with thionyl chloride to give a 
cyclic sulfite which is oxidised without isolation to the sulfate (S,S)-2.81. Reaction of 
ޤbis(phosphino)benzene 2.82 with two equivalents of the sulfate using four equivalents of 
nޤEXW\Olithium as base provided (R,R)-2.30. 
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Scheme 40 
 
2.4.4 N-Diphenylphosphinoylimines 
N-Phosphinoylimines can be prepared in a number of ways, but for this project they have been 
made from the aldehyde, and diphenylphosphinic amide in the presence of triethylamine and 
titanium tetrachloride (Route A, Scheme 41).[110,111] N-Diphenylphosphinoylimines are stable 
enough to be purified by prompt column chromatography.[110,111] The titanium tetrachloride 
acts as a Lewis acid increasing the electrophilicity of the aldehyde to the extent that it will react 
with the relatively unreactive nitrogen of the phosphinamide. The low nucleophilicity of 
phosphinamide is due to pʌ-dʌ or n-ıERQGLQg between nitrogen and phosphorus.[112] 
 
Scheme 41 
Another method for the preparation of N-phosphinoylimines is the reaction of an oxime 2.85 
with chlorodiphenylphosphine at low temperature to give an unstable O-phosphinyloxime 2.86 
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(Route B). Homolytic cleavage of N-O bond and recombination of the resulting radical pair 
gives the isolated product of the N-diphenylphosphinoyl imine.[17,113] This method of imine 
preparation has been reported to give variable yields of imine,[111,114] possibly dependant on the 
scale of the reaction. 
A third route to N-diphenylphosphinoyl protected imines is the preparation of a 
sulfinyl adduct from the arylaldehyde 2.83, diphenylphosphinic amide 2.84 and sulfinic acid 
(Route C).[80] This can then release the imine by elimination on treatment with base, either 
before the reaction or in situ. This is particularly powerful for the synthesis of aliphatic imines. 
 
2.4.5 Further Optimisation of Dimethylzinc Addition 
When an initial reaction of the rhodium-catalysed addition of dimethylzinc to 
diphenylphospinoyl protected p-tolyl imine 2.20b was carried out, a small impurity was noted 
in the crude 1H NMR spectrum. A triplet was observed at 4.09 ppm, close to the multiplet due 
WR WKH Į-hydrogen at 4.41-4.31 ppm. Attempts to separate this impurity from the desired 
product by column chromatography or crystallisation were unsuccessful. It was hypothesised 
that the triplet observed in the 1H NMR spectra corresponded to the two benzylic hydrogens 
present in the reduced imine 2.88b (Scheme 42). 
 
Scheme 42 
The mechanism of how the reduction had occurred was unclear at this stage, but the structure 
was confirmed by synthesis of 2.88b from 4-methylbenzylamine and diphenylphosphinic 
chloride. Higher levels of impurity were observed when a lower ratio of catalyst to ligand was 
employed (Table 12).[106] However, if a high ratio was used the conversion decreased and the 
enantiomeric excess declined, therefore, an optimum ratio of 1:1.8 was settled upon (Entry 4). 
  
 41 
Table 12[a] 
 
Entry Rh:(R,R)-2.30 Conversion [%][b] (R)-2.21d:2.88d[b] ee [%][c] 
1 1:0 100 10:90 0 
2 1:0.9 100 88:12 91 
3 1:1.4 100 92:8 82 
4 1:1.8 100 95:5 86 
5 1:2.2 86 94:6 80 
6 1:3.0 11 72:28 78 
[a] Reaction run with [RhCl(C2H4)2]2 (2.9 mol/%) and varying amounts of (R,R)-2.30; [b] from crude 1H NMR 
spectrum; [c] determined by GC of trifluoroacetamide derivative; [d] reaction run without [RhCl(C2H4)2]2 or 
(R,Rޤ. 
If neither (R,R)-MeDuPHOS (R,R)-2.30 nor rhodium catalyst is present then methyl addition is 
the only product, but in very low conversion. This leads us to believe that the reduction is 
catalysed by rhodium. From the results in Table 12 it was concluded that a rhodium species not 
bearing a phosphine ligand is responsible for the reduction. It was hoped that if the 
[RhCl((R,R)-2.30)]2 2.90 complex[115] (Scheme 43) could be synthesised, and was used to 
catalyse the methyl addition the side reaction would be eradicated. So first [RhCl(coe)2]2 2.89 
was prepared from rhodium(III) chloride trihydrate in 61% yield by a literature method.[116] 
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Scheme 43 
The obtained [RhCl(coe)2]2 2.89 could then be converted to the desired complex 2.90. This 
reaction was run in various solvents; with the cleanest reaction taking place in cyclooctene 
(Scheme 43), in other solvents (THF, hexanes and toluene) insoluble polymeric species were 
isolated. When this complex was used in the catalytic reaction a disappointing result was 
achieved (Entry 2, Table 13), the conversion was poor and the product and impurity were 
formed in a 1:1 ratio. The [RhCl(coe)2]2 complex gave a result comparable to that of 
[RhCl(C2H4)2]2. 
Table 13 
 
Entry Catalyst Conversion [%][a] (R)-2.21b:2.88b[a] ee [%][b] 
1 [RhCl(coe)2]2[c] 75 93:7 90 
2 [RhCl((R,R)-2.30)]2 29 51:49 n.d. 
[a] From crude 1H NMR spectrum; [b] Determined by GC of acetamide derivative; [c] 1:1.8 ratio of catalyst to 
(R,Rޤ. 
 
In the next attempt to reduce the side reaction, modifications were made to the reaction 
conditions. Firstly, instead of stirring the rhodium catalyst and ligand at room temperature for 
30 minutes before the reaction, they were stirred at reflux for 1 hour to aid the formation of the 
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catalytic species. However, this led to an increase in the level of benzylamine 2.88b (Entry 2, 
Table 14). 
Table 14 
 
Entry Conditions (R)-2.21b:2.88b[a] 
1 Normal 96:4 
2 Pre-stirring ligand and catalyst at reflux 1 h 88:12 
3 25 °C overnight 78:22 
[a] From crude 1H NMR spectrum. 
 
The reaction was then run at the reduced temperature of 25 °C overnight (Entry 3), this lead to 
a marked increase in reduced imine, suggesting the reduction has a lower activation barrier that 
the methyl addition. Consequently, it was decided to increase the temperature, but as the 
standard reaction is carried out in THF at reflux, higher boiling ethers were used. The reaction 
was carried out at both 66 °C and reflux in each of these solvents (Table 15). 
 
 
Table 15 
 
Entry Solvent T [ºC] Conversion [%][a] (R)-2.21b:2.88b[a] ee [%][b] 
1 Me-THF 66 40 54:46 n.d.[c] 
2 Me-THF 78 0 0:100 n.d. 
3 dioxane 66 57 84:16 n.d. 
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4 dioxane 101 75 86:14 89 
5 DME 66 20 53:47 n.d. 
6 DME 85 64 84:16 90 
[a] From crude 1H NMR spectrum; [b] determined by GC of acetamide derivative; [c] not determined. 
 
Using Me-THF the reduction reaction was favoured; in fact no methyl addition product was 
observed at reflux (Entry 2). Dioxane and DME gave similar results at reflux, with a slight 
increase in impurity and a slight decrease in enantiomeric excess (Entries 4 and 6). 
The proposed catalytic cycle leading to the methyl addition product is outlined below 
(Scheme 44). The catalytic species A is formed in situ from [RhCl(C2H4)2]2, (R,R)-2.30 and 
dimethylzinc. The imine complexes with the rhodium species, methyl addition occurs and 
transmetallation with dimethylzinc regenerates the catalytic complex A and gives species C 
that releases the product on work up. 
 
Scheme 44 
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Reduction is often seen when diethylzinc LVXVHGGXH WRȕޤHOLPLQDWLRQIURPWKHDON\OJURXS
+RZHYHU LQ WKH PHWK\O FDVH WKHUH DUH QR ȕ-hydrogens to be eliminated, so a different 
mechanism must operate. It was thought that if species B could complex with a second 
molecule of imine rather than undergoing transmetallation with dimethylzinc a hydrogen 
transfer could occur in a Meerwein-Varley-Ponndorf (MVP) type mechanism (Scheme 45). 
 
Scheme 45 
This type of reduction of imines does have literature precedent, for example Scheidt reports an 
enantioselective reduction with of N-phospinoyl ketimines with (BINOL)AlIII to give chiral 
amines.[100] However, in this case isopropanol is used as the hydride source. The theoretical 
E\ޤSURGXFW IURP WKH 093 UHGXFWLRQ WKH NHWLPLQH 2.92 was prepared from the appropriate 
acetophenone, via the oxime 2.91 (Scheme 46).[17,113] It is believed that this ketimine (and the 
acetophenone that it decomposes to) have been isolated after column chromatography of the 
crude reaction mixture as these methyl groups have been seen in the 1H NMR spectra of early 
fractions. 
 
Scheme 46 
We hypothesised that intermediate B (Scheme 44) formed in the catalytic cycle could suffer 
interception by further starting material imine resulting in reduction, rather than 
transmetallation with ZnMe2 resulting in the desired product. It was found that subjecting a 1:1 
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mixture of methyl addition product and imine, to the normal reaction conditions did not lead to 
an increase in the amount of reduction product. Therefore, once the methyl addition product 
has formed and dissociated from the catalytic species it cannot re-associate and act as the 
hydride source for the MVP reduction. So if the concentration of imine in the reaction is kept 
low, either by slow addition or by diluting the reaction mixture the side reaction should be 
suppressed. 
Subsequently experiments were run using a syringe pump and slowly adding a 
solution of the imine to a refluxing solution of dimethylzinc, catalyst and ligand, in varying 
volumes of THF; the results are shown in Table 16. Addition over 2 h 40 min leads to a better 
conversion than very slow addition over 5 h, which gave a complex mixture in which the 
product could not be clearly identified (Entry 2 vs. Entry 3). Altering the volume of THF that 
the reaction was carried out in had little effect on the impurity ratio (Entries 1, 2 and 4). 
Table 16 
 
Entry Volume [mL] 
ZnMe2 
[Eq] 
Time 
[h][a] 
Conversion 
[%][b] (R)-2.21:2.88b
[b]
 
ee 
[%][c] 
1 3 2 2.6 55 94 : 6 n.d.[d] 
2 6 2 2.6 66 95 : 5 89.3 
3 6 2 5.0 0 n.d. n.d. 
4 12 2 2.6 68 96 : 4 91.4 
[a] Imine in THF (4 ml) added via syringe pump; [b] from crude 1H NMR spectrum; [c] determined by GC of 
acetamide derivative; [d] not determined. 
 
2.4.6 Scope of Methylation 
Up to this point, most reactions had been carried out using the p-tolyl imine 2.20b. As a range 
of substituted aryl imines were in hand, it was decided to subject these to the improved reaction 
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conditions. The racemate of each addition product was made by adding methylmagnesium 
bromide to the imine (Table 17). 
Table 17 
 
Entry Ar Substrate 2.21 [%] Product 
1 Ph  2.20a 63 2.21a 
2 4-MeC6H4  2.20b 59 2.21b 
3 4-FC6H4  2.20c 49 2.21c 
4 4-ClC6H4  2.20d 60 2.21d 
5 4-BrC6H4  2.20e 65 2.21e 
6 4-CF3C6H4  2.20f 70 2.21f 
7 3-MeC6H4  2.20g 60 2.21g 
8 3-ClC6H4  2.20h 44 2.21h 
9 2-MeC6H4  2.20i 34 2.21i 
10 2-Naphthyl  2.20j 73 2.21j 
 
Chiral gas chromatography (GC) was used to determine the enantiomeric excess as the 
reduction product and the desired product co-elute by HPLC. However, the 
diphenylphospinoyl-protected product 2.21 must first be derivatised before the GC can be run. 
For the majority of the products the trifluoroacetate derivative was used but in two cases the 
acetate was used. The addition of dimethylzinc was carried out using ten varying imines using 
the improved syringe pump addition conditions (Table 18). 
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Table 18 
 
Entry Ar (R)-2.21 [%][a] Product (R)-2.21:2.88[b] X ee [%][c] 
1 Ph 63 (R)-2.21a 96:4 CF3 93 
2 4-MeC6H4 59 (R)-2.21b 97:3 CH3 92 
3 4-FC6H4 49 (R)-2.21c 94:6 CF3 84 
4 4-ClC6H4 60 (R)-2.21d 93:7 CF3 86 
5 4-BrC6H4 65 (R)-2.21e 93:7 CF3 75 
6 4-CF3C6H4 70 (R)-2.21f 95:5 CF3 78 
7 3-MeC6H4 60 (R)-2.21g 95:5 CF3 89 
8 3-ClC6H4 44 (R)-2.21h 89:11 CF3 78 
9 2-MeC6H4  34 (R)-2.21i 91:9 CF3 79 
10 2-Naphthyl 73 (R)-2.21j 96:4 CH3 84 
[a] Isolated yield; [b] from crude 1H NMR spectrum; [c] determined by GC of acetamide or trifluoroacetamide 
derivative. 
 
The reduction reaction is present in all cases. The results show that ortho substituents have a 
detrimental effect on the yield of the reaction (Entry 9). The enantiomeric excess is best in the 
case of the unsubstituted phenyl at 93%. When the reaction was run using 2-chloro imine 2.20k 
as the starting material, there appeared to be rotamers present in the 1H NMR spectrum. 
However, when the 1H NMR spectrum was run at an elevated temperature (70 °C) no change 
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in ratio was observed. Further analysis of the 1H NMR spectrum showed a peak at 2.04 ppm 
this lead us to deduce that the ortho-chlorine had be replaced by a methyl in ~50% of the 
product (Scheme 47). This was confirmed by the comparison with an independently prepared 
sample of the 2-methyl product 2.21i. This could be explained mechanistically by the insertion 
of rhodium into the carbon-chlorine bond (Scheme 48). Transmetallation with dimethylzinc 
followed by reductive elimination would lead to the ortho methyl compound. 
 
Scheme 47 
 
Scheme 48 
In conclusion, conditions have been found that allow for methyl addition to the activated 
N,NޤGLSKHQ\OSKRVSKLQR\O LPLQHV 2.20 in moderate to good yields and good to excellent 
enantiomeric excesses. Complications were observed due to competing chemoselectivity 
(reduction) issues. Fortunately, the phosphinamides 2.21 are all crystalline compounds and 
further enantioselective enrichment can be achieved through simple recrystallisation. 
 The aim from here was to investigate a new protecting group rather than the high 
molecular weight N,N-diphenylphosphinoyl group and the look at the addition of other groups, 
in particular aryl groups. 
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Chapter 3 
3.1 Chiral Diarylmethylamines 
Chiral diarylmethylamines are valuable chemical motifs occurring in pharmaceutical targets as 
can be seen in Scheme 49. Cetirizine (Zyrtec®) is a second-generation, non-sedating, 
antihistamine drug,[117] the levo enantiomer (S)-Cetirizine dihydrochloride (Xyzal®, (S)-3.1) 
(Scheme 49) was found to have a two-fold higher affinity for H1 receptors than the racemic 
Cetirizine.[118] Asymmetric synthesis and administration of the eutomer (S)-3.1 is therefore, a 
much more efficient strategy than using the racemate, Cetirizine (±)-3.1. 
 
Scheme 49 
Further biologically active diarylmethylamine containing molecules include: non-peptidal 
įޤUHFHSWRUDJRQLVWV[119-121] for example SNC 80; Tianeptine an antidepressant;[122] Lomerizine a 
calcium channel blocker used for the treatment of migraines;[123] Vorozole for the treatment of 
breast cancer,[124] a series of Thromboxane A2 receptor agonists[125] amongst others.[126-129] 
Some of these are limited to symmetrical diarylmethylamines (for example Lomerizine, 
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Scheme 49), possibly due to the lack of commercially available chiral diarylmethylamines and 
limitations to their synthesis on scale. Diarylmethylamines have also been used as protecting 
JURXSVIRUH[DPSOHLQWKHV\QWKHVLVRIFDUEDSHQHPLQWHUPHGLDWHVE\,WR¶VJURXS[130] and in the 
SUHSDUDWLRQRIĮ-DU\OJO\FLQHVE\3HWDVLV¶JURXS[131] 
 
3.1.1 Synthesis of Levocetirizine 
Routes to levocetirizine (S)-3.1 based on resolution of 4-chlorobenzhydrylamine with 
ޤWDUWDULFDFLG[132] and preparative chiral HPLC of an amide derivative[133] have been reported. 
The first enantioselective synthesis was reported by Corey et al. in 1996[134] using a 
&RUH\ޤ%DNVKL-Shibata (CBS) reduction of 4->Ș6-chromium tricarbonylbenzoyl]chlorobenzene 
3.2 to give the enantioenriched alcohol 3.3 (Scheme 50). Introduction of the piperazine unit 
proceeded with complete retention of configuration due to the stability of the chromium 
stabilised carbocation.[135] The synthesis of Xyzal® (S)-3.1 was completed in a further two 
steps. Other approaches to levocetirizine (S)-3.1 have been based on asymmetric additions of 
organometallic nucleophiles to activated imines. As this type of reaction is central to this 
Thesis, such approaches will be discussed in more detail in the next section. 
 
Scheme 50 
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3.2 Additions to Activated Aldimines 
Investigations into the arylations of imines have lagged behind that into the arylation 
of aldehydes.[136,137] This is due to the inherent lower electrophilicity of imines, the risk of 
hydrolysis under the arylation conditions and the need for an activating group that can then be 
removed from the amine addition product. The current state of the literature up to 2012 for 
arylation of activated aldimines will now be surveyed, looking at each type of nucleophile in 
turn. 
 
3.2.1 Aryllithium Reagents 
Aryllithium reagents are both highly nucleophilic and basic species, which limits the range of 
functional groups that can be present in the substrates they are reacted with. Aryllithium 
reagents can be made by lithium-halogen exchange from the appropriate aromatic halide; only 
phenyllithium is commercially available. Aryllithium reagents can be added to achiral imines 
in the presence of enantiopure chiral ligands. This approach relies on the ligand-aryllithium 
complex being more reactive than the uncoordinated aryllithium reagent, so low temperatures 
are employed to minimise the background reaction. Tomioka et al.[62] reported the first 
example in 1990 using a stoichiometric amount of an enantiopure amino-ether ligand (S)-2.6 in 
the addition of phenyllithium to p-methoxyphenylimine 3.4 to give the enantioenriched 
addition product 3.5 (the absolute stereochemistry was not defined) (Scheme 51). A further 
example from the Tomioka group using a bulkier 4-methoxynaphthyl protecting group gave an 
excellent enantiomeric excess of 92%.[69] 
 
Scheme 51 
Later the group of Alexakis reported 1,2-diamine ligand (R,R)-3.7 that could be used in 
substoichiometric quantities to give addition product 3.6 (Scheme 52).[138,139] However, 
consistently higher yields were achieved when stoichiometric ligand loadings were used. The 
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p-methoxyphenyl protecting group can be removed by reduction with ammonium cerium(IV) 
nitrate (CAN). 
 
Scheme 52 
Alternatively, an aryllithium reagent can be added to an imine bearing an enantiopure chiral 
activating group. Delorme and co-workers[140] reported the diastereoselective addition of 
phenyllithium to imines (R)-2.11 (in equilibrium with oxalidinone (R)-2.11a) derived from an 
aryl aldehyde and (R)-phenylglycinol (Scheme 53). The auxiliary could be removed by 
treatment with lead tetraacetate to give the free amine in 60% yield. 
 
Scheme 53 
 
3.2.2 Aryl Grignard Reagents 
Aryl Grignard reagents are highly nucleophilic and basic species, similar to aryllithium 
reagents, which limits the range of functional groups that can be present in the substrates they 
are reacted with. Aryl Grignard reagents can be synthesised from the appropriate aryl bromide 
and magnesium turnings; there are more examples of commercially available aryl Grignard 
reagents than aryllithium reagents. 
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Ellman has developed a chiral auxiliary approach using enantiopure 
NޤtertޤEXWDQHVXOILQ\O LPLQHV Scheme 54).[141] The sulfinyl group both increases the 
electrophilicity of the imine and promotes diastereofacial selectivity. The chiral auxiliary 
(Rޤ can be made in two steps from di-tert-butyl disulfide in 65% overall yield and >99% 
ee[142] and both enantiomers are now commercially available. The imine (R)-3.19 is then made 
by condensation with the aldehyde in the presence of a Lewis acid, typically CuSO4 (Scheme 
54).[143] Addition of Grignard reagents to these imines proceeds with high diastereoselectivity 
via a proposed six-membered ring transition state 3.11 with magnesium chelating the oxygen 
of the sulfinyl group,[141] non-coordinating solvents are found to give the highest 
diastereoselectivities as the transition state is not disturbed. Plobeck et al.[144] prepared 
diarylmethylamines (RS,R)-3.10 in generally good yields and diastereomeric ratio using this 
method (Scheme 54). They found using aryllithium reagents gave a switch in 
diastereoselectivity, as the six-membered ring transition state is not formed. This approach has 
also been applied to the synthesis of levocetirizine (S)-3.1.[145] 
 
Scheme 54 
The free amine can be isolated using mild acidic conditions[146] and the chiral auxiliary can be 
recycled.[147] Colobert et al.[20,74] have developed a P-chirogenic N-phosphinoylimine (±)-2.18 
(Scheme 55) and have achieved some encouraging diastereoselectivity with the addition of aryl 
Grignard reagents, however, only racemic imine has been used so far. 
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Scheme 55 
 
3.2.3 Aryl Stannanes 
Stannane nucleophiles are much less nucleophilic than aryllithium and aryl Grignard reagents 
and typically a catalyst will be need to be employed with them. However, the low 
nucleophilicity and basicity of these species is an advantage as it increases the range of 
functional groups that can be tolerated in the reaction. A disadvantage of stannane reagents is 
their high toxicity. Some tributylaryl stannanes and fewer trimethylaryl stannanes are 
commercially available. Trimethylaryl stannanes are made from the appropriate aryl Grignard 
reagent and trimethyl tin bromide. 
 
Scheme 56 
The groups of Miyaura[148] and Oi[149,150] reported the first examples of transition metal 
catalysed additions to aldimines 2.21 and 3.13 using trimethylphenyl stannane as the 
nucleophile and a cationic rhodium complex as complex (Scheme 56). The addition of 
phosphine ligands was detrimental to the reaction. 
 
Scheme 57 
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The first example of an asymmetric transition metal catalysed synthesis of diarylmethylamines 
was reported by Hayashi et al. in 2000 (Scheme 57).[151] Aryl stannanes were added to 
NޤDON\OLGHQHVXOIRQDPLGHV 3.16 using a neutral rhodium catalyst and an enantiopure chiral 
monodentate phosphine ligand (R)-1.41. The highest enantioselectivity was achieved with a 
nosyl protecting group. The use of five equivalents of toxic stannane reagents has led to the 
pursuit of other nucleophiles. 
 
3.2.4 Arylzinc Reagents 
 
Scheme 58 
Following their success with the enantioselective addition of diphenylzinc to aldehydes, Bräse 
et al. studied phenyl transfer to N-formyl imines 3.20 (Scheme 58).[152] A mixed diorganozinc 
species was formed in situ from diphenylzinc and diethylzinc. Mixed diorganozinc reagents are 
less reactive than diarylzincs, which presumably lowers the background reaction. The NޤIRUP\O
imines 3.20 were formed in situ from the sulfinate adduct 3.18. The [2.2]paracyclophane-based 
ketimine ligand (RP,S)-3.21 shown in Scheme 58 was found to give the best 
enantioselectivities with no ethylation product observed. The N-formylamines 3.19 can be 
deprotected by acidic methanolysis with no racemisation. A limitation of this approach is that 
substitution can only be introduced on the aryl group of the imine, as no substituted diarylzinc 
reagents are available. 
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3.2.5 Aryl Titanium Reagents 
 
Scheme 59 
Hayashi et al. found aryl titanium reagents can undergo transmetallation with rhodium 
complexes and give addition products imines.[153] The titanium reagents were prepared from 
the appropriate aryllithium and chlorotriisopropoxytitanium.[154] The optimised conditions used 
the imine activated with a bulky 2,4,6-triisopropylbenzenesulfonyl group 3.22 and (SޤVHJSKRV
(S)-2.61 (Scheme 59). The protecting group can be removed from the resulting amine 3.23 
using the usual methods for tosyl deprotection (SmI2 in HMPA/THF, Li/NH3(liq) in THF or 
RedAl in toluene). 
 
3.2.6 Aryl Boron Reagents 
Organoboron sp2-nucleophiles have the advantage of often being stable to air, oxygen and 
moisture, compatible with a wide range of functional groups and give non-toxic 
E\ޤSURGXFWV[28,155] No special handling techniques are needed and they are only weakly 
nucleophilic so many functional groups can be tolerated. The success of the Suzuki-Miyaura 
cross-coupling has lead to the commercial availability of many substituted aryl boronic acids. 
Aryl boronic acids can be synthesised from aryl Grignard/lithium reagents 3.24 and trialkyl 
borates followed by hydrolysis of the intermediate boronic ester or by palladium catalysed 
cross-coupling of aryl halides or triflates 3.26 with the expensive diborylpinacolate 3.27 which 
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is commercially available and allows more sensitive functional groups to be present (Scheme 
60).[155] 
 
Scheme 60 
 
Scheme 61 
Boroxines 3.28 (also called boronic acid anhydrides) are dehydrated boronic acids. Although 
boroxine formation is entropically favoured due to the formation of three equivalents of water, 
boronic acids tend to exist as mixture of the boronic acid and anhydride, and in solution the 
two species are in equilibrium (Scheme 61).[156] Boroxines are isoelectronic with benzene, 
however, they not considered aromatic heterocycles.[157-160] They are known to readily form 
Lewis acid-base adducts with amines typically 1:1 boroxine:amine.[161,162] Aryl boronic acids 
bearLQJ HOHFWURQޤGRQDWLQJ JURXSV form boroxines with increased stability whilst electron-
withdrawing groups and ortho-substituents destabilise the boroxine and accelerate their 
hydrolysis.[156,161] Boroxines have a C3-symmetric planar structure in the solid state (as shown 
by X-ray crystallography), with some exceptions e.g. ortho-methyl which has a propeller like 
structure with the phenyl rings twisted out of plane. Boroxines have applications in materials 
chemistry such as flame retardants and lithium ion battery anion acceptors.[163] 
The group of Tokunaga[164] studied the formation of hetero-aryl boroxines from a 
mixture of two boronic acids using 1H NMR spectroscopy to calculate the equilibrium 
constants in solution. Scheme 62 shows the experimental distribution of boroxines was found 
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to be close to the statistical distribution of 1:3:3:1. However, no attempt was made to separate 
the boroxines. 
 
Scheme 62 
 
3.2.6.1 Rhodium Catalysis 
The first transition-metal catalysed addition of an aryl boron nucleophile to an activated imine 
was reported by the group of Miyaura in 2000 (Entry 1, Table 19).[148] Using sodium 
tetraphenylborate 3.29 as the aryl source and a cationic rhodium complex with a phosphine 
ligand 1.33 gave addition product 3.15 in good yield. However, there are few commercially 
available functionalised sodium tetraarylborates and 5.2 equivalents of the aryl group with 
respect to the imine are required. 
Table 19 
 
Entry Boron Species Conditions 3.15 [%] 
1 3.29 (1.3 eq) [Rh(cod)(MeCN)2]BF4 (3 mol/%), 1.33 (3 
mol/%), dioxane, 90 °C, 3-16 h 
68-94 
6 examples[148] 
2 3.25 (2 eq) [Rh(cod)(MeCN)2]BF4 (3 mol/%),  dioxane, 95 °C, 16 h 
68-99 
8 examples[165] 
 
Later the same year, Miyaura et al.[165] reported the first catalysed addition of aryl boronic 
acids (and esters) using similar conditions (Entry 2, Table 19). Many groups have since worked 
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on optimising an asymmetric, rhodium catalysed, boronic acid/boroxine arylation due to the 
utility of aryl boronic acid nucleophiles. 
Tomioka and co-workers used a N-Boc-Ȯ-valine connected amidomonophosphane 
ligand (R,S)-3.32 with a rhodium(I) catalyst to arylate N-tosylimines with aryl boroxines 3.28 
(Entry 1, Table 20).[166] The highest enantioselectivities were reported with imines bearing an 
ortho-trimethylsilyl group, which could then be replaced by a proton or halogen. Later steric 
tuning of the ligand allowed arylation of N-diphenylphosphinoyl aldimines with higher 
enantiomeric excess and the advantage of a milder deprotection (Entry 2, Table 20) although 
higher catalyst loadings and longer reaction times were needed.[167] In an attempt to limit imine 
hydrolysis the group of Tomioka have recently reported the use of triphenylborane 3.31 as the 
aryl source in an anhydrous reaction system (Entry 3, Table 20).[168,169] 
Table 20 
 
Entry PG Conditions 3.41 [%] ee [%] 
1 Ts 
3.28 (1.7 eq), Rh(acac)(C2H4)2 (3 mol/%), 
(R,S)-3.32 (3.3 mol/%), nPrOH,  
60-100 °C, 1-3 h 
83-99 
11 examples 
66-94 
(R)[166] 
2 P(O)Ph2 
3.28 (1.7 eq), Rh(acac)(C2H4)2 (6 mol/%), 
(S,S)-3.33 (6.6 mol/%), 4 Å M.S., 
dioxane/nPrOH, 80 °C, 12 h 
76-96 
14 examples 
86-99 
(S)[167] 
3 P(O)Ph2 
3.31 (1.7 eq), Rh(acac)(C2H4)2 (6 mol/%), 
(S,S)-3.33 (6.6 mol/%), KF/Celite (2 eq), 
tBuOH, 100 °C, 1-12 h 
84-94 
8 examples 
90-96 
(S)[168-169] 
 
A series of cyclic chiral diene ligands have been developed in the Hayashi group and have been 
applied to the arylation of both N-tosyl- and N-nosylarylimines. Chiral diene ligands will be 
discussed in more detail in Section 3.2.7. The addition of aryl boroxines 3.28 to 
NޤWRV\ODU\OLPLQHV XVLQJ >5K&O&2H4)2]2 and (R,R)-Ph-bod (R,R)-2.39 (Entry 1, Table 21) 
resulted in high yield and enantioselectivities.[170] 
 61 
Table 21 
 
Entry PG Conditions 3.30 [%] ee [%] 
1 Ts 
3.28 (1.2 eq), [RhCl(C2H4)2]2 (3 mol/%), 
(R,Rޤ (3.3 mol/%), KOH(aq) (20 mol/%), 
dioxane, 60 °C, 6 h 
94-99 
11 
examples 
92-99 (R)[170] 
2 Ns 3.28 (1.2 eq), [RhCl((R,R)-3.34)]2 (3 mol/%), KOH(aq) (20 mol/%), dioxane, 60 °C, 6 h 
94-99 
12 
examples 
95-99 (R)[171] 
3 Ns 
3.28 (0.67 eq), [RhCl(C2H4)2]2 (0.3 mol/%), 
(R,R)-3.35 (0.33 mol/%), KOH(aq) (20 mol/%), 
dioxane, 60 °C, 6 h 
90-98 
10 
examples 
97->99 (R)[172] 
4 Ts 3.28 (1 eq), [RhCl((S)-3.36)]2 (2.5 mol/%), KOH (2 eq), dioxane:H2O 50:1, 60 °C, 6 h 
70-95 
13 
examples 
89-98 (S)[173] 
5 Ts 
3.28 (2 eq), [RhCl(C2H4)2]2 (0.75 mol/%), 
(R,S)-3.37 (1.65 mol/%), KOH (2 mol/%), 
MeOH/CH2Cl2 (10:1), rt, 3h 
91 94[174] 
6 Ts 
3.25 (2 eq), [RhCl(C2H4)2] (3 mol/%), 
(S,Sޤ (3.3 mol/%), Et3N (2 eq), toluene, 
55 °C, 4-5 h 
56-99 
20 
examples 
98-99 (R)[175] 
 
 
Scheme 63 
However, deprotection of the tosyl protected amine (S)-3.39 using SmI2 in HMPA/THF lead to 
partial dechlorination of addition products bearing chlorine (Scheme 63).[170] The focus then 
moved to N-nosylarylimines, which can be deprotected under milder conditions (see Section 
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1.2). The (R,R)-Ph-bnd ligand (R,R)-3.34 was more effective than (R,R)-Ph-bod (R,R)-2.39 
with N-nosylarylimines (Entry 2).[171] A bicyclo[2.2.2]octadiene ligand (R,R)-3.35 was 
developed with a simpler synthesis than previous dienes and also was effective in arylation of 
N-nosylarylimines (Entry 3).[172] The Hayashi group have also developed a bidentate 
phosphine-olefin ligand (S)-3.36 which was successfully used in the addition of aryl boroxines 
to N-tosylimines (Entry 4).[173] Another chiral diene ligand (R,S)-3.37 designed by the group of 
Carnell has been used to give product 3.30 in good yield and enantioselectivity (Entry 5).[174] 
Lin et al. designed a tetrahydropentalene ligand (S,S)-3.38 with which boronic acids rather 
than boroxines were effective arylating agents (Entry 6).[175] When an imine bearing an ortho-
ester group 3.41 was used, lactamisation occurred under the reaction conditions to give a chiral 
isoindolinone (S)-3.42 (Scheme 64), however, deprotection was not reported. 
 
Scheme 64 
 
Scheme 65 
Zhou et al. reported a spiro-monophosphite ligand (S)-3.43 used with a rhodium catalyst for 
the addition of boronic acids to N-tosylimines (Scheme 65).[176] Hayashi et al. have recently 
reported the use of diene ligand (R,R)-3.46 (Scheme 66) for the rhodium catalysed aryl 
addition to N-tosylketimines 3.44.[177] Although an undesirable aryl source is used in sodium 
tetraphenyl borate this is a rare example of the synthesis of enantiopure tertiary amines such as 
3.45. 
 63 
 
Scheme 66 
Feringa and co-workers reported the low molecular weight N,N-dimethylsulfamoyl group as a 
protecting and activating group for the arylation of imines.[178] A rhodium/phosphoramidite 
(R)-3.49 system achieved up to 94% ee of sulfamide 3.48 (Entry 1, Table 22). More recently 
Du et al. have used a novel acyclic binaphthyl-based chiral diene ligand (S)-3.50 for the 
addition of boronic acids to these N,N-dimethylsulfamoylimines (Entry 2).[179] Deprotection to 
the free amine 3.40 could be achieved by transamination with 
ޤGLDPLQRSURSDQHHWK\OHQHGLDPLQHRU LQDPLFURZDYH UHDFWRUZLWKRXW ORVVRIHQDQWLRSXULW\
(Scheme 67). 
Table 22 
 
Entry 3.25 [Eq] Conditions 3.48 [%] ee [%] 
1 1.3 Rh(acac)(C2H4)2 (3 mol/%), (R)-3.49 (7.5 
mol/%), acetone, 40 °C, 4 h 
72-97 
10 examples 82-94
[178] 
2 2.0 [RhCl(C2H4)2]2 (2.5 mol/%), (S)-3.50 (6.0 
mol/%), Et3N (2.0 eq), toluene, 30 °C, 4 h 
48-82 
10 examples 70-84
[179] 
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Scheme 67 
 
Scheme 68 
In addition to his work with chiral N-tert-butanesulfinimines, Ellman has also developed a 
rhodium catalysed aryl boronic acid addition to N-Boc-imine generated in situ from the 
sulfinate adduct 3.51 (Scheme 68).[180] Miyaura et al. have reported a rhodium catalysed aryl 
boronic acid addition using a novel N-linked bidentate phosphoramidite ligand (R,R)-3.54 
(Scheme 69).[181] They give 38 examples of aryl addition as well as chiral isoindolinone 
formation and synthesis of cryptostyline II. 
 
Scheme 69 
 65 
Ellman also investigated the rhodium catalysed addition of boronic acids to enantioenriched 
Nޤtert-butanesulfinimines (R)-3.9.[182] High diastereoselectivities were achieved with a 
rhodium catalyst, bis-phosphine ligand 3.55 and slow addition of the boronic acid via a syringe 
pump (Entry 1, Table 23). Aliphatic aldimines were also compatible with this procedure. Batey 
et al. reported a similar system using triethylamine as an additive and no need for a phosphine 
ligand or slow boronic acid addition (Entry 2).[183] 
Table 23 
 
Entry Conditions (RS,S)-3.10 [%] de [%] 
1 Rh(acac)(coe)2 (5 mol%), 3.55 (5.5 mol/%), dioxane, 70 °C, slow addition of boronic acid, 6-10 h 
70-96 
4 examples 92-98
[182] 
2 [Rh(cod)(MeCN)2]BF4 (5 mol/%), Et3N (2 eq), dioxane/H2O (1:2), rt, 2 h 
47-quant. 
13 examples 83-97
[183] 
 
3.2.6.2 Palladium Catalysis 
The addition of aryl boron nucleophiles to activated aldimines has also been attempted with 
palladium catalysis. In 2000 Hu et al. reported the use of phosphinite-based palladacycle 3.56 
to give racemic 3.30 in good yield (Entry 1, Table 24).[184] Another set of conditions were 
developed by Ding (Entry 2).[185] An asymmetric example using the C2-symmetric 
NޤKHWHURF\FOLFFDUEHQHSDOODGLXPFRPSOH[3.57 with mild conditions which tolerates a range 
of functional groups has been reported by the group of Shi (Entry 3).[186] 
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Table 24 
 
Entry PG Conditions 3.30 [%] ee [%] 
1 Bs/Ts 3.25 (2 eq), 3.56 (5 mol/%), K3PO4 (1 eq), toluene, rt, 24-48 h 
63-90 
9 examples[184] n.a. 
2 Ts 
3.25 (2 eq), PdCl2(PhCN)2 (5 mol/%), 
iPr2NPPh2 (5 mol/%), K2CO3 (3 eq), 4 Å 
M.S., dioxane, 80 °C, 24 h 
31-85 
26 
examples[185] 
n.a. 
3 Ts 
3.25 (2 eq), (R)-3.57 (3 mol/%), 
K3PO4.3H2O 
(1 eq), 4 Å M.S., THF, 4 °C, 12-36 h 
64-99 
26 examples 60-94 (R)
[186] 
 
3.2.7 Diene Ligands 
One of WKHILUVWROHILQFRPSOH[HVUHSRUWHGZDV=HLVH¶VVDOWLQDȘ2-bonded ethylene and 
platinum complex 3.58 (Scheme 70).[187,188] Olefin complexes have been reported with Ni, Pd, 
Rh and Ir since then. Rhodium-olefin complexes 3.59 and 3.60 (Scheme 70) are commercially 
available and commonly used as precursors for chiral catalyst complexes. Yet only recently has 
the field of using chiral alkenes as ligands in asymmetric catalysis been investigated. 
 
Scheme 70 
Traditionally chiral ligands chelate through phosphorus or nitrogen atoms with much stronger 
binding than alkenes. Precatalysts such as 3.59 and 3.60 are used and the alkenes are displaced 
by the chiral nitrogen or phosphorus ligands in solution. If the ligand exchange is incomplete, 
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the enantioselectivity may be reduced. Olefin ligands have the advantage of increased lability 
compared to nitrogen or phosphorus based ligands, which gives fast and quantitative exchange 
to the desired olefin complex. Olefin complexes have been found to catalyse some reactions 
faster than phosphine based ligands.[189] 
The Dewar-Chatt-Duncanson model[190,191] IRUPHWDOROHILQELQGLQJGHVFULEHVDı-bond 
IRUPHGE\GRQDWLRQRIDSDLURIHOHFWURQVIURPWKHʌ-orbital of the double bond to a vacant d 
orbital on the metal centre (Scheme 71)7KLV LVFRPSOHPHQWHGE\DʌEDFNGRQDWLRQ IURPD
filled d orbital on the metDO WR WKH DQWLERQGLQJ ʌ RUELWDO RI WKH DONHQH UHVXOWLQJ LQ D
rehybridisation of the carbon centres. 
 
Scheme 71 
The amount of back donation increases with the principal quantum number of the metal centre, 
as the back donation increases there is increasing sp3 character in the alkene carbon leading to a 
shift of around 1 ppm 1H NMR spectra and 100-150 cm-1 LQ WKH ,5 VSHFWUD ȣC=C).[189] 
(OHFWURQޤZLWKGUDZLQJJURXSVRQWKHDONHQHLQFUHDVHWKHDPRXQWRI back-donation and increase 
the stability of the complex. 
 
Scheme 72 Comparative increase of K for Equation 1. 
Diene complexes are generally more stable than mono-olefin complexes due to the chelate 
effect. The relative stability of various diene ligands was investigated by Hogeveen et al. by 
studying the equilibrium constants of the ligand exchange (Equation 1, Scheme 72).[192] 
Bicyclo[2.2.1]hept-2,5-diene 3.61 was found to form some of the most stable complexes due to 
having an optimal bite angle and lack of steric hindrance or electron-donating groups around 
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the double bond. The rehybridisation of the carbon atoms that occurs on complexation also 
helps to reduce the ring strain of the carbocycle. 
 
Scheme 73 
The Hayashi group have synthesised these ligands using asymmetric hydrosilylation 
((R,Rޤ)[193] or preparative HPLC ((R,R)-2.39, (R,R)-3.34)[170,171,194,195] to give the 
enantioenriched ligand (Scheme 73). Lin et al. used an enzymatic resolution of a diol 
intermediate to make ligand (S,S)-3.38.[175] Enzymatic resolution was also used to resolve 
racemic (±)-3.72 (made from the commercially available dimer of dimethyl succinate) in the 
synthesis of (R,S)-3.37 by Carnell et al.[174] Carreira used a readily available enantiopure 
starting material (R)-carvone (R)-3.70 to make ligand (S,R,R)-3.71.[196] Recently 
SKRVSKRUXVޤROHILQ[173,197-201] DQG QLWURJHQޤROHILQ[202] hybrid ligands have been developed by a 
number of groups. 
 
3.3 Other Routes to Chiral Diarylmethylamines 
Aryl additions to activated aldimines are not the only approach to chiral diarylmethylamines; 
the current literature of other synthetic routes will be reviewed in the following section. 
 69 
Resolution of diarylmethylamines is much less common than arylethanamines presumably due 
to the two substituents being of a similar steric bulk. 
 
3.3.1 Reduction of Ketimines 
 
Scheme 74 
Asymmetric hydrogenation of cyclic activated imines 3.73 gave cyclic sulfamidates (X = O) 
and sulfamides (X = NH) 3.74 (Scheme 74).[203] The cyclic imines were prepared from 
oޤK\GUR[\EHQ]RSKHQRQHVRU o-aminobenzophenones and sulfamoyl chloride (formed in situ). 
The cyclic sulfamidates (X = O) can be opened with lithium aluminium hydride to give amines 
3.75, this and the need for an ortho-hydroxy/amino group significantly limit the substrate 
scope. 
 
Scheme 75 
The asymmetric hydrogenation of benzophenone imines 3.76 has been reported by the group of 
Gosselin.[99,204] The imines are prepared by Grignard reagent additions to benzonitriles. A 
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monodentate phosphoramidite ligand (S)-3.78 with an iridium catalyst was found to give full 
conversion with a hydrogen pressure of 1500 psi (Scheme 75). The highest enantioselectivities 
(82-91%) were observed when an ortho substituent was present, compared to a p-methyl 
substituent (31%). 
3.3.2 Other Routes 
 
Scheme 76 
The group of Botta devised a novel route to a chiral benzhydrylamine based on an enzymatic 
kinetic resolution of N-acetyl-1-aryl-1-propargylamine 3.79.[205] The second ring was then built 
up using a methylene-free tandem metathesis[206] and oxidation with DDQ (Scheme 76). 
 
3.4 Results and Discussion 
3.4.1 Aims and Objectives 
As discussed in the introduction (Chapter 1), imines need electron withdrawing groups on the 
nitrogen to activate them towards nucleophilic addition. This group also must be easily 
removed, once the nucleophile has been added to give the free amine. The most commonly 
used protecting group in the aryl addition to imines is the tosyl group. However, the conditions 
to remove a tosyl group (Li/NH3(liq), Na/naphthalene) are incompatible with many functional 
groups, limiting the scope of diarylmethylamines accessible by this chemistry. It was our aim 
therefore, to use an activating group that could be removed under much milder conditions. We 
aimed to develop a catalytic asymmetric 1,2-addition of methyl or aryl nucleophiles to these 
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arylaldimines. The group used to activate the imine must be convenient to install from 
commercially available materials, have a low molecular weight, and be removed from the 
amine product using mild conditions that would be compatible with sensitive functionality. The 
ideal reaction would use readily available nucleophiles, ligands, and catalyst precursors. Once 
an addition protocol has been developed, the aim is to prove its utility by investigating the 
UHDFWLRQ¶VVXEVWUDWHVFRSH 
 
3.4.2 Bis-Sulfamyl Imines 
In 1986 Davis et al. reported the synthesis of a new class of imines 3.85 from the condensation 
of aryl aldehydes and sulfamide (Scheme 77).[207] Grignard and organolithium reagents could 
be added to these imines to give sulfamides 3.86 and then the sulfamide linker cleaved to give 
two molecules of the beta-branched amine 3.87. The deprotection occurred under very mild 
conditions using 5% H2O-pyridine. 
 
Scheme 77 
From our perspective, however, this looked an attractive substrate for rhodium-catalysed aryl 
addition and no asymmetric additions to this substrate have been reported. Since this was 
reported relatively few groups have made use of this route to secondary amines.[208] Pansare et 
al. have used these imines as substrates for an intramolecular reductive cross-coupling with 
zinc (Scheme 78) to make vicinal diamines 3.89[209] and diketones 3.90.[210] 
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Scheme 78 
The condensation of benzaldehyde 2.83a and sulfamide following the procedure of Davis[207] 
gave the bis-sulfamyl imine 3.85a in good yield as a crystalline solid (Table 25), following this 
success a range of imines 3.85 were prepared. Unfortunately, some of the desired imines could 
not be isolated cleanly due to their insolubility. For example, in the condensation of 
ޤWULIOXRURPHWK\OEHQ]DOGHK\GHZLWKVXOIDPLGHDPL[WXUHRI mono- and bis-sulfamyl imines 
crashed out of the reaction mixture and then could not be separated by recrystallisation. 
Table 25 
 
Entry Ar1 Imine 3.85 [%] 
1 Ph 3.85a 66 
2 4-FC6H4 3.85b 77 
3 4-MeC6H4 3.85d 57 
4 2-MeC6H4 3.85e 45 
5 4-MeOC6H4 3.85f 71 
6 3-MeC6H4 3.85h 72 
7 4-BrC6H4 3.85i 43 
 
For comparison, methods for making N-tosyl imines 2.21 will be reviewed briefly. Nޤ7RV\O
imines 2.21 can be prepared from the amine and non-enolisable aldehydes using the titanium 
tetrachloride procedure of Jennings et al. (Scheme 79, Route A).[110,111] A milder Lewis acid 
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approach (Route B) was developed by Love et al. using tetraethyl orthosilicate.[211,212] Or also 
by use of an ion exchange resin and azeotropic removal of water as seen in Scheme 77.[213] 
Georg et al. described a two-step procedure via the reaction of NޤWULPHWK\OVLO\O LPLQH 3.91 
with tosyl chloride (Route C).[214] 
 
Scheme 79 
The Hudson reaction (Route D), forms N-tosyl imines 2.21 by treatment of oximes 3.92 with a 
sulfinyl chloride[215-217] or sulfinyl cyanide[218] to give an intermediate which undergoes a 
radical rearrangement (an analogous route to N-diphenylphosphoryl imines was described in 
Section 2.1). The Kresze reaction (Route E) proceeds by [2+2]-cycloaddition of an aldehyde 
with N-sulfinyl sulfonamides (prepared from a sulfonamide and thionyl chloride) to give an 
intermediate which eliminates sulphur dioxide to give the imine product.[70] 
Another route to N-tosyl imines is the preparation of a sulfinyl adduct 3.94 from the 
aldehyde, a sulfonamide and p-tolylsulfinic acid (Route F). This can then release the imine by 
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elimination on treatment with base often in situ during the addition reaction. This is 
particularly powerful for the synthesis of aliphatic imines.[219] Finally, oxidation of N-sulfinyl 
imines 3.95 with m-CPBA (Route G) is another route to N-tosyl imines.[220] 
 
3.4.3 Methyl Addition to Bis-Sulfamyl Imine 
 
Scheme 80 
Addition of an excess of methylmagnesium bromide to imine 3.85a gave 3.96 in a 1:1 ratio of 
the rac- and meso-diastereoisomers (Scheme 80). The diastereoisomers were distinguishable 
by 1H NMR spectroscopy; however, the diastereoisomers could not be separated on TLC or by 
crystallisation. The rac- and meso-diastereoisomers were synthesised separately to confirm the 
1H NMR assignment. 
 
3.4.3.1 Synthesis of Diastereoisomers 
 
Scheme 81 
The rac-diastereoisomer (R,R)-3.96 was synthesised from the commercial 
(RޤޤSKHQ\OHWK\ODPLQH (R)-2.1 and sulfuryl chloride (Scheme 81).[221] Synthesis of the 
mesoޤGLDVWHUHRLVRPHUUHTXLUHGDURXWHZKHUHLQWZRGLIIHUHQWDPLQHVFRXOGEHLQWURGXFHGLQD
controlled fashion. Borghese et al.[222] described a route to non-symmetrical sulfamides using 
an N-sulfamoyloxazolidinone intermediate such as (R)-3.98 (Scheme 82). This methodology 
was used to make meso-3.96 in good yield. Other routes to unsymmetrical sulfamides will be 
discussed in Section 4.5. 
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Scheme 82 
 
3.4.3.2 Asymmetric Methyl Addition 
 
Scheme 83 
Subjecting this imine 3.85a to the optimised rhodium-catalysed dimethylzinc addition (see 
Section 2.4.5) gave no desired product using either (R,R)-MeDuPHOS (R,R)-2.30 or Hayashi 
diene (R,R)-3.99[172] as the ligand (Scheme 83). With ligand (R,R,R)-3.99 only reduction of the 
imine was observed. The reactions were also run using the higher concentrations typical of 
+D\DVKL¶VSURWRFROV[172] but again with no success. It was therefore, decided to focus on aryl 
additions to give diarylmethylamine products. 
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3.4.4 Aryl Addition to Bis-Sulfamyl Imines 
 
Scheme 84 
Phenylmagnesium bromide addition to the 4-fluoro imine 3.85b also gave a 1:1 mixture of racޤ
and meso-diastereoisomers of addition product 3.100b (Scheme 84). Unlike the methyl 
addition products, the two diastereoisomers were indistinguishable by 1H NMR spectroscopy. 
In the 13C NMR spectrum, some diastereotopic peaks were seen and a clear doublet was 
present in the 19F NMR spectrum. Chiral HPLC showed three peaks in a ratio of 1:2:1, from 
the two enantiomers of the rac-diastereoisomer and the meso-diastereoisomer (Figure 1). 
 
Figure 1 
Mixtures of diastereoisomers of the addition product 3.100 were prepared by aryl Grignard 
reagent additions to the imines, these all occurred in good yield (Table 26). Addition product 
3.100c was made from (4-chlorophenyl)(phenyl)methanamine 3.40c and sulfuryl chloride 
(Scheme 85). Chiral HPLC conditions were then developed for all the addition products. 
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Table 26 
 
Entry Ar1 Ar2 Sulfamide 3.100 [%] 
1 Ph Ph 3.100a 78 
2 4-FC6H4 Ph 3.100b 62 
3 Ph 4-MeC6H4 3.100d 76 
4 2-MeC6H4 Ph 3.100e 69 
5 4-MeOC6H4 Ph 3.100f 65 
6 Ph 4-CO2EtC6H4 3.100g 43 
7 3-MeC6H4 Ph 3.100h 67 
8 4-BrC6H4 Ph 3.100i 86 
9 4-FC6H4 4-MeC6H4 3.100j 74 
 
 
Scheme 85 
 
3.4.4.1 Addition of Aryl Boron Nucleophiles 
$ UDQJH RI FRQGLWLRQV IRU DGGLQJ DU\O ERURQ QXFOHRSKLOHV ZHUH WHVWHG ZLWK +D\DVKL¶V
conditions for adding phenyl boroxine being by far the most successful (Entry 5, Table 27). 
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Table 27 
 
Entry Boron species Conditions 3.100 [%][a] 
1 4-MePhB(OH)2 3.25d (2.6 eq) 
[RhCl(C2H4)2]2 (3 mol/%), (S,S,S)-2.42 (14 mol/%), 
acetone, 40 °C, 4 h[178] 0 
2 4-MePhB(OH)2 3.25d (4 eq) 
[RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 
mol/%), Et3N (4 eq), toluene, 55 °C, 5 h[175] trace 
3 4-MePhB(OH)2 3.25d (4 eq) 
[RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 
mol/%), CsF (4 eq), toluene, 55 °C, 5 h 0 
4 [PhBF3]K 3.101 (4 eq) 
[RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 
mol/%), toluene, 55 °C 0 
5 (PhBO)3 3.28a (2.4 eq) 
[RhCl(C2H4)2]2 (1.5 mol/%), (R,R,R)-3.99 (3.3 
mol/%), KOH(aq) (40 mol/%), dioxane, 60 °C, 3 h[172] 93/77
[b]
 
[a] Conversion from crude 1H NMR spectrum; [b] Isolated yield. 
Phenyl boroxine 3.28a (see Section 3.2.6) was made from phenyl boronic acid by azeotropic 
UHPRYDO RI ZDWHU +D\DVKL¶V GLHQH OLJDQG (R,R,R)-3.99 was made from (R)-D-phelladrene 
(Rޤ via a cycloaddition with naphthalen-2-yl propiolate 3.103 (Scheme 86).[172] This is a 
much more convenient synthesis than some of the other diene ligands, see Section 3.2.7. 
 
Scheme 86 
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3.4.4.2 Optimisation of Aryl Addition 
This reaction was repeated with a substituted aryl boroxine so the enantioselectivity of the 
reaction could be studied. Addition of 4-chlorophenyl boroxine 3.28c under the same 
conditions gave the mono-addition product A (see below) as the major product. A range of 
partial addition and hydrolysis products were seen in the crude 1H NMR spectrum. A screen of 
conditions was carried out using potassium hydroxide and caesium fluoride as base, with 
varying amounts of water and boron species (Table 28). All reactions were run for 3 h in 
dioxane and the conversions were determined from the crude 1H NMR spectra. However, at 
60 °C at most 15% conversion to bis-addition (R,R)-3.100c was seen (Entry 2) but with 63% of 
mono-addition A this was an encouraging result. 
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Table 28[a] 
 
Entry Boron Species Base (R,R)-3.100c[b] A[b] B[b] C[b] 3.85a[b] D[b] 
1 3.25c KOH(aq) 6 57 15 14 1 8 
2 3.28c KOH(aq) 15 63 12 8 0 1 
3 3.28c KOH(aq)[c] 0 0 0 36 0 64 
4 3.28c KOH[d] 0 11 0 24 48 17 
5 3.28c H2O[e] 0 54 0 12 26 8 
6 3.28c CsF[d] 0 42 0 14 39 5 
7 3.28c CsF(aq) 1 52 9 7 13 17 
[a] Reactions were carried out using imine 3.85a (0.25 mmol), (4-ClC6H4BO)3 3.28c (0.6 mmol) or 4-ClC6H4B(OH)2 
3.25c (1.8 mmol), [RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 mol/%), base (40 mol/%) and (Entries 1, 2 and 7) H2O 
(1.8 mmol) in dioxane (1.6 mL) at 60 °C for 3 h; [b] from crude 1H NMR spectrum; [c] 3.1 M KOH(aq), 161 µL, 1 eq; 
[d] no water added; [e] 3.6 eq, 1.8 mmol H2O. 
 
Some of these conditions (Entries 1, 2, 5-7, Table 28) were then run at 80 °C (Table 29) in an 
aim to increase the rate of aryl addition. Interestingly the aryl boroxine 3.28c performs much 
better than the aryl boronic acid 3.25c (Entry 2 vs. 1). As under the reaction conditions the aryl 
boroxine and water are in equilibrium with the aryl boronic acid this difference seems strange. 
It may be that using the aryl boroxine and adding water allows the amount of water to be more 
closely controlled then using the boronic acid.[223] Another noteworthy point is that adding the 
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aqueous base by syringe pump improved the conversion (Entry 3 vs. 2). Caesium fluoride was 
found to be as good as potassium hydroxide as the base (Entry 3 vs. 6). 
Table 29[a] 
Entry Boron Species Base 
(R,R)-
3.100c[b] A
[b]
 B[b] 3.85a[b] C[b] D[b] dr[c] ee [%][c] 
1 3.25c KOH(aq) 12 47 13 3 22 0 - - 
2 3.28c KOH(aq) 66 19 13 0 0 3 94:6 
>99 
(R,R)[d] 
3 3.28c KOH(aq)[e] 81 14 4 0 0 2 93:7 
>99 
(R,R)[d] 
4 3.28c H2O[f] 35 38 24 0 0 3 - - 
5 3.28c CsF[g] 4 61 0 28 6 0 - - 
6 3.28c CsF(aq) 81 9 10 0 0 0 - - 
[a] Reactions were carried out using imine 3.85a (0.25 mmol), (4-ClC6H4BO)3 3.28c (0.6 mmol) or 4-ClC6H4B(OH)2 
3.25c (1.8 mmol), [RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 mol/%), base (40 mol/%) and (Entries 1-3, 6) H2O (1.8 
mmol) in dioxane (1.6 mL) at 80 °C for 3 h; [b] from crude 1H NMR spectrum; [c] determined by HPLC using 
Chiralcel OD-H and Chiralcel OD columns in series, 90:10 hexanes:iPrOH; [d] stereochemistry determined by 
deprotecting and comparing the optical rotation with literature values; [e] added via syringe pump; [f] 3.6 eq, 1.8 mmol 
water; [g] no water added. 
The best of these conditions were run at 100 °C (Table 30). The optimum conditions were 
found to using aqueous KOH (40 mol/%) as the base (Entry 2). At 100 °C this gave a 
conversion of 91% of the bis-addition product (R,R)-3.100c; this reaction also gave the best 
diastereomeric ratio. 
Table 30[a] 
Entry Boron Species Base 
(R,R)-
3.100c[b] A
[b]
 B[b] 3.85a[b] C[b] D[b] dr[c] ee [%][c] 
1 3.25c KOH(aq) 16 32 32 2 15 3 - - 
2 3.28c KOH(aq) 91 0 9 0 0 0 95:5 
>99 
(R,R)[d] 
3 3.28c CsF(aq) 82 3 15 0 0 0 92:8 
>99 
(R,R)[d] 
[a] Reactions were carried out using imine 3.85a (0.25 mmol), (4-ClC6H4BO)3 3.28c (0.6 mmol) or 4-ClC6H4B(OH)2 
3.25c (1.8 mmol), [RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 mol/%), base (40 mol/%) and (Entries 1, 2, 5-7, 10 and 
11) H2O (1.8 mmol) in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H NMR spectrum; [c] determined by HPLC 
using Chiralcel OD-H and Chiralcel OD columns in series, 90:10 hexanes:iPrOH; [d] stereochemistry determined by 
deprotecting and comparing the optical rotation with literature values. 
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Next the amount of aryl boroxine 3.28c required was investigated; so far each reaction had 
been run with 1.2 equivalents of aryl boroxine (3.6 equivalents ³$U-%´ ZLWK UHVSHFW WR WKH
imine functional group and it was hoped that this could be reduced. However, as Table 31 
shows as the equivalents of aryl boroxine 3.28c are reduced the amount of hydrolysis products 
increases, even when the amount of base is reduced in keeping with the equivalents of 
boroxine. 
Table 31[a] 
Entry 3.28c [Eq] (R,R)-3.100c[b] A[b] B[b] 3.85a[b] C[b] D[b] 
1 1.2 81 3 16 0 0 0 
2 0.8 78 3 19 0 0 0 
3 0.8[c] 78 8 12 0 1 0 
4 0.4 37 8 15 1 18 21 
5 0.4[c] 24 62 12 0 3 0 
6 0.3 0 0 0 4 53 43 
7 0.3[c] 16 70 7 0 5 2 
[a] Reactions were carried out using imine 3.85a (0.25 mmol), (4-ClC6H4BO)3 3.28c, [RhCl(C2H4)2]2 (3 mol/%), 
(R,R,R)-3.99 (6.6 mol/%), 3.1 M KOH(aq) (40 mol/%) in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H NMR 
spectrum; [c] KOH(aq) scaled down pro rata from 0.1 mmol to 0.066, 0.083 or 0.028 mmol respectively. 
 
So far, only aryl boroxine and aryl boronic acid nucleophiles had been added. It was decided to 
look at what other boron species could be used with the aim of reducing the number of 
equivalents used. 
 
Scheme 87 
Hayashi had successfully used the lithium aryl boronate 3.105 in his 1,4-addition to 
ĮޤȕޤXQVDWXUDWHG HVWHUV[224] The boronate was prepared by lithiation of bromobenzene and 
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trapping with trimethoxyborane, addition of this to imine 3.85 (Scheme 87) proceeded in 
equivalent yield to the addition of phenyl boroxine (Entry 5, Table 27). 
This result and the need for water to be present suggests that quaternarisation of the 
boron is required for the reaction to proceed. The nucleophilicity of the organic group can be 
increased by coordination of a negatively charged base to the boron atom.[28] Therefore, various 
boronate species were trailed in the reaction. 
Sodium trihydroxyborates can be isolated are free flowing powders and then 
subsequently used in cross-coupling reactions.[225] Sodium trihydroxyphenylborate was 
preformed[226] and added to the reaction; this gave an encouraging yield of the mono-addition 
product (Entry 1, Table 32). With phenyl potassium trifluoroborate 3.101, no addition product 
was observed (Entry 3). Sodium tetraphenyl borate gave a moderate yield of the mono-addition 
product A (QWU\KRZHYHULWGRHVQRWKHOSUHGXFHWKHQXPEHURI³$U-%´HTXLYDOHQWVLQXVH
The triol boronate species 3.106 was investigated, but lead to only hydrolysis of the imine 
rather than addition (Entry 5). The pinacol boronic ester 3.107 and self-activating boronic ester 
3.108[227] also gave no addition products with or without base (Entries 6-9). 
 
Table 32[a] 
 
Entry Boron Species Additive 3.100a[b] A[b] B[b] 3.85 C[b] D[b] 
1 [PhB(OH)3Na] 3.109a  19 70 5 0 6 1 
2 PhB(OH)2 H3BO3 21 44 19 1 16 0 
3 3.101 (60 °C)  0 0 0 69 28 2 
4 3.29  26 55 0 0 1 18 
5 3.106  0 0 0 5 45 50 
6 3.107  0 0 0 100 0 0 
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7 3.107 KOH(aq) 0 0 0 1 9 90 
8 3.108  0 0 0 58 42 0 
9 3.108 KOH(aq) 0 0 0 4 26 70 
[a] Reactions were carried out using imine 3.85a (0.25 mmol), Boron Species (0.6 mmol, except entry 1: 1.8 mmol), 
[RhCl(C2H4)2]2 (3 mol/%), (R,R,R)-3.99 (6.6 mol/%), (Entry 7 and 9) 3.1 M KOH(aq) (40 mol/%) in dioxane (1.6 mL) 
at 100 °C (except entry 3) for 3 h; [b] from crude 1H NMR spectrum, addition and hydrolysis products shown in Table 
28 however, unsubstituted in this case. 
 
3.4.4.3 Mechanism and Stereochemistry 
 
Scheme 88 
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The accepted mechanism for the rhodium catalysed boronic acid/boroxine addition is shown in 
Scheme 88.[31] The ethylene ligands of the precursor 3.59 are displaced by the chiral diene 
ligand; typically these two components are stirred together before the addition of the substrates 
to ensure complete ligand exchange to species 3.110. Transmetallation of 3.110 with the aryl 
boronic acid is very slow, it is thought that rhodium hydroxide species 3.111 is formed and 
then fast transmetallation occurs to give aryl rhodium complex 3.112.[31] The imine 3.85 then 
coordinates (b) and then (c) the imine inserts into the rhodium-carbon bond, in an 
enantioselective manner when chiral ligands are present.[228] The rhodium amide 3.114 is then 
hydrolysed (d) to regenerate the active hydroxo-rhodium complex 3.111. The rhodium 
hydroxide and aryl rhodium complexes with (S)-BINAP (S)-1.34 as the ligand have been 
observed by 31P NMR spectroscopy in the rhodium catalysed 1,4-addition of boronic acids to 
enones.[36] A possible side reaction is the hydrolytic protodeboronation of the aryl boron 
reagent, i.e. hydrolysis of the aryl-rhodium complex 3.112, to give the catalytic species 3.111 
and aromatic 3.116 (Scheme 88), before it reacts with the imine. Increasing the equivalents of 
boron nucleophile is a common way of getting around this. It is thought that the 
WUDQVPHWDOODWLRQRFFXUVWKRXJKȕޤHOLPLQDWLRQIURPWKHLQWHUPHGLDWHVKRZQLQScheme 89.[229] 
 
Scheme 89 
7KHDEVROXWHVWHUHRFKHPLVWU\RIWKHSURGXFWLVFRQVLVWHQWZLWK+D\DVKL¶VRZQUHVXOWVXVLQJWKLV
ligand.[172] The aryl-rhodium bond will form trans to the double bond bearing the 
HOHFWURQޤZLWKGUDZLQJ HVWHU JURXS 7KH LPLQH ZLOO FRRUGLQDWH LQ WKH UHPDLQLQJ IUHH VLWH WKH
siޤIDFHRI WKH LPLQH LVSUHIHUUHG WRDYRLGD VWHULFFODVKEHWZHHQ WKHHVWHU VXEVWLWXHQWDQG WKH
sulfamide group (Scheme 90). 
 
Scheme 90 
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3.4.4.4 Synthesis of Meso-Diastereoisomer 
 
Scheme 91 
It was decided to synthesise the meso-diastereoisomer of the 4-fluorophenyl addition product 
meso-3.100b (Scheme 91) so the peaks seen by HPLC and the diastereotopic peaks in the 19F 
NMR spectrum could be assigned. To make this compound both enantiomers of 
ޤIOXRURSKHQ\OSKHQ\OPHWKDQDPLQH 3.40b were required. Firstly resolution of racemic 
ޤIOXRURSKHQ\OSKHQ\OPHWKDQDPLQHZLWKWDUWDULFDFLGZDVDWWHPSWHGWKLVZDVQRWDNQRZQ
resolution but the method had been reported with (4-chlorophenyl)(phenyl)methanamine.[230] 
The racemic amine was made from 4-fluorobenzaldehyde 2.83b using a Grignard reagent 
addition, oxidation and reductive amination (Scheme 92). 
 
Scheme 92 
Unfortunately, attempted resolution using (±)-tartaric acid gave an enantiomeric excess of only 
55% (determined by chiral HPLC on the acetamide). So a new approach was employed using 
the asymmetric rhodium-catalysed aryl addition and subsequent deprotection to make both 
enantiomers from the appropriately substituted starting materials (Table 33). 
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Table 33 
 
Entry Ar1 Ar2 3.100b [%] dr[a] ee [%][a] 3.40b [%] ee [%][b] 
1 Ph 4-FC6H4 46 96:4 >99 (R,R) 85 90 (R) 
2 4-FC6H4 Ph 75 94:6 86 (S,S) 86 86 (S) 
[a] Determined by HPLC using Chiralcel OD-H and Chiralcel OD columns in series, 90:10 hexanes:iPrOH; [b] 
determined on the acetamide by HPLC using Chiralcel OD, 90:10 hexanes:iPrOH. 
 
As both enantiomers have been synthesised the meso peak on the HPLC can be identified by 
elimination. Nevertheless, for completeness the meso-diastereoisomer was made using the 
route discussed in Section 3.6.2. Firstly, the route was trialled using aminodiphenylmethane 
3.40a and then the enantiomers prepared above were used to make meso-3.100b (Scheme 93). 
The resulting HPLC traces of the rac: meso mixtures, both rac-enantiomers and the 
mesoޤGLDVWHUHRLVRPHUDUHVKRZQEHORZ)LJXUHV-5). 
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Scheme 93 
 
Figure 2: HPLC trace of 1:1 rac: meso-3.100b 
 
Figure 3: HPLC trace of (R,R)-3.100b 
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Figure 4: HPLC trace of (S,S)-3.100b 
 
Figure 5: HPLC trace of meso-3.100b 
 
3.4.5 Deprotection of Addition Products 
 
Scheme 94 
The addition products were then deprotected to the amines under the mild conditions stated in 
the paper of Davis via the hydrogen sulfate salt 3.120.[207] The diphenyl compound gave a 
higher yield than the methyl addition product (Scheme 94). 
To understand the mechanism of the hydrolysis other conditions were investigated. 
Davis[207] also reported that attempted hydrolysis of the methyl addition product 3.96 with 
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conc. HCl gave 1,3-diphenyl-1-butene 3.121 (Scheme 95). This sulfamide was also found to be 
unreactive to LiAlH4 and 30% NaOH.[207] 
 
Scheme 95 
Table 34 
 
Entry Conditions Result 
1 H2O, 100 °C, 18 h Recovered starting material 
2 2 M HCl(aq), 100 °C, 18 h Recovered starting material 
3 5% H2O-MeCN, 82 °C, 18 h Recovered starting material 
4 DMAP (5 mol/%), 5% H2O-MeCN, 82 °C, 18 h Recovered starting material 
 
Sulfamide 3.100 gave no hydrolysis product after reflux in water or dilute aqueous acid 
(Entries 1 and 2, Table 34). However, this may have been due to its insolubility in these 
systems. Therefore, hydrolysis was attempted in aqueous acetonitrile (Entry 3) and in the 
presence of DMAP (Entry 4) but still, no hydrolysis product was observed. 
 
Scheme 96 
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Scheme 97 
It was found that when both nitrogen atoms were substituted with methyl groups 3.122 that 
deprotection no longer occurred under the aqueous pyridine conditions and only starting 
material was recovered (Scheme 96). Similarly Davis found that when 3.96 was doubly 
NޤEHQ]\ODWHGK\GURO\VLVQRORQJHURFFXUUHGZLWKDTXHRXVS\ULGLQHKRZHYHU1D-naphthalene 
conditions were successful.[207] So the presence of the free NH was crucial to the hydrolysis 
mechanism. Interestingly, in the case of unsymmetrical sulfamide 3.123 (synthesised as shown 
in Scheme 97) with only one free NH present deprotection still occurred in 73% yield. 
 
Scheme 98 
Davis postulates a route involving pyridine induced hydrolysis to intermediate 3.125[231] which 
can be attacked by water to give sulfamic acid 3.126 (Scheme 98). Sulfamic acids 3.126 are 
known to hydrolyse to hydrogen sulfate salts 3.120.[232] N-Sulfonylamine 3.125 has been 
implicated in the mechanism of the reaction of sulfamoyl chlorides with anilines.[233-235] 
Spillane has hypothesised a hydrolysis via transition state 3.127.[232] 
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Scheme 99 
The free amine must be derivatised as the acetamide before the enantiomeric excess can be 
measured by chiral HPLC. Pyridine acts as a catalyst for acylations so it is possible to make the 
acetamide in one pot without isolating the free amine 3.40 (Scheme 99). 
 
3.4.6 Scope 
With optimised aryl addition conditions and a mild deprotection in hand, the scope of the 
reaction was investigated. 
Table 35[a] 
 
Entry Ar1 Ar2 Conversion [%][b] Yield [%] dr[c] ee [%][c] 
1 Ph 4-FC6H4 85 
69 
(R,R)-3.100b 97:3 
>99 
(R,R) 
2 Ph 4-ClC6H4 77 
61 
(R,R)-3.100c 94:6 
>99 
(R,R)[d] 
3 Ph 4-MeC6H4 81 
58 
(R,R)-3.100d 93:7 
>99 
(R,R) 
4 Ph 2-MeC6H4 77 
71 
(R,R)-3.100e >99:1 
90 
(R,R) 
5 Ph 4-MeOC6H4 92 
72 
(R,R)-3.100f 92:8 
>99 
(R,R) 
6 Ph 4-CO2EtC6H4 51 
37 
(R,R)-3.100g 97:3
[e]
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(R,R)[e] 
7 4-FC6H4 Ph 100 
73 
(S,S)-3.100b 92:8 
>99 
(S,S) 
8 4-MeC6H4 Ph 83 
73 
(S,S)-3.100d 92:8 
>99 
(S,S) 
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9 2-MeC6H4 Ph 79 
69 
(S,S)-3.100e 96:4 
98 
(S,S) 
10 4-MeOC6H4 Ph 90 
69 
(S,S)-3.100f 95:5 
>99 
(S,S) 
11 3-MeC6H4 Ph 89 
75 
(S,S)-3.100h 92:8 
>99 
(S,S) 
12 4-BrC6H4 Ph 75 
62 
(S,S)-3.100i 91:9 
>99 
(S,S)[d] 
13 4-FC6H4 4-MeC6H4 100 
76 
(S,S)-3.100j 91:9 
98 
(S,S) 
[a] Reactions were carried out using imine 3.85 (0.25 mmol), boroxine 3.28 (0.6 mmol), [RhCl(C2H4)2]2 (3 mol/%), 
(R,R,R)-3.99 (6.6 mol/%), 3.1 M KOH(aq) (40 mol/%) in dioxane (1.6 mL) at 100 °C for 3 h; [b] From crude 1H NMR 
spectrum; [c] determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] stereochemistry determined 
by deprotecting and comparing the optical rotation with literature values, other cases were assigned by analogy; [e] 
calculated from ee of derived acetate 3.128g, a chiral HPLC method has yet to be found for 3.100g. 
 
Firstly, the unsubstituted imine 3.85a was reacted with a range of aryl boroxines both 
HOHFWURQޤZLWKGUDZLQJJURXSV(QWULHVDQGTable 35) and electron-donating groups (Entry 
5) were tolerated. The yield for the boroxine bearing a para-ester group (Entry 6) was 
disappointing; it is possible that some hydrolysis occurred under the reaction conditions. The 
enantiomeric excess is excellent in most cases with the presumably the ortho substituent 
lowering the result to 90% in Entry 4 (although this case has the best diastereomeric ratio). 
The substitution on the imine was investigated; again, electron-withdrawing groups 
(Entry 7) and electron-donating groups (Entry 10) are well tolerated. Ortho-substitution on the 
imine (Entry 9) has a smaller impact on the enantiomeric excess than on the boroxine. 
It was hoped that recrystallisation would allow the rac:meso ratio to be improved 
upon. However, when the 4-fluoro addition product (S,S)-3.100b was recrystallised (both from 
hot ethanol and by liquid-liquid diffusion of CH2Cl2/hexanes) the diastereomeric ratio of the 
crystalline solid remained the same or become worse. The filtrate became enriched with the 
rac-diastereoisomer but this was less the 10% of the material. 
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Table 36 
 
Entry Ar1 Ar2 3.40 [%] Amine ee [%][a] 
1 Ph 4-FC6H4 80 (R)-3.40b 94 (R) 
2 Ph 4-ClC6H4 93 (R)-3.40c 87 (R)[b] 
3 Ph 4-MeC6H4 72 (R)-3.40d 92 (R) 
4 Ph 2-MeC6H4 53 (R)-3.40e 97 (R) 
5 Ph 4-MeOC6H4 95 (R)-3.40f 86 (R) 
6 Ph 4-CO2EtC6H4 31  (R)-3.40g 91 (R) 
7 4-FC6H4 Ph 79  (S)-3.40b 82/91[c] (S) 
8 4-MeC6H4 Ph 60  (S)-3.40d 92 (S) 
9 2-MeC6H4 Ph 32  (S)-3.40e 96 (S) 
10 4-MeOC6H4 Ph 85  (S)-3.40f 94 (S) 
11 3-MeC6H4 Ph 73  (S)-3.40h 86 (S) 
12 4-BrC6H4 Ph 61  (S)-3.40i 95 (S)[b] 
13 4-FC6H4 4-MeC6H4 99  (S)-3.40j 92 (S) 
[a] Measured on acetamide by chiral HPLC (see Experimental for conditions); [b] stereochemistry determined by 
comparison of the optical rotation with literature values, other cases were assigned by analogy; [c] after 
recrystallisation of HCl salt from water. 
 
The chiral diarylmethylamines 3.40 were isolated in good enantiomeric excess, 
reflecting the diastereomeric ratio of the aryl addition. The yields were good in most cases with 
orthoޤVXEVWLWXWLRQ DJDLQ DSSHDULQJ WR EH GHWULPHQWDO (QWULHV  DQG  Table 36) and an 
isolation issue lowered the yield of the ester substituted amine (Entry 6). The enantiomeric 
excess of a free amine has been improved, by recrystallisation of the HCl salt from water, from 
82% to 91% (Entry 7). It has been confirmed that no epimerisation occurs during the 
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deprotection by subjecting a free amine of known enantiomeric excess to the hydrolysis 
conditions. 
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Chapter 4 
4.1 Aims and Objectives 
The diastereoselectivity and subsequent inseparable diastereoisomers of the current rhodium 
catalysed aryl addition reaction, to bis-sulfamyl imines as described in Chapter 3, are its main 
limitations, as after deprotection the enantiomeric excess is lowered. The mildness of the 
deprotection makes this chemistry very attractive, so it was proposed that a mono-imine of the 
type 4.1 (Scheme 100FRXOGEHDXVHIXOVXEVWUDWHZKHUH³5´LVDORZPROHFXODUZHLJKWDON\O
group. After asymmetric addition of the aryl boronic acid the resulting unsymmetrical 
sulfamide 4.2 could be deprotected using the same mild conditions to give the enantioenriched 
amine 3.40 and a low molecular weight amine 4.3 that can easily be separated. 
 
Scheme 100 
It is thought that the presence of the NH in the protecting group is key to the ease of 
deprotection. When Davis alkylated this position the amine could no longer be deprotected.[207] 
From our own experience the bis-methylated sulfamide 3.122 could not be deprotected under 
these conditions (see Section 3.8). Feringa et al.[178] have used an N,N¶-dimethylsulfamoyl 
activating group for the imine substrate undergoing aryl boronic acid addition. However, the 
deprotection of resulting amine 3.48, although milder than tosyl deprotection did require 
prolonged heating in a microwave (see Section 3.2.6.1). 
This type of imine is unprecedented in the existing literature, however, it was 
envisaged that these imines could be made from the condensation of an aryl aldehyde 2.83 with 
the appropriate mono-substituted sulfamide 4.4 (Scheme 101). We decided on a small set of R 
groups ranging from methyl to phenylethyl (Scheme 101), to investigate whether the steric 
bulk of the protecting group would influence the yield of the aryl addition or enantioselectivity 
and with the two enantiomers of phenylethyl whether there was a favoured enantiomer. The 
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sulfamides 4.4 would need to be synthesised on a large scale from readily available starting 
materials. 
 
Scheme 101 
 
4.1.1 Sulfamide Synthesis 
Primary sulfamides 4.4 can be prepared from the appropriate N-sulfamoyl chloride 4.5 and 
ammonia.[236,237] Few N-sulfamoyl chlorides 4.5 are commercially available. They can be made 
by a number of routes (Scheme 102), firstly by refluxing the hydrogen chloride salt of an 
amine 4.6 with excess sulfuryl chloride. However, this approach can be low yielding and is 
limited in amine scope.[238,239] 
 
Scheme 102 
Secondly, N-sulfamoyl chlorides 4.5 can be prepared from an alkyl isocyanate 4.7 using the 
hazardous and corrosive materials of fuming sulfuric acid and phosphorus pentachloride.[240] 
Finally, addition of an alcohol to chlorosulfonyl isocyanate 3.97 (CSI) followed by elimination 
of carbon dioxide also gives the N-sulfamoyl chloride 4.5.[241,242] Alternatively the 
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unsubstituted sulfamoyl chloride 4.8 can be synthesised from CSI 3.97 and formic acid and 
reacted immediately with an amine to give the primary sulfamide 4.4 (Scheme 103).[242] 
 
Scheme 103 
Another method for non-volatile amines is the transamination of sulfamide. This method was 
used to prepare N-benzylsulfamide 4.4f by displacement of sulfamide 3.84 with benzylamine 
4.3f (Scheme 104).[243] However, it was desirable to use a smaller alkyl group to keep the 
molecular weight of the activating group low. Therefore, as amines of a higher volatility than 
benzylamine needed to be used, another method for the synthesis of N-alkylsulfamides from 
chlorosulfonyl isocyanate was employed. 
 
Scheme 104 
Chlorosulfonyl isocyanate 3.97 is prepared from cyanogen chloride and sulfur trioxide.[244] It is 
a powerful bielectrophile, but it is possible to react the isocyanate and the chlorosulfonic acid 
sequentially. Reacting chlorosulfonyl isocyanate sequentially with tert-butanol and a primary 
amine gives N-Boc-protected sulfamide 4.10 (Scheme 105).[245,246] Standard Boc-deprotection 
then gives the desired primary sulfamide 4.4. 
 
Scheme 105 
Masui et al.[247] adapted this approach for use with aqueous solutions of primary amines. As 
methylamine and ethylamine are typically available as their aqueous solutions, this is very 
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useful. CSI 3.97 is sequentially reacted with tert-butanol and pyridine to give a Burgess-type 
intermediate 4.11 (Scheme 106). This is reacted in situ with aqueous methylamine to give the 
Nޤ%RF-protected sulfamide 4.10a, which can be deprotected as before. 
ޤ'LPHWK\ODPLQRS\ULGLQHKDVDOVREHHQXVHGWRPDNHD%XUJHVV-type intermediate 4.12 which 
was stable enough to be isolated.[248] 
 
Scheme 106 
This type of intermediate was first reported in 1968 by the group of Burgess (Scheme 107).[249] 
Burgess salts have been employed as a dehydration agents to convert secondary or tertiary 
alcohols to alkenes[250] or amides to nitriles.[251] Another use of Burgess salts is the preparation 
of carbamates from alcohols[252] or in the synthesis of unsymmetrical sulfamides from 
aminoalcohols or amines[253,254] and the synthesis of sulfamidates from diols.[254] 
 
Scheme 107 
Using these two sets of conditions the N-Boc protected sulfamides 4.10 required were 
synthesised (Table 37). The Burgess intermediate route (method A) worked well for the 
smaller, more nucleophilic amines (Entries 1 and 2) and was carried out on a 0.1 mol scale in 
the case of 4.4a, however an excess of the amine is required. Therefore, for more elaborate 
amines such as enantiopure 1-phenylethylamine, method B was preferred (Entries 9 and 10). 
Subsequent deprotection with trifluoroacetic acid gave the sulfamides 4.4 in good yield. 
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Table 37 
 
Entry R  Conditions 4.10 [%] 
N-Boc-
Sulfamide 
4.4 
[%] Sulfamide 
1 Me a A 82 4.10a 83 4.4a 
2 Et b A 94 4.10b 9  4.4b 
3 Et b B 98 4.10b - - 
4 iPr c A 63 4.10c 70 4.4c 
5 tBu d A 89 4.10d 95 4.4d 
6 Ph e A 80 4.10e 79 4.4e 
7 Ph e B 78 4.10e - - 
8 Bn g B 59 4.10f 64 4.4f 
9 
 
g B 55 (R)-4.10g 80 (R)-4.4g 
10 
 
g B 58 (S)-4.10g 73 (S)-4.4g 
 
4.1.2 Sulfamyl Imine Synthesis 
Condensation of N-benzylsulfamide 4.4f with benzaldehyde using the standard bis-
sulfamyl imine formation conditions (see Section 3.5) gave only a 26% yield (Entry 1, Table 
38). However, after a small screen of conditions it was found that employing Ti(OEt)4 as a 
Lewis acid in THF gave a good yield (Entry 4). 
  
 101 
Table 38 
 
Entry Conditions Yield 4.1fa [%] 
1 Amberlyst 15®, benzene, reflux, Dean-Stark 26 
2 MgSO4, PPTS, CH2Cl2, rt trace 
3 CuSO4, CH2Cl2, rt trace 
4 Ti(OEt)4, THF, reflux 65 
 
Therefore, the N-alkylsulfamides 4.4 in hand were condensed with benzaldehyde to give 
sulfamyl imines 4.1 in pleasing yields (Table 39). The N-methyl sulfamyl imine 4.1aa was the 
most attractive substrate for aryl additions at this stage due to its high yielding synthesis, 
crystallinity and lowest molecular weight. 
 
Table 39 
 
Entry R 
 
Yield [%] Product[a] 
1 Me a 86 4.1aa 
2 Et b 86 4.1ba 
3 iPr c 90 4.1ca 
4 tBu d 75 4.1da 
5 Ph e 85 4.1ea 
6 Bn f 65 4.1fa 
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7 
 
g 89 (R)-4.1ga 
8 
 
g 83 (S)-4.1ga 
[a] Compound labels: first letter refers to R substituent, second letter refers to aryl group from aldehyde. 
 
4.1.3 Synthesis of Racemates and Deprotection 
It was decided to use 4-chlorobenzene boronic acid as the test substrate for the aryl addition. 
Therefore, it was necessary to synthesise the racemates of the 4-chlorophenyl addition 
products. Lithium-halogen exchange of 4-bromochlorobenzene with n-butyllithium and 
addition of the resulting aryllithium species to the imine 4.1 gave the racemic sulfamides 4.2 in 
good yield (Table 40). 
Table 40 
 
Entry R 
 
Yield [%] Addition Product[a] 
1 Me a 98 (±)-4.2aab 
2 Et b 74 (±)-4.2bab 
3 iPr c 86 (±)-4.2cab 
4 tBu d 93 (±)-4.2dab 
5 Ph e 96 (±)-4.2eab 
6 Bn f 100 (±)-4.2fab 
7 
 
g 36 (R,±)-4.2gab 
8 
 
g 88 (S,±)-4.2gab 
[a] Compound labels: first letter refers to R substituent, second letter refers to aryl group from imine, third refers to 
aryl group from aryllithium. 
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The principal reason for the development of these monoalkyl sulfamide addition products was 
that they would undergo deprotection to the free diarylmethylamines 3.40 under mild 
conditions, with good recovery and ideally no chromatography. Hence, the racemic addition 
products 4.2 were subjected to the aqueous pyridine deprotection protocol (see Section 3.4.5) 
and pleasingly each case gave amine 3.40c in usable yield (Table 41). It was found that when R 
was a small alkyl group, the diarylmethylamine 3.40c was isolated cleanly after the aqueous 
work-up (Entries 1-4). As would be expected deprotection of 4.2eab, 4.2fab, (R)-4.2gab and 
(S)-4.2gab required purification by column chromatography to remove the unwanted amine 
component (Entries 5-8). Therefore, a small alkyl group was the preferred R group and 
NޤPHWK\OVXOIDP\OLPLQH4.1aa was chosen as the substrate for aryl addition optimisation. 
Table 41 
 
Entry R (±)-3.40c [%] 
1 Me 77 
2 Et 84 
3 iPr 87 
4 tBu 79 
5 Ph 78[a] 
6 Bn 83[a] 
7 
 
59[a] 
8 
 
72[a] 
[a] After column chromatography. 
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4.2 Optimisation of Aryl Addition to N-Methyl-
N
ޤ>DU\OPHWK\OLGHQH@VXOIDPLGH 
The addition of phenyl boroxine 3.28a to the methyl protected imine 4.1aa using the previous 
optimal conditions (see Section 3.4.4.2) gave the addition product in 84% conversion (Entry 1, 
Table 42). However, when the more electron deficient 4-chlorophenyl boroxine 3.28c was used 
the conversion dropped to 32% (Entry 2). 
Table 42[a] 
 
Entry Ar2 4.2 [%][b] Addition Product 
1 Ph 84 4.2aaa 
2 4-ClC6H4 32 4.2aac 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), (Ar2BO)3 3.28c (0.6 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R,R)-3.99 (3.3 mol/%), base in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H NMR spectrum. 
 
The main by-product observed was benzaldehyde 2.83a from hydrolysis of the starting 
material. Running the aryl boroxine addition reaction with no aqueous base (Entry 1, Table 43) 
gave no addition product at all. Using only water or more equivalents of aqueous potassium 
hydroxide with the aryl boroxine 3.28c did not improve the conversion to addition product 
(Entries 2 and 4). 4-Chlorophenyl boronic acid 3.25c alone with no aqueous base also gave no 
addition product (Entry 5). Addition of boronic acid 3.25c with 20 mol/% aqueous potassium 
hydroxide gave a conversion similar to that using 4-chlorophenyl boroxine 3.28c (Entry 6 vs. 
3). Use of aqueous caesium fluoride instead of aqueous potassium hydroxide gave a conversion 
of 22% with less hydrolysis (Entry 7). The conversion was lower if no water was present 
(Entry 8). Sodium trihydroxyborate 3.109c achieved the highest conversion so far when 3.6 
equivalents were employed (Entry 9), however, (4-chlorophenyl)(phenyl)methanol 3.117c was 
observed in the crude 1H NMR spectrum (presumably from aryl addition to benzaldehyde from 
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imine hydrolysis). The rhodium catalysed addition of 4-chlorophenyl boronic acid to 
benzaldehyde 2.83a was carried out with a good conversion of 84% into alcohol 3.117c, 
however minimal enantioselectivity was achieved (Scheme 108). 
Table 43[a] 
 
Entry Boron Species Base Eq Additive 
4.2aac 
[%][b] 
4.1aa 
[%][b] 
2.83a 
[%][b] 
3.117c 
[%][b] 
1 3.28c - - - 0 79 21 0 
2 3.28c - - H2O[d] 16 31 53 0 
3 3.28c KOH 0.2 H2O[d] 32 26 42 0 
4 3.28c KOH 3.6 H2O[d] 0 0 100 0 
5 3.25c - - - 0 44 56 0 
6 3.25c KOH 0.2 H2O[d] 28 44 28 0 
7 3.25c CsF 0.2 H2O[d] 22 65 13 0 
8 3.25c CsF 0.2 - 16 54 30 0 
9 3.109c - - - 73 1 4 22 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), (4-ClC6H4BO)3 3.28c (0.6 mmol), [4-ClC6H4B(OH)3Na] 
3.109c (1.8 mmol) or 4-ClC6H4B(OH)2 3.25c (1.8 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), (R,R,R)-3.99 (3.3 mol/%) and 
base in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H NMR spectrum; [c] 20 mol/%; [d] 1.8 mmol; [e] 300 mg. 
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Scheme 108 
Encouraged by the imine result (Entry 9, Table 43), the addition of sodium trihydroxyborate 
3.109c was repeated with a variety of dehydrating agents with the aim of preventing hydrolysis 
(Table 44). However, in all cases this was unsuccessful. A range of other aryl boron species 
was screened however, no improvement was seen (Table 45). 
Table 44[a] 
 
Entry Drying Agent 4.2aac [%][b] 4.1aa [%][b] 2.83a [%][b] 3.117c [%][b] 
1 Powdered 4 Å M.S.[c] 0 3 70 27 
2 4 Å M.S[c] 0 12 61 27 
3 MgSO4[c] 0 16 78 6 
4 Ti(OEt)4[d] 2 10 79 8 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), [4-ClC6H4B(OH)3Na] 3.109c (1.8 mmol), [RhCl(C2H4)2]2 
(1.5 mol/%), (R,R,R)-3.99 (3.3 mol/%) and drying agent in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H 
NMR spectrum; [c] 300 mg; [d] 2 eq, 1.0 mmol. 
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Table 45[a] 
 
Entry Boron Species 4.2aaa [%][b] 4.1aa [%][b] 2.83a [%][b] 
1 3.101 0 96 4 
2 3.107 0 83 17 
3 3.108 0 69 31 
4 4.14 0 46 54 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), boron species (1.8 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R,R)-3.99 (3.3 mol/%) in dioxane (1.6 mL) at 100 °C for 3 h; [b] from crude 1H NMR spectrum. 
 
It was decided to investigate other boronic acid additions systems that have been reported. The 
use of triethylamine in toluene as reported by Lin et al.[175] gave a hopeful conversion (Entry 1, 
Table 46). Increasing the temperature increased the amount of hydrolysis (Entry 2); however, 
addition of water (Entry 3) improved the conversion to addition product 4.2aac. 
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Table 46[a] 
 
Entry Additive T [°C] 4.2aac [%][b] 4.1aa [%][b] 2.83a [%][b] 
1 - 55 38 35 27 
2 - 100 12 29 59 
3 H2O[c] 100 35 12 53 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), 4-ClC6H4B(OH)2 3.25c (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), (R,R,R)-3.99 (3.3 mol/%) in toluene (2 mL) for 4 h; [b] from crude 1H NMR spectrum; [c] 1.8 mmol. 
 
Using the biphasic conditions of Zhou et al.[176] gave an excellent yield of sulfamide adduct 
4.2aac with an encouraging enantiomeric excess of 84% (Entry 1, Table 47). The presence of 
water was found to be critical (Entry 4). Increasing the temperature to 50 °C increased the 
proportion of hydrolysis product 2.83a (Entry 2), whilst running the reaction at room 
temperature impeded the aryl addition reaction (Entry 3). Dichloromethane was found to be as 
good a solvent as toluene (Entry 5), however solvents that were miscible with water led only to 
hydrolysis (Entries 6 and 7). Various bases were screened for the addition of boronic acids 
under these, conditions with CsF, K3PO4, K2CO3 and Cs2CO3 also found to promote the 
addition (Table 48). The group of Lin have reported a similar rhodium catalysed aryl addition 
system using KHF2 (Entry 7, Table 48).[255] 
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Table 47[a] 
 
Entry Solvent T [°C] (R)-4.2aac [%][b] 4.1aa [%][b] 2.83a [%][b] ee [%][c] 
1 toluene:H2O 35 84(73)[d] 1 15 84 (R) 
2 toluene:H2O 50 42 0 58 - 
3 toluene:H2O rt 50 7 43 - 
4 toluene 35 35 12 53 - 
5 CH2Cl2:H2O 35 87(79)[d] 0 13 85 (R) 
6 dioxane:H2O 35 0 0 100 - 
7 DMF: H2O 35 0 0 100 - 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), 4-ClC6H4B(OH)2 3.25c (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), (R,R,R)-3.99 (3.3 mol/%) and KF (3.8 eq) in solvent (2 mL) for 16 h; [b] from crude 1H NMR spectrum; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
 
Table 48[a] 
 
Entry Base (R)-4.2aac [%][b] 4.1aa [%][b] 2.83a [%][b] 
1 - 13 5 82 
2 CsF 70 4 26 
3 TBAF 0 0 100 
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4 KOH 0 0 100 
5 Et3N 0 0 100 
6 K3PO4 85 0 10 
7 KHF2 57 1 42 
8 K2CO3 93 1 6 
9 Cs2CO3 81 0 19 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), 4-ClC6H4B(OH)2 3.25c (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), (R,R,R)-3.99 (3.3 mol/%) and KF (3.8 eq) in 1:1 H2O:toluene (2 mL) for 16 h at 35 °C; [b] from crude 1H 
NMR spectrum. 
 
We hoped to improve upon the current enantiomeric excess of 85% (Entry 5, Table 47), 
therefore a derivative of the current diene ligand (R,R,R)-3.99 was prepared bearing the bulky 
2,6-dimethylphenyl group 4.15.[172] The reaction was run with this bulkier ligand 4.15 and a 
similar enantiomeric excess was achieved, but with a diminished conversion (Entry 1, Table 
49), the solvent system of 1:1 dichloromethane:water was chosen due to the slightly higher 
enantiomeric excess that the toluene system (Entry 5 vs. 1, Table 47). A better result was 
DFKLHYHGZLWK+D\DVKL¶V R,R)-Ph-bod (R,R)-2.39;[170] this gave an excellent conversion with 
an improvement in enantiomeric excess (Entry 2, Table 49). (R,R)-Ph-bod (R,R)-2.39 is 
commercially available as both enantiomers, but it is expensive (~£100 for 100 mg) as this 
ligand is made using chiral preparative HPLC to resolved the enantiomers (see Section 3.2.6). 
Using this ligand (R,R)-2.39 also allowed the number of equivalents of 4-chlorophenyl boronic 
acid to be reduced to 1.3 eq. with little impact on conversion (Entry 3). This result appears to 
contradict the findings of Hayashi et al.[172] who observed that the rhodium catalysed addition 
of phenyl boroxine to the nosylimine of 4-chlorobenzaldehyde proceeded at a faster rate with 
ligand (R,R,R)-3.99 than with (R,R)-Ph-bod (R,R)-2.39. 
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Table 49[a] 
 
Entry Ligand 3.25c [Eq] (R)-4.2aac [%][b] 4.1aa [%][b] 2.83a [%][b] ee [%][c] 
1 (R,R,R)-4.15 2 68(67)[d] 3 30 83 (R) 
2 (R,R)-2.39 2 98(82)[d] 0 2 91 (R) 
3 (R,R)-2.39 1.3 95(91)[d] 2 4 93 (R) 
[a] Reactions were carried out using imine 4.1aa (0.5 mmol), 4-ClC6H4B(OH)2 3.25c (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), ligand (3.3 mol/%) and KF (3.8 eq) in 1:1 H2O:CH2Cl2 (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR 
spectrum; [c] determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
 
Next, the scope of the reaction was tested with these conditions and it was found that when an 
electron-withdrawing chloro group was present on the imine, hydrolysis dominated (Entry 2, 
Table 50). 
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Table 50[a] 
 
Entry Ar1 Ar2 4.2aac [%][b] 4.1 [%][b] 2.83 [%][b] 
1 Ph 4-ClC6H4 95 2 4 
2 4-ClC6H4 Ph 6 3 92 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), Ar2B(OH)2 3.25 (0.65 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R)-2.39 (3.3 mol/%) and KF (3.8 eq) in 1:1 H2O:CH2Cl2 (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR 
spectrum. 
 
Returning to the previous conditions of (R,R,R)-3.99 as the ligand and two equivalents of 
boronic acid also showed a fall in conversion to the sulfamide 4.2aac with an 
HOHFWURQޤZLWKGUDZLQJJURXSRQ WKH LPLQH (QWU\, Table 51). Alcohol 3.117c resulting from 
aryl addition to benzaldehyde was also observed. Use of toluene gave improved conversions 
over dichloromethane and no alcohol by-product was detected (Entry 1 vs. 2). Increasing the 
catalyst loading to 3 mol/% had no effect (Entry 3). Use of a pH 7.4 buffered aqueous system 
was detrimental (Entries 4 and 5). The same lowered conversions were achieved when the 
unsubstituted phenyl boronic acid 3.25a was added to the unsubstituted imine 4.1aa (Entries 6 
and 7). 
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Table 51[a] 
 
Entry Ar1 Solvent 4.2 [%][b] 
Addition 
Product 
4.1 
[%][b] 
2.83 
[%][b] 
3.117 
[%][b] 
1 4-ClC6H4 CH2Cl2:H2O 42 (S)-4.2aac 0 17 41 
2 4-ClC6H4 toluene:H2O 66 (S)-4.2aac 2 32 0 
3[d] 4-ClC6H4 toluene:H2O 66 (S)-4.2aac 5 29 0 
4 4-ClC6H4 CH2Cl2:Buffer[c] 30 (S)-4.2aac 1 44 25 
5 4-ClC6H4 toluene:Buffer[c] 57 (S)-4.2aac 2 38 3 
6 Ph CH2Cl2:H2O 41 4.2aaa 1 36 22 
7 Ph toluene:H2O 54 4.2aaa 1 45 0 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), PhB(OH)2 3.25a (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R,R)-3.99 (3.3 mol/%) and KF (3.8 eq) in solvent (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR spectrum; [c] 
pH 7.4 phosphate buffer; [d] 3 mol/% [RhCl(C2H4)2]2. 
 
The reaction was run at lower temperatures with the aim of slowing the hydrolysis (Entries 1 
and 2, Table 52), and possibly running the reaction at 5 °C for an extended reaction time would 
give reasonable conversion. Varying the base to potassium carbonate gave a good conversion 
(Entry 4). 
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Table 52[a] 
 
Entry Base T [°C] (R)-4.2aac [%][b] 4.1ac [%][a] 2.83c [%][a] 
1 KF 5 45 44 10 
2 KF rt 39 9 51 
3 CsF 35 38 9 53 
4 K2CO3 35 90 0 7 
5 K3PO4 35 16 2 82 
[a] Reactions were carried out using imine 4.1ac (0.5 mmol), PhB(OH)2 3.25a (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), (R,R,R)-3.99 (3.3 mol/%) and base (3.8 eq) in 1:1 toluene:H2O (2 mL) for 16 h; [b] from crude 1H NMR 
spectrum. 
Using potassium carbonate gave good conversions with the electron-withdrawing 
paraޤFKORULQHJURXSon the imine (Entry 1, Table 53). However, with no substituent group on 
the aryl group of the imine mainly hydrolysis was seen (Entry 2).  
Table 53[a] 
 
Entry Ar1 Ar2 4.2 [%][b] Addition Product 4.1 [%]
[b]
 2.83 [%][b] ee [%][c] 
1 4-ClC6H4 Ph 90(87)[d] (S)-4.2aac 0 7 71 (S) 
2 Ph Ph 11 4.2aaa 1 88 - 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), Ar2B(OH)2 3.25 (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R,R)-3.99 (3.3 mol/%) and K2CO3 (3.8 eq) in 1:1 toluene:H2O (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR 
spectrum; [c] determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
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4.3 Sulfamyl Imine Scope 
Despite extensive optimisation it appeared that the methyl substituted N-sulfamyl imine 4.1a 
was too prone to hydrolysis to be an effective substrate for our requirements. Therefore it was 
decided to screen the set of N-sulfamylimines 4.1 (Table 39) with the hope that a larger alkyl 
group would give increased stability and reduced hydrolysis. The effect of the R group on the 
enantioselectivity of the aryl addition reaction could also be studied. 
Table 54[a] 
 
Entry R (R)-4.2 [%][b] Addition Product ee [%]
[c] (R)-3.122c ee [%][c] 
1 Me 65 (R)-4.2aac 86 88 
2 Et 50 (R)-4.2bac 87 86 
3 iPr 28 (R)-4.2cac 86 86 
4 tBu 83 (R)-4.2dac 86 87 
5 Ph 64 (R)-4.2eac 90 89 
6 Bn 61 (R)-4.2fac 88 89 
7 
 
58 (R,R)-4.2gac - 83 
8 
 
46 (S,R)-4.2gac - 85 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), 4-ClC6H4B(OH)2 3.25c (1.0 mmol), [RhCl(C2H4)2]2 (1.5 
mol/%), (R,R,R)-3.99 (3.3 mol/%) and KF (3.8 eq) in 1:1 toluene:H2O (2 mL) for 16 h at 35 °C; [b] isolated yield; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions). 
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In general, moderate yields of addition product were achieved. The lowest yield was found 
with the N-iso-propylsulfamylimine 4.1ac (Entry 3, Table 54). The highest yield of addition 
product was seen with the bulky tert-butyl group (Entry 4). This imine, like the methyl 
analogue 4.1aa, is an easy to handle, crystalline solid which can be synthesised in high yields 
and on reasonable scale. It was decided to focus on this N-tert-butylsulfamylimine 4.1ad.  
Unfortunately, the size of the alkyl group on the sulfamyl activating group had little 
effect on the enantioselectivity of the aryl addition. In each case, the enantiomeric excess was 
confirmed by converting the sulfamide 4.2 to the acetamide 3.122 and measuring its 
enantiomeric excess as well. A slight increase was seen with the benzyl and phenyl substituents 
(Entries 5 and 6), but as these require column chromatography to remove the unwanted amine 
after deprotection we did not want to pursue these substrates. There was little difference 
between the two enantiomers of imine 4.1ag (Entries 7 and 8), suggesting that the chiral centre 
is too far away to exact an influence on the new chiral centre that is being formed. 
 
4.4 Aryl Addition to N-tert-Butyl-N'-
[arylmethylidene]sulfamide 
Investigation into the aryl addition to the tert-butyl sulfamylimine began by studying the 
tolerance of and electron-withdrawing substituent on both the electrophilic and nucleophilic 
components. With the electron-withdrawing 4-chloro substituent the tert-butyl imine gave a 
good conversion to addition product 4.2 (Entry 1, Table 55), and the enantiomeric excess was 
good at 81%. Again the use of dichloromethane in place of toluene lead to an increase yield of 
alcohol 3.117 (Entry 2 vs. 1). When the substitution was swapped, the addition proceeded 
much more slowly (Entry 3). As a high percentage of starting material 4.1 remained, the 
reaction was run for 30 h rather than 16 h, but with no real improvement (Entry 4). 
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Table 55[a] 
 
Entry Ar1 Ar2 Solvent 4.2 [%][b] 
4.1 
[%][b] 
2.83 
[%][b] 
3.117 
[%][b] 
1 4-Cl-C6H4 Ph toluene:H2O 
90 
(89)[d] 4 7 0 
2 4-Cl-C6H4 Ph CH2Cl2:H2O 65 0 15 21 
3 Ph 4-Cl-C6H4 toluene:H2O 47 41 13 0 
4[e] Ph 4-Cl-C6H4 toluene:H2O 59 32 8 0 
5 Ph 4-Cl-C6H4 CH2Cl2:H2O 43 49 8 0 
6 Ph Ph toluene:H2O 58 22 20 0 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), Ar2B(OH)2 3.25 (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R,R)-3.99 (3.3 mol/%) and KF (3.8 eq) in solvent (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR spectrum; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets; [e] reaction 
time 30 h. 
 
The addition of aryl boronic acids to the tert-butyl substituted sulfamyl imine was also tested 
using the (R,R)-Ph-bod (R,R)-2.39 ligand (Table 56). The addition of the electron deficient 
boronic acid 3.25c gave excellent conversion in both solvent systems (Entries 1 and 3). The 
enantiomeric excess was improved with (R,R)-Ph-bod (R,R)-2.39 at 94% rather than 81% with 
(R,R)-3.99. In contrast, when the substitution pattern was swapped, hydrolysis dominated 
(Entries 2 and 4). It was clear that the (R,R)-Ph-bod (R,R)-2.39 ligand was more sensitive to 
the electronics of the imine and boronic acid than the other chiral diene ligand (R,R)-3.99. 
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Table 56[a] 
 
Entry Ar1 Ar2 Solvent 4.2dac [%][b] 
4.1 
[%][b] 
2.83 
[%][b] 
3.117c 
[%][b] 
ee 
[%][c] 
1 Ph 4-Cl-C6H4 toluene:H2O 98(84)[d] 2 0 0 94 (R) 
2 4-Cl-C6H4 Ph toluene:H2O 18 10 69 4 - 
3 Ph 4-Cl-C6H4 CH2Cl2:H2O 93(92)[d] 3 3 0 - 
4 4-Cl-C6H4 Ph CH2Cl2:H2O 17 8 75 0 - 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), Ar2B(OH)2 3.25 (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
(R,R)-2.39 (3.3 mol/%) and KF (3.8 eq) in solvent (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR spectrum; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
 
4.4.1 Scope of Aryl Addition 
It was also evident despite much investigation the current system was unlikely to be optimal 
for a wide scope of substrates. However, we decided to apply it to a range of substrates to learn 
about the requirements for this system and the differences between these two ligands. To this 
end a range of sulfamyl imines bearing a testing variety of electron-withdrawing and donating 
groups were prepared (Table 57). 
Table 57 
 
Entry Ar1 
 
4.1 [%] Product[a] 
1 Ph a 75 4.1da 
2 4-ClC6H4 c 64 4.1dc 
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3 4-MeC6H4 d 88 4.1dd 
4 4-FC6H4 b 59 4.1db 
5 3-MeC6H4 h 76 4.1dh 
6 3-MeOC6H4 k 89 4.1dk 
7 4-CF3C6H4 l 84 4.1dl 
[a] Compound labels: first letter refers to R substituent, second letter refers to aryl group from aldehyde. 
 
The racemates would also need to be prepared to allow a HPLC assay to be developed. 
Consequently, phenylmagnesium chloride was added to each imine to give the racemic 
addition product 4.2 (Table 58). The deprotection conditions of aqueous pyridine were also 
tested on this series of sulfamides 4.2 and the free amines 3.40 were isolated in good yields. 
Table 58 
 
Entry Ar1 (±)-4.2 [%] Addition Product (±)-3.40 [%] Amine 
1 Ph 86[a] (±)-4.2daa 87 (±)-3.40a 
2 4-ClC6H4 93 (±)-4.2dac 79 (±)-3.40c 
3 4-MeC6H4 89 (±)-4.2dad 78 (±)-3.40d 
4 4-FC6H4 83 (±)-4.2dab 88 (±)-3.40b 
5 3-MeC6H4 93 (±)-4.2dah 78 (±)-3.40h 
6 3-MeOC6H4 83 (±)-4.2dak 73 (±)-3.40k 
7 4-CF3C6H4 87 (±)-4.2dal 99 (±)-3.40l 
[a] Prepared from 4.30 using method of Borghese et al.[222] (see Section 4.5 and Chapter 6 Experimental). 
 
The prepared imines were subjected to the rhodium-catalysed addition of phenyl boronic acid 
using both (R,R,R)-3.99 and (R,R)-2.39 as the ligand (Table 59). The substitution was then 
reversed and the substituted aryl boronic acids were added to the sulfamyl imine derived from 
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benzaldehyde, again using both ligands, the results are shown below in Table 60. Where the 
conversion was over 40% the sulfamide was isolated and its enantiomeric excess measured. 
The enantiomeric excesses were confirmed by conversion of the sulfamides 4.2 to the 
acetamides 3.122. 
In general addition of phenyl boronic acid gave highest conversions with ligand 
(R,R,R)-3.99 (Entries 3, 5, 7, 9, 11 and 13, Table 59). Only the unsubstituted imine 4.1da gave 
a better conversion with (R,R)-2.39 (Entry 1 vs. 2). The conversions were highest with the 
strongly electron-withdrawing groups of 4-chloro- and trifluoromethyl- (Entries 3 and 13). The 
enantiomeric excesses that were measured were good at 78-86%. 
Table 59[a] 
 
Entry Ar1 Ligand 4.2 [%][b] Sulfamide ee [%][c] 
1 Ph (R,R)-3.99 58 4.2daa n/a 
2 Ph (R,R)-2.39 80(60)[d] 4.2daa n/a 
3 4-ClC6H4 (R,R)-3.99 90(89)[d] (S)-4.2dac 81 (S) 
4 4-ClC6H4 (R,R)-2.39 17 (S)-4.2dac - 
5 4-MeC6H4 (R,R)-3.99 33 (S)-4.2dad - 
6 4-MeC6H4 (R,R)-2.39 12 (S)-4.2dad - 
7 4-FC6H4 (R,R)-3.99 45(41)[d] (S)-4.2dab 80 (S) 
8 4-FC6H4 (R,R)-2.39 12 (S)-4.2dab - 
9 3-MeC6H4 (R,R)-3.99 54(53)[d] (S)-4.2dah 85 (S) 
10 3-MeC6H4 (R,R)-2.39 7 (S)-4.2dah - 
11 3-MeOC6H4 (R,R)-3.99 46(34)[d] (S)-4.2dak 86 (S) 
12 3-MeOC6H4 (R,R)-2.39 19 (S)-4.2dak - 
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13 4-CF3C6H4 (R,R)-3.99 86(71)[d] (S)-4.2dal 78 (S) 
14 4-CF3C6H4 (R,R)-2.39 17 (S)-4.2dal - 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), PhB(OH)2 3.25 (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
ligand (3.3 mol/%) and KF (3.8 eq) in 1:1 toluene:H2O (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR spectrum; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
 
The additions of substituted aryl boronic acids to benzaldehyde derived sulfamyl imine 4.1da 
had generally higher conversions, than the case with the opposite substitution pattern (Table 59 
vs. Table 60). Another difference observed was that with the substituted aryl boronic acids, the 
conversions were in general higher with ligand (R,R)-2.39 (Entries 2, 4, 6, 8, 12 and 14, Table 
60) with 3-methylbenzene boronic acid proving the only exception (Entries 9 and 10). The aryl 
additions with ligand (R,R)-2.39 tolerated electron-donating and electron-withdrawing groups. 
Ligand (R,R)-2.39 gave excellent enantiomeric excesses 94-98% with the enantiomeric excess 
being higher than that achieved with ligand (R,R,R)-3.99 in every comparable case. 
Table 60[a] 
 
Entry Ar2 Ligand 4.2 [%][b] Sulfamide ee [%][c] 
1 Ph (R,R)-3.99 58 4.2daa n/a 
2 Ph (R,R)-2.39 80(60)[d] 4.2daa n/a 
3 4-ClC6H4 (R,R)-3.99 86(83)[d] (R)-4.2dac 86 (R) 
4 4-ClC6H4 (R,R)-2.39 98(84)[d] (R)-4.2dac 94 (R) 
5 4-MeC6H4 (R,R)-3.99 72(68)[d] (R)-4.2dad 78 (R) 
6 4-MeC6H4 (R,R)-2.39 94(71)[d] (R)-4.2dad 95 (R) 
7 4-FC6H4 (R,R)-3.99 53(42)[d] (R)-4.2dab 87 (R) 
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8 4-FC6H4 (R,R)-2.39 92(90)[d] (R)-4.2dab 95 (R) 
9 3-MeC6H4 (R,R)-3.99 43(35)[d] (R)-4.2dah 76 (R) 
10 3-MeC6H4 (R,R)-2.39 7 (R)-4.2dah - 
11 3-MeOC6H4 (R,R)-3.99 51(37)[d] (R)-4.2dak 84 (R) 
12 3-MeOC6H4 (R,R)-2.39 93(91)[d] (R)-4.2dak 97 (R) 
13 4-CF3C6H4 (R,R)-3.99 46(32)[d] (R)-4.2dal 90 (R) 
14 4-CF3C6H4 (R,R)-2.39 94(84)[d] (R)-4.2dal 98 (R) 
[a] Reactions were carried out using imine 4.1 (0.5 mmol), PhB(OH)2 3.25 (1.0 mmol), [RhCl(C2H4)2]2 (1.5 mol/%), 
ligand (3.3 mol/%) and KF (3.8 eq) in 1:1 toluene:H2O (2 mL) for 16 h at 35 °C; [b] from crude 1H NMR spectrum; [c] 
determined by chiral HPLC (see Chapter 6: Experimental for conditions); [d] isolated yield in brackets. 
 
In conclusion, a new activating group for imines has been developed namely the N-sulfamyl 
group. The imines can be simply made be condensation of the N-alkylsulfamide and 
arylaldehyde in the presence of a Lewis acid. The N-alkylsulfamides can be readily prepared 
from the appropriate amine and chlorosulfonyl isocyanate in two high yielding steps. Addition 
of Grignard reagents to these activated imines gives racemic sulfamides in good yield. 
Rhodium catalysed addition of aryl boronic acids proceeds in varying yields The optimum 
yield being achieved with the (R,R)-2.39 ligand and the unsubstituted benzaldehyde derived 
imine 4.1da. These aryl additions give enantioenriched sulfamides with excellent enantiomeric 
excess. 
4.5 Sulfamide as a Protecting Group 
 
Scheme 109 
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These sulfamide groups could be used as a general protecting group for amines. If an amine 
4.16 (Scheme 109) could be derivatised to the sulfamide 4.17 a functional group 
interconversion could be carried out on the protected amine to give sulfamide 4.18. Finally, the 
amine 4.19 could be isolated using the mild aqueous pyridine conditions. The procedure will 
be limited to primary amines to maintain the N-H groups in 4.18 required for deprotection. 
Therefore, methods for the transformation of 4.16 to 4.17 were investigated. 
Symmetrical sulfamides 4.20 can be prepared via route A (Scheme 110) from sulfuryl 
chloride and two equivalents of the desired amine (as in Section 3.4.3.1).[221] Unsymmetrical 
sulfamides 4.21 can be prepared from the appropriate N-sulfamoyl chloride 4.5 and a primary 
amine (Route B).[242] The synthesis of N-sulfamoyl chlorides was discussed in Section 4.1.1 
and typically involves hazardous and corrosive reagents. 
 
Scheme 110 
 
Scheme 111 
It is possible to elaborate the N-Boc-protected sulfamide 4.10 (Section 4.1.1) with a Mitsunobu 
reaction with an alcohol to give an unsymmetrical sulfamide 4.21 after deprotection (Route C, 
Scheme 111).[221,246] Other routes for the synthesis of unsymmetrical sulfamides require a 
sulfuryl chloride equivalent with leaving groups that can be displaced sequentially. DuBois 
found that catechol sulfate 4.24 could be used to synthesise dialkylsulfamide (Route D, 
Scheme 112), however the reaction with anilines proved much slower.[256,257] 
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Scheme 112 
Borghese et al. used N-sulfamoyloxazolidinones 4.25 prepared from chlorosulfonyl isocyanate 
3.97, displacement of the oxalidinone with a primary amine gave sulfamide 4.21 (Route E, 
Scheme 112).[222] It was found that if a secondary amine was employed, 
NޤVXOIDPR\OR[D]ROLGLQRQHV4.25 could be prepared, however the subsequent displacement did 
not occur. 
Beaudoin et al. looked at using imidazole as a leaving group; alkylation on the 
nitrogen increases the leaving group ability (Scheme 113).[258] They found that alkylation of 
N,N-sulfuryldiimidazole 4.26 with methyl triflate followed by displacement of the imidazolium 
group with an amine gave intermediate 4.28. These steps could then be repeated (a higher 
temperature was required for the second amine displacement) to give the unsymmetrical 
sulfamide 4.21. 
 
Scheme 113 
The method of Borghese was trialled as it was found that oxalidinone intermediate 4.30 
(Scheme 114) could be prepared from tert-butylamine in excellent yield. Displacement of the 
oxalidinone also proceeded in excellent yield to give 4.2daa, which can be deprotected to the 
 125 
diarylmethylamine in 87% yield under the standard aqueous pyridine conditions (Entry 1, 
Table 58). 
 
Scheme 114 
To conclude a method to introduce a sulfamide group to a primary amine has been found. The 
use of this protecting group is limited to primary amines as the presence of a free NH is crucial 
for the subsequent deprotection (see Section 3.4.5). The stability of this group would require 
further investigation, however in the course of this research it has shown to be stable to 
refluxing acidic conditions (Entry 2, Table 34) and has been reported to be stable to the strong 
reducing agent LiAlH4.[207] The possibility of tuning the properties of the group by modifying 
the R group also provides valuable flexibility. 
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Chapter 5 
5.1 Chiral 1-Aryl-2-propenylamines 
Enantioenriched allylic amines 5.1 (Scheme 115) are useful synthetic building blocks and 
appear in biologically active natural products.[259,260] The double bond can be oxidised, 
UHGXFHGRUIXUWKHUIXQFWLRQDOLVHGWRĮ- DQGȕ-amino acids.[261,262] 
 
Scheme 115 
One strategy to synthesise these amines is the addition of an alkenyl reagent 5.3 to an activated 
aldimine 5.2 (Route A, Scheme 116). Alternatively, these allylic amines can be synthesised by 
the arylation of an activated imine derivHG IURPDQĮȕ-unsaturated aldehyde (Route B). For 
both cases a non-racemic amine could be achieved either by the use of a chiral auxiliary in the 
imine component 5.2/5.5 or by use of a chiral ligand. 
 
Scheme 116 
 
5.1.1 Alkenyl Addition 
In 1999, Oi et al. reported the first addition of an alkenyl stannane 5.7 to N-tosyl imine 2.27, 
with rhodium catalysis, to give the racemic allylic amine (±)-5.8 (Scheme 117).[149] Taguchi, 
Hanzawa, and co-workers used rhodium catalysed addition of alkenyl zirconocene reagents 5.9 
(from hydrozirconation of the appropriate alkyne with the Schwartz reagent) (Scheme 117).[263] 
 127 
 
Scheme 117 
Ellman et al. used rhodium catalysis for the diastereoselective addition of 
alkenyltrifluoroborates to imine (R)-3.9 to give amines 5.12 in excellent diastereomeric ratios 
(Scheme 118).[264] Alkenyltrifluoroborates are more stable and less prone to hydrolysis than the 
equivalent alkenyl boronic acids. 
 
Scheme 118 
5.1.2 Aryl Addition 
The group of Hayashi reported the use of a stannane, but in this case a trimethylphenyl 
stannane 5.14 ZDV XVHG WR DU\ODWH D QRV\O SURWHFWHG Įȕ-unsaturated imine 5.13 (Scheme 
119).[151,265] The addition proceeded in a 1,2-fashion with no 1,4-addition product observed. 
This gave protected allylic amine (R)-5.15 in good yield and excellent enantioselectivity over a 
range of substrates. 
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Scheme 119 
 
5.1.3 Reductive Coupling of Alkynes 
The group of Krische have developed a novel carbon-carbon bonding forming hydrogenation 
protocol. This allows the coupling of an alkyne 5.16 to an activated imine 5.2 to give the allylic 
amine 5.17 using iridium catalysis (Scheme 120). The product is equivalent to that of the 
addition of a vinyl organometallic, but does not require a stoichiometric amount of metal. 
 
Scheme 120 
Using 2-butyne 5.20, allylic amines 5.21 were made with excellent control over the double 
bond geometry and no further reduction of the double bond (Scheme 121).[266] It was found 
necessary to have a carboxylic acid promoter present, in this case Ph3CCO2H. If an 
unsymmetrical alkyne such as 4-methyl-2-pentyne 5.23 were used then the reaction also 
proceeded with excellent regioselectivity (Scheme 122). Replacing the achiral BIPHEP ligand 
5.21 with (R)-Cl,MeO-BIPHEP (R)-5.24 gave enantioenriched amines (Scheme 122).[267] 
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Scheme 121 
 
Scheme 122 
5.2 Results and Discussion 
5.2.1 Aims and Objectives 
The aim was to attempt use the newly developed N-sulfamyl imines 4.1 (Chapter 4) as a 
substrate for a reductive alkyne coupling to give to protected allylic amine 5.25 (Equation 1, 
Scheme 123). It was hoped that the reaction could be optimised through variation of the 
following parameters: hydrogen pressure, iridium catalyst precursor, ligand, temperature and 
solvent. Ideally, the reaction would proceed with good regioselectivity and good 
enantioselectivity if a chiral ligand were employed. 
 130 
 
Scheme 123 
Secondly, we hoped that an intramolecular reaction using a substrate such as 5.26 could give 
the bicyclic product 5.27. 
 
5.2 Intermolecular Reductive Coupling 
Initially, N-tosyl furaldehyde imine 5.28 and 4-methyl-2-pentyne 5.23 were chosen as the test 
substrate to try to replicate the results of the Krische group. The achiral BIPHEP 5.21 ligand 
was used as an alternative to the (R)-5.24. The reductive coupling reaction product was formed 
in 34% conversion (Entry 1, Table 61). The mass balance was made up of the sulfamide 5.30, 
from reduction of the imine and starting material. An attempt to increase the coupling product 
by increasing the equivalents of alkyne was unsuccessful giving mainly recovered starting 
material. It was hypothesised that excess alkyne suppresses the activity of the catalyst. 
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Table 61[a] 
 
Entry Alkyne [Eq] 5.29 [%][b] 5.28 [%][b] 5.30 [%][b] 
1 3 34 31 34 
2 30 6 85 9 
[a] Reactions were carried out using imine 5.28 (0.2 mmol), 4-methyl-2-pentyne, [Ir(cod)2]BArF (5 mol/%), 5.21 (5 
mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in toluene (4 mL) under H2 (1 bar) for 16 h at 60 °C; [b] 
conversion from crude 1H NMR spectrum. 
 
It was clear some optimisation of the reaction conditions would be required so it was decided 
to switch to the N-sulfamyl imine substrates of interest. At this point, the N-sulfamyl imine for 
which we had an efficient synthesis route in hand was 4.1fa (Scheme 124). As it was clear that 
a major side reaction was likely to be reduction, 4.1fa was treated with sodium borohydride to 
give the reduced product 5.31 for use as an analytical standard. 
 
Scheme 124 
 
5.2.1 Optimisation 
Firstly, the reductive coupling reaction between 4.1fa and 4-methyl-2-pentyne was carried out 
using the optimal conditions of Krische.[266] A conversion to product 5.32 of 15% was observed 
(Entry 1, Table 62). As expected reduction to sulfamide 5.31 was seen in 38% conversion, 
another side product observed was primary sulfamide 4.4f; this must be due to hydrogenolysis 
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of 5.31. Only a trace amount of benzaldehyde was observed and no benzyl alcohol therefore 
hydrolysis of the starting material 4.1fa is not a major side reaction. 
Table 62[a] 
 
Entry Catalyst H2 Uptake [mmol] 
5.32 
[%][b] 
4.1fa 
[%][b] 
4.4f 
[%][b] 
5.31 
[%][b] 
1 Preformed 0.846 15 8 38 38 
2 Formed in situ 0.938 15 9 30 46 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)((R)-5.24)]BArF 
(5 mol/%) or [Ir(cod)2]BArF (5 mol/%) and (R)-5.24 (5 mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in 
toluene (4 mL) under H2 (1 bar) for 16 h at 60 °C; [b] conversion from crude 1H NMR spectrum. 
 
The initial reaction (Entry 1) had been carried out using the preformed iridium/ligand complex 
synthesised from [Ir(cod)Cl]2 using the method of Fackler Jnr. et al. for the synthesis of similar 
rhodium complexes with bidentate phosphine ligands (Scheme 125).[268] For the purposes of 
ligand screening the in situ formation of the complex from [Ir(cod)2]BArF and ligand would be 
more practical, so the two approaches were compared. Near identical conversions to product 
were achieved (Entry 2) with the side reaction of imine reduction being slightly higher. 
 
Scheme 125 
A variety of ligands (Scheme 126) was tested in the reaction (Table 63). None were found to 
give better conversions than (R)-Cl,MeO-BIPHEP (R)-5.24 (Entry 2). The presence of a ligand 
is necessary for the reductive coupling (Entry 1). Biaryl systems such as (R)-BINAP (R)-1.34, 
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(R)-SYNPHOS (R)-5.33, (R)-DIFLUORPHOS (R)-5.44, and CTH-(R)-P-PHOS (R)-5.45 gave 
slightly lower conversions (Entries 3, 4, 18 and 19). (R)-Phanephos (R)-2.79, (S,S)-Norphos 
(S,S)-5.34, (S,S)-Chiraphos (S,S)-5.35, and (R)-(S)-Josiphos (R,S)-5.36 also gave some product 
(Entries 5-8). CTH-(R)-SpiroP (R)-5.39 and (S,S)-DIOP (S,S)-5.42 gave some as yet 
unidentified side-products. 
Table 63[a] 
 
Entry Ligand H2 Uptake [mmol] 
5.32 
[%][b] 
4.1fa 
[%][b] 
4.4f 
[%][b] 
5.31 
[%][b] 
1 no ligand 0.419 0 38 55 7 
2 
(R)-5.24 
(R)-Cl,MeO-
BIPHEP 
1.018 25 0 32 42 
3 (R)-1.34 (R)-BINAP 1.020 13 5 46 37 
4 (R)-5.33 (R)-SYNPHOS 1.134 10 0 52 37 
5 (R)-2.79 (R)-Phanephos 1.056 10 0 9 81 
6 (S,S)-5.34 (S,S)-Norphos 1.060 15 0 13 71 
7 (S,S)-5.35 (S,S)-Chiraphos 0.848 17 4 47 32 
8 (R,S)-5.36 (R,S)-Josiphos 1.251 7 0 5 88 
9 (R)-5.37 (R)-C4-Tunaphos 0.992 0 34 40 26 
10 (S,S)-2.30 
 (S,S)-MeDUPHOS 0.576 0 13 48 40 
11 (R,R)-5.38 (R,R)-MeBPE 0.013 0 53 32 15 
12 (R)-5.39 CTH-(R)-SpiroP 0.513 0 - - - 
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13 (R)-5.40 (R)-MONOPHOS[c] 0.266 0 17 69 14 
14 (R)-5.41 0.272 0 54 37 9 
15 (S,S)-5.42 (S,S)-DIOP 0.839 0 - - - 
16 (R,S)-5.43 0.781 0 68 8 23 
17 (R)-2.71 (R)-QUINAP 0.324 0 63 20 17 
18 
(R)-5.44 
(R)-
DIFLUORPHOS 
0.663 8 20 64 7 
19 (R)-5.45 CTH-(R)-P-PHOS 0.830 15 8 56 19 
20 PPh3[c] 0.995 0 0 36 64 
21 PCy3[c] 0.958 0 10 60 30 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)2]BArF (5 
mol/%) and ligand (5 mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in toluene (4 mL) under H2 (1 bar) for 16 
h at 60 °C; [b] conversion from crude 1H NMR spectrum; [c] ligand (10 mol/%) used. 
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Scheme 126 
The reaction was run in a range of solvents; however, in each case unreacted starting material 
was the major component (Table 64). It was hoped that reducing the pressure would slow the 
hydrogenation of the starting material and increase the proportion of C-C bond formation. 
However, the conversion was no better at 0.5 bar, although there was more unreacted starting 
material remaining (Entry 2, Table 65). Lowering the pressure further gave a lower conversion 
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still (Entry 3). Varying the temperature had also little effect on the improving the conversion 
(Table 66). 
Table 64[a] 
Entry Solvent H2 Uptake [mmol] 5.32 [%][b] 
4.1fa 
[%][b] 
4.4f 
[%][b] 
5.31 
[%][b] 
1 THF -0.122 0 84 3 13 
2 EtOAc -0.019 0 91 2 6 
3 1,2-dichloroethane 0.401 0 37 10 53 
4 MeOH -0.007 0 80 10 11 
5 acetone -0.245 0 90 1 9 
6 MeCN -0.100 0 90 2 8 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)((R)-5.24)]BArF 
(5 mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in solvent (4 mL) under H2 (1 bar) for 16 h at 60 °C; [b] 
conversion from crude 1H NMR spectrum. 
 
Table 65[a] 
Entry H2 Pressure [bar] H2 Uptake [mmol] 5.32 [%][b] 
4.1fa 
[%][b] 
4.4f 
[%][b] 
5.31 
[%][b] 
1 1.0 0.938 15 9 30 46 
2 0.5 0.769 13 27 34 28 
3 0.2 -0.002 9 52 35 3 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)2]BArF (5 
mol/%), (R)-5.24 (5 mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in toluene (4 mL) under H2 for 16 h at 60 
°C; [b] conversion from crude 1H NMR spectrum. 
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Table 66[a] 
Entry T [°C] H2 Uptake [mmol] 5.32 [%][b] 4.1fa [%][b] 4.4f [%][b] 5.31 [%][b] 
1 40 1.113 8 5 68 19 
2 60 1.166 16 0 39 45 
3 80 0.943 15 9 35 41 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)2]BArF (5 
mol/%), (R)-5.24 (5 mol/%), Ph3CCO2H (5 mol/%) and Na2SO4 (0.4 mmol) in toluene (4 mL) under H2 (1 bar) for 16 
h; [b] conversion from crude 1H NMR spectrum. 
 
The amount of acid promoter present was also varied. It was found that reductive coupling 
product could still be formed in its absence (Entry 1, Table 67). However, a boost to 
conversion was achieved if the acid was recrystallised before use (Entry 3). A screen of other 
acidic additives (Entries 6-9) showed that phenol could promote the reaction just as well as 
Ph3CCO2H (Entry 8). 
Table 67[a] 
Entry Additive [mol/%] H2 Uptake [mmol] 
5.32 
[%][b] 
4.1fa 
[%][b] 
4.4f 
[%][b] 
5.31 
[%][b] 
1 Ph3CCO2H 0 0.987 11 23 41 24 
2 Ph3CCO2H 1 1.017 9 10 53 27 
3 Ph3CCO2H[c] 5 0.711 28 9 24 39 
4 Ph3CCO2H 10 1.145 6 17 52 24 
5 Ph3CCO2H 20 0.989 0 21 61 18 
6 MeOH 5 1.177 4 0 46 50 
7 3-NO2C6H4CO2H 5 0.902 10 0 49 40 
8 PhOH 5 0.829 27 2 27 40 
9 TFA 5 1.182 0 0 55 45 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), 4-methyl-2-pentyne (0.6 mmol), [Ir(cod)2]BArF (5 
mol/%), (R)-5.24 (5 mol/%), additive and Na2SO4 (0.4 mmol) in toluene (4 mL) under H2 (1 bar) for 16 h at 60 °C; [b] 
conversion from crude 1H NMR spectrum, [c] acid recrystallised from methanol prior to use. 
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The substrates were subjected to the reductive coupling conditions to assess their stability. 
After 16 h with a hydrogen pressure of 1 bar, no imine 4.1fa remained with major product 
being the reduced sulfamide 5.31 and an appreciable amount of hydrogenolysis to the primary 
sulfamide 4.4f (Entry 1, Table 68). With no hydrogen present, imine was recovered after 16 h 
with 44% 4.4f this time presumably for hydrolysis of the imine. 
Table 68[a] 
 
Entry H2 Pressure [bar] H2 Uptake [mmol] 4.1fa [%][b] 4.4f [%][b] 5.31 [%][b] 
1 1 0.140 0 21 78 
2 0 0.000 56 44 0 
[a] Reactions were carried out using imine 4.1fa (0.2 mmol), [Ir(cod)((R)-5.24)]BArF (5 mol/%), Ph3CCO2H (5 mol/%) 
and Na2SO4 (0.4 mmol) in solvent (4 mL) under H2 for 16 h at 60 °C; [b] conversion from crude 1H NMR spectrum. 
 
When the alkyne 5.23 alone was subjected to the reductive coupling conditions, hydrogen 
uptake was still recorded indicting reduction of the alkyne. The reductive coupling with imine 
4.1fa was repeated using d6-benzene as the solvent, the resulting 1H NMR spectrum showed 
the presence of the cis-alkene 5.36 (Scheme 127). However, in the absence of the imine 
substrate alkane 5.37 is observed by 1H NMR after 16 h. If the reaction is stopped after 2 h 
alkene 5.36 is observed. Hydrogenation of the alkyne 5.23 was found to be more rapid than 
hydrogenation of the imine 4.1fa. 
 
Scheme 127 
 139 
Increasing the catalyst loading with the aim of increasing conversion to 5.32 was not 
investigated as the current loading of 5 mol/% was already thought to be high. Despite 
extensive optimisation the conversion to 5.32 could not be improved from a disappointing 
DVLPLODUFRQYHUVLRQZDVREVHUYHGZLWK.ULVFKH¶VRZQVXEVWUDWHVTable 61). As a result, 
no enantiomeric excesses were determined for these reactions. The competition of side 
reactions in the form of imine and alkyne reduction could not be worked around. 
 
5.2.3 Intramolecular Reductive Coupling 
5.2.3.1 Synthesis of Substrate 
 
Scheme 128 
First, the aldehyde was protected as acetal 5.39 (Scheme 128), the Grignard reagent was 
formed and coupled to give 5.40 in good yield. Deprotection of the acetal and TMS groups 
were carried out without isolation of the intermediate to give aldehyde 5.41. This was then 
coupled with the sulfamide 4.4f to yield the substrate 5.42. 
 
5.2.3.2 Intramolecular Reductive Coupling 
Unfortunately, when exposed to the coupling conditions, no hydrogen uptake was recorded and 
no desired product was observed in the crude 1H NMR spectrum. The one isolated side product 
appears to be the isomerised alkyne 5.44 (Scheme 129). 
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Scheme 129 
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Chapter 6 Experimental 
All experiments were carried out under an argon atmosphere using standard Schlenk 
techniques. Solvents were dried prior to use: THF, diethyl ether, DME and dioxane were 
distilled from sodium-benzophenone ketyl and dichloromethane from calcium hydride. Proton, 
13C, 19F and 31P NMR spectra were recorded on Bruker DPX400, Bruker AV400 and Bruker 
AV(III)400 spectrometers using Me4Si or residual solvent as an internal reference. 19F NMR 
spectra for compounds 3.100b, meso-3.100b, (R,R)-3.100b and (S,S)-3.100b were referenced 
WR 7)( DW í SSP $OO J values are in Hz. Infrared spectra were recorded on a Bruker 
Tensor 27 machine. Mass spectra were recorded using Electrospray (ES) or electron impact 
(EI) techniques using a Bruker ApexIV FT-ICR machine. Optical rotations were measured 
using a Bellingham Stanley ADP440 digital polarimeter at ambient temperature in units of 10í 
° cm2 gí (c in g/100 mL). Diastereoselectivities and enantioselectivities were determined by 
chiral HPLC and chiral GC. HPLC analyses were performed on a Varian Prostar System using 
Daicel columns under the conditions given. GC analyses were performed on a Varian 430 gas 
chromatograph using a CP-ChiraSil-Dex CB column under the conditions given. Thin layer 
chromatography (TLC) was performed on Merck silica gel 60 F254+366 pre-coated plates (0.25 
mm) silica. The plates were visualised by the use of a combination of ultraviolet light (254 and 
366 nm) and/or aqueous potassium permanganate with heating. Liquid chromatography was by 
forced flow (flash chromatography) with the solvent systems indicated using silica gel 60 (220-
240 mesh) supplied by Fluka. 
6.1 General Methods 
General Method A: N-Diphenylphosphinoyl Imine 2.20 Preparation[110,111] 
Titanium tetrachloride (5.0 mmol, 0.5 eq) in CH2Cl2 (4 mL) was added dropwise to a stirred 
solution of the aldehyde (10.0 mmol, 1 eq), diphenylphosphinic amide (10.0 mmol, 1 eq) and 
triethylamine (35.0 mmol, 3.5 eq) in CH2Cl2 (50 mL) at 0 °C. The solution was stirred at 0 °C 
for 1 h and room temperature for 1 h. The suspension was filtered through a silica pad, washed 
with 1:1 CH2Cl2:EtOAc. The filtrate was concentrated to a cream solid and purified by flash 
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chromatography (1:1 CH2Cl2:EtOAc). Imines 2.20a-k were prepared by Samir El 
Hajjaji.[106,269] 
 
General Method B: Racemic Methylation of N-Diphenylphosphinoyl Imines 2.20 
A flame dried Schlenk tube was charged with imine 2.20 (0.6 mmol, 1 eq) in dried Et2O (10 
mL). The suspension was cooled to 0 °C, a minimum amount of CH2Cl2 was added (~5 mL) to 
dissolve the compound. Methylmagnesium bromide (3.0 M in Et2O solution, 0.6 mL, 1.8 
mmol, 3 eq) was slowly added to the solution. The reaction mixture was stirred first at 0 °C for 
30 min and then at room temperature for 1 h after which time it was quenched at 0 °C with 
water (10 mL). The product was extracted into CH2Cl2 (3 × 20 mL), the combined organic 
extracts were washed successively with water (20 mL) and brine (20 mL), dried (Na2SO4) and 
the solvent removed in vacuo to afford the crude amine. Purification by flash chromatography 
(EtOAc) gave the pure protected secondary amines (±)-2.21. 
 
General Method C: Enantioselective Methylation of N-Diphenylphosphinoyl Imines 2.20 
A flame-dried Schlenk tube was charged with [RhCl(C2H4)2]2 (6.8 mg, 2.9 mol/%), (R,R)-
MeDuPHOS (R,R)-2.30 (19.1 mg, 10.4 mol/%) and THF (6 mL). The solution was stirred at 
room temperature for 30 min before the imine 2.20 (0.6 mmol, 1 eq) in THF (4 mL) was 
added. After a further 5 min dimethylzinc (2.0 M in toluene, 0.6 mL, 1.2 mmol, 2 eq) was 
added dropwise. The reaction mixture was stirred at reflux for 3 h, then quenched with sat. 
NH4Cl solution (20 mL), extracted with CH2Cl2 (3 × 20 mL). The organics were dried 
(Na2SO4) and concentrated in vacuo to an oil, which was purified using flash chromatography 
(EtOAc). 
 
General Method D: Protecting Group Exchange ± Conversion of 2.21 into Trifluoroacyl 
or Acyl Derivatives 2.93 
A 10 mL vial equipped with a magnetic stirrer was charged with the pure protected secondary 
amine 2.21 (30 mg) and trifluoroacetic anhydride (50 eq) or acetyl chloride (50 eq) with 
DMAP (7 mol/%). The suspension was stirred for 30 min before the cautious addition of 2 
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drops of water. The resulting solution was stirred overnight and the reaction mixture was 
transferred in a larger container before quenching it cautiously with sat. NaHCO3 solution (30 
mL). The mixture was extracted with CH2Cl2 (3 x 20 mL), dried (Na2SO4) and concentrated. 
The residue was purified by filtration over a pad of silica (CH2Cl2) or by flash chromatography 
(1:1 pet. ether:EtOAc). Samples of 2.93, assessed pure by 1H NMR spectroscopy, were used 
directly for ee determination by GC. Assays were carried out on an autosampler equipped 
Varian 430 using the conditions and columns described in Table 69. 
General Method E: Bis-Sulfamyl Imine 3.85 Preparation 
A suspension of sulfamide (25 mmol, 1 eq), aldehyde (50 mmol, 2 eq) and Amberlyst® 15 (0.3 
g) in benzene (60 mL) was refluxed overnight using a Dean-Stark trap. The reaction mixture 
was allowed to cool, CH2Cl2 (50 mL) was added, the Amberlyst® 15 was removed by 
filtration. 
 
General Method F: Aryl Boroxine 3.28 Preparation 
A suspension of the aryl boronic acid 3.25 in benzene/toluene (50 mL) was stirred at reflux for 
6-18 h with a Dean-Stark trap. After cooling the resulting white precipitate was collected by 
filtration and washed with hexanes (in some cases a second crop could be obtained from the 
filtrate) the boroxines 3.28 were obtained in quantitative yield (5-15% boronic acid remaining). 
 
General Method G: Aryl Grignard Reagent Addition to Bis-Sulfamyl Imines 3.85 
A flame dried Schlenk was charged with the imine 3.85 (0.75 mmol, 1 eq), and Et2O (10 mL) 
and cooled to 0 °C. Arylmagnesium bromide (3.00 mmol, 4 eq) was added dropwise with 
stirring at 0 °C. The solution was stirred 4-18 h and allowed to warm to rt. The reaction 
mixture was then quenched with sat. NH4Cl solution (20 mL), extracted with Et2O (2 × 20 
mL), the organics were dried (Na2SO4) and concentrated. 
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General Method H: Rhodium Catalysed Aryl Boroxine 3.28 Addition to Bis-Sulfamyl 
Imines 3.85 
A flame dried Schlenk was charged with [RhCl(C2H4)2]2 (2.9 mg, 7.5 µmol, 3 mol/%), 
(R,R,R)-3.99 (5.5 mg, 16.5 µmol, 6.6 mol/%) and dioxane (0.4 mL), the orange solution was 
stirred at rt for 10 min. Imine 3.85 (0.25 mmol, 1 eq), aryl boroxine 3.28 (0.6 mmol, 2.4 eq), 
3.1 M KOH(aq) (32.2 µL, 40 mol/%) and dioxane (1.2 mL) were added. The yellow solution 
was stirred at 100 °C for 3 h and became dark brown. The mixture was filtered through a pad 
of silica, flushed with Et2O (20 mL), the filtrate was concentrated and purified by column 
chromatography. 
 
General Method I: Deprotection of 3.100 and 4.2 to Free Diarylmethylamines 3.40 
A solution of the sulfamide 3.100/4.2 in 5% H2O-pyridine (10 mL) was stirred at reflux 
overnight. The pyridine was removed in vacuo and the residue was partitioned between 1 M 
HCl (20 mL) and Et2O (20 mL). The aqueous layer was basified with 2 M NaOH and extracted 
with Et2O (2 × 15 mL), the combined organic extracts were dried (Na2SO4) and concentrated to 
give the product with no further purification necessary. In the cases of 4.2 where R = Ph, Bn, 
CH(CH3)Ph column chromatography was required (1:1 pet. ether:EtOAc). 
 
General Method J: Acetylation of Free Diarylmethylamines 3.40 
Acetyl chloride (1.1 eq) was added to a stirred solution of the amine 3.40 (1 eq) and pyridine (2 
eq) in CH2Cl2 or CHCl3 (2 mL). The solution was stirred at rt for 4-18 h. The reaction mixture 
was then diluted with CH2Cl2 (10 mL) washed with sat. NaHCO3 solution (15 mL) and 2 M 
HCl (15 mL). The combined organic extracts were dried (Na2SO4) and concentrated to give the 
product. 
 
General Method K: Deprotection and Acetylation 
A solution of the sulfamide 3.100 in 5% H2O-pyridine (10 mL) was stirred at reflux overnight. 
The solution was allowed to cool and acetic anhydride (10 eq) was added, stirred at rt for 7 h. 
Then 1 M HCl (20 mL) was added, the mixture was extracted with Et2O (2 × 15 mL). The 
combined organic extracts were washed with 2 M HCl (2 × 20 mL), H2O (20 mL) and brine 
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(20 mL) then dried (Na2SO4) and concentrated to give the product with no further purification 
necessary. 
 
General Method L: Synthesis of tert-Butyl N-alkylsulfamoylcarbamate 4.10 
Chlorosulfonyl isocyanate (8.7 mL, 0.1 mol, 1 eq) in toluene (10 mL) was added dropwise to a 
stirred solution of tert-butanol (9.4 mL, 0.1 mol, 1 eq) in toluene (100 mL) at 3 °C over 30 
min. The colourless suspension was stirred at 3 °C for 45 min, then pyridine (17.7 mL, 0.22 
mol, 2.2 eq) was added dropwise over 15 min and the suspension stirred at 7 °C for 60 min. 
Primary amine (40-70 wt. % in H2O, 0.6 mol, 6 eq) was added dropwise at 5 °C over 30 min 
and the biphasic mixture was stirred for 2 hr at 5 °C. The layers were separated, the aqueous 
was washed with toluene (100 mL). The combined organic extracts were washed with H2O 
(100 mL). The combined aqueous extracts were acidified with 2 M HCl to pH 1 and the 
precipitate was collected by filtration to afford the product 4.10 as a white crystalline solid. 
 
General Method M: Synthesis of tert-Butyl N-alkylsulfamoylcarbamate 4.10 
A solution of tert-butanol (2.62 mL, 28 mmol, 1.4 eq) in CH2Cl2 (5 mL) was added dropwise 
to stirred solution of chlorosulfonyl isocyanate (1.74 mL, 20 mmol, 1 eq) in CH2Cl2 (20 mL) at 
0 °C. Stirred at 0 °C for 1 h. A solution of the primary amine (20 mmol, 1 eq) and 
triethylamine (3.07 mL, 22 mmol, 1.1 eq) in CH2Cl2 (5 mL) was added dropwise. Allowed to 
warm to rt and stirred for 16 h. The colourless suspension was washed with 0.2 M HCl (2 × 50 
mL). The combined aqueous layers were washed with CH2Cl2 (25 mL). The combined 
organics extracts were dried (Na2SO4) and concentrated to a white solid. 
 
General Method N: N-Boc Deprotection of 4.10 to Sulfamide 4.4 
Trifluoroacetic acid (240 mmol) in CH2Cl2 (20 mL) was added dropwise to a stirred suspension 
of tert-butyl N-alkylsulfamoylcarbamate 4.10 (80 mmol) in CH2Cl2 (100 mL) at 0 °C. The 
solution was stirred overnight and allowed to warm to rt, then the solution was concentrated in 
vacuo. The residue was taken up in EtOAc (75 mL), washed with sat. NaHCO3 solution (2 × 
50 mL), dried (Na2SO4) and concentrated to a colourless oil. Purification by column 
chromatography gave the product as a white crystalline solid. 
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General Method O: Synthesis of Sulfamyl Imines 4.1 
N-Alkylsulfamide 4.4 (3.63 mmol, 1 eq) was added to a stirred solution of arylaldehyde 2.83 
(4.00 mmol, 1.1 eq) and Ti(OEt)4 (1.95g, 7.26 mmol, 2 eq) in THF (10 mL). The solution was 
stirred at reflux for 7 h. Allowed to cool then poured into stirred brine (100 mL), EtOAc (50 
mL) was added and the mixture stirred vigorously. The mixture was then filtered through celite 
and flushed with further EtOAc, the filtrate was separated and the aqueous was washed with 
EtOAc (50 mL). The combined organic extracts were washed with brine (50 mL), dried 
(Na2SO4) and concentrated to a cream solid. Purification by column chromatography or 
trituration gave the product as a white solid. 
 
General Method P: Phenylmagnesium Chloride Addition to Sulfamyl Imines 4.1 
A flame dried Schlenk was charged with 4.1 (0.5 mmol, 1 eq), and THF (10 mL) and cooled to 
0 °C. Phenylmagnesium chloride (2.0 M in THF, 1 mL, 2.00 mmol, 4 eq) was added dropwise 
with stirring at 0 °C. The solution was stirred 18 h and allowed to warm to rt. The reaction 
mixture was then quenched with sat. NH4Cl solution (20 mL), extracted with Et2O (2 × 20 
mL), the combined organic extracts were dried (Na2SO4) and concentrated to a light yellow oil 
and purified by column chromatography to give the pure product. 
 
General Method Q: Lithium-halogen Exchange then Addition to Sulfamyl Imines 4.1 
n-Butyllithium (1.6 M in hexanes, 2.5 mL, 4.0 mmol, 4 eq) was added dropwise to a stirred 
solution of 4-bromochlorobenzene (765.8 mg, 4.0 mmol, 4 eq) in THF (15 mL) at (?78 °C and 
stirred for 30 min. 4.1 (1.0 mmol, 1 eq) in THF (5 mL) was added dropwise at (?78 °C. The 
suspension was stirred for 3 h. Sat. NH4Cl solution (20 mL) was added to quench, then 
extracted with Et2O (2 × 25 mL). The combined organic extracts were washed with brine (20 
mL), dried (Na2SO4), concentrated to a yellow oil and purified by column chromatography to 
give the pure product. 
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General Method R: Rhodium Catalysed Boronic Acid Addition Sulfamyl Imines 4.1 
A flame dried Schlenk was charged with [RhCl(C2H4)2]2 (2.9 mg, 7.5 µmol, 1.5 mol/%), ligand 
(16.5 µmol, 3.3 mol/%) and toluene (0.4 mL), the orange solution was stirred at rt for 10 min. 
Toluene (0.6 mL), H2O (1 mL), boronic acid 3.25 (1 mmol, 2 eq), KF (110.4 mg, 1.9 mmol, 
3.8 eq) and sulfamyl imine 4.1 (0.5 mmol, 1 eq) were added sequentially. The biphasic mixture 
was gently stirred at 35 °C for 16 h. H2O (10 mL) added and washed with CH2Cl2 (2 × 20 mL). 
The combined organic extracts were washed with brine (10 mL), dried (Na2SO4) and 
concentrated. Unreacted starting material could be removed by stirring residue in 1:1 CH2Cl2:2 
M HCl (10 mL). Purification by column chromatography gave product. 
 
6.2 Compound Data 
P,P-Diphenyl-N-(1-phenylethyl)phosphinic amide (±)-2.21a[79] 
 
Prepared from 2.20a (183.2 mg, 0.6 mmol) using general method B to give the product (177.4 
mg, 92%); Rf 0.16 (EtOAc); M.p. 160-163 °C; lit. 158-162 °C;[270] IR (CHCl3Ȟmax/cmí 3379, 
3063, 1439, 1408, 1184, 1124, 1108, 959; 1H NMR (400.1 MHz, CDCl3įH 7.93-7.88 (m, 2H, 
CHaryl), 7.85-7.80 (m, 2H, CHaryl), 7.51-7.22 (m, 11H, CHaryl), 4.44-4.35 (m, 1H, NHCH), 3.20 
(dd, J = 8.8, 5.6 Hz, 1H, NHCH), 1.57 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, 
CDCl3įC 145.0 (C, d, 3JCP = 6.1 Hz), 133.1 (C, d, 1JCP = 127 Hz), 132.4 (CH, d, 2JCP = 9.1 
Hz), 132.1 (C, d, 1JCP = 130 Hz), 131.8 (CH, d, 2JCP = 9.1 Hz), 131.75 (CH), 131.67 (CH, d, 
4JCP = 3.0 Hz), 128.5 (CH), 128.4 (CH), 128.3 (CH, d, 3JCP = 12.2 Hz), 127.0 (CH), 125.9 
(CH), 51.0 (CH), 25.9 (CH3, d, 3JCP = 4.5 Hz); 31P NMR (161.7 MHz, CDCl3įP 22.5; HRMS 
(ESI Positive) calcd. for C20H20NOP, [M+Na] 344.1175, found 344.1164. These data were 
consistent with literature values.[271] 
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(R)-P,P-Diphenyl-N-(1-phenylethyl)phosphinic amide (R)-2.21a[79] 
 
Prepared from 2.20a (183.2 mg, 0.6 mmol) using general method C to give the product (121.4 
mg, 63%). Analytical data as for (±)-2.21a except: >Į@D = +31.0 (c = 1.07, MeOH, for 93% ee 
material; lit.[270] íIRUee S antipode, c = 0.78, MeOH). 
 
P,P-Diphenyl-N-(1-p-tolylethyl)phosphinic amide (±)-2.21b[95] 
 
Prepared from 2.20b (115.0 mg, 0.6 mmol) using general method B to give the product (166.9 
mg, 83%); Rf 0.30 (EtOAc); M.p. 126-128 °C; IR (CHCl3Ȟmax/cmí3379, 3011, 2983, 1439, 
1184, 1124, 1098, 960; 1H NMR (400.1 MHz, CDCl3įH 7.94-7.81 (m, 4H, CHaryl), 7.51-7.35 
(m, 6H, CHaryl), 7.18 (d, J = 7.7 Hz, 2H, CHaryl), 7.12 (d, J = 7.7 Hz, 2H, CHaryl), 4.41-4.31 (m, 
1H, NHCH), 3.15 (dd, J = 9.6, 6.0 Hz, 1H, NHCH), 2.33 (s, 3H, ArCH3), 1.56 (d, J = 6.8 Hz, 
3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 142.0 (C, d, 3JCP = 6.1 Hz), 136.6 (CH), 133.2 
(C, d, 1JCP = 128 Hz), 132.4 (CH, d, 2JCP = 10.7 Hz), 132.1 (C, d, 1JCP = 130 Hz), 131.9 (CH, d, 
2JCP = 10.7 Hz), 131.73 (CH, d, 4JCP = 3.0 Hz), 131.66 (CH, d, 4JCP = 3.1 Hz), 129.2 (CH), 
128.4 (CH, d, 3JCP = 12.2 Hz), 128.3 (CH, d, 3JCP = 12.2 Hz), 125.8 (CH), 50.8 (CH), 25.9 
(CH3, d, 3JCP = 3.0 Hz), 21.0 (CH3); 31P NMR (161.7 MHz, CDCl3 įP 22.4; HRMS (ESI 
Positive) calcd. for C21H22NOP, [M+H] 336.1512, found 336.1509. These data were consistent 
with literature values.[95]  
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(R)-P,P-Diphenyl-N-(1-p-tolylethyl)phosphinic amide (R)-2.21b[95] 
 
Prepared from 2.20b (115.0 mg, 0.6 mmol) using general method C to give the product (118.6 
mg, 59%). Analytical data as for (±)-2.21b except: >Į@D = +26.1 (c = 1.03, MeOH, for 92% ee 
material; lit.[95] íIRUee S antipode, c = 1.08, MeOH (8 °C)). 
 
N-(1-(4-Fluorophenyl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21c[95] 
 
Prepared from 2.20c (194.0 mg, 0.6 mmol) using general method B to give the product (189.4 
mg, 93%); Rf 0.16 (EtOAc); M.p. 153-155 °C; lit. 157-159 °C;[272] IR (CHCl3Ȟmax/cmí3378, 
2894, 1605, 1511, 1439, 1186, 1124, 1108, 960; 1H NMR (400.1 MHz, CDCl3įH 7.92-7.88 
(m, 2H, CHaryl), 7.82-7.78 (m, 2H, CHaryl), 7.52-7.42 (m, 4H, CHaryl), 7.39-7.34 (m, 2H, CHaryl), 
7.27-7.23 (m, 2H, CHaryl), 7.00-6.95 (m, 2H, CHaryl), 4.43 (m, 1H, NHCH), 3.20 (dd, J = 8.4, 
5.2 Hz, 1H, NHCH), 1.55 (d, J = 6.4 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3 įC 
161.8 (C, d, 1JCF = 244 Hz), 140.8 (C, dd, 3JCP = 6.1 Hz, 4JCF = 3.1 Hz), 132.8 (C, d, 1JCP = 134 
Hz), 132.3 (CH, d, 2JCP = 10.7 Hz), 131.90 (CH, d, 2JCP = 9.1 Hz), 131.90 (CH, d, 4JCP = 3.1 
Hz), 131.8 (CH, d, 4JCP = 3.0 Hz), 128.4 (CH, app. t, 3JCP = 12.1 Hz), 127.6 (CH, d, 3JCF = 9.1 
Hz), 115.2 (CH, d, 2JCF = 21.3 Hz), 50.3 (CH), 25.9 (CH3, d, 3JCP = 4.6 Hz); 31P NMR (161.7 
MHz, CDCl3įP 22.5; 19F NMR (376.5 MHz, CDCl3įF -115.8; HRMS (ESI Positive) calcd. 
for C20H19FNOP, [M+Na] 362.1081, found 362.1070. These data were consistent with 
literature values.[95] 
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(R)-N-(1-(4-Fluorophenyl)ethyl)-P,P-diphenylphosphinic amide (R)-2.21c[95] 
 
Prepared from 2.20c (194.0 mg, 0.6 mmol) using general method C to give the product (99.8 
mg, 49%). Analytical data as for (±)-2.21c except: >Į@D = +14.5 (c = 1.01, MeOH, for 84% ee 
material; lit.[95] íIRUee S antipode, c = 1.04, MeOH (8 °C)). 
 
N-(1-(4-Chlorophenyl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21d[95] 
 
Prepared from 2.20d (203.9 mg, 0.6 mmol) using general method B to give the product (204.9 
mg, 96%); Rf 0.17 (EtOAc); M.p. 147-150 °C; IR (CHCl3Ȟmax/cmí3379, 2983, 1493, 1439, 
1187, 1124, 1069, 959; 1H NMR (400.1 MHz, CDCl3įH 7.92-7.87 (m, 2H, CHaryl), 7.82-7.77 
(m, 2H, CHaryl), 7.52-7.42 (m, 4H, CHaryl), 7.39-7.34 (m, 2H, CHaryl), 7.28-7.25 (m, 2H, CHaryl), 
7.23-7.20 (m, 2H, CHaryl), 4.42-4.32 (m, 1H, NHCH), 3.19 (dd, J = 9.6, 5.6 Hz, 1H, NHCH), 
1.55 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 143.5 (C, d, 3JCP = 6.1 
Hz), 132.8 (C, d, 1JCP = 127 Hz), 132.6 (C), 132.2 (CH, d, 2JCP = 9.1 Hz), 132.0 (C, d, 1JCP = 
130 Hz), 131.8 (CH, d, 2JCP = 9.1 Hz), 131.7 (CH, d, 4JCP = 3.1 Hz), 128.5 (CH), 128.5 (CH, 
app t, 3JCP = 12.2 Hz), 127.4 (CH), 50.3 (CH), 25.7 (CH3, d, 3JCP = 3.0 Hz); 31P NMR (161.7 
MHz, CDCl3 įP 22.6; HRMS (ESI Positive) calcd. for C20H19ClNOP, [M+Na] 378.0785, 
found 378.0793. These data were consistent with literature values.[95] 
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(R)-N-(1-(4-Chlorophenyl)ethyl)-P,P-diphenylphosphinic amide (R)-2.21d[95] 
 
Prepared from 2.20d (203.9 mg, 0.6 mmol) using general method C to give the product (133.7 
mg, 60%). Analytical data as for (±)-2.21d except: >Į@D = +24.6 (c = 1.99, MeOH, for 86% ee 
material; lit.[95] íIRUee S antipode, c = 1.14, MeOH (8 °C)). 
 
N-(1-(4-Bromophenyl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21e[273] 
 
Prepared from 2.20e (230.5 mg, 0.6 mmol) using general method B to give the product (208.9 
mg, 87%); Rf 0.15 (EtOAc); M.p. 143-145 °C; IR (CHCl3Ȟmax/cmí 3379, 2983, 1489, 1439, 
1187, 1124, 1096, 959; 1H NMR (400.1 MHz, CDCl3įH 7.92-7.87 (m, 2H, CHaryl), 7.82-7.76 
(m, 2H, CHaryl), 7.53-7.40 (m, 6H, CHaryl), 7.39-7.35 (m, 2H, CHaryl), 7.16 (dt, J = 8.4, 2.2 Hz, 
2H, CHaryl), 4.40-4.30 (m, 1H, NHCH), 3.18 (dd, J = 9.6, 5.6 Hz, 1H, NHCH), 1.55 (d, J = 6.8 
Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 144.0 (C, d, 3JCP = 6.0 Hz), 132.8 (C, d, 
1JCP = 128 Hz), 132.2 (CH, d, 2JCP = 9.2 Hz), 132.0 (C, d, 1JCP = 130 Hz), 131.8 (CH, d, 2JCP = 
10.7 Hz), 131.7 (CH, d, 4JCP = 3.0 Hz), 131.4 (CH), 128.4 (CH, app t, 3JCP = 12.2 Hz), 127.8 
(CH), 120.7 (C), 50.4 (CH), 25.7 (CH3, d, 3JCP = 4.5 Hz); 31P NMR (161.7 MHz, CDCl3įP 
22.6; HRMS (ESI Positive) calcd. for C20H19BrNOP, [M+Na] 422.0280, found 422.0289. 
These data were consistent with literature values.[273] 
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(R)-N-(1-(4-Bromophenyl)ethyl)-P,P-diphenylphosphinic amide (R)-2.21e[273] 
 
Prepared from 2.20e (230.5 mg, 0.6 mmol) using general method C to give the product (156.1 
mg, 65%). Analytical data as for (±)-2.21e except: >Į@D = +27.9 (c = 1.04, MeOH, for 75% ee 
material). 
 
P,P-Diphenyl-N-(1-(4-(trifluoromethyl)phenyl)ethyl)phosphinic amide (±)-2.21f[274] 
 
Prepared from 2.20f (224.0 mg, 0.6 mmol) using general method B to give the product (207.9 
mg, 89%); Rf 0.20 (EtOAc); M.p. 131-133 °C; IR (CHCl3Ȟmax/cmí 3378, 2984, 1621, 1483, 
1327, 1169, 1126, 1096, 960, 840; 1H NMR (400.1 MHz, CDCl3įH 7.93-7.88 (m, 2H, CHaryl), 
7.81-7.75 (m, 2H, CHaryl), 7.56-7.50 (m, 3H, CHaryl), 7.47-7.43 (m, 3H, CHaryl), 7.40-7.33 (m, 
4H, CHaryl), 4.50-4.40 (m, 1H, NHCH), 3.23 (dd, J = 9.2, 5.6 Hz, 1H, NHCH), 1.58 (d, J = 6.8 
Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 149.0 (C, d, 3JCP = 5.6 Hz), 132.7 (C, d, 
1JCP = 128 Hz), 132.2 (CH, d, 2JCP = 9.1 Hz), 132.0 (C, d, 1JCP = 130 Hz), 131.9 (CH, d, 2JCP = 
9.2 Hz), 131.8 (CH), 131.7 (CH, d, 4JCP = 3.0 Hz), 129.1 (C, q, 2JCF = 32 Hz), 128.4 (CH, d, 
3JCP = 12.2 Hz), 128.3 (CH, d, 3JCP = 12.2 Hz), 126.4 (CH), 125.3 (CH, q, 3JCF = 3.1 Hz), 124.1 
(C, q, 1JCF = 270 Hz), 50.6 (CH), 25.7 (CH3, d, 3JCP = 3.0 Hz); 31P NMR (161.7 MHz, CDCl3) 
įP 22.7; 19F NMR (376.5 MHz, CDCl3 įF í HRMS (ESI Positive) calcd. for 
C21H19F3NOP, [M+Na] 412.1049, found 412.1052. These data were consistent with literature 
values.[274] 
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(R)-P,P-Diphenyl-N-(1-(4-(trifluoromethyl)phenyl)ethyl)phosphinic amide (R)-2.21f[274] 
 
Prepared from 2.20f (224.0 mg, 0.6 mmol) using general method C to give the product (163.5 
mg, 70%). Analytical data as for (±)-2.21f except: >Į@D = +17.1 (c = 1.17, MeOH, for 78% ee 
material). 
 
P,P-Diphenyl-N-(1-m-tolylethyl)phosphinic amide (±)-2.21g[79] 
 
Prepared from 2.20g (191.6 mg, 0.6 mmol) using general method B to give the product (197.2 
mg, 98%); Rf 0.26 (EtOAc); M.p. 110-112 °C; IR (CHCl3Ȟmax/cmí3380, 2983, 1439, 1184, 
1124, 965, 889; 1H NMR (400.1 MHz, CDCl3įH 7.93-7.80 (m, 4H, CHaryl), 7.51-7.35 (m, 6H, 
CHaryl), 7.21 (t, J = 7.6 Hz, 1H, CHaryl), 7.10-7.04 (m, 3H, CHaryl), 4.41-4.31 (m, 1H, NHCH), 
3.15 (dd, J = 8.8, 6.0 Hz, 1H, NHCH), 2.33 (s, 3H, ArCH3), 1.56 (d, 3H, J = 6.8 Hz, CHCH3); 
13C NMR (100.6 MHz, CDCl3įC 144.9 (C, d, 3JCP = 6.1 Hz), 137.9 (C), 133.2 (C, d, 1JCP = 
127 Hz), 132.8 (C), 132.3 (CH, d, 2JCP = 9.1 Hz), 131.7 (CH, d, 2JCP = 9.1 Hz), 131.6 (CH, d, 
4JCP = 3.0 Hz), 131.5 (CH, d, 4JCP = 3.0 Hz), 128.2 (CH, d, 3JCP = 10.7 Hz), 128.1 (CH, d, 3JCP 
= 13.7 Hz), 127.6 (CH), 126.6 (CH), 122.8 (CH), 50.9 (CH), 25.8 (CH3, d, 3JCP = 3.0 Hz), 21.3 
(CH3); 31P NMR (161.7 MHz, CDCl3įP 22.4; HRMS (ESI Positive) calcd. for C21H22NOP, 
[M+H] 336.1512, found 336.1506. These data were consistent with literature values.[270] 
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(R)-P,P-Diphenyl-N-(1-m-tolylethyl)phosphinic amide (R)-2.21g[79] 
 
Prepared from 2.20g (191.6 mg, 0.6 mmol) using general method C to give the product (120.7 
mg, 60%). Analytical data as for (±)-2.21g except: >Į@D = +11.4 (c = 0.54, CH2Cl2, for 89% ee 
material; lit.[270] íIRUee S antipode, c = 0.57, CH2Cl2). 
 
N-(1-(3-Chlorophenyl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21h 
 
Prepared from 2.20h (203.9 mg, 0.6 mmol) using general method B to give the product (200.8 
mg, 94%); Rf 0.19 (EtOAc); M.p. 168-170 °C; IR (CHCl3Ȟmax/cmí3377, 2986, 1439, 1189, 
1124, 1108, 963; 1H NMR (400.1 MHz, CDCl3įH 7.93-7.87 (m, 2H, CHaryl), 7.82-7.77 (m, 
2H, CHaryl), 7.53-7.42 (m, 4H, CHaryl), 7.39-7.34 (m, 2H, CHaryl), 7.24-7.14 (m, 4H, CHaryl), 
4.42-4.32 (m, 1H, NHCH), 3.22 (dd, 1H, J = 9.6, 5.6 Hz, NHCH), 1.55 (d, 3H, J = 6.8 Hz, 
CHCH3); 13C NMR (100.6 MHz, CDCl3įC 147.1 (C, d, 3JCP = 5.9 Hz), 134.3 (C), 132.8 (C, d, 
1JCP = 128 Hz), 132.3 (CH, d, 2JCP = 10.2 Hz), 131.9 (C, d, 1JCP = 129 Hz), 131.9 (CH, d, 4JCP = 
2.9 Hz), 131.8 (CH, d, 4JCP = 4.3 Hz), 129.8 (CH), 128.5 (CH, app t, 3JCP = 13.1 Hz), 127.2 
(CH), 126.1 (CH), 124.3 (CH), 50.6 (CH), 25.8 (CH3, d, 3JCP = 2.9 Hz); 31P NMR (161.7 MHz, 
CDCl3 įP 22.7; HRMS (ESI Positive) calcd. for C20H19ClNOP, [M+H] 356.0966, found 
356.0974; Anal. Calc. for C20H19ClNOP: C, 67.51; H, 5.38; N, 3.94%. Found: C, 67.36; H, 
5.36; N, 3.88%. 
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(R)-N-(1-(3-Chlorophenyl)ethyl)-P,P-diphenylphosphinic amide (R)-2.21h 
 
Prepared from 2.20h (203.9 mg, 0.6 mmol) using general method C to give the product (94.0 
mg, 44%). Analytical data as for (±)-2.21h except: >Į@D = +15.5 (c = 1.06, MeOH, for 78% ee 
material). 
 
P,P-Diphenyl-N-(1-o-tolylethyl)phosphinic amide (±)-2.21i 
 
Prepared from 2.20i (191.6 mg, 0.6 mmol) using general method B to give the product (187.1 
mg, 93%); Rf 0.13 (1:1 CH2Cl2:EtOAc); M.p. 201-204 °C; IR (CHCl3Ȟmax/cmí3382, 2984, 
1439, 1183, 1125, 1086, 958; 1H NMR (400.1 MHz, CDCl3 įH 7.93-7.87 (m, 2H, CHaryl), 
7.76-7.71 (m, 2H, CHaryl), 7.51-7.40 (m, 5H, CHaryl), 7.33-7.28 (m, 2H, CHaryl), 7.25 (t, J = 6.8 
Hz, 1H, CHaryl), 7.14 (td, J = 7.4, 1.2 Hz, 1H, CHaryl), 7.05 (d, J = 7.6 Hz, 1H, CHaryl), 4.65-
4.55 (m, 1H, NHCH), 3.28 (dd, J = 8.8, 5.6 Hz, 1H, NHCH), 2.00 (s, 3H, ArCH3), 1.50 (d, J = 
6.4 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 143.7 (C, d, 3JCP = 7.3 Hz), 134.0 (C), 
133.2 (C, d, 1JCP = 125 Hz), 132.4 (CH, d, 2JCP = 8.7 Hz), 131.8 (CH, d, 2JCP = 8.7 Hz), 131.8 
(CH, d, 4JCP = 2.9 Hz), 131.7 (CH, d, 4JCP = 2.9 Hz), 131.3 (C), 130.3 (CH), 128.4 (CH, d, 3JCP 
= 11.6 Hz), 128.3 (CH, d, 3JCP = 13.1 Hz), 126.8 (CH), 126.5 (CH), 124.7 (CH), 47.1 (CH), 
26.0 (CH3, d, 3JCP = 2.9 Hz), 18.8 (CH); 31P NMR (161.7 MHz, CDCl3įP 22.7; HRMS (ESI 
Positive) calcd. for C21H22NOP, [M+H] 336.1512, found 336.1499. 
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(R)-P,P-Diphenyl-N-(1-o-tolylethyl)phosphinic amide (R)-2.21i 
 
Prepared from 2.20i (191.6 mg, 0.6 mmol) using general method C to give the product (68.4 
mg, 34%). Analytical data as for (±)-2.21i except: >Į@D = +7.1 (c = 1.02, MeOH, for 79% ee 
material). 
 
N-(1-(Naphthalen-2-yl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21j[95] 
 
Prepared from 2.20j (213.2 mg, 0.6 mmol) using general method B to give the product (205.0 
mg, 92%); Rf 0.16 (1:1 CH2Cl2:EtOAc); M.p. 135-137 °C; IR (CHCl3Ȟmax/cmí 3380, 2983, 
1439, 1184, 1125; 1H NMR (400.1 MHz, CDCl3įH 7.95-7.90 (m, 2H, CHaryl), 7.86-7.77 (m, 
5H, CHaryl), 7.65 (br s, 1H, CHaryl), 7.53- 7.40 (m, 7H, CHaryl), 7.35-7.31 (m, 2H, CHaryl), 4.61-
4.51 (m, 1H, NHCH), 3.27 (dd, J = 8.8, 5.2 Hz, 1H, NHCH), 1.66 (d, J = 6.4 Hz, 3H, CHCH3); 
13C NMR (100.6 MHz, CDCl3įC 142.3 (C, d, 3JCP = 6.7 Hz), 133.2 (C), 133.1 (C, d, 1JCP = 
127 Hz), 132.5 (C), 132.4 (CH, d, 2JCP = 9.6 Hz), 132.0 (C, d, 1JCP = 130 Hz), 131.9 (CH, d, 
2JCP = 9.4 Hz), 131.8 (C), 131.7 (C, d, 4JCP = 2.4 Hz), 128.4 (CH, app t, 3JCP = 12.2 Hz), 127.8 
(CH), 127.6 (CH), 126.1 (CH), 125.8 (CH), 124.5 (CH), 124.3 (CH), 51.1 (CH), 25.9 (CH3, d, 
3JCP = 3.1 Hz); 31P NMR (161.7 MHz, CDCl3 įP 22.6; HRMS (ESI Positive) calcd. for 
C24H22NOP, [M+H] 372.1512, found 372.1503. These data were consistent with literature 
values.[95] 
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(R)-N-(1-(Naphthalen-2-yl)ethyl)-P,P-diphenylphosphinic amide (R)-2.21j[95] 
 
Prepared from 2.20j (213.2 mg, 0.6 mmol) using general method C to give the product (162.7 
mg, 73%). Analytical data as for (±)-2.21j except: >Į@D = +24.9 (c = 1.06, MeOH, for 84% ee 
material; lit.[95] íIRUee S antipode, c = 1.02, MeOH (8 °C)). 
 
N-(1-(2-Chlorophenyl)ethyl)-P,P-diphenylphosphinic amide (±)-2.21k 
 
Prepared from 2.20k (203.9 mg, 0.6 mmol) using general method B to give the product (194.3 
mg, 73%); Rf 0.17 (EtOAc); M.p. 209-211 °C; IR (CHCl3Ȟmax/cmí3379, 2985, 1602, 1439, 
1186, 1124, 1108, 958; 1H NMR (400.1 MHz, CDCl3įH 7.91-7.86 (m, 2H, CHaryl), 7.79-7.73 
(m, 2H, CHaryl), 7.52-7.40 (m, 4H, CHaryl), 7.38-7.30 (m, 3H, CHaryl), 7.28-7.23 (m, 2H, CHaryl), 
7.16 (td, J = 7.6, 2.0 Hz, 1H, CHaryl), 4.79-4.69 (m, 1H, NHCH), 3.49 (dd, J = 9.6, 6.0 Hz, 1H, 
NHCH), 1.57 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 142.3 (C, d, 3JCP 
= 5.6 Hz), 132.9 (C, d, 1JCP = 127 Hz), 132.3 (CH, d, 2JCP = 9.6 Hz), 132.0 (C), 131.9 (C), 
131.8 (CH, d, 2JCP = 9.4 Hz), 131.7 (CH), 131.2 (C d, 1JCP = 130 Hz), 129.8 (CH), 128.4 (CH, 
d, 3JCP = 12.4 Hz), 128.2 (CH, d, 3JCP = 12.5 Hz), 128.2 (CH), 127.4 (CH), 127.1 (CH), 49.1 
(CH), 25.0 (CH3, d, 3JCP = 3.7 Hz); 31P NMR (161.7 MHz, CDCl3 įP 22.8; HRMS (ESI 
Positive) calcd. for C20H19ClNOP, [M+Na] 378.0785, found 378.0781. 
 
N-(4-Methylbenzyl)-P,P-diphenylphosphinic amide 2.88b[275] 
 
Diphenylphosphinic chloride (0.75 mL, 3.93 mmol) was added dropwise to triethylamine (1.09 
mL, 7.86 mmol) and 4-methyl benzylamine (0.5 mL, 3.93 mmol) in CH2Cl2 (25 mL) at 0 °C. 
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The solution was stirred at 0 °C for 1 h and rt for 45 min before washing with water (2 × 20 
mL) and brine (20 mL). The organics were dried (Na2SO4) and concentrated to a yellow oil. 
Purification by column chromatography (EtOAc) gave 2.88b as a white crystalline solid (1.04 
g, 83%); Rf 0.22 (EtOAc); M.p. 110-112 °C; IR (CHCl3Ȟmax/cmí 2984, 1439, 1400, 1183, 
1124; 1H NMR (400.1 MHz, CDCl3įH 7.97-7.91 (m, 4H, CHaryl), 7.52-7.42 (m, 6H, CHaryl), 
7.25 (d, J = 7.2 Hz, 2H, CHaryl), 7.14 (d, J = 8.0 Hz, 2H, CHaryl), 4.09 (t, J = 7.2 Hz, 2H, CH2), 
3.11 (q, J = 6.2 Hz, 1H, NH), 2.33 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3įC 137.1 (C), 
136.5 (C, d, 3JCP = 7.3 Hz), 132.2 (C, d, 1JCP = 128 Hz), 132.1 (CH, d, 2JCP = 9.2 Hz), 131.8 
(CH, d, 4JCP = 3.0 Hz), 129.3 (CH), 128.5 (CH, d, 3JCP = 13.7 Hz), 127.7 (CH), 44,4 (CH2), 
21.0 (CH3); 31P NMR (161.7 MHz, CDCl3 įP 23.5; HRMS (ESI Positive) calcd. for 
C20H20NOP, [M+H] 322.1355, found 322.1373; Anal. Calc. for C20H20NOP: C, 74.75; H, 6.27; 
N, 4.36%. Found: C, 74.60; H, 6.30; N, 4.33%. 
 
Table 69 
No. Ar X Column Programme Retention times [min] 
2.93a Ph CF3 CP-ChiraSil-Dex CB[a] 
100 °C 
(isothermal) 
(R) 17.7 
(S) 18.2 
2.93b 4-MeC6H4 CH3 CP-ChiraSil-Dex CB 
165 °C 
(isothermal) 
(R) 9.0 
(S) 9.3 
2.93c 4-FC6H4 CF3 CP-ChiraSil-Dex CB 
100 °C 
(isothermal) 
(R) 22.6 
(S) 23.6 
2.93d 4-ClC6H4 CF3 CP-ChiraSil-Dex CB 
120 °C 
(isothermal) 
(R) 22.0 
(S) 22.7 
2.93e 4-BrC6H4 CF3 CP-ChiraSil-Dex CB 
115 to 125 °C 
at 0.2 °C/min 
+ 15 min at 125 °C 
(R) 43.1 
(S) 43.8 
2.93f 4-CF3C6H4 CF3 CP-ChiraSil-Dex CB 
100 °C 
(isothermal) 
(R) 35.1 
(S) 35.9 
2.93g 3-MeC6H4 CF3 2,6-Ȗ-cyclodextrin[b] 70 °C (isothermal) 
(S) 134.0 
(R) 134.1 
2.93h 3-ClC6H4 CF3 CP-ChiraSil-Dex CB 
115 °C 
(isothermal) 
(R) 25.6 
(S) 27.7 
2.93i 2-MeC6H4 CF3 CP-ChiraSil-Dex CB 
100 °C 
(isothermal) 
(R) 22.5 
(S) 23.0 
2.93j 2-Naphthyl CH3 CP-ChiraSil-Dex CB 160 °C (isothermal) 
(S) 47.5 
(R) 49.6 
2.93k 2-ClC6H4 CF3 CP-ChiraSil-Dex CB 
120 °C 
(isothermal) 
(R) 12.1 
(S) 13.3 
[a] Column: CP-ChiraSil-'H[&%PP[ȝP[P>E@&ROXPQ2FWDNLV-di-O-methyl-3-O-pentyl)-Ȗ-
F\FORGH[WULQȝPLGLQ29ZZ 
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2,2,2-Trifluoro-N-(1-phenylethyl)acetamide (±)-2.93a[276] 
 
Prepared directly from (±)-2.21a by general method D; Rf 0.50 (CH2Cl2); M.p. 90-92 °C; IR 
(CHCl3Ȟmax/cmí 3430, 1724, 1530, 1171; 1H NMR (400.1 MHz, CDCl3įH 7.41-7.37 (m, 
2H, CHaryl), 7.35-7.31 (m, 3H, CHaryl), 6.42 (br s, 1H, NHCH), 5.16 (quintet, J = 7.2 Hz, 1H, 
NHCH), 1.60 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 156.3 (C, q, 2JCF 
= 36.6 Hz), 140.9 (C), 129.0 (CH), 128.1 (CH), 126.1 (CH), 115.8 (C, q, 1JCF = 287 Hz), 49.8 
(CH), 21.0 (CH3); 19F NMR (376.5 MHz, CDCl3įF íHRMS (ESI Negative) calcd. for 
C10H10F312 >0í+@  IRXQG  7KHVH GDWD ZHUH consistent with literature 
values.[276] 
 
N-(1-p-Tolylethyl)acetamide (±)-2.93b[277] 
 
Prepared directly from (±)-2.21a by general method D; Rf 0.11 (1:1 pet. ether:EtOAc); M.p. 
48-51 °C; IR (CHCl3Ȟmax/cmí3442, 3011, 1711, 1665, 1363; 1H NMR (400.1 MHz, CDCl3) 
įH 7.19 (d, J = 8.0 Hz, 2H, CHaryl), 7.11 (d, J = 7.6 Hz, 2H, CHaryl), 6.40 (br d, J = 7.2 Hz, 1H, 
NHCH), 5.05 (quintet, J = 7.2 Hz, 1H, NHCH), 2.31 (s, 3H, ArCH3), 1.92 (s, 3H, COCH3), 
1.43 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3 įC 169.2 (C), 140.3 (C), 
136.5 (C), 130.0 (CH), 126.9 (CH), 48.3 (CH), 23.0 (CH3), 21.9 (CH3), 20.8 (CH3); HRMS 
(ESI Positive) calcd. for C11H15NO, [M+H] 178.1226, found 178.1218. These data were 
consistent with literature values.[277] 
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2,2,2-Trifluoro-N-(1-(4-fluorophenyl)ethyl)acetamide (±)-2.93c 
 
Prepared directly from (±)-2.21c by general method D; Rf 0.53 (CH2Cl2); M.p. 55-57 °C; IR 
(CHCl3Ȟmax/cmí 3429, 1723, 1607, 1513, 1170, 837; 1H NMR (400.1 MHz, CDCl3įH 7.31-
7.26 (m, 2H, CHaryl), 7.07-7.03 (m, 2H, CHaryl), 6.48 (br s, 1H, NHCH), 5.12 (quintet, J = 7.2 
Hz, 1H, NHCH), 1.58 (d, J = 7.2 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 162.4 
(C, d, 1JCF = 245 Hz), 156.3 (C, q, 2JCF = 37.1 Hz), 136.7 (C, d, 4JCF = 3.0 Hz), 127.9 (CH, d, 
3JCF = 7.6 Hz), 115.9 (CH, d, 2JCF = 21.3 Hz), 115.7 (C, d, 1JCF = 286 Hz), 49.1 (CH), 21.0 
(CH3); 19F NMR (376.5 MHz, CDCl3 įF í í HRMS (ESI Negative) calcd. for 
C10H9F412>0í+@IRXQG 
 
N-(1-(4-Chlorophenyl)ethyl)-2,2,2-trifluoroacetamide (±)-2.93d 
 
Prepared directly from (±)-2.21d by general method D; Rf 0.67 (CH2Cl2); M.p. 106-107 °C; IR 
(CHCl3Ȟmax/cmí3429, 1725, 1530, 1495, 1170, 828; 1H NMR (400.1 MHz, CDCl3įH 7.36-
7.33 (m, 2H, CH1), 7.27-7.24 (m, 2H, CH2), 6.47 (br s, 1H, NHCH), 5.11 (quintet, J = 7.2 Hz, 
1H, NHCH), 1.57 (d, J = 7.0 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 156.4 (C, q, 
2JCF = 36.6 Hz), 139.4 (C), 133.9 (C), 129.1 (CH), 127.5 (CH), 115.7 (C, q, 1JCF = 286 Hz), 
49.2 (CH), 21.0 (CH3); 19F NMR (376.5 MHz, CDCl3įF íHRMS (ESI Negative) calcd. 
for C10H9ClF312>0í+@IRXQG$QDO&DOFIRU&10H9ClF3NO: C, 47.73; 
H, 3.61; N, 5.57%. Found: C, 47.60; H, 3.59; N, 5.40%. 
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N-(1-(4-Bromophenyl)ethyl)-2,2,2-trifluoroacetamide (±)-2.93e[278] 
 
Prepared directly from (±)-2.21e by general method D; Rf 0.57 (CH2Cl2); M.p. 123-125 °C; IR 
(CHCl3Ȟmax/cmí3429, 1725, 1530, 1492, 1170, 1010, 824; 1H NMR (400.1 MHz, CDCl3įH 
7.52-7.49 (m, 2H, CH1), 7.21-7.18 (m, 2H, CH2), 6.47 (br s, 1H, NHCH), 5.10 (quintet, J = 7.2 
Hz, 1H, NHCH), 1.57 (d, J = 7.0 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 156.3 
(C, q, 2JCF = 36.6 Hz), 139.9 (C), 132.1 (CH), 127.8 (CH), 122.0 (C), 115.7 (C, q, 1JCF = 286 
Hz), 49.2 (CH), 21.0 (CH3); 19F NMR (376.5 MHz, CDCl3įF íHRMS (ESI Negative) 
calcd. for C10H9BrF312>0í+@ IRXQG7KHVHGDWDZHUH consistent with 
literature values.[278] 
 
2,2,2-Trifluoro-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamide (±)-2.93f 
 
Prepared directly from (±)-2.21f by general method D; Rf 0.66 (CH2Cl2); M.p. 78-80 °C; IR 
(CHCl3 Ȟmax/cmí 3429, 1726, 1531, 1327, 1171, 1132, 1070, 841; 1H NMR (400.1 MHz, 
CDCl3 įH 7.64 (d, J = 8.0 Hz, 2H, CH1), 7.44 (d, J = 8.4 Hz, 2H, CH2), 6.48 (br s, 1H, 
NHCH), 5.19 (quintet, J = 7.2 Hz, 1H, NHCH), 1.61 (d, J = 7.2 Hz, 3H, CHCH3); 13C NMR 
(100.6 MHz, CDCl3įC 156.5 (C, q, 2JCF = 37.1 Hz), 144.9 (C), 130.4 (C, q, 2JCF = 32.5 Hz), 
126.5 (CH), 126.0 (CH, q, 3JCF = 3.7 Hz), 123.9 (C, q, 1JCF = 271 Hz), 115.7 (C, q, 1JCF = 286 
Hz), 49.5 (CH), 21.2 (CH3); 19F NMR (376.5 MHz, CDCl3 įF í í HRMS (ESI 
Negative) calcd. for C11H9F612 >0í+@  IRXQG  7KLV FRPSRXQG LV
reported in the literature but no analytical data are quoted.[279] 
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2,2,2-Trifluoro-N-(1-m-tolylethyl)acetamide (±)-2.93g 
 
Prepared directly from (±)-2.21g by general method D; Rf 0.85 (CH2Cl2); M.p. 65-66 °C; IR 
(CHCl3Ȟmax/cmí3429, 1722, 1529, 1171; 1H NMR (400.1 MHz, CDCl3įH 7.28-7.25 (td, J = 
7.2, 1.2 Hz, 1H, CHaryl), 7.14-7.10 (m, 3H, CHaryl), 6.52 (br s, 1H, NHCH), 5.10 (quintet, J = 
6.8 Hz, 1H, NHCH), 2.36 (s, 3H, ArCH3), 1.57 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 
MHz, CDCl3įC 156.2 (C, q, 2JCF = 36.6 Hz), 140.8 (C), 138.8 (C), 128.9 (CH), 128.9 (CH), 
127.0 (CH), 123.1 (CH), 115.8 (C, q, 1JCF = 287 Hz), 49.9 (CH), 21.4 (CH3), 21.1 (CH3); 19F 
NMR (376.5 MHz, CDCl3įF íHRMS (ESI Negative) calcd. for C11H12F312>0í+@
230.0798, found 230.0810. 
 
 N-(1-(3-Chlorophenyl)ethyl)-2,2,2-trifluoroacetamide (±)-2.93h 
 
Prepared directly from (±)-2.21h by general method D; Rf 0.67 (CH2Cl2); M.p. 52-54 °C; IR 
(CHCl3Ȟmax/cmí 3428, 2984, 1724, 1530, 1169, 879; 1H NMR (400.1 MHz, CDCl3) GH 7.33-
7.28 (m, 3H, CHaryl), 7.21-7.19 (m, 1H, CHaryl), 6.59 (br s, 1H, NHCH), 5.10 (quintet, J = 7.2 
Hz, 1H, NHCH), 1.57 (d, J = 7.0 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 156.5 
(C, q, 2JCF = 37.1 Hz), 143.0 (C), 134.9 (C), 130.4 (CH), 128.4 (CH), 126.4 (CH), 124.5 (CH), 
115.8 (C, q, 1JCF = 286 Hz), 49.4 (CH), 21.1 (CH3); 19F NMR (376.5 MHz, CDCl3įF í
HRMS (ESI Negative) calcd. for C10H9F3&O12 >0í+@  IRXQG  $QDO
Calc. for C10H9F3ClNO: C, 47.73; H, 3.61; N, 5.57%. Found: C, 48.06; H, 3.65; N, 5.23%. 
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2,2,2-Trifluoro-N-(1-o-tolylethyl)acetamide (±)-2.93i 
 
Prepared directly from (±)-2.21i by general method D; Rf 0.55 (CH2Cl2); M.p. 65-67 °C; IR 
(CHCl3Ȟmax/cmí 3428, 3012, 1723, 1528, 1171;  1H NMR (400.1 MHz, CDCl3įH 7.31-7.19 
(m, 4H, CHaryl), 6.37 (br s, 1H, NHCH),  5.34 (quintet, J = 7.2 Hz, 1H, NHCH), 2.37 (s, 3H, 
ArCH3), 1.58 (d, J = 7.2 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC  156.1 (C, q, 2JCF 
= 36.6 Hz), 138.8 (C), 136.0 (C), 131.0 (CH), 128.1 (CH), 126.6 (CH), 124.6 (CH), 115.8 (C, 
q, 1JCF = 286 Hz), 46.3 (CH), 20.5 (CH3), 19.0 (CH3); 19F NMR (376.5 MHz, CDCl3įF í
HRMS (ESI Negative) calcd. for C11H12F312>0í+@IRXQG 
 
N-(1-(Naphthalen-2-yl)ethyl)acetamide (±)-2.93j[280] 
 
Prepared directly from (±)-2.21j by general method D; Rf 0.60 (1:1 pet. ether:EtOAc); IR 
(CHCl3 Ȟmax/cmí 3441, 3011, 1666, 1507; 1H NMR (400.1 MHz, CDCl3 įH 7.82-7.79 (m, 
3H, CHaryl), 7.75 (br s, 1H, CHaryl), 7.48-7.42 (m, 3H, CHaryl), 5.89 (br d, J = 5.6 Hz, 1H, 
NHCH), 5.29 (quintet, J = 7.2 Hz, 1H, NHCH), 2.00 (s, 3H, COCH3), 1.57 (d, J = 6.8 Hz, 3H, 
CHCH3); 13C NMR (100.6 MHz, CDCl3įC 169.1 (C), 140.5 (C), 133.3 (C), 132.7 (C), 128.6 
(CH), 127.8 (CH), 127.6 (CH), 126.2 (CH), 125.9 (CH), 124.7 (CH), 124.5 (CH), 48.8 (CH), 
23.5 (CH3), 21.6 (CH3); HRMS (ESI Positive) calcd. for C14H15NO, [M+H] 214.1226, found 
214.1216. These data were consistent with literature values.[280] 
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N-(1-(2-Chlorophenyl)ethyl)-2,2,2-trifluoroacetamide (±)-2.93k 
 
Prepared directly from (±)-2.21k by general method D; Rf 0.75 (CH2Cl2);  M.p. 101-103 °C; 
IR (CHCl3Ȟmax/cmí3432, 1726, 1530, 1171, 1041; 1H NMR (400.1 MHz, CDCl3įH 7.42-
7.39 (m, 1H, CHaryl), 7.34-7.31 (m, 1H, CHaryl), 7.30-7.25 (m, 2H, CHaryl), 6.78 (br s, 1H, 
NHCH), 5.42 (quintet, J = 7.2 Hz, 1H, NHCH), 1.61 (d, J = 7.2 Hz, 3H, CHCH3); 13C NMR 
(100.6 MHz, CDCl3 įC 156.1 (C, q, J = 37.1 Hz), 138.0 (C), 133.0 (C), 130.5 (CH), 129.3 
(CH), 127.4 (CH), 127.4 (CH), 115.8 (C, q, J = 286 Hz), 48.2 (CH), 20.2 (CH3); 19F NMR 
(376.5 MHz, CDCl3 įF í HRMS (ESI Negative) calcd. for C10H9ClF312 >0í+@
250.0252, found 250.0255. 
 
1-p-Tolylethanone oxime 2.91[281] 
 
Hydroxylamine hydrochloride (903 mg, 13 mmol) and triethylamine (1.18 mL, 13 mmol) were 
added to stirred solution of 4-methylacetophenone (1.34 mL, 10 mmol) in EtOH (10 mL). The 
solution was stirred at reflux for 3 hours and then concentrated to a colourless oil, which was 
partitioned between water (50 mL) and EtOAc (2 × 30 mL). The organics were washed with 
brine (20 mL), dried (MgSO4) and concentrated to a white crystalline solid (1.40 g, 93%); Rf 
0.82 (EtOAc); M.p. 82-85 °C; lit. 86-88 °C;[282] IR (CHCl3Ȟmax/cmí 3584, 3313, 3009, 1516, 
1369, 1291, 1277, 1003, 919, 823; 1H NMR (400.1 MHz, CDCl3įH 9.48 (br s, 1H, OH), 7.51 
(d, J = 8.4 Hz, 2H, CHaryl), 7.18 (d, J = 7.6 Hz, 2H, CHaryl), 2.36 (s, 3H, ArCH3), 2.21 (s, 3H, 
N=CCH3); 13C NMR (100.6 MHz, CDCl3 įC 155.9 (C), 139.3 (C), 133.6 (C), 129.2 (CH), 
125.9 (CH), 21.2 (CH3), 12.3 (CH3); HRMS (ESI Positive) calcd. for C9H11NO, [M+H] 
150.0913, found 150.0909. These data were consistent with literature values.[283] 
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(E)-P,P-Diphenyl-N-(1-p-tolylethylidene)phosphinic amide 2.92[284] 
 
Chlorodiphenyl phosphine (0.95 mL, 5 mmol) in CH2Cl2 (5 mL) was added dropwise over 20 
min to a solution of 2.91 (746 mg, 5 mmol) and triethylamine (0.69 mL, 5 mmol) in 
CH2Cl2SHWHWKHUP/DWí&7KHVXVSHQVLRQZDVVWLUUHGDWí&IRUPLQDQGWKHQ
allowed to warm to rt over 2 h. The suspension was concentrated to a cream solid, dissolved in 
CH2Cl2 (25 mL), washed with sat. NaHCO3 solution (20 mL) and brine (20 mL). The organics 
were dried (MgSO4) and concentrated to a cream solid which was purified by column 
chromatography (1:1 pet. ether:EtOAc) to afford the product as a white solid (1.20 g, 72%); Rf 
0.19 (1:1 pet. ether:EtOAc); M.p. 118-120 °C; IR (CHCl3Ȟmax/cmí 3358, 2988, 1637, 1606, 
1438, 1279, 1183, 833; 1H NMR (400.1 MHz, CDCl3įH 8.00-7.95 (m, 6H, CHaryl), 7.46-7.40 
(m, 6H, CHaryl), 7.31-7.26 (m, 2H, CHaryl), 2.93 (d, J = 2.0 Hz, 3H, N=CCH3), 2.43 (s, 3H, 
ArCH3); 13C NMR (100.6 MHz, CDCl3įC 181.4 (d, J = 7.6 Hz), 143.2, 136.9 (d, 3JCP = 23.9 
Hz), 134.9 (d, 1JCP = 130 Hz), 131.6 (d, 2JCP = 9.0 Hz), 131.3 (d, 4JCP = 2.7 Hz), 129.2, 128.4 
(d, 3JCP = 12.3 Hz), 128.0, 23.0 (d, 3JCP = 12.5 Hz), 21.5; 31P NMR (161.7 MHz, CDCl3įP 
18.7; HRMS (ESI Positive) calcd. for C21H20NOP, [M+H] 334.1355, found 334.1343. These 
data were consistent with literature values.[284] 
 
N,N¶-Bis(phenylmethylene) sulfamide 3.85a[207] 
 
Prepared from benzaldehyde (5.10 mL, 50 mmol) using general method E. The filtrate was 
concentrated to a cream solid which was recrystallised from iPrOH to afford the product as 
white crystals (4.51 g, 66%); Rf 0.10 (3:1 pet. ether:EtOAc); M.p. 145-146 °C (iPrOH); lit. 
149-150 °C;[285] IR (CHCl3 Ȟmax/cmí 1611, 1599, 1571, 1453, 1329, 1150, 824; 1H NMR 
(400.1 MHz, CDCl3 įH 9.18 (s, 2H, N=CH), 8.01-7.98 (m, 4H, CHaryl), 7.67-7.64 (m, 2H, 
CHaryl), 7.55-7.51 (m, 4H, CHaryl); 13C NMR (100.6 MHz, CDCl3įC 173.2 (CH), 135.3 (CH), 
132.3 (C), 131.5 (CH), 129.2 (CH); HRMS (ESI Positive) calcd. for C14H12N2O2S, [M+H] 
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273.0692, found 273.0692; Anal. Calc. for C14H12N2O2S: C, 61.75; H, 4.44; N, 10.29%. Found: 
C, 61.49; H, 4.50; N, 10.22%. These data were consistent with literature values.[285] 
 
N,N'-Bis[(4-fluorophenyl)methylidene]sulfamide 3.85b 
 
Prepared from 4-fluorobenzaldehyde (2.15 mL, 20 mmol) using general method E. Large 
crystals formed and were collected by filtration and then physically separated from the 
Amberlyst® 15 to give the product as white crystals (2.28 g, 77%); Rf 0.70 (8:2 EtOAc:pet. 
ether); M.p. 208-210 °C; IR 1XMROȞmax/cmí 3414, 1600, 1583, 1236, 1144, 839; 1H NMR 
(400.1 MHz, DMSO-d6įH 9.25 (s, 2H, N=CH), 8.23-8.18 (m, 4H, CHaryl), 7.49-7.43 (m, 4H, 
CHaryl); 13C NMR (100.6 MHz, DMSO-d6įC 172.4 (CH), 166.3 (C, d, 1JCF = 254 Hz), 134.4 
(CH), 129.0 (C), 116.7 (CH, d, 2JCF = 22.9 Hz); 19F NMR (376.5 MHz, DMSO-d6įF í
HRMS (ESI Positive) calcd. for C14H10F2N2O2S, [M+Na] 331.0323, found 331.0334; Anal. 
Calc. for C14H10F2N2O2S: C, 54.54; H, 3.27; N, 9.09%. Found: C, 54.31; H, 3.20; N, 9.01%. 
 
N,N'-Bis[(4-methylphenyl)methylidene]sulfamide 3.85d[209,210] 
 
A suspension of sulfamide (961 mg, 10 mmol), p-tolualdehyde (2.37 mL, 20 mmol) and 
methanesulfonic acid (17 µL, 0.5 mmol) in benzene (25 mL) was refluxed overnight using a 
Dean-Stark trap. A white precipitate formed and was collected by filtration and washed with 
hexanes. Trituration with iPrOH gave the product as a white powder (1.17 g, 57%); Rf 0.51 
(1:1 pet. ether:EtOAc); M.p. 212-213 °C; IR (CHCl3Ȟmax/cmí 3045, 1594, 1561, 1327, 1148, 
829; 1H NMR (400.1 MHz, CDCl3įH 9.12 (s, 2H, N=CH), 7.88 (d, J = 8.0 Hz, 4H, CHaryl), 
7.32 (d, J = 8.0 Hz, 4H, CHaryl), 2.45 (s, 6H, ArCH3); 13C NMR (100.6 MHz, CDCl3įC 172.2 
(CH), 146.8 (C), 131.6 (CH), 130.0 (CH), 129.8 (C), 21.1 (CH3); HRMS (ESI Positive) calcd. 
for C16H16N2O2S, [M+Na] 323.0825, found 323.0811; Anal. Calc. for C16H16N2O2S: C, 63.98; 
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H, 5.37; N, 9.33%. Found: C, 63.81; H, 5.34; N, 9.30%. This compound is reported in the 
literature but no analytical data are quoted.[209,210] 
 
N,N'-Bis[(2-methylphenyl)methylidene]sulfamide 3.85e 
 
Prepared from o-tolualdehyde (2.31 mL, 20 mmol) using general method E. Hexanes was 
added to the filtrate and the resulting cream precipitate was filtered and recrystallised from 
iPrOH to afford the product as white needles (1.34g, 45%); Rf 0.23 (4:1 pet. ether:EtOAc); 
M.p. 139-140 °C (iPrOH); IR (CHCl3Ȟmax/cmí 3043, 1607, 1588, 1562, 1327, 1150, 836; 1H 
NMR (400.1 MHz, CDCl3įH 9.49 (s, 2H, N=CH), 8.09 (dd, J = 7.8, 1.0 Hz, 2H, CHaryl), 7.51 
(td, J = 7.6, 1.6 Hz, 2H, CHaryl) 7.32 (t, J = 7.8 Hz, 2H, CHaryl), 7.30 (dt, J = 7.6, 0.6 Hz, 2H, 
CHaryl), 2.65 (s, 6H, ArCH3); 13C NMR (100.6 MHz, CDCl3įC 171.4 (CH), 142.5 (C), 134.9 
(CH), 131.6 (CH), 130.6 (CH), 130.4 (C), 126.7 (CH), 19.6 (CH3); HRMS (ESI Positive) 
calcd. for C16H16N2O2S, [M+Na] 323.0825, found 323.0823; Anal. Calc. for C16H16N2O2S: C, 
63.98; H, 5.37; N, 9.33%. Found: C, 63.92; H, 5.42; N, 9.23%. 
 
N,N'-Bis[(4-methoxyphenyl)methylidene]sulfamide 3.85f[285] 
 
Prepared from p-anisaldehyde (2.25 mL, 20 mmol) using general method E. The filtrate was 
concentrated to a cream solid which was triturated with iPrOH to afford the product (2.34g, 
71%); Rf 0.16 (3:1 pet. ether:EtOAc); M.p. 181-182 °C; lit. 184-185 °C;[285] IR (CHCl3) 
Ȟmax/cmí 3043, 1589, 1558, 1514, 1317, 1265, 1115, 825; 1H NMR (400.1 MHz, CDCl3įH 
9.06 (s, 2H, N=CH), 7.94 (dt, J = 8.8, 2.4 Hz, 4H, CHaryl), 7.00 (dt, J = 8.8, 2.3 Hz, 4H, CHaryl), 
3.90 (s, 6H, OCH3); 13C NMR (100.6 MHz, CDCl3 įC 171.4 (CH), 165.4 (C), 133.9 (CH), 
125.2 (C), 114.7 (CH), 55.7 (CH3); HRMS (ESI Positive) calcd. for C16H16N2O4S, [M+Na] 
355.0723, found 355.0717; Anal. Calc. for C16H16N2O4S: C, 57.82; H, 4.85; N, 8.43%. Found: 
C, 57.69; H, 4.83; N, 8.48%. These data were consistent with literature values.[285] 
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N,N'-Bis[(3-methylphenyl)methylidene]sulfamide 3.85h 
 
Prepared from m-tolualdehyde (2.36 mL, 20 mmol) using general method E. The filtrate was 
concentrated to a light brown solid which was recrystallised from iPrOH to afford the product 
as white crystals (2.15 g, 72%); Rf 0.51 (1:1 pet. ether:EtOAc); M.p. 101-103 °C (iPrOH); IR 
(CHCl3Ȟmax/cmí 1595, 1575, 1299, 1150, 837; 1H NMR (400.1 MHz, CDCl3įH 9.14 (s, 2H, 
N=CH), 7.84-7.83 (m, 2H, CHaryl), 7.77 (dm, J = 7.6 Hz, 2H, CHaryl) 7.47 (dm, J = 7.6 Hz, 2H, 
CHaryl), 7.41 (t, J = 7.6 Hz, 2H, CHaryl), 2.42 (s, 6H, ArCH3); 13C NMR (100.6 MHz, CDCl3) 
įC 173.3 (CH), 139.2 (C), 136.2 (CH), 132.3 (C), 131.5 (CH), 129.2 (CH), 129.1 (CH), 21.1 
(CH3); HRMS (ESI Positive) calcd. for C16H16N2O2S, [M+H] 301.1005, found 301.1007; 
Anal. Calc. for C16H16N2O2S: C, 63.98; H, 5.37; N, 9.33%. Found: C, 63.63; H, 5.41; N, 
9.31%. 
 
N,N'-Bis[(4-bromophenyl)methylidene]sulfamide 3.85i 
 
Prepared from m-tolualdehyde 4-bromobenzaldehyde (3.70 g, 20 mmol) using general method 
E. The resulting suspension was allowed to cool, the Amberlyst® 15 and white solid were 
removed by filtration. The Amberlyst® 15 was removed by hot filtration with toluene, on 
cooling a white solid formed which was collected by filtration (1.83 g, 43%); M.p. 260-262 
°C; IR 1XMROȞmax/cmí 1585, 1558, 1324, 1146, 872; 1H NMR (400.1 MHz, DMSO-d6įH 
9.24 (s, 2H, N=CH), 8.03 (d, J = 8.4 Hz, 4H, CHaryl), 7.84 (d, J = 8.4 Hz, 4H, CHaryl); 13C 
NMR (100.6 MHz, DMSO-d6 įC 192.4, 165.8, 132.5, 132.1, 131.3; Anal. Calc. for 
C14H10Br2N2O2S: C, 39.09; H, 2.34; N, 6.51%. Found: C, 38.93; H, 2.28; N, 6.32%. 
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N,N'-Sulfonyl bis-[1-phenylethylamine] 3.96[207] 
 
Methylmagnesium bromide (3.0 M in Et2O, 0.73 mL, 2.20 mmol) was added dropwise to a 
stirred solution of N,N¶-bis(phenylmethylene) sulfamide 3.85a (150 mg, 0.55 mmol) in Et2O (5 
mL) at 0 °C. The solution was stirred for 3 h and allowed to warm to rt, sat. NH4Cl solution (10 
mL) was added. The solution was extracted with Et2O (2 × 20 mL), the organics dried 
(Na2SO4) and concentrated to a colourless oil which was crystallised from Et2O/hexane to give 
white crystals (118 mg, 70%); Rf 0.82 (EtOAc); M.p. 77-79 °C (Et2O/hexane); IR (CHCl3) 
Ȟmax/cmí 3383, 3011, 2978, 1455, 1418, 1329, 1155, 970; 1H NMR (400.1 MHz, CDCl3įH 
7.33-7.30 (m, 2H, CHaryl), 7.27-7.20 (m, 6H, CHaryl), 7.14-7.11 (m, 2H, CHaryl), 4.59 (d, J = 6.0 
Hz, 1H, NHCHmeso), 4.53 (d, J = 6.4 Hz, 1H, NHCHrac), 4.39 (m, 2H, NHrac+mesoCH), 1.44 (d, J 
= 6.8 Hz, 3H, CHCH3rac), 1.24 (d, J = 6.8 Hz, 3H, CHCH3meso); 13C NMR (100.6 MHz, CDCl3) 
įC 143.0 (Cmeso), 142.6 (Crac), 128.7 (CH), 127.6 (CH), 126.2 (CHmeso), 126.1 (CHrac), 53.8 
(CHrac), 53.6 (CHmeso), 23.6 (CH3rac), 23.5 (CH3meso); HRMS (ESI Positive) calcd. for 
C16H20N2O2S, [M+H] 305.1318, found 305.1335; Anal. Calc. for C16H20N2O2S: C, 63.13; H, 
6.62; N, 9.20%. Found: C, 63.09; H, 6.61; N, 9.13%. This compound is reported in the 
literature but no analytical data are quoted,[207] but (R,R)-3.96 has data in lit.[221] 
 
N,N'-Sulfonyl bis-[(R)-1-phenylethylamine] (R,R)-3.96[221] 
 
Sulfuryl chloride (0.16 mL, 2 mmol) was added dropwise to a stirred solution of (R)-1-
phenylethylamine (R)-2.1 (0.54 mL, 4.2 mmol) and triethylamine (1.67 mL, 12 mmol) in 
CH2Cl2 (25 mL) at 0 °C. The yellow solution was allowed to warm to rt and stirred overnight. 
The solution was washed with 10% NaHSO4 solution (2 × 50 mL), sat. NaHCO3 solution (50 
mL) and brine (50 mL), then dried (Na2SO4) and concentrated to a yellow oil. Column 
chromatography (3:1 hexanes:EtOAc) resulted in a cream solid (140 mg, 23%); Rf 0.26 (4:1 
hexanes:EtOAc); M.p. 95-97 °C; lit. 96-97 °C;[221] >Į@D = +15.3 (c = 0.64, CHCl3); IR (CHCl3) 
Ȟmax/cmí 3383, 2980, 1455, 1418, 1329, 1154, 970; 1H NMR (400.1 MHz, CDCl3įH 7.27-
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7.21 (m, 6H, CHaryl), 7.15-7.13 (m, 4H, CHaryl), 4.46-4.38 (m, 4H, NHCH and NHCH), 1.46 (d, 
J = 6.4 Hz, 6H, CHCH3); 13C NMR (100.6 MHz, CDCl3 įC 142.5 (C), 128.7 (CH), 127.6 
(CH), 126.1 (CH), 53.8 (CH), 23.6 (CH3); HRMS (ESI Positive) calcd. for C16H20N2O2S, 
[M+H] 305.1318, found 305.1335; Anal. Calc. for C16H20N2O2S: C, 63.13; H, 6.62; N, 9.20%. 
Found: C, 63.02; H, 6.61; N, 9.16%. These data were consistent with literature values.[221] 
 
2-Oxo-N-((R)-1-phenylethyl)oxazolidine-3-sulfonamide (R)-3.98[286] 
 
Synthesised following the procedure of Borghese et al.,[222] 2-bromoethanol (0.71 mL, 10 
mmol) in CH2Cl2 (2 mL) was added dropwise to a stirred solution of chlorosulfonyl isocyanate 
(0.87 mL, 10 mmol) in CH2Cl2 (10 mL) at 0 °C. The colourless solution was stirred for 1 h at 
0 °C. A solution of (R)-1-phenylethylamine (R)-2.1 (1.42 mL, 11 mmol) and triethylamine 
(3.07 mL, 11 mmol) in CH2Cl2 (5 mL) was added dropwise to the cooled solution. The ice bath 
was removed and the white suspension was stirred at rt for 1 h. The reaction mixture was 
extracted with 0.2 M HCl (20 mL). The organics were concentrated to a white solid which was 
washed with water to give the product (2.66 g, 98%); Rf 0.20 (3:1 pet. ether:EtOAc); M.p. 
159-162 °C; lit. 164-166 °C;[286] >Į@D = +14.1 (c = 1.03, EtOH; lit.[286] +26.1, c = 1.00, EtOH); 
IR (CHCl3 Ȟmax/cmí 3364, 1769, 1424, 1391, 1179, 1161, 623; 1H NMR (400.1 MHz, 
CDCl3įH 7.41-7.32 (m, 5H, CHaryl), 5.92 (d, J = 8.0 Hz, 1H, NHCH), 4.62 (quintet, J = 7.2 
Hz, 1H, NHCH), 4.09 (dt, J = 6.8, 8.2 Hz, 1H, OCHĮCH2N), 3.73 (dt, J = 6.8, 8.8 Hz, 1H, 
OCH2CHĮN), 3.65 (dt, J = 6.4, 8.4 Hz, 1H, OCHȕCH2N), 3.09 (dt, J = 6.8, 8.8 Hz, 1H, 
OCH2CHȕN), 1.55 (d, J = 7.2 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3įC 152.9 (C), 
141.3 (C), 129.0 (CH), 128.2 (CH), 126.2 (CH), 62.4 (CH2), 55.2 (CH), 44.6 (CH2), 23.0 
(CH3); HRMS (ESI Positive) calcd. for C11H14N2O4S, [M+Na] 293.0566, found 293.0557; 
Anal. Calc. for C11H14N2O4S: C, 48.88; H, 5.22; N, 10.36%. Found: C, 48.95; H, 5.19; N, 
10.19%. These data were consistent with literature values.[286] 
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N-[(R)-1-Phenylethyl]-N'-[(S)-1-phenylethyl]sulfamide meso-3.96 
 
Following the procedure of Borghese et al.,[222] a suspension of (R)-2-oxo-N-(1-
phenylethyl)oxazolidine-3-sulfonamide (R)-3.98 (297 mg, 1.1 mmol), (S)-1-phenylethylamine 
(S)-2.1 (129 µL, 1 mmol) and triethylamine (383 µL, 2.75 mmol) in MeCN (10 mL) was 
stirred at reflux for 3 h. The reaction mixture was concentrated and the residue was partitioned 
between EtOAc (30 mL) and H2O (30 mL). The organics were washed with 1 M HCl (30 mL) 
and 1 M NaOH (30 mL), dried (Na2SO4) and concentrated to a yellow oil. This was purified by 
column chromatography (4:1 pet. ether:EtOAc) to give a colourless oil which formed white 
crystals on standing (250 mg, 82%); Rf 0.22 (4:1 pet. ether:EtOAc); M.p. 85-87 °C; IR 
(CHCl3Ȟmax/cmí 3383, 2979, 1417, 1330, 1155, 968; 1H NMR (400.1 MHz, CDCl3įH 7.34-
7.22 (m, 10H, CHaryl), 4.65 (d, J = 8.0 Hz, 2H, NHCH), 4.37 (quintet, J = 6.8 Hz, 2H, NHCH), 
1.22 (d, J = 6.8 Hz, 6H, CHCH3); 13C NMR (100.6 MHz, CDCl3įC 143.1 (C), 128.6 (CH), 
127.5 (CH), 126.2 (CH), 53.6 (CH), 23.5 (CH3); HRMS (ESI Positive) calcd. for 
C16H20N2O2S, [M+Na] 327.1138, found 327.1132; Anal. Calc. for C16H20N2O2S: C, 63.13; H, 
6.62; N, 9.20%. Found: C, 63.19; H, 6.63; N, 9.16%. 
 
N-(Diphenylmethyl)-2-oxo-1,3-oxazolidine-3-sulfonamide 3.119a 
 
Synthesised as (R)-3.98 following the procedure of Borghese et al.,[222] using 
aminodiphenylmethane 3.40a (379 µL, 2.2 mmol). Work up gave a yellow oil which was 
purified using column chromatography (2:1 pet. ether:EtOAc) to give the product as a white 
solid (261 mg, 39%); Rf 0.24 (2:1 pet. ether:EtOAc); M.p. 175-177 °C; IR (CHCl3Ȟmax/cmí 
3368, 3068, 1774, 1424, 1390, 1178, 1161, 1048; 1H NMR (400.1 MHz, DMSO-d6įH 9.63 
(d, J = 9.6 Hz, 1H, NHCH), 7.41-7.39 (m, 4H, CHaryl), 7.35-7.32 (m, 4H, CHaryl), 7.26 (tt, J = 
7.2, 1.7 Hz, 2H, CHaryl), 5.70 (d, J = 9.6 Hz, 1H, NHCH), 3.96-3.92 (m, 2H, NCH2CH2O), 
3.76-3.72 (m, 2H, NCH2CH2O); 13C NMR (100.6 MHz, CDCl3įC 151.7 (C), 141.1 (C), 128.4 
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(CH), 127.3 (CH), 127.1 (CH), 62.0 (CH2), 60.8 (CH), 45.1 (CH2); HRMS (ESI Positive) 
calcd. for C16H16N2O4S, [M+Na] 355.0723, found 355.0730; Anal. Calc. for C16H16N2O4S: C, 
57.82; H, 4.85; N, 8.43%. Found: C, 57.79; H, 4.82; N, 8.39%. 
 
N-[(R)-(4-Fluorophenyl)(phenyl)methyl]-2-oxo-1,3-oxazolidine-3-sulfonamide (R)-3.119b 
 
Synthesised as (R)-3.98 following the procedure of Borghese et al.[222] using (R)-(4-
fluorophenyl)(phenyl)methanamine (R)-3.40b (90% ee, 138 mg, 0.686 mmol). Work up gave a 
white solid which was purified using column chromatography (2:1 pet. ether:EtOAc) to give 
the product as a white solid (78 mg, 36%); Rf 0.28 (2:1 pet. ether:EtOAc); M.p. 181-183 °C; 
IR (CHCl3Ȟmax/cmí 3368, 3204, 1773, 1510, 1390, 1177, 1161, 1050; >Į@D = +2.3 (c = 0.80, 
EtOH); 1H NMR (400.1 MHz, DMSO-d6įH 9.64 (d, J = 10.0 Hz, 1H, NHCH), 7.45-7.32 (m, 
6H, CHaryl), 7.29-7.25 (m, 1H, CHaryl) 7.19-7.14 (m, 2H, CHaryl), 5.73 (d, J = 9.6 Hz, 1H, 
NHCH), 4.05-3.96 (m, 2H, NCH2CH2O), 3.83-3.73 (m, 2H, NCH2CH2O); 13C NMR (100.6 
MHz, DMSO-d6įC 161.3 (C, d, 1JCF = 241 Hz), 151.7 (C), 141.0 (C), 137.4 (C), 129.2 (CH, d, 
3JCF = 7.6 Hz), 128.5 (CH), 127.4 (CH), 127.0 (CH), 115.2 (CH, d, 2JCF = 21.3 Hz), 62.1 
(CH2), 60.0 (CH), 45.1 (CH2); 19F NMR (376.5 MHz, CDCl3 įF í HRMS (ESI 
Positive) calcd. for C16H15FN2O4S, [M+Na] 373.0629, found 373.0638; Anal. Calc. for 
C16H15FN2O4S: C, 54.85; H, 4.32; N, 8.00%. Found: C, 54.49; H, 4.23; N, 7.88%. 
 
N,N'-Sulfonyl bis-[diphenylmethanamine] 3.100a[207] 
 
Synthesised following the borate addition procedure of Hayashi et al.[224] A flame dried 
Schlenk was charged with bromobenzene (0.13 mL, 1.25 mmol) and Et2O (0.5 mL) then 
cooled to 0 °C. n-Butyllithium (1.6 M in hexanes, 0.78 mL, 1.25 mmol) was added dropwise. 
The solution was stirred at rt for 1 h, then cooled to ±78 °C. Freshly distilled trimethyl borate 
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(0.14 mL, 1.25 mmol) was added dropwise. After stirring at ±78 °C for 30 min the solution was 
allowed to warm to rt then imine 3.85a (68.1 mg, 0.25 mmol), [RhCl(C2H4)2]2 (2.9 mg, 7.5 
µmol), (R,R,R)-3.99 (5.5 mg, 16.5 µmol), 3.1 M KOH(aq) (32.2 µL, 40 mol/%) and dioxane (2 
mL) were added and the yellow suspension was stirred at 80 °C for 3 h. The mixture became 
brown, and was quenched with sat. Na2CO3 solution (20 mL), extracted with EtOAc (2 × 20 
mL). The organics were dried (Na2SO4) and concentrated to a brown solid. Purification by 
column chromatography (3:1 Pet ether:EtOAc) gave the product as a yellow solid which was 
triturated with hexanes to give a pure white powder (80.1 mg, 75%). 
Synthesised as meso-3.96 following the procedure of Borghese et al.,[222] using 
aminodiphenylmethane (47 µL, 0.274 mmol). Work up gave a white solid which was purified 
using column chromatography (3:1 pet. ether:EtOAc) to give the product as a white solid (88.0 
mg, 75%). 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (3:1 pet. ether:EtOAc) to afford the product as 
a white solid (83.3 mg, 78%); Rf 0.65 (1:1 pet. ether:EtOAc); M.p. 154-155 °C; IR (Nujol) 
Ȟmax/cmí 3352, 3294, 1493, 1321, 1145, 973; 1H NMR (400.1 MHz, acetone-d6įH 7.30-7.18 
(m, 20H, CHaryl), 6.83 (d, J = 8.0 Hz, 2H, NHCH), 5.59 (d, J = 8.4 Hz, 2H, NHCH); 13C NMR 
(100.6 MHz, acetone-d6 įC 143.6 (C), 129.2 (CH), 128.4 (CH), 127.9 (CH), 62.1 (CH); 
HRMS (ESI Positive) calcd. for C26H24N2O2S, [M+H] 451.1451, found 451.1456; Anal. Calc. 
for C26H24N2O2S: C, 72.87; H, 5.64; N, 6.54%. Found: C, 72.70; H, 5.66; N, 6.54%. This 
compound is reported in the literature but no analytical data are quoted.[207] 
 
N,N'-Sulfonyl bis-[(4-fluorophenyl)(phenyl)methanamine] 3.100b 
 
Prepared from 3.85b (231 mg, 0.75 mmol) using general method G, purified by column 
chromatography (4:1 pet. ether:EtOAc) to afford the product as a white solid (217 mg, 62%) as 
a 1:1 mixture of rac and meso diastereoisomers; Rf 0.45 (3:1 pet. ether:EtOAc); M.p. 141-143 
°C; IR (CHCl3 Ȟmax/cmí 3384, 1606, 1510, 1333, 1157; 1H NMR (400.1 MHz, CDCl3 įH 
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7.27-7.22 (m, 6H, CHaryl), 7.12-7.06 (m, 8H, CHaryl), 6.93-6.86 (m, 4H, CHaryl), 5.52 (d, J = 6.8 
Hz, 2H, NHCH), 4.94 (d, J = 6.8 Hz, 2H, NHCH); 13C NMR (100.6 MHz, CDCl3įC 162.0 
(C, d, 1JCF = 245 Hz), 140.8 (Cmeso/rac), 140.7 (Crac/meso) 136.8 (C, app. t, 4JCF = 3.0 Hz), 128.9 
(CHmeso/rac), 128.8 (CHrac/meso), 128.8 (CH), 127.8 (CH), 127.1 (CHmeso/rac), 127.0 (CHrac/meso), 
115.5 (CH, d, 2JCF = 21.4 Hz), 60.8 (CH); 19F NMR (376.5 MHz, CDCl3įF -114.66 (rac), -
114.68 (meso); HRMS (ESI Positive) calcd. for C26H22F2N2O2S, [M+Na] 487.1262, found 
487.1263; Anal. Calc. for C26H22F2N2O2S: C, 67.23; H, 4.77; N, 6.03%. Found: C, 67.07; H, 
4.75; N, 5.95%; HPLC: Daicel Chiralcel OD-H and Chiralcel OD columns in series (total 
column length = 50 cm), 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer tR = 
82.1 min, meso tR = 101.0 min, (R,R)-enantiomer tR = 106.5 min. 
 
N-[(R)-(4-fluorophenyl)(phenyl)methyl]-N'-[(S)-(4-
fluorophenyl)(phenyl)methyl]sulfamide meso-3.100b 
 
Synthesised as meso-3.96 following the procedure of Borghese et al.,[222] using (S)-(4-
fluorophenyl)(phenyl)methanamine (S)-3.40b (86% ee, 50 mg, 0.143 mmol). Work up gave a 
colourless oil which was purified using column chromatography (4:1 pet. ether:EtOAc) to give 
the product as a white solid (53.8 mg, 81%, 93:7 dr). Analytical data as for 3.100b except: 13C 
NMR (100.6 MHz, CDCl3įC 162.1 (C, d, 1JCF = 245 Hz), 140.7 (C) 136.8 (C), 129.0 (CH), 
128.9 (CH), 127.9 (CH), 127.1 (CH), 115.5 (CH, d, 2JCF = 21.3 Hz), 60.9 (CH); 19F NMR 
(376.5 MHz, CDCl3įF -114.64. 
 
N,N'-Sulfonyl bis-[(R)-(4-fluorophenyl)(phenyl)methanamine] (R,R)-3.100b 
 
Prepared from 3.85b (77.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
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(89.7 mg, 73%, 97:3 dr, >99% ee). Analytical data as for 3.100b except: >Į@D = ±3.1 (c = 1.11, 
CHCl3, for 97:3 dr, >99% ee material); 13C NMR (100.6 MHz, CDCl3įC 162.1 (d, 1JCF = 246 
Hz, C), 140.7 (C) 136.8 (C), 128.9 (CH), 128.8 (CH), 127.9 (CH), 127.1 (CH), 115.5 (d, 2JCF = 
21.9 Hz, CH), 60.8 (CH); 19F NMR (376.5 MHz, CDCl3įF -114.61. 
 
N,N'-Sulfonyl bis-[(S)-(4-fluorophenyl)(phenyl)methanamine] (S,S)-3.100b 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28b (219 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(80.5 mg, 69 %, 92:8 dr, >99% ee). Analytical data as for (R,R)-3.100b except; >Į@D = ±0.8 (c 
= 1.00, CHCl3, for 92:8 dr, >99% ee material). 
 
N,N'-Sulfonyl bis-[(4-chlorophenyl)(phenyl)methanamine] 3.100c 
 
Sulfuryl chloride (57 µL, 0.70 mmol) was added to a stirred solution of (4-
chlorophenyl)(phenyl)methanamine 3.40c (320 mg, 1.46 mmol) and triethylamine (582 µL, 
4.19 mmol) in CH2Cl2 (10 mL) at 0 °C. Stirred overnight and allowed to warm to rt. Then 
washed with 10% NaHSO4 solution (2 × 25 mL), sat. NaHCO3 solution (25 mL) and brine (25 
mL). The organics were dried (Na2SO4) and concentrated to a yellow oil which was purified by 
column chromatography (3:1 pet. ether:EtOAc) to afford the product as a white solid (61 mg, 
18%) as a 1:1 mixture of rac and meso diastereoisomers; Rf 0.45 (3:1 pet. ether:EtOAc); M.p. 
103-105 °C; IR (CHCl3 Ȟmax/cmí 3380, 1492, 1421, 1334, 1155; 1H NMR (400.1 MHz, 
CDCl3įH 7.27-7.22 (m, 6H, CHaryl), 7.21-7.16 (m, 4H, CHaryl), 7.10-7.04 (m, 8H, CHaryl), 5.50 
(d, J = 6.8 Hz, 2H, NHCH), 4.90 (d, J = 6.8 Hz, 2H, NHCH); 13C NMR (100.6 MHz, CDCl3) 
įC 140.5 (C), 139.4 (C), 133.6 (Crac), 133.5 (Cmeso), 128.9 (CH), 128.8 (CH), 128.5 (CHrac), 
128.4 (CHmeso), 128.0 (CH), 127.1 (CHrac), 127.0 (CHmeso), 60.9 (CH); HRMS (ESI Positive) 
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calcd. for C26H22Cl2N2O2S, [M+Na] 519.0671, found 519.0681; Anal. Calc. for 
C26H22Cl2N2O2S: C, 62.78; H, 4.46; N, 5.63%. Found: C, 62.65; H, 4.44; N, 5.55%; HPLC: 
Daicel Chiralcel OD-H and Chiralcel OD columns in series (total column length = 50 cm), 
90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer tR = 83.7 min, meso tR = 109.2 
min, (R,R)-enantiomer tR = 117.5 min. 
 
N,N'-Sulfonyl bis-[(R)-(4-chlorophenyl)(phenyl)methanamine] (R,R)-3.100c 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28c (249 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(75.5 mg, 61%, 94:6 dr, >99% ee). Analytical data as for 3.100c except; >Į@D = +2.7 (c = 1.04, 
CHCl3, for 94:6 dr, >99% ee material); 13C NMR (100.6 MHz, CDCl3 įC 140.4 (C), 139.4 
(C), 133.6 (C), 128.9 (CH), 128.8 (CH), 128.5 (CH), 128.0 (CH), 127.1 (CH), 60.9 (CH). 
 
N,N'-Sulfonyl bis-[(4-methylphenyl)(phenyl)methylamine] 3.100d 
 
Prepared from 3.85a (204 mg, 0.75 mmol) using general method G and p-tolylmagnesium 
bromide (1.0 M in THF, 3.0 mL, 3.0 mmol), purified by column chromatography (3:1 pet. 
ether:EtOAc) to afford the product as a white solid (261 mg, 76%) as a 1:1 mixture of rac and 
meso diastereoisomers; Rf 0.39 (3:1 pet. ether:EtOAc); M.p. 138-140 °C; IR (CHCl3) 
Ȟmax/cmí 3385, 3009, 1422, 1332, 1154, 1050, 958; 1H NMR (400.1 MHz, CDCl3įH 7.25-
7.20 (m, 6H, CHaryl), 7.17-7.14 (m, 4H, CHaryl), 7.03 (s, 8H, CHaryl), 5.52 (d, J = 6.4 Hz, 2H, 
NHCH), 4.73 (d, J = 6.0 Hz, 2H, NHCH), 2.29 (s, 6H, ArCH3); 13C NMR (100.6 MHz, 
CDCl3įC 141.23 (Crac/meso), 141.21 (Cmeso/rac), 138.1 (C), 137.4 (C), 129.3 (CH), 128.6 (CH), 
127.6 (CHrac), 127.5 (CHmeso), 127.13 (CH), 127.12 (CH), 61.4 (CH), 21.0 (CH3); HRMS (ESI 
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Positive) calcd. For C28H28N2O2S, [M+Na] 479.1764, found 479.1761; Anal. Calc. for 
C28H28N2O2S: C, 75.65; H, 6.18; N, 6.14%. Found: C, 73.60; H, 6.18; N, 6.12%; HPLC: 
Daicel Chiralcel OD-H column, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer 
tR = 33.7 min, meso tR = 40.8 min, (R,R)-enantiomer tR = 47.9 min. 
 
N,N'-Sulfonyl bis-[(R)-(4-methylphenyl)(phenyl)methylamine] (R,R)-3.100d 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28d (212 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(65.8 mg, 58%, 93:7 dr, >99% ee). Analytical data as for 3.100d except; >Į@D = + 3.8 (c = 1.01, 
CHCl3, for 93:7 dr, >99% ee material); 13C NMR (100.6 MHz, CDCl3 įC 141.2 (C), 138.1 
(C), 137.4 (C), 129.4 (CH), 128.6 (CH), 127.7 (CH), 127.14 (CH), 127.13 (CH), 61.4 (CH), 
21.0 (CH3). 
 
N,N'-Sulfonyl bis-[(S)-(4-methylphenyl)(phenyl)methylamine] (S,S)-3.100d 
 
Prepared from 3.85d (75.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(83.6 mg, 73%, 92:8 dr, >99% ee). Analytical data as for (R,R)-3.100d except; >Į@D = ±5.2 (c = 
1.27, CHCl3, for 92:8 dr, >99% ee material). 
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N,N'-Sulfonyl bis-[(2-methylphenyl)(phenyl)methylamine] 3.100e 
 
Prepared from 3.85e (225 mg, 0.75 mmol) using general method G, purified by column 
chromatography (4:1 pet. ether:EtOAc) to afford the product as a white solid (235 mg, 69%) 
recrystallised from CH2Cl2/hexanes as a 1:3.4 mixture of rac and meso diastereoisomers; Rf 
0.40 (3:1 pet. ether:EtOAc); M.p. 145-147 °C (CH2Cl2/hexanes); IR (CHCl3Ȟmax/cmí3385, 
3066, 3009, 1494, 1336, 1154, 1045, 960; 1H NMR (400.1 MHz, CDCl3 įH Meso 
diastereoisomer: 7.28-7.04 (m, 18H, CHaryl), 5.78 (d, J = 6.4 Hz, 2H, NHCH), 4.64 (d, J = 6.4 
Hz, 2H, NHCH), 2.16 (s, 6H, ArCH3); Rac diastereoisomer: 7.28-7.04 (m, 18H, CHaryl), 5.81 
(d, J = 6.4 Hz, 2H, NHCH), 4.62 (d, J = 5.6 Hz, 2H, NHCH), 2.18 (s, 6H, ArCH3); 13C NMR 
(100.6 MHz, CDCl3įC 140.3 (C), 138.9 (C), 135.5 (C), 130.9 (CH), 128.7 (CH), 127.7 (CH), 
127.6 (CH), 127.5 (CH), 126.5 (CH), 126.3 (CH), 58.2 (CH), 19.4 (CH3); HRMS (ESI 
Positive) calcd. for C28H28N2O2S, [M+Na] 449.1764, found 479.1772; Anal. Calc. for 
C28H28N2O2S: C, 73.65; H, 6.18; N, 6.14%. Found: C, 73.26; H, 6.18; N, 6.18%; HPLC: 
Daicel Chiralpak AD-H and Chiralpak AD columns in series (total column length = 50 cm), 
95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer tR = 59.8 min, meso tR = 62.6 min, 
(R,R)-enantiomer tR = 74.3 min. 
 
N,N'-Sulfonyl bis-[(R)-(2-methylphenyl)(phenyl)methylamine] (R,R)-3.100e 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28e (212 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(80.9 mg, 71%, >99:1 dr, 90% ee). Analytical data as for 3.100e except; >Į@D = ±14.4 (c = 1.05, 
CHCl3, for >99:1 dr, 90% ee material); 1H NMR (400.1 MHz, CDCl3įH 7.25-7.08 (m, 18H, 
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CHaryl), 5.81 (d, J = 6.8 Hz, 2H, NHCH), 4.68 (d, J = 6.8 Hz, 2H, NHCH), 2.18 (s, 6H, 
ArCH3). 
N,N'-Sulfonyl bis-[(S)-(2-methylphenyl)(phenyl)methylamine] (S,S)-3.100e 
 
Prepared from 3.85e (75.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product 
(78.5 mg, 69%, 96:4 dr, 98% ee). Analytical data as for (R,R)-3.100e except; >Į@D = +14.1 (c = 
0.99, CHCl3, for 96:4 dr, 98% ee material). 
 
N,N'-Sulfonyl bis-[(4-methoxyphenyl)(phenyl)methanamine] 3.100f 
 
Prepared from 3.85f (249 mg, 0.75 mmol) using general method G purified by column 
chromatography (4:1 pet. ether:EtOAc then 3:1 pet. ether:EtOAc) to give the product as a 
yellow oil (240 mg, 65%) as a 1:1 mixture of rac and meso diastereoisomers; Rf 0.11 (3:1 pet. 
ether:EtOAc); IR (CHCl3 Ȟmax/cmí 3384, 3011, 1611, 1512, 1254, 1154; 1H NMR (400.1 
MHz, CDCl3 įH 7.27-7.20 (m, 6H, CHaryl), 7.16-7.14 (m, 4H, CHaryl), 7.07-7.05 (m, 2H, 
CHaryl), 7.04-7.03 (m, 2H, CHaryl), 6.74 (m, 4H, CHaryl), 5.38 (d, J = 6.4 Hz, 2H, NHCH), 4.79 
(d, J = 6.4 Hz, 2H, NHCH), 3.75 (s, 3H, OCH3rac), 3.74 (s, 3H, OCH3meso); 13C NMR (100.6 
MHz, CDCl3įC 158.9 (C), 141.33 (Cmeso), 141.30 (Crac), 133.24 (Cmeso), 133.21 (Crac), 128.6 
(CH), 128.5 (CH), 127.5 (CH), 127.1 (CH), 114.0 (CH), 61.0 (CH), 55.2 (CH3); HRMS (ESI 
Positive) calcd. for C28H28N2O4S, [M+Na] 511.1662, found 511.1671; HPLC: Daicel Chiralcel 
OD-H column, 80:20 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer tR = 20.2 min, 
meso tR = 30.0 min, (R,R)-enantiomer tR = 41.8 min. 
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N,N'-Sulfonyl bis-[(R)-(4-methoxyphenyl)(phenyl)methanamine] (R,R)-3.100f 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28f (241 mg, 0.6 mmol) using general 
method H, purified by column chromatography (3:1 pet. ether:EtOAc) to afford the product 
(88.3 mg, 72%, 92:8 dr, >99% ee). Analytical data as for 3.100f except; >Į@D = +6.1 (c = 1.18, 
CHCl3, for 92:8 dr, >99% ee material); 1H NMR (400.1 MHz, CDCl3įH 7.26-7.22 (m, 6H, 
CHaryl), 7.18-7.16 (m, 4H, CHaryl), 7.07-7.05 (m, 4H, CHaryl), 6.77 (dt, J = 8.8, 2.5 Hz, 4H, 
CHaryl), 5.52 (d, J = 6.4 Hz, 2H, NHCH), 4.76 (d, J = 6.4 Hz, 2H, NHCH), 3.75 (s, 6H, OCH3); 
13C NMR (100.6 MHz, CDCl3įC 159.0 (C), 141.3 (C), 133.2 (C), 128.6 (CH), 128.4 (CH), 
127.5 (CH), 127.1 (CH), 114.0 (CH), 61.0 (CH), 55.2 (CH3). 
 
N,N'-Sulfonyl bis-[(S)-(4-methoxyphenyl)(phenyl)methanamine] (S,S)-3.100f 
 
Prepared from 3.85f (83.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (3:1 pet. ether:EtOAc) to afford the product 
(79.9 mg, 69%, 95:5 dr, >99% ee). Analytical data as for (R,R)-3.100f except; >Į@D = ±7.9 (c = 
1.01, CHCl3, for >99% ee, 95:5 dr material). 
 
N,N'-Sulfonyl bis-[(4-(ethoxycarbonyl)phenyl)(phenyl)methanamine] 3.100g 
 
A flame-dried flask was charged with ethyl 4-iodobenzoate (3.32 mL, 20 mmol) and THF (25 
mL) and cooled to ±40 °C. i-Propylmagnesium bromide (2.0 M in THF, 10 mL, 20 mmol) was 
added dropwise, stirred at ±40 °C for 2.5 h, the solution became dark brown. A second flame 
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dried Schlenk was charged with 3.85a (204 mg, 0.75 mmol) and THF (10 mL) and cooled to ±
40 °C. The prepared aryl Grignard reagent solution (0.57 M in THF, 5.25 mL, 3.0 mmol) was 
added dropwise. The solution was allowed to warm to rt and stirred overnight. Then quenched 
with sat. NH4Cl solution (20 mL), extracted with Et2O (2 ×20 mL). The organics were dried 
(Na2SO4) and concentrated to a light yellow oil, purified by column chromatography (4:1 pet. 
ether:EtOAc) to afford the product as a white solid (449 mg, 43%) as a 1:1 mixture of rac and 
meso diastereoisomers; Rf 0.07 (4:1 pet. ether:EtOAc); M.p. 152-154 °C; IR (CHCl3) 
Ȟmax/cmí3382, 2985, 1714, 1281, 1109; 1H NMR (400.1 MHz, CDCl3įH 7.88 (dt, J = 8.4, 
1.8 Hz, 4H, CHaryl), 7.23-7.20 (m, 10H, CHaryl), 7.09-7.07 (m, 4H, CHaryl), 5.57 (d, J = 6.8 Hz, 
2H, NHCH), 5.11 (d, J = 7.2 Hz, 2H, NHCH), 4.35 (q, J = 7.1 Hz, 2H, OCH2meso) overlapped 
by 4.34 (q, J = 7.2 Hz, 2H, OCH2rac), 1.372 (t, J = 7.0 Hz, 3H, CH2CH3meso) overlapped by 
1.367 (t, J = 7.2 Hz, 3H, CH2CH3rac); 13C NMR (100.6 MHz, CDCl3įC 166.1 (C), 145.7 (C), 
140.3 (C), 129.9 (CH), 129.8 (C), 128.9 (CH), 128.0 (CH), 127.2 (CHrac), 127.1 (CHmeso), 
127.1 (CHmeso), 127.0 (CHrac), 61.2 (CH), 61.0 (CH2), 14.3 (CH3); HRMS (ESI Positive) calcd. 
for C32H32N2O6S, [M+Na] 595.1873, found 595.1862; Anal. Calc. for C32H32N2O6S: C, 67.11; 
H, 5.63; N, 4.89%. Found: C, 66.76; H, 5.63; N, 4.67%; HPLC: Daicel Chiralcel OD-H 
column in series, 80:20 hexanes:iPrOH; 0.5 mL/min; 200 nm; (R,R)-enantiomer tR = 33.2 min, 
meso and (S,S)-enantiomer tR = 44.5 min 
 
N,N'-Sulfonyl bis-[(R)-(4-(ethoxycarbonyl)phenyl)(phenyl)methanamine] (R,R)-3.100g 
 
Prepared from 3.85a (68.1 mg, 0.25 mmol) and 3.28g (317 mg, 0.6 mmol) using general 
method H, purified by column chromatography (2:1 pet. ether:EtOAc) to afford the product 
(52.3 mg, 37%, 97:3 dr and 94 % ee (calculated from ee of derived acetate 3.128g)); Analytical 
data as for 3.100g except; >Į@D = +1.3 (c = 0.96, CHCl3, for 94 % ee and 97:3 dr material); 1H 
NMR (400.1 MHz, CDCl3įH 7.87 (dm, J = 8.8 Hz, 4H, CHaryl), 7.23-7.20 (m, 10H, CHaryl), 
7.08-7.06 (m, 4H, CHaryl), 5.57 (d, J = 6.8 Hz, 2H, NHCH), 5.24 (d, J = 7.2 Hz, 2H, NHCH), 
4.33 (q, J = 7.1 Hz, 4H, OCH2), 1.36 (t, J = 7.0 Hz, 6H, CH2CH3); 13C NMR (100.6 MHz, 
 182 
CDCl3įC 166.1 (C), 145.8 (C), 140.3 (C), 129.8 (CH), 129.7 (C), 128.8 (CH), 128.0 (CH), 
127.2 (CH), 127.0 (CH), 61.2 (CH), 61.0 (CH2), 14.3 (CH3). 
 
N,N'-Sulfonyl bis-[(3-methylphenyl)(phenyl)methylamine] 3.100h 
 
Prepared from 3.85h (225 mg, 0.75 mmol) using general method G purified by column 
chromatography (4:1 pet. ether:EtOAc) to give the product as a yellow oil (231 mg, 67%) as a 
1:1 mixture of rac and meso diastereoisomers; Rf 0.40 (4:1 pet. ether:EtOAc); M.p. 83-85 °C; 
IR (CHCl3Ȟmax/cmí 3385, 3011, 1454, 1417, 1333, 1153; 1H NMR (400.1 MHz, CDCl3įH 
7.26-7.11 (m, 12H, CHaryl), 7.04-7.02 (m, 2H, CHaryl), 6.97-6.03 (m, 4H, CHaryl), 5.53 (d, J = 
6.4 Hz, 2H, NHCH), 4.77 (d, J = 6.4 Hz, 2H, NHCH), 2.26 (s, 6H, ArCH3); 13C NMR (100.6 
MHz, CDCl3įC 141.2 (Crac), 141.1 (Cmeso), 141.04 (Cmeso), 141.01 (Crac), 138.4 (Crac), 138.3 
(Cmeso), 128.62 (CHrac), 128.60 (CHmeso), 128.56 (CH), 128.5 (CHrac), 128.4 (CHmeso), 127.9 
(CHmeso), 127.8 (CHrac), 127.6 (CHrac), 127.5 (CHmeso), 127.2 (CHrac), 127.1 (CHmeso), 124.2 
(CHmeso), 124.1 (CHrac), 61.5 (CH), 21.4 (CH3); HRMS (ESI Positive) calcd. For C28H28N2O2S, 
[M+Na] 479.1764, found 479.1767; HPLC: Daicel Chiralpak AD-H and Chiralpak AD 
columns in series (total column length = 50 cm), 95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; 
(S,S)-enantiomer tR = 68.8 min, meso tR = 75.8 min, (R,R)-enantiomer tR = 78.7 min. 
 
N,N'-Sulfonyl bis-[(S)-(3-methylphenyl)(phenyl)methylamine] (S,S)-3.100h 
 
Prepared from 3.85h (75.1 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general 
method H, purified by column chromatography (3:1 pet. ether:EtOAc) to afford the product 
(86.1 mg, 75%, 92:8 dr, >99% ee). Analytical data as for 3.100h except; >Į@D = +1.3 (c = 0.94, 
CHCl3, for 92:8 dr, >99% ee material); 13C NMR (100.6 MHz, CDCl3 įC 141.2 (C), 141.0 
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(C), 138.4 (C), 128.7 (CH), 128.56 (CH), 128.5 (CH), 127.8 (CH), 127.6 (CH), 127.2 (CH),  
124.2 (CH), 61.6 (CH), 21.4 (CH3). 
 
N,N'-Sulfonyl bis-[(4-bromophenyl)(phenyl)methanamine] 3.100i 
 
Prepared from 3.85i (323 mg, 0.75 mmol) using general method G purified by column 
chromatography (3:1 pet. ether:EtOAc) to give the product as a yellow oil (378 mg, 86%) as a 
1:1 mixture of rac and meso diastereoisomers; Rf 0.44 (3:1 pet. ether:EtOAc); M.p. 163-165 
°C; IR (CHCl3Ȟmax/cmí 3382, 3008, 1488, 1422, 1334, 1155, 1011; 1H NMR (400.1 MHz, 
CDCl3 įH 7.38-7.33 (m, 4H, CHaryl), 7.28-7.24 (m, 6H, CHaryl), 7.10-7.08 (m, 4H, CHaryl), 
7.04-7.01 (m, 4H, CHaryl), 5.51 (d, J = 6.8 Hz, 2H, NHCH), 4.75 (d, J = 6.8 Hz, 2H, NHCH); 
13C NMR (100.6 MHz, CDCl3įC 140.4 (C), 139.9 (C), 131.8 (CH), 128.9 (CH), 128.8 (CH), 
128.0 (CH), 127.1 (CHrac), 127.0 (CHmeso), 121.8 (C), 61.0 (CH); HRMS (ESI Positive) calcd. 
for C26H22Br2N2O2S, [M+Na] 606.9661, found 606.9646; Anal. Calc. for C26H22Br2N2O2S: C, 
53.26; H, 3.78; N, 4.78%. Found: C, 53.27; H, 3.77; N, 4.68%; HPLC: Daicel Chiralcel OD-H 
column, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S,S)-enantiomer tR = 51.4 min, meso tR = 
67.6 min, (R,R)-enantiomer tR = 73.5 min. 
 
N,N'-Sulfonyl bis-[(S)-(4-bromophenyl)(phenyl)methanamine] (S,S)-3.100i 
 
Prepared from 3.85i (108 mg, 0.25 mmol) and 3.28a (187 mg, 0.6 mmol) using general method 
H, purified by column chromatography (4:1 pet. ether:EtOAc) to afford the product (87.6 mg, 
62%, 91:9 dr, >99% ee). Analytical data as for 3.100i except; >Į@D = ±3.3 (c = 1.23, CHCl3, for 
91:9 dr, >99% ee material); 13C NMR (100.6 MHz, CDCl3 įC 140.4 (C), 139.9 (C), 131.8 
(CH), 128.9 (CH), 128.8 (CH), 128.0 (CH), 127.1 (CH), 121.7 (C), 60.9 (CH). 
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N,N'-Sulfonyl bis-[(4-fluorophenyl)(4-methylphenyl)methanamine] 3.100j 
 
Prepared from 3.85b (231 mg, 0.75 mmol) using general method G and p-tolylmagnesium 
bromide (1.0 M in THF, 3 mL, 3.0 mmol), purified by column chromatography (3:1 pet. 
ether:EtOAc) to give the product as a white solid (274.4 mg, 74%) as a 1:1 mixture of rac and 
meso diastereoisomers; Rf  0.63 (3:1 pet. ether:EtOAc); M.p. 96-98 °C; IR (CHCl3Ȟmax/cmí 
3604, 3382, 3009, 1605, 1510, 1157; 1H NMR (400.1 MHz, CDCl3 įH 7.15-7.04 (m, 8H, 
CHaryl), 7.00 (t, J = 7.6 Hz, 4H, CHaryl), 6.95-6.88 (m, 4H, CHaryl), 5.50 (d, J = 6.0 Hz, 2H, 
NHCH), 4.67 (d, J = 6.4 Hz, 2H, NHCH), 2.31 (s, 3H, CH3meso), 2.30 (s, 3H, CH3rac); 13C 
NMR (100.6 MHz, CDCl3įC 162.0 (C, d, 1JCF = 245 Hz), 137.9 (Cmeso), 137.8 (Crac), 137.63 
(Crac), 137.60 (Cmeso), 137.0 (C, app. t, 4JCF = 3.8 Hz), 129.4 (CH), 128.8 (CH, d, 3JCF = 7.7 
Hz), 127.0 (CHrac), 126.9 (CHmeso), 115.4 (CH, d, 2JCF = 21.3 Hz), 60.6 (CH), 21.0 (CH3); 19F 
NMR (376.5 MHz, CDCl3įF íracímeso); HRMS (ESI Positive) calcd. for 
C28H26F2N2O2S, [M+Na] 515.1575, found 515.1570; Anal. Calc. for C28H26F2N2O2S: C, 68.27; 
H, 5.32; N, 5.69%. Found: C, 68.24; H, 5.33; N, 5.61%; HPLC: Daicel Chiralcel OD-H 
column, 90:10 hexanes:iPrOH; 0.5 mL/min; 200 nm; (R,R)-enantiomer tR = 34.6 min, meso tR = 
37.8 min, (S,S)-enantiomer tR = 41.3 min. 
 
N,N'-Sulfonyl bis-[(S)-(4-fluorophenyl)(4-methylphenyl)methanamine] (S,S)-3.100j 
 
Prepared from 3.85b (77.1 mg, 0.25 mmol) and 3.28d (213 mg, 0.6 mmol) using general 
method H, purified by column chromatography (3:1 pet. ether:EtOAc) to afford the product 
(94.2 mg, 76%, 91:9 dr, 98% ee). Analytical data as for 3.100j except; >Į@D = +1.8 (c = 0.91, 
CHCl3, for 91:9 dr, 98% ee material); 1H NMR (400.1 MHz, CDCl3 įH 7.15-7.11 (m, 4H, 
CHaryl), 7.08-6.98 (m, 8H, CHaryl), 6.96-6.90 (m, 4H, CHaryl), 5.51 (d, J = 6.4 Hz, 2H, NHCH), 
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4.64 (d, J = 6.0 Hz, 2H, NHCH), 2.30 (s, 6H, ArCH3); 13C NMR (100.6 MHz, CDCl3 įC 
162.1 (C, d, 1JCF = 245 Hz), 137.8 (C), 137.7 (C), 137.0 (C, d, 4JCF = 3.0 Hz), 129.5 (CH), 
128.8 (CH, d, 3JCF = 7.6 Hz), 127.0 (CH), 115.5 (CH, d, 2JCF = 21.4 Hz), 60.7 (CH), 21.0 
(CH3); 19F NMR (376.5 MHz, CDCl3įF í 
 
Naphthalen-2-yl propiolate 3.103[172] 
 
Propiolic acid 3.102 (2.37 mL, 38.2 mmol) and DCC (7.88 g, 38.2 mmol) were added to a 
stirred solution of 2-naphthol (5.0 g, 34.7 mmol) and DMAP (42.3 mg, 0.35 mmol) in CH2Cl2 
(75 mL). The resulting yellow suspension was allowed to warm to rt and stirred for 5 h. The 
white precipitate was filtered and the filtrate concentrated in vacuo. The residue was purified 
by column chromatography (19:1 pet. ether:EtOAc) to afford the product as a white solid (5.19 
g, 76%); Rf 0.33 (19:1 hexanes:EtOAc); M.p. 69-70 °C; lit. 71-73 °C;[172] IR (CHCl3) 
Ȟmax/cmí 3299, 2129, 1732, 1192; 1H NMR (400.1 MHz, CDCl3įH 7.87-7.79 (m, 3H, CHaryl), 
7.62 (d, J = 2.8 Hz, 1H, CHaryl), 7.52-7.45 (m, 2H, CHaryl), 7.26 (dd, J = 8.8, 2.4 Hz, 1H, 
CHaryl), 3.08 (s, 1H, C{CH); 13C NMR (100.6 MHz, CDCl3įC 151.0 (C), 147.4 (C), 133.5 
(C), 131.7 (C), 129.7 (CH), 127.8 (CH), 127.7 (CH), 126.8 (CH), 126.1 (CH), 120.3 (CH), 
118.5 (CH), 76.9 (C), 74.2 (CH); HRMS (ESI Positive) calcd. for C13H8O2, [M+Na] 219.0417, 
found 219.0411. These data were consistent with literature values.[287] 
 
(1R,4R,7R)-Naphthalen-2-yl 7-isopropyl-5-methylbicyclo[2.2.2]octa-2,5-diene-2-
carboxylate (R,R,R)-3.99[172] 
 
Dimethylaluminium chloride (1.0 M in hexanes, 29.4 mL, 29.4 mmol) was added slowly to a 
stirred solution of naphthalen-2-yl propiolate 3.103 (5.25 g, 26.8 mmol) and (R)-D-phelladrene 
(R)-3.104 (~50% chemical purity, 9.57 mL, 29.4 mmol) in CH2Cl2 (70 mL) at ±78 °C. The 
orange solution was stirred and allowed to warm to rt over 24 h. The solution was poured onto 
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a slurry of ice (50 g) and 2 M HCl (50 mL), this was extracted with CH2Cl2 (3 × 50 mL). The 
organics were washed with brine (2 × 100 mL), dried (Na2SO4) and concentrated to a yellow 
oil. This was purified by column chromatography (19:1 pet. ether:EtOAc) resulting in a yellow 
oil, which was recrystallised from CH2Cl2/hexanes to give a white solid (3.93 g, 44%); Rf 0.28 
(19:1 pet. ether:EtOAc); M.p. 89-91 °C (CH2Cl2/hexanes); lit. 92-94 °C;[172] >Į@D = +2.6 (c = 
1.19, CHCl3; lit.[172] +4.4, c = 1.12, CHCl3); IR (CHCl3 Ȟmax/cmí 3011, 2962, 1721, 1240, 
1157, 1061; 1H NMR (400.1 MHz, CDCl3įH 7.85-7.77 (m, 3H, CHaryl), 7.60-7.58 (m, 2H, 
CH3 and CHaryl), 7.49-7.42 (m, 2H, CHaryl), 7.26 (dd, J = 8.8, 2.4 Hz, 1H, CHaryl), 5.89 (dt, J = 
6.4, 1.6 Hz, 1H, CH4), 4.21 (dt, J = 6.0, 2.0 Hz, 1H, CH5), 3.48 (dq, J = 6.0, 1.6 Hz, 1H, CH2), 
1.87 (d, J = 1.6 Hz, 3H, CH31), 1.66 (ddd, J = 12.0, 8.8, 3.2 Hz, 1H, CHĮ), 1.33-1.27 (m, 1H, 
CH7), 1.19-1.10 (m, 1H, CH8), 1.04 (ddd, J = 11.6, 4.8, 2.4 Hz, 1H, CHȕ), overlapped by 1.02 
(d, J = 6.4 Hz, 3H, CH3Į), 0.85 (d, J = 6.4 Hz, 3H, CH3ȕ); 13C NMR (100.6 MHz, CDCl3įC 
163.6 (C), 148.7 (C), 148.3 (CH), 143.3 (C), 140.5 (C), 133.8 (C), 131.3 (C), 129.2 (CH), 
127.7 (CH), 127.6 (CH), 126.4 (CH), 125.5 (CH), 124.3 (CH), 121.4 (CH), 118.6 (CH), 47.7 
(CH), 44.3 (CH), 39.7 (CH), 33.8 (CH), 31.5 (CH2), 21.9 (CH3), 21.4 (CH3), 19.0 (CH3); 
HRMS (ESI Positive) calcd. for C23H24O2, [M+H] 333.1849, found 333.1835. These data were 
consistent with literature values.[172] 
 
(1R,4R,7R)-2,6-Dimethylphenyl 7-isopropyl-5-methylbicyclo[2.2.2]octa-2,5-diene-2-
carboxylate (R,R,R)-4.15[172] 
 
(R,R,R)-3.99 (803 mg, 2.42 mmol) was added portionwise to a stirred solution of NaOMe (261 
mg, 4.83 mmol) in methanol (10 mL). The suspension was stirred at rt for 16 h, then 
concentrated to a brown oil and purified by column chromatography (19:1 hexanes:EtOAc) the 
afford the product as a colourless oil (465 mg, 89%); A solution of the resultant oil (400 mg, 
1.82 mmol) and LiOH.H2O (306 mg, 7.28 mmol) in MeOH (10 mL) and H2O (3 mL) was 
stirred at 50 °C for 4 h. Diluted with 2M HCl (10 mL) and extracted with CHCl3 (3 × 20 mL). 
The combined organic extracts were dried (MgSO4) and concentrated. The residue was taken 
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up in CH2Cl2 (10 mL) and cooled to 0 °C. 2,6-Dimethylphenol (222 mg, 1.82 mmol, DCC (412 
PJPPRODQG'0$3PJȝPROZHUHDGGHGDQGWKHVROXWLRQVWLUUHGDWUWIRU
h. The resulting white precipitate was removed by filtration and the filtrate concentrated to a 
yellow oil. Purification by column chromatography (19:1 hexanes:EtOAc) gave the product as 
a cream solid (436 mg, 77%); Rf 0.18 (19:1 hexanes:EtOAc); M.p. 78-80 °C; lit. 74-76 °C;[172] 
>Į@D = +3.2 (c = 1.12, CHCl3; lit.[172] +12.3, c = 1.19, CHCl3); IR (CHCl3 Ȟmax/cmí 2962, 
1718, 1613, 1473, 1245, 1171; 1H NMR (400.1 MHz, CDCl3įH 7.56 (dd, J = 6.2, 2.2 Hz, 1H, 
CH3), 7.07-7.01 (m, 3H, CH11,12), 5.86 (app. dt, J = 5.9, 1.6 Hz, 1H, CH4), 4.20 (app. dt, J = 
6.0, 2.0 Hz, 1H, CH5), 3.46 (app. dq, J = 6.0, 2.5 Hz, 1H, CH2), 2.13 (s, 6H, CH310), 1.86 (d, J 
= 2.0 Hz, 3H, CH31), 1.64 (ddd, J = 11.6, 8.6, 2.4 Hz, 1H, CHĮ), 1.28-1.07 (m, 2H, CH7 and 
CH8), 1.03 (ddd, J = 11.6, 4.8, 2.8 Hz, 1H, CHȕ) overlapped by 1.00 (d, J = 6.4 Hz, 3H, 
CH3Į), 0.85 (d, J = 6.0 Hz, 3H, CH3ȕ); 13C NMR (100.6 MHz, CDCl3įC 162.7 (C), 148.3 
(C), 147.9 (CH), 143.3 (C), 140.2 (C), 130.4 (C), 128.4 (CH), 125.5 (CH), 124.1 (CH), 48.0 
(CH), 44.2 (CH), 39.7 (CH), 33.8 (CH), 31.5 (CH2), 21.9 (CH3), 21.4 (CH3), 19.0 (CH3), 16.4 
(CH3); HRMS (ESI Positive) calcd. for C21H26O2, [M+H] 311.2006, found 311.1988. These 
data were consistent with literature values.[172] 
 
Phenyl boroxine 3.28a[288] 
Synthesised from phenyl boronic acid using general method F to give a white powder; Rf 0.08 
(3:1 pet. ether:EtOAc); M.p. 213-214 °C; lit. 214-216 °C;[289] IR (CHCl3 Ȟmax/cmí 1603, 
1442, 1368, 1350, 1311; 1H NMR (400.1 MHz, CDCl3įH 8.25 (d, J = 6.8 Hz, 6H, CHaryl), 
7.63-7.59 (m, 3H, CHaryl), 7.54-7.50 (m, 6H, CHaryl); 13C NMR (100.6 MHz, CDCl3įC 135.6 
(CH), 132.7 (CH), 128.0 (CH), (C-B not seen). These data were consistent with literature 
values.[288] 
 
4-Fluorophenyl boroxine 3.28b[223] 
Synthesised from 4-fluorophenyl boronic acid using general method F to give a white powder; 
Rf 0.08 (3:1 pet. ether:EtOAc); M.p. 261-263 °C; lit. 265-266 °C;[290] IR (CHCl3 Ȟmax/cmí 
1598, 1405, 1371, 1349, 1240, 1158, 841; 1H NMR (400.1 MHz, CDCl3įH 8.21 (dd, J = 8.6, 
6.2 Hz, 6H, CHaryl), 7.19 (tt, J = 8.8, 2.1 Hz, 6H, CHaryl); 13C NMR (100.6 MHz, CDCl3įC 
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166.1 (d, 1JCF = 251 Hz, C), 138.0 (d, 3JCF = 9.2 Hz, CH), 115.3 (d, 2JCF = 19.8 Hz, CH), (C-B 
not seen); 19F NMR (376.5 MHz, CDCl3įF -105.8. These data were consistent with literature 
values.[223] 
 
4-Chlorophenyl boroxine 3.28c[223] 
Synthesised from 4-chlorophenyl boronic acid using general method F to give a white powder; 
Rf 0.08 (3:1 pet. ether:EtOAc); M.p. 284-286 °C; lit. 261-262.5;[289] IR (CHCl3 Ȟmax/cmí 
1594, 1398, 1366, 1345, 1311, 1088; 1H NMR (400.1 MHz, CDCl3įH 8.13 (d, J = 8.4 Hz, 
6H, CHaryl), 7.49 (d, J = 8.4 Hz, 6H, CHaryl); 13C NMR (100.6 MHz, CDCl3 įC 139.4 (C), 
137.0 (CH), 134.9 (CH), 128.4 (CH), (C-B not seen). These data were consistent with literature 
values.[223] 
 
4-Methylphenyl boroxine 3.28d[291] 
Synthesised from 4-methylphenyl boronic acid using general method F to give a white powder; 
Rf 0.36 (1:1 pet. ether:EtOAc); M.p. 253-257 °C; lit. 246-248 °C;[289] IR (CHCl3 Ȟmax/cmí 
3010, 1612, 1403, 1348, 1183; 1H NMR (400.1 MHz, CDCl3 įH 8.11 (d, J = 8.0 Hz, 6H, 
CHaryl), 7.30 (d, J = 7.6 Hz, 6H, CHaryl), 2.43 (s, 9H, ArCH3); 13C NMR (100.6 MHz, CDCl3) 
įC 142.9 (C), 135.7 (CH), 128.7 (CH), 21.9 (CH3) (C-B not seen). These data were consistent 
with literature values.[291] 
 
2-Methylphenyl boroxine 3.28e[292] 
Synthesised from 2-methylphenyl boronic acid using general method F to give a white powder; 
Rf 0.15 (3:1 pet. ether:EtOAc); M.p. 157-159 °C; lit. 165-166 °C;[292] IR (CHCl3 Ȟmax/cmí 
3009, 1599, 1441, 1348, 1302; 1H NMR (400.1 MHz, CDCl3įH 8.22 (dd, J = 7.6, 1.6 Hz, 3H, 
CHaryl), 7.45 (td, J = 7.4, 1.7 Hz, 3H, CHaryl), 7.33-7.27 (m, 6H, CHaryl), 2.82 (s, 9H, ArCH3); 
13C NMR (100.6 MHz, CDCl3 įC 146.2 (C), 137.2 (CH), 132.2 (CH), 130.6 (CH), 125.2 
(CH), 23.1 (CH3), (C-B not seen). These data were consistent with literature values.[292] 
 
  
 189 
4-Methoxyphenyl boroxine 3.28f[293] 
Synthesised from 4-methoxyphenyl boronic acid using general method F to give a white 
powder; Rf 0.08 (3:1 pet. ether:EtOAc); M.p. 205-206 °C; lit. 206-207 °C;[294] IR (CHCl3) 
Ȟmax/cmí 3009, 1603, 1413, 1345, 1313, 1248, 1173, 1011; 1H NMR (400.1 MHz, CDCl3įH 
8.17 (dt, J = 8.8, 2.0 Hz, 6H, CHaryl), 7.02 (dt, J = 8.8, 2.2 Hz, 6H, CHaryl), 3.90 (s, 9H, OCH3); 
13C NMR (100.6 MHz, CDCl3įC 163.2 (C), 137.5 (CH), 113.5 (CH), 55.2 (CH3), (C-B not 
seen). These data were consistent with literature values.[293] 
 
4-(Ethoxycarbonyl)phenyl boroxine 3.28g[289] 
A flame-dried flask was charged with ethyl 4-iodobenzoate (3.32 mL, 20 mmol) and THF (25 
mL) and cooled to ±40 °C. i-Propylmagnesium bromide (2.0 M in THF, 10 mL, 20 mmol) was 
added dropwise, stirred at ±40 °C for 2.5 h, the solution became dark brown (5.25 mL, 3.0 
mmol was removed for preparation of 3.100g). Cooled to ±78 °C and freshly distilled trimethyl 
borate (3.79 mL, 34 mmol) was added dropwise. The solution was allowed to warm to rt and 
stirred overnight, the reaction mixture became a viscous yellow suspension. 1 M HCl (40 mL) 
was added and the mixture was stirred for 2 h at rt. Extracted with Et2O (2 × 50 mL), the 
organics were dried (Na2SO4) and concentrated to a light yellow solid. The solid was 
suspended in benzene (25 mL) and stirred at reflux with a Dean-Stark overnight. The white 
solid was collected by filtration (1.56 g, 52%); Rf 0.27 (1:1 pet. ether:EtOAc); M.p. 150-153 
°C; IR (CHCl3 Ȟmax/cmí 3214, 1713, 1350, 1280, 1112; 1H NMR (400.1 MHz, CDCl3 įH 
8.33 (d, J = 8.0 Hz, 6H, CHaryl), 8.21 (d, J = 8.4 Hz, 6H, CHaryl), 4.47 (q, J = 7.0 Hz, 6H, 
OCH2CH3), 1.48 (t, J = 7.2 Hz, 9H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3įC 166.4 (C), 
135.5 (CH), 134.3 (C), 128.9 (CH), 61.3 (CH2), 14.3 (CH3), (C-B not seen). 
 
4,4,5,5-Tetramethyl-2-phenyl-1,3,2-dioxaborolane 3.107[295] 
 
A solution of phenyl boronic acid 3.25a (366 mg, 3 mmol) and pinacol (355 mg, 3 mmol) in 
Et2O (12 mL) was stirred at rt for 1.5 h. The solution was concentrated to a light brown oil 
which crystallised on standing (550 mg, 90%); Rf 0.77 (1:1 pet. ether:EtOAc); M.p. 25-26 °C; 
 190 
lit. 27-28 °C;[295] IR (CHCl3Ȟmax/cmí 2983, 1604, 1360, 1144, 1090; 1H NMR (400.1 MHz, 
CDCl3įH 7.82-7.80 (m, 2H, CHaryl), 7.46 (tt, J = 7.4, 1.7 Hz, 1H, CHaryl), 7.39-7.34 (m, 2H, 
CHaryl), 1.35 (s, 12H, CH3); 13C NMR (100.6 MHz, CDCl3įC 134.7 (CH), 131.2 (CH), 127.7 
(CH), 83.8 (C), 24.9 (CH3), (C-B not seen). These data were consistent with literature 
values.[295] 
 
4,5,7,8-Tetrahydro-2-(phenyl)-6H-[1,3,6,2]dioxazaborocane 3.108[227] 
 
Diethanolamine (193 µL, 2 mmol) was added to a stirred suspension of phenyl boronic acid 
3.25a (244 mg, 2 mmol) in Et2O (25 mL). The suspension was stirred at rt for 6 h, the product 
was collected by filtration as a white powder (371 mg, 97%); M.p. 209-211 °C; lit. >200 
°C;[227] IR (CHCl3Ȟmax/cmí 2983, 2871, 1249, 1249, 1083, 1066, 924; 1H NMR (400.1 MHz, 
CDCl3įH 7.45-7.42 (m, 2H, CHaryl), 7.20-7.11 (m, 3H, CHaryl), 6.86 (br s, 1H, NH), 3.87 (td, J 
= 9.3, 5.3 Hz, 2H, OCHĮ), 3.78 (qd, J = 6.3, 3.3 Hz, 2H, OCHȕ), 3.08 (tdd, J = 9.3, 7.6, 5.3 
Hz, 2H, NHCHĮ), 2.84 (dqd, J = 12.0, 3.4, 2.4 Hz, 2H, NHCHȕ); 13C NMR (100.6 MHz, 
CDCl3įC 132.6 (CH), 126.6 (CH), 126.3 (CH), 62.9 (CH2), 50.7 (CH2), (C-B not seen). These 
data were consistent with literature values.[227] 
 
(4-Fluorophenyl)(phenyl)methanol 3.117b[296] 
 
A flame dried Schlenk tube was charged with Et2O (5 mL) and 4-fluorobenzaldehyde (2.08 
mL, 20 mmol) and cooled to 0 °C. Phenylmagnesium bromide (3.0 M in Et2O, 13.3 mL, 40 
mmol) was added dropwise with stirring. The solution was stirred overnight and allowed to 
warm to rt. The reaction mixture was then quenched with sat. NH4Cl solution (20 mL), 
extracted with Et2O (2 × 20 mL), the organics were dried (Na2SO4) and concentrated to a 
yellow oil. This was purified by column chromatography (3:1 pet. ether:EtOAc) to afford the 
product as a yellow oil (3.16 g, 78%); Rf 0.50 (3:1 pet. ether:EtOAc); IR (CHCl3Ȟmax/cmí 
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3604, 3010, 1604, 1510, 1157, 1015, 909; 1H NMR (400.1 MHz, CDCl3įH 7.34-7.24 (m, 7H, 
CHaryl), 7.00 (tt, J = 8.8, 2.5 Hz, 2H, CHaryl), 5.79 (s, 1H, OHCH), 2.36 (br s, 1H, OHCH); 13C 
NMR (100.6 MHz, CDCl3įC 162.1 (C, d, 1JCF = 244 Hz), 143.6 (C), 139.5 (C), 128.6 (CH), 
128.2 (CH, d, 3JCF = 8.7 Hz), 127.7 (CH), 126.4 (CH), 115.2 (CH, d, 2JCF = 21.8 Hz), 75.6 
(CH); 19F NMR (376.5 MHz, CDCl3 įF í HRMS (EI) calcd. for C13H11FO, [M+] 
202.0788, found 202.0784. These data were consistent with literature values.[296] 
 
(4-Fluorophenyl)(phenyl)methanone 3.118[297] 
 
Manganese dioxide (27.1 g, 0.31 mol) was added to a solution of (4-
fluorophenyl)(phenyl)methanol 3.117c (3.16 g, 15.6 mmol) in CH2Cl2 (100 mL) under argon. 
The suspension was stirred at rt overnight. The manganese dioxide was removed by filtration 
through celite, flushing with CH2Cl2. The filtrate was concentrated to give the product as a 
yellow oil (2.40 g, 77 %); Rf 0.61 (3:1 pet. ether:EtOAc); M.p. 40-43 °C; lit. 43-45 °C;[298] IR 
(CHCl3Ȟmax/cmí 3011, 1659, 1600, 1506, 1278, 1240, 1156; 1H NMR (400.1 MHz, CDCl3) 
įH 7.87-7.82 (m, 2H, CHaryl), 7.79-7.76 (m, 2H, CHaryl), 7.60 (tt, J = 7.4, 1.6 Hz, 1H, CHaryl), 
7.51-7.47 (m, 2H, CHaryl), 7.19-7.13 (m, 2H, CHaryl); 13C NMR (100.6 MHz, CDCl3įC 195.2 
(C), 165.4 (C, d, 1JCF = 251 Hz), 137.5 (C), 133.8 (C), 132.6 (CH, d, 3JCF = 9.2 Hz), 132.4 
(CH), 129.8 (CH), 128.3 (CH), 115.4 (CH, d, 2JCF = 21.3 Hz); 19F NMR (376.5 MHz, CDCl3) 
įF í HRMS (ESI Positive) calcd. for C13H9FO, [M+Na] 223.0530, found 223.0530. 
These data were consistent with literature values.[297] 
 
N,N'-Bis-methyl-N,N'-sulfonyl bis-[diphenylmethanamine] 3.122 
 
Sodium hydride (60% w/w in mineral oil) (20.5 mg, 0.513mmol) was added to a stirred 
solution of 3.100a (11 mg, 0.233mmol) in THF (10 mL) at 0 °C, and stirred at 0 °C for 1 h. 
Methyl iodide (32.0 µL, 0.513 mmol) was added at 0 °C, stirred for 18 h and allowed to warm 
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to rt. Partitioned between H2O (25 mL) and Et2O (2 × 25 mL). The organics were dried 
(Na2SO4) and concentrated to a light yellow oil. Purification by column chromatography (4:1 
pet. ether:EtOAc) gave the product as a white crystalline solid (55.9 mg, 52%); Rf 0.56 (4:1 
pet. ether:EtOAc); M.p. 129-131 °C; IR (CHCl3Ȟmax/cmí 3011, 2927, 1601, 1318, 1161, 946, 
832; 1H NMR (400.1 MHz, CDCl3įH 7.34-7.28 (m, 12H, CHaryl), 7.22-7.19 (m, 8H, CHaryl), 
6.41 (s, 2H, N(CH3)CH), 2.57 (s, 6H, CH3); 13C NMR (100.6 MHz, CDCl3 įC 138.9 (C), 
128.8 (CH), 128.4 (CH), 127.5 (CH), 65.0 (CH), 31.2 (CH3); HRMS (ESI Positive) calcd. for 
C28H28N2O2S, [M+Na] 479.1764, found 479.1775; Anal. Calc. for C28H28N2O2S: C, 73.65; H, 
6.18; N, 6.14%. Found: C, 73.99; H, 6.58; N, 5.80%. 
 
Diphenylmethanamine 3.40a[299] 
 
Prepared from 3.100a (85.7 mg, 0.2 mmol) using general method I, to afford the product as a 
colourless oil (69.1 mg, 94%); Rf 0.29 (1:1 pet. ether:EtOAc); IR (CHCl3 Ȟmax/cmí 3086, 
3009, 2970, 1601, 1492, 1452, 904; 1H NMR (400.1 MHz, CDCl3 įH 7.37-7.34 (m, 4H, 
CHaryl), 7.31-7.27 (m, 4H, CHaryl), 7.20 (tt, J = 7.0, 1.7 Hz, 2H, CHaryl), 5.18 (s, 1H, NH2CH), 
1.78 (s, 2H, NH2); 13C NMR (100.6 MHz, CDCl3įC 145.5 (C), 128.4 (CH), 126.8 (CH), 59.7 
(CH) two peaks overlapped. These data were consistent with literature values.[299] 
 
(4-Fluorophenyl)(phenyl)methanamine.hydrogen chloride 3.40b.HCl[144] 
 
Following the procedure of Caballero et al.,[300] ammonium acetate (14.8 g, 0.19 mol) and 
sodium cyanoborohydride (2.41 g, 38.4 mmol) were added to a solution of 3.118 in EtOH (100 
mL) and CH2Cl2 (5 mL). The suspension was stirred at reflux for 20 h. The solvent was 
removed in vacuo and the residue dissolved in EtOAc (100 mL) and washed with sat. Na2CO3 
solution (2 × 100 mL). The organics were dried (Na2SO4) and concentrated to a light brown oil 
(2.60 g). HCl (1.0 M in Et2O, 13 mL) was added and the resulting white precipitate collected 
by filtration (1.85 g, 65%); M.p. >230 °C dec.; lit. 306-306 °C dec.;[301] IR (CHCl3Ȟmax/cmí 
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2894, 1602, 1516, 1240; 1H NMR (400.1 MHz, DMSO-d6įH 9.15 (br s, 3H, NH3CH), 7.59-
7.56 (m, 2H, CHaryl), 7.54-7.51 (m, 2H, CHaryl), 7.45-7.41 (m, 2H, CHaryl), 7.38-7.34 (m, 1H, 
CHaryl), 7.30-7.24 (m, 2H, CHaryl), 5.67 (br s, 1H, NH3CH); 13C NMR (100.6 MHz, DMSO-d6) 
įC 161.8 (C, d, 1JCF = 244 Hz), 138.1 (C), 134.5 (C, d, 4JCF = 3.0 Hz), 129.7 (CH, d, 3JCF = 9.1 
Hz), 128.8 (CH), 128.3 (CH), 127.2 (CH), 115.6 (CH, d, 2JCF = 21.4 Hz), 56.3 (CH); 19F NMR 
(376.5 MHz, DMSO-d6įF í7KHVHGDWDZHUHconsistent with literature values.[144] 
 
(R)-(4-Fluorophenyl)(phenyl)methanamine (R)-3.40b[299] 
 
Prepared from (R,R)-3.100b (74.1 mg, 0.15 mmol) using general method I, to afford the 
product as a colourless oil (49.4 mg, 80%, 94% ee); Rf 0.24 (1:1 pet. ether:EtOAc); >Į@D = ±
1.38 (c = 1.06, CHCl3, for 94% ee material measured on acetamide); IR (CHCl3 Ȟmax/cmí 
3065, 1604, 1509, 1240, 1157; 1H NMR (400.1 MHz, CDCl3įH 7.36-7.28 (m, 6H, CHaryl), 
7.24-7.20 (m, 1H, CHaryl), 7.00-6.95 (m, 2H, CHaryl), 5.17 (s, 1H, NH2CH), 1.75 (s, 2H, 
NH2CH); 13C NMR (100.6 MHz, CDCl3įC 161.7 (C, d, 1JCF = 244 Hz), 145.4 (C), 141.3 (C, 
d, 4JCF = 3.1 Hz), 128.5 (CH, d, 3JCF = 7.6 Hz), 128.3 (CH), 127.0 (CH), 126.7 (CH), 115.1 
(CH, d, 2JCF = 21.4 Hz), 59.0 (CH); 19F NMR (376.5 MHz, CDCl3 įF í HRMS (EI) 
calcd. for C13H12FN, [M+] 201.0954, found 201.0951. These data were consistent with 
literature values.[299] 
 
(S)-(4-Fluorophenyl)(phenyl)methanamine (S)-3.40b[299] 
 
Prepared from (S,S)-3.100b (37.1 mg, 0.08 mmol) using general method I, to afford the 
product as a colourless oil (25.3 mg, 79%, 82% ee). Analytical data as for (R)-3.40b except; 
>Į@D = +1.0 (c = 1.11, CHCl3, for 82% ee material measured on acetamide). 
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(R)-(4-Chlorophenyl)(phenyl)methanamine (R)-3.40c[299] 
 
Prepared from (R,R)-3.100c (63.5 mg, 0.13 mmol) using general method I, to afford the 
product as a yellow oil (51.6 mg, 93%, 87% ee); Rf 0.20 (1:1 pet. ether:EtOAc); >Į@D = ±1.1 (c 
= 1.28, EtOH, for 87% ee material (measured on acetamide); lit.[230] ±10.9 (c = 5.05, EtOH R 
antipode); IR (CHCl3Ȟmax/cmí 3378, 3065, 3011, 1601, 1488, 1091; 1H NMR (400.1 MHz, 
CDCl3įH 7.35-7.21 (m, 9H, CHaryl), 5.18 (s, 1H, NH2CH), 1.74 (s, 2H, NH2CH); 13C NMR 
(100.6 MHz, CDCl3įC 145.2 (C), 144.0 (C), 132.6 (C), 128.6 (CH), 128.5 (CH), 128.3 (CH), 
127.1 (CH), 126.8 (CH), 59.1 (CH); HRMS (EI) calcd. for C13H12ClN, [M+] 217.0658, found 
217.0662. These data were consistent with literature values.[299] 
 
(R)-(4-Methylphenyl)(phenyl)methanamine (R)-3.40d[299] 
 
Prepared from (R,R)-3.100d (48.5 mg, 0.11 mmol) using general method I, to afford the 
product as a yellow oil (30.0 mg, 72%, 92% ee); Rf 0.26 (1:1 pet. ether:EtOAc); >Į@D = +7.7 (c 
= 0.52, CHCl3, for 92% ee material measured on acetamide); IR (CHCl3 Ȟmax/cmí 3010, 
2966, 2864, 1602, 1513, 1493, 1452, 908; 1H NMR (400.1 MHz, CDCl3įH 7.38-7.35 (m, 2H, 
CHaryl), 7.32-7.19 (m, 5H, CHaryl), 7.11 (d, J = 7.6 Hz, 2H, CHaryl), 5.17 (s, 1H, NH2CH), 2.31 
(s, 3H, ArCH3), 1.75 (s, 2H, NH2CH); 13C NMR (100.6 MHz, CDCl3įC 145.8 (C), 142.7 (C), 
136.5 (C), 129.1 (CH), 128.4 (CH), 126.81 (CH), 126.76 (CH), 59.4 (CH) 21.0 (CH3) two 
peaks overlapped; HRMS (EI) calcd. for C14H15N, [M+] 197.1204, found 197.1199. These data 
were consistent with literature values.[299] 
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(S)-(4-Methylphenyl)(phenyl)methanamine (S)-3.40d[299] 
 
Prepared from (S,S)-3.100d (83.6 mg, 0.18 mmol) using general method I, to afford the 
product as a yellow oil (43.0 mg, 60%, 92% ee). Analytical data as for (R)-3.40d except; >Į@D 
= ±1.7 (c = 1.02, CHCl3, for 92% ee material measured on acetamide). 
 
(R)-(2-Methylphenyl)(phenyl)methanamine (R)-3.40e[302] 
 
Prepared from (R,R)-3.100e (63.6 mg, 0.14 mmol) using general method I, to afford the 
product as a yellow oil (28.8 mg, 53%, 97% ee). Analytical data as for (S)-3.40e except; >Į@D = 
±10.2 (c = 1.39, CHCl3, for 97% ee material measured on acetamide). 
 
(S)-(2-Methylphenyl)(phenyl)methanamine (S)-3.40e[302] 
 
Prepared from (S,S)-3.100e (66.2 mg, 0.15 mmol) using general method I, to afford the 
product as a yellow oil (18.3 mg, 32%, 96% ee); Rf 0.35 (1:1 pet. ether:EtOAc); >Į@D = +11.1 
(c = 0.92, CHCl3, for 96% ee material measured on acetamide); IR (CHCl3Ȟmax/cmí 3066, 
3011, 1601, 1491, 1453, 909; 1H NMR (400.1 MHz, CDCl3įH 7.53 (dd, J = 7.8, 1.0 Hz, 1H, 
CHaryl), 7.29-7.11 (m, 8H, CHaryl), 5.37 (s, 1H, NH2CH), 2.35 (s, 3H, ArCH3), 1.76 (br s, 2H, 
NH2CH); 13C NMR (100.6 MHz, CDCl3 įC 144.9 (C), 143.2 (C), 135.4 (C), 130.5 (CH), 
128.4 (CH), 127.3 (CH), 126.8 (CH), 126.1 (CH), 126.0 (CH), 56.1 (CH), 19.5 (CH3) two 
peaks overlapped; HRMS (EI) calcd. for C14H151>^0í+`+] 196.1126, found 196.1120. 
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(R)-(4-Methoxyphenyl)(phenyl)methanamine (R)-3.40f[299] 
 
Prepared from (R,R)-3.100f (78.8 mg, 0.16 mmol) using general method I, to afford the 
product as a colourless oil (65.6 mg, 95%, 86% ee). Analytical data as for (S)-3.40f except; 
>Į@D = +1.4 (c = 1.01, CHCl3, for 86% ee material measured on acetamide). 
 
(S)-(4-Methoxyphenyl)(phenyl)methanamine (S)-3.40f[299] 
 
Prepared from (S,S)-3.100f (60.9 mg, 0.13 mmol) using general method I, to afford the product 
as a colourless oil (45.4 mg, 85%, 94% ee); Rf 0.18 (1:1 pet. ether:EtOAc); >Į@D = ±2.2 (c = 
1.27, CHCl3, for 94% ee material measured on acetamide); IR (CHCl3Ȟmax/cmí 3011, 1612, 
1511, 1248, 1034, 838; 1H NMR (400.1 MHz, CDCl3įH 7.37-7.35 (m, 2H, CHaryl), 7.32-7.26 
(m, 4H, CHaryl), 7.21 (tt, J = 7.4, 1.8 Hz, 1H, CHaryl), 6.84 (dt, J = 8.8, 2.7 Hz, 2H, CHaryl), 5.16 
(s, 1H, NH2CH), 3.77 (s, 3H, OCH3), 1.75 (br s, 2H, NH2CH); 13C NMR (100.6 MHz, CDCl3) 
įC 158.4 (C), 145.8 (C), 137.8 (C), 128.4 (CH), 127.9 (CH), 126.8 (CH), 126.7 (CH), 113.7 
(CH), 59.0 (CH), 55.1 (CH3); HRMS (EI) calcd. for C14H15NO, [M+] 213.1154, found 
213.1144. These data were consistent with literature values.[299] 
 
(R)-Ethyl 4-(amino(phenyl)methyl)benzoate (R)-3.40g 
 
Prepared from (R,R)-3.100g (60.9 mg, 0.09 mmol) using general method I, pyridine removed 
in vacuo and the resulting yellow solid was purified by column chromatography (1:1 pet. 
ether:EtOAc) to afford the product as a yellow oil (14.6 mg, 31%, 91% ee); Rf 0.11 (1:1 pet. 
ether:EtOAc); >Į@D = ±2.3 (c = 0.45, CHCl3, for 91% ee material measured on acetamide); IR 
(CHCl3Ȟmax/cmí 2985, 2929, 1714, 1282, 1194; 1H NMR (400.1 MHz, CDCl3įH 7.98 (d, J 
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= 8.4 Hz, 2H, CHaryl), 7.36-7.22 (m, 7H, CHaryl), 5.30 (s, 1H, CHNH2), 4.37 (q, J = 7.2 Hz, 2H, 
CH2), 1.38 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3įC 165.9 (C), 141.2 (C), 
136.1 (C), 130.8 (C), 130.2 (CH), 129.2 (CH), 129.1 (CH), 127.2 (CH), 126.9 (CH), 61.2 
(CH2), 58.6 (CH), 14.3 (CH3); HRMS (EI) calcd. for C16H17NO2, [M+] 255.1259, found 
255.1250. 
 
(S)-(3-Methylphenyl)(phenyl)methanamine (S)-3.40h[303] 
 
Prepared from (S,S)-3.100h (86.1 mg, 0.19 mmol) using general method I, to afford the 
product as a yellow oil (54.4 mg, 73%, 86% ee); Rf 0.33 (1:1 pet. ether:EtOAc); >Į@D = +1.3 (c 
= 1.09, CHCl3, for 86% ee material measured on acetamide); IR (CHCl3 Ȟmax/cmí 3011, 
2964, 1605, 1493, 1453, 883; 1H NMR (400.1 MHz, CDCl3 įH 7.37-7.35 (m, 2H, CHaryl), 
7.31-7.27 (m, 2H, CHaryl), 7.22-7.13 (m, 4H, CHaryl), 7.03-7.01 (m, 1H, CHaryl), 5.15 (s, 1H, 
NH2CH), 2.31 (s, 3H, ArCH3), 1.76 (br s, 2H, NH2CH); 13C NMR (100.6 MHz, CDCl3 įC 
145.6 (C), 145.5 (C), 138.0 (C), 128.4 (CH), 128.3 (CH), 127.6 (CH), 127.5 (CH), 126.8 (CH), 
123.9 (CH), 59.6 (CH), 21.4 (CH3) two peaks overlapped; HRMS (ESI) calcd. for C14H15N, 
[M+] 197.1204, found 197.1200. 
 
(S)-(4-Bromophenyl)(phenyl)methanamine (S)-3.40i[230] 
 
Prepared from (S,S)-3.100i (77.4 mg, 0.13 mmol) using general method I, to afford the product 
as a yellow oil (41.9 mg, 61%, 95% ee); Rf 0.32 (1:1 pet. ether:EtOAc); >Į@D = +12.2 (c = 0.89, 
EtOH, for 95% ee material measured on acetamide; lit.[171] +9.9 for 98% ee S antipode, c = 
0.62, EtOH); IR (CHCl3Ȟmax/cmí 3065, 1484, 1072, 1026; 1H NMR (400.1 MHz, CDCl3įH 
7.42 (dt, J = 8.8, 2.2 Hz, 2H, CHaryl), 7.35-7.20 (m, 7H, CHaryl), 5.16 (s, 1H, NH2CH), 1.74 (br 
s, 2H, NH2CH); 13C NMR (100.6 MHz, CDCl3įC 145.1 (C), 144.5 (C), 131.5 (CH), 128.6 
(CH), 128.5 (CH), 127.1 (CH), 127.8 (CH), 120.7 (C), 59.2 (CH); HRMS (ESI Positive) calcd. 
for C13H12BrN, [M-NH2] 244.9960, found 244.9962. 
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(S)-(4-Fluorophenyl)(4-methylphenyl)methanamine (S)-3.40j 
 
Prepared from (S,S)-3.100j (38.0 mg, 0.07 mmol) using general method I, to afford the product 
as a yellow oil (28.9 mg, 99%, 92% ee); Rf 0.34 (1:1 pet. ether:EtOAc); >Į@D = +2.9 (c = 1.37, 
CHCl3, for 92% ee material measured on acetamide); IR (CHCl3Ȟmax/cmí3009, 1603, 1509, 
1296, 1157; 1H NMR (400.1 MHz, CDCl3įH 7.40-7.35 (m, 2H, CHaryl), 7.27 (dt, J = 8.4, 1.8 
Hz, 2H, CHaryl), 7.16 (d, J = 7.6 Hz, 2H, CHaryl), 7.02 (tt, J = 8.8, 2.4 Hz, 2H, CHaryl), 5.20 (s, 
1H, NH2CH), 2.36 (s, 3H, ArCH3), 1.82 (br s, 2H, NH2); 13C NMR (100.6 MHz, CDCl3įC 
161.7 (C, d, 1JCF = 243 Hz), 142.5 (C), 141.4 (C), 136.7 (C), 129.2 (CH), 128.3 (CH, d, 3JCF = 
7.3 Hz), 126.6 (CH), 115.1 (CH, d, 2JCF = 20.3 Hz), 58.8 (CH), 21.0 (CH3); 19F NMR (376.5 
MHz, CDCl3įF íHRMS (EI) calcd. for C14H14FN, [M+] 215.1105, found 215.1111. 
 
(3-Methoxyphenyl)(phenyl)methanamine (±)-3.40k 
 
Prepared from (±)-4.2dak (109.3 mg, 0.31 mmol) using general method I, to give a yellow oil 
(49.1 mg, 73%); IR (CHCl3Ȟmax/cmí 3375, 3005, 2963, 1599, 1488, 1454, 1260, 1048; 1H 
NMR (400.1 MHz, CDCl3įH 7.38-7.35 (m, 2H, CHaryl), 7.31-7.27 (m, 2H, CHaryl), 7.24-7.19 
(m, 2H, CHaryl), 6.96-6.93 (m, 2H, CHaryl), 6.77-6.74 (m, 1H, CHaryl), 5.16 (s, 1H, NH2CH), 
3.76 (s, 3H, OCH3), 1.77 (br s, 2H, NH2CH); 13C NMR (100.6 MHz, CDCl3 įC 159.7 (C), 
147.2 (C), 145.4 (C), 129.4 (CH), 128.4 (CH), 126.9 (CH), 126.8 (CH), 119.2 (CH), 112.5 
(CH), 112.1 (CH), 59.6 (CH), 55.1 (CH3); HRMS (ESI Positive) calcd. for C14H15NO, [M-
NH2] 197.0966, found 197.0987. This compound is reported in the literature but no analytical 
data are quoted.[304] 
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(4-(Trifluoromethyl)phenyl)(4-methylphenyl)methanamine (±)-3.40l 
 
Prepared from (±)-4.2dal (75.7 mg, 0.2 mmol) using general method I to give the product as a 
colourless oil (48.6 mg, 99%); IR (CHCl3 Ȟmax/cmí 2964, 1620, 1416, 1326, 1261, 1168, 
1018; 1H NMR (400.1 MHz, CDCl3įH 7.49-7.42 (m, 4H, CHaryl), 7.29-7.22 (m, 4H, CHaryl), 
7.18-7.14 (m, 1H, CHaryl), 5.18 (s, 1H, NH2CH), 1.70 (br s, 2H, NH2CH); 13C NMR (100.6 
MHz, CDCl3įC 149.5 (C), 144.8 (C), 129.2 (C, q, 2JCF = 32.1 Hz), 128.7 (CH), 127.3 (CH), 
127.2 (CH), 126.8 (CH), 125.4 (CH, q, 3JCF = 3.7 Hz), 124.2 (C, q, 1JCF = 270 Hz), 59.5 (CH); 
19F NMR (376.5 MHz, CDCl3įF íHRMS (EI) calcd. for C14H12F3N, [M+] 251.0916, 
found 251.0926. These data were consistent with literature values.[151] 
 
N-Benzhydrylacetamide 3.128a[305] 
 
Prepared from 3.40a (75 mg, 0.175 mmol) using general method J to give the product as a 
white solid (60.3 mg, 77%); Rf 0.26 (1:1 pet. ether:EtOAc); M.p. 143-145 °C; lit. 147-148 
°C;[305] IR (CHCl3Ȟmax/cmí 3442, 3010, 1673, 1496; 1H NMR (400.1 MHz, CDCl3įH 7.35-
7.22 (m, 10H, CHaryl), 6.25 (d, J = 8.0 Hz, 1H, NHCH), 6.05 (d, J = 6.8 Hz, 1H, NHCH), 2.07 
(s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 169.2 (C), 141.5 (C), 128.5 (CH), 127.4 
(CH), 127.3 (CH), 56.9 (CH), 23.1 (CH3); HRMS (ESI Positive) calcd. for C15H15NO, [M+Na] 
248.1046, found 248.1037. These data were consistent with literature values.[305] 
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N-((4-Fluorophenyl)(phenyl)methyl)acetamide 3.128b[306] 
 
Prepared from 3.40b.HCl (14.4 mg, 0.06 mmol) using general method J (4 equiv. pyridine 
used) to give a white solid (8.9 mg, 61%); Rf 0.24 (1:1 pet. ether:EtOAc); M.p. 147-149 °C; 
lit. 152-153 °C;[306] IR (CHCl3 Ȟmax/cmí 3442, 3011, 1674, 1509, 1239; 1H NMR (400.1 
MHz, CDCl3 įH 7.36-7.26 (m, 3H, CHaryl), 7.21-7.15 (m, 4H, CHaryl), 7.04-6.98 (m, 2H, 
CHaryl), 6.22 (d, J = 8.0 Hz, 1H, NHCH), 6.07 (d, J = 7.6 Hz, 1H, NHCH), 2.05 (s, 3H, 
(CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 169.4 (C), 161.8 (C, d, 1JCF = 245 Hz), 141.3 
(C), 137.3 (C, d, 4JCF = 4.6 Hz), 129.0 (CH, d, 3JCF = 7.6 Hz), 128.5 (CH), 127.4 (CH), 127.3 
(CH), 115.2 (CH, d, 2JCF = 21.3 Hz), 56.2 (CH), 22.8 (CH3); 19F NMR (376.5 MHz, CDCl3įF 
í HRMS (ESI Positive) calcd. for C15H14FNO, [M+Na] 266.0952, found 266.0953; 
HPLC: Daicel Chiralcel OD column, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-
enantiomer tR = 8.8 min, (R)-enantiomer tR = 13.6 min. These data were consistent with 
literature values.[306] 
 
N-((4-Chlorophenyl)(phenyl)methyl)acetamide 3.128c[307] 
 
4-Chlorobenzhydrylamine hydrochloride (385 mg, 1.53 mmol) was partitioned between EtOAc 
and 2 M NaOH(aq), the organics were dried (Na2SO4) and concentrated to a yellow oil (333.4 
mg, 1.53 mmol). This oil was taken up in CH2Cl2 P/S\ULGLQHȝ/PPRODQG
DFHW\O FKORULGH  ȝ/  PPRO ZHUH DGGHG DQG WKH VROXWLRQ VWLUUHG RYHUQLJKW 7KH
solution was diluted with CH2Cl2 (20 mL) and washed with sat. NaHCO3 solution (2 × 20 mL) 
and 2 M HCl (2 × 20 mL), dried (Na2SO4) and concentrated to an orange oil. Purification by 
column chromatography (3:1 pet. ether:EtOAc) gave the product as a white solid (280 mg, 
71%); Rf 0.18 (1:1 pet. ether:EtOAc); M.p. 126-128 °C; lit. 133-135 °C;[307] IR (CHCl3) 
Ȟmax/cmí 3442, 3009, 1674, 1494; 1H NMR (400.1 MHz, CDCl3įH 7.36-7.28 (m, 5H, CHaryl), 
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7.21-7.15 (m, 4H, CHaryl), 6.21 (d, J = 8.0 Hz, 1H, NHCH), 6.00 (d, J = 7.2 Hz, 1H, NHCH), 
2.07 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3 įC 169.1 (C), 141.0 (C), 140.0 (C), 
133.3 (C), 128.8 (CH), 128.8 (CH), 128.7 (CH), 127.8 (CH), 127.5 (CH), 56.5 (CH), 23.3 
(CH3); HRMS (ESI Positive) calcd. for C15H14ClNO, [M+Na] 282.0656, found 282.0657; 
HPLC: Daicel Chiralcel OD column, 95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-
enantiomer tR = 20.2 min, (R)-enantiomer tR = 33.6 min. These data were consistent with 
literature values.[307] 
 
N-((4-Methylphenyl)(phenyl)methyl)acetamide 3.128d[308] 
 
Prepared from 3.40d (79.1 mg, 0.173 mmol) using general method J to give the product as a 
cream solid (62.9 mg, 76%); Rf 0.25 (1:1 pet. ether:EtOAc); M.p. 126-128 °C; lit. 129-131 
°C;[308] IR (CHCl3Ȟmax/cmí 3442, 3011, 1673, 1497; 1H NMR (400.1 MHz, CDCl3įH 7.33-
7.20 (m, 5H, CHaryl), 7.13-7.08 (m, 4H, CHaryl), 6.20 (br s, 2H, overlapped NHCH and NHCH), 
2.31 (s, 3H, ArCH3), 2.01 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3 įC 169.0 (C), 
141.7 (C), 138.6 (C), 137.1 (C), 129.3 (CH), 128.5 (CH), 127.3 (CH), 127.2 (CH), 56.7 (CH), 
23.3 (CH3), 21.0 (CH3) two peaks overlapped; HRMS (ESI Positive) calcd. for C16H17NO, 
[M+H] 240.1383, found 240.1377; HPLC: Daicel Chiralcel OD-H column, 90:10 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 8.0 min, (R)-enantiomer tR = 10.1 
min. These data were consistent with literature values.[308] 
 
N-((2-Methylphenyl)(phenyl)methyl)acetamide 3.128e[308] 
 
Prepared from 3.40e (44.1 mg, 0.097 mmol) using general method J to give the product as a 
cream solid (40.3 mg, 87%); Rf 0.41 (1:1 pet. ether:EtOAc); M.p. 130-132 °C; lit. 147-155 
°C;[308] IR (CHCl3Ȟmax/cmí 3442, 3011, 1673, 1497; 1H NMR (400.1 MHz, CDCl3įH 7.32-
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7.09 (m, 9H, CHaryl), 6.40 (d, J = 8.0 Hz, 1H, NHCH), 6.08 (br d, J = 6.8 Hz, 1H, NHCH), 2.29 
(s, 3H, ArCH3), 2.03 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 168.9 (C), 141.0 
(C), 139.5 (C), 136.3 (C), 130.8 (CH), 128.6 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 126.6 
(CH), 126.1 (CH), 54.0 (CH), 23.2 (CH3), 23.4 (CH3); HRMS (ESI Positive) calcd. for 
C16H17NO, [M+Na] 262.1202, found 262.1193; HPLC: Daicel Chiralpak AD-H and Chiralpak 
AD columns in series (total column length = 50 cm), 95:5 hexanes:iPrOH; 1.0 mL/min; 200 
nm; (S)-enantiomer tR = 27.6 min, (R)-enantiomer tR = 32.0 min. These data were consistent 
with literature values.[308] 
 
N-((4-Methoxyphenyl)(phenyl)methyl)acetamide 3.128f[305] 
 
Prepared from 3.40f (89.3 mg, 0.183 mmol) using general method J to give the product as a 
cream solid (65.2 mg, 70%); Rf 0.21 (1:1 pet. ether:EtOAc); M.p. 154-156 °C; lit. 158.5 
°C;[305] IR (CHCl3 Ȟmax/cmí 3442, 3010, 1672, 1512, 1250, 1034; 1H NMR (400.1 MHz, 
CDCl3 įH 7.35-7.30 (m, 2H, CHaryl), 7.28-7.21 (m, 3H, CHaryl), 7.16-7.12 (m, 2H, CHaryl), 
6.88-6.84 (dm, J = 8.8 Hz, 2H, CHaryl), 6.21 (d, J = 8.0 Hz, 1H, NHCH), 5.97 (br d, J = 8.4 Hz, 
1H, NHCH), 3.79 (s, 3H, OCH3), 2.06 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 
169.0 (C), 158.9 (C), 141.7 (C), 133.7 (C), 128.62 (CH), 128.58 (CH), 127.3 (CH), 127.2 
(CH), 114.0 (CH), 56.4 (CH), 55.3 (CH3), 23.4 (CH3); HRMS (ESI Positive) calcd. for 
C16H17NO2, [M+Na] 278.1151, found 278.1135; HPLC: Daicel Chiralcel OD column, 90:10 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 14.2 min, (R)-enantiomer tR = 16.6 
min. These data were consistent with literature values.[305] 
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Ethyl 4-(acetamido(phenyl)methyl)benzoate 3.128g 
 
Prepared from 3.40g (92.4 mg, 0.161 mmol) using general method J to give the product as a 
colourless oil (72.7 mg, 85%); Rf 0.33 (1:1 pet. ether:EtOAc); M.p. 100-102 °C; IR (CHCl3) 
Ȟmax/cmí 3442, 3011, 1713, 1676, 1496, 1280, 1109; 1H NMR (400.1 MHz, CDCl3įH 8.00 
(dm, J = 8.8 Hz, 2H, CHaryl), 7.36-7.28 (m, 5H, CHaryl), 7.22-7.20 (m, 2H, CHaryl), 6.61 (br d, J 
= 7.6 Hz, 1H, NHCH), 6.28 (d, J = 8.8 Hz, 1H, NHCH), 4.37 (q, J = 7.1 Hz, 2H, COOCH2), 
2.06 (s, 3H, (CO)CH3), 1.40 (t, J = 7.2 Hz, 3H, CH2CH3); 13C NMR (100.6 MHz, CDCl3įC 
169.4 (C), 166.2 (C), 146.4 (C), 140.8 (C), 129.8 (CH), 129.5 (C), 128.8 (CH), 127.8 (CH), 
127.5 (CH), 127.2 (CH), 60.9 (CH2), 56.9 (CH), 23.1 (CH3), 14.3 (CH3); HRMS (ESI Positive) 
calcd. for C18H19NO3, [M+Na] 320.1257, found 320.1246; Anal. Calc. for C18H19NO3: C, 
72.71; H, 6.44; N, 4.71%. Found: C, 72.68; H, 6.45; N, 4.66%; HPLC: Daicel Chiralcel OD 
column, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 14.3 min, (R)-
enantiomer tR = 18.5 min. 
 
N-((3-Methylphenyl)(phenyl)methyl)acetamide 3.128h[303] 
 
Prepared from 3.40h (69.7 mg, 0.153 mmol) using general method J to give the product as a 
white solid (45.1 mg, 62%); Rf 0.23 (1:1 pet. ether:EtOAc); M.p. 99-101 °C; lit. 97 °C;[303] IR 
(CHCl3Ȟmax/cmí 3443, 3010, 1673, 1497; 1H NMR (400.1 MHz, CDCl3įH 7.34-7.19 (m, 
6H, CHaryl), 7.09-7.00 (m, 3H, CHaryl), 6.20 (d, J = 8.0 Hz, 1H, NHCH), 6.12 (br d, J = 8.0 Hz, 
1H, NHCH), 2.32 (s, 3H, ArCH3), 2.04 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 
169.0 (C), 141.6 (C), 141.4 (C), 138.3 (C), 128.6 (CH), 128.5 (CH), 128.2 (CH), 128.1 (CH), 
127.4 (CH), 127.3 (CH), 124.4 (CH), 56.9 (CH), 23.4 (CH3), 21.4 (CH3); HRMS (ESI 
Positive) calcd. for C16H17NO, [M+Na] 262.1202, found 262.1191; HPLC: Daicel Chiralpak 
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AD-H and Chiralpak AD columns in series (total column length = 50 cm), 95:5 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 31.2 min, (R)-enantiomer tR = 35.4 
min. These data were consistent with literature values.[303] 
 
N-((2-Bromophenyl)(phenyl)methyl)acetamide 3.128i[307] 
 
Prepared from 3.40i (67.6 mg, 0.115 mmol) using general method J to give the product as a 
cream solid (59.6 mg, 85%); Rf 0.36 (1:1 pet. ether:EtOAc); M.p. 143-147 °C; IR (CHCl3) 
Ȟmax/cmí 3442, 3010, 1676, 1495, 1030; 1H NMR (400.1 MHz, CDCl3įH 7.43 (dm, J = 8.4 
Hz, 2H, CHaryl), 7.34-7.26 (m, 3H, CHaryl), 7.19-7.16 (m, 2H, CHaryl), 7.09 (dm, J = 8.4 Hz, 2H, 
CHaryl), 6.28 (br d, J = 7.6 Hz, 1H, NHCH), 6.16 (d, J = 8.0 Hz, 1H, NHCH), 2.01 (s, 3H, 
(CO)CH3); 13C NMR (100.6 MHz, CDCl3 įC 169.2 (C), 140.9 (C), 140.5 (C), 131.6 (CH), 
129.0 (CH), 128.8 (CH), 127.7 (CH), 127.4 (CH), 121.3 (C), 56.5 (CH), 23.2 (CH3); HRMS 
(ESI Positive) calcd. for C15H14BrNO, [M+Na] 326.0151, found 326.0138; Anal. Calc. for 
C15H14BrNO: C, 59.23; H, 4.64; N, 4.60%. Found: C, 59.14; H, 4.66; N, 4.30%; HPLC: Daicel 
Chiralcel OD column, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 10.8 
min, (R)-enantiomer tR = 15.1 min. These data were consistent with literature values.[307] 
 
N-((4-Fluorophenyl)(4-methylphenyl)methyl)acetamide 3.128j 
 
Prepared from 3.40j (88 mg, 0.179 mmol) using general method J to give the product as a 
cream solid (80.4 mg, 87%); Rf 0.28 (1:1 pet. ether:EtOAc); M.p. 135-137 °C; IR (CHCl3) 
Ȟmax/cmí 3442, 3010, 1674, 1509, 1240; 1H NMR (400.1 MHz, CDCl3įH 7.24-7.16 (m, 4H, 
CHaryl), 7.12 (d, J = 8.4 Hz, 2H, CHaryl), 7.03 (tt, J = 8.8, 2.5 Hz, 2H, CHaryl), 6.21 (d, J = 7.6 
Hz, 1H, NHCH), 6.12 (br d, J = 8.0 Hz, 1H, NHCH), 2.37 (s, 3H, ArCH3), 2.07 (s, 3H, 
(CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 169.0 (C), 162.0 (C, d, 1JCF = 244 Hz), 138.3 
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(C), 137.5 (C, d, 4JCF = 3.1 Hz), 137.4 (C), 129.4 (CH), 128.9 (CH, d, 3JCF = 7.6 Hz), 127.3 
(CH), 115.4 (CH, d, 2JCF = 21.3 Hz), 56.1 (CH), 23.3 (CH3), 21.0 (CH3); 19F NMR (376.5 
MHz, CDCl3įF -115.3; HRMS (ESI Positive) calcd. for C16H16FNO, [M+H] 258.1289, found 
258.1279; HPLC: Daicel Chiralcel OD-H and Chiralcel OD columns in series (total column 
length = 50 cm), 95:5 hexanes:iPrOH; 0.5 mL/min; 200 nm; (S)-enantiomer tR = 72.1 min, (R)-
enantiomer tR = 80.8 min. 
 
N-((3-Methoxyphenyl)(phenyl)methyl)acetamide 3.128k 
 
Prepared from 4.2dak (110 mg, 0.32 mmol) using general method J, purified by column 
chromatography (1:1 pet. ether:EtOAc) to give the product as a white crystalline solid (54.9 
mg, 68%); Rf 0.20 (1:1 pet. ether:EtOAc); M.p. 98-101 °C; IR (CHCl3Ȟmax/cmí 3442, 3008, 
1673, 1494, 1260, 995; 1H NMR (400.1 MHz, CDCl3įH 7.31-7.19 (m, 6H, CHaryl), 6.80-6.77 
(m, 3H, CHaryl), 6.49 (d, J = 8.0 Hz, 1H, NHCH), 6.17 (d, J = 8.4 Hz, 1H, NHCH), 3.73 (s, 3H, 
OCH3), 1.97 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 169.1 (C), 159.7 (C), 143.1 
(C), 141.4 (C), 129.6 (CH), 128.5 (CH), 127.4 (CH), 127.3 (CH), 119.7 (CH), 113.4 (CH), 
112.4 (CH), 56.9 (CH), 55.1 (CH3), 23.2 (CH3); HRMS (ESI Positive) calcd. for C16H17NO2, 
[M+Na] 278.1151, found 278.1147; Anal. Calc. for C16H17NO2: C, 75.27; H, 6.71; N, 5.49%. 
Found: C, 75.30; H, 6.71; N, 5.49%; HPLC: Daicel Chiralpak OD-H, 90:10 hexanes:iPrOH; 
1.0 mL/min; 200 nm; (S)-enantiomer tR = 13.7 min, (R)-enantiomer tR = 27.9 min. This 
compound is reported in the literature but no analytical data are quoted.[204] 
 
N-((4-(Trifluoromethyl)phenyl)(phenyl)methyl)acetamide 3.128l 
 
Prepared from 4.2dal (112 mg, 0.29 mmol) using general method J, purified by column 
chromatography (1:1 pet. ether:EtOAc) to give a white solid (64 mg, 75%); Rf 0.23 (4:1 pet. 
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ether:EtOAc); M.p. 125-127 °C; IR (CHCl3Ȟmax/cmí 3441, 3011, 1676, 1496, 1326, 1169, 
1130; 1H NMR (400.1 MHz, CDCl3įH 7.54 (d, J = 8.0 Hz, 2H, CHaryl), 7.33-7.25 (m, 5H, 
CHaryl), 7.18-7.16 (m, 2H, CHaryl), 6.67 (br d, J = 7.6 Hz, 1H, NHCH), 6.22 (d, J = 7.6 Hz, 1H, 
NHCH), 1.97 (s, 3H, (CO)CH3); 13C NMR (100.6 MHz, CDCl3įC 169.5 (C), 145.5 (C), 140.6 
(C), 129.5 (C, q, 2JCF = 32.5 Hz), 128.8 (CH), 127.8 (CH), 127.5 (CH), 125.4 (CH, q, 3JCF = 3.4 
Hz), 124.0 (C, q, 1JCF = 270 Hz), 56.7 (CH), 23.0 (CH3), two peaks overlapped; 19F NMR 
(376.5 MHz, CDCl3 įF í HRMS (ESI Positive) calcd. for C16H14F3NO, [M+Na] 
316.0920, found 316.0912; HPLC: Daicel Chiralpak OD-H, 90:10 hexanes:iPrOH; 1.0 
mL/min; 200 nm; (S)-enantiomer tR = 6.6 min, (R)-enantiomer tR = 11.0 min. These data were 
consistent with literature values.[309] 
 
tert-Butyl N-methylsulfamoylcarbamate 4.10a[247] 
 
Prepared from methylamine (40 wt. % in H2O, 51.8 mL, 0.6 mol) using general method L to 
afford the product as a white crystalline solid (17.2 g, 82%); Rf 0.50 (5% MeOH/CH2Cl2); 
M.p. 144 °C dec.; IR (CHCl3Ȟmax/cmí 3690, 3399, 3296, 2985, 1737, 1602, 1438, 1145; 1H 
NMR (400.1 MHz, CDCl3įH 7.33 (br s, 1H, NHBoc), 5.22 (app. d, J = 4.8 Hz, 1H, NHCH3), 
2.76 (d, J = 5.2 Hz, 3H, NHCH3), 1.50 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) įC 
150.2 (C), 83.9 (C), 29.8 (CH3), 28.0 (CH3); HRMS (ESI Positive) calcd. for C6H14N2O4S, 
[M+Na] 233.0566, found 233.0569; Anal. Calc. for C6H14N2O4S: C, 34.28; H, 6.71; N, 
13.32%. Found: C, 34.06; H, 6.64; N, 13.21%. These data were consistent with literature 
values.[310,247] 
 
tert-Butyl N-ethylsulfamoylcarbamate 4.10b 
 
Prepared from ethylamine (70 wt. % in H2O, 4.85 mL, 0.6 mol) using general method L to 
afford the product as a white crystalline solid (2.11 g, 94%). 
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Prepared from ethylamine.HCl (1.03 g, 12.6 mmol) using general method M to afford the 
product as a white crystalline solid (2.78 g, 98%). 
Rf 0.69 (10% MeOH/CH2Cl2); M.p. 125-127 °C; IR (CHCl3 Ȟmax/cmí 3400, 2985, 1737, 
1435, 1403, 1144; 1H NMR (400.1 MHz, CDCl3įH 7.34 (br s, 1H, NHBoc), 5.19 (t, J = 5.6 
Hz, 1H, NHCH2CH3), 3.14 (dq, J = 6.0, 7.2 Hz, 2H, NHCH2CH3), 1.50 (s, 9H, C(CH3)3), 1.23 
(t, J = 7.2 Hz, 3H, NHCH2CH3); 13C NMR (100.6 MHz, CDCl3įC 150.2 (C), 83.8 (C), 38.9 
(CH2), 28.0 (CH3), 14.5 (CH3); HRMS (ESI Positive) calcd. for C7H16N2O2S, [M+Na] 
247.0723, found 247.0719; Anal. Calc. for C7H16N2O2S: C, 37.49; H, 7.19; N, 12.49%. Found: 
C, 37.34; H, 7.16; N, 12.33%. 
 
tert-Butyl N-isopropylsulfamoylcarbamate 4.10c 
 
Prepared from isopropylamine (4.91 mL, 60 mmol) using general method L to afford the 
product as a white crystalline solid after recrystallisation from ethanol (1.50 g, 63%); Rf 0.73 
(10% MeOH/CH2Cl2); M.p. 147 °C dec. (ethanol); IR (CHCl3 Ȟmax/cmí 3399, 2983, 1737, 
1434, 1404, 1143; 1H NMR (400.1 MHz, CDCl3įH 7.18 (br s, 1H, NHBoc), 4.96 (d, J = 6.8 
Hz, 1H, NHCH(CH3)2), (app. sextet, J = 6.6 Hz, 1H, CH(CH3)2), 1.50 (s, 9H, C(CH3)3), 1.23 
(d, J = 6.4 Hz, 6H, CH(CH3)2); 13C NMR (100.6 MHz, CDCl3įC 150.2 (C), 83.7 (C), 47.1 
(CH), 28.0 (CH3), 23.1 (CH3); HRMS (ESI Positive) calcd. for C8H18N2O4S, [M+Na] 
261.0879, found 261.0882; Anal. Calc. for C8H18N2O4S: C, 40.32; H, 7.61; N, 11.76%. Found: 
C, 40.30; H, 7.59; N, 11.70%. These data were consistent with literature values.[311] 
 
tert-Butyl N-tert-butylsulfamoylcarbamate 4.10d 
 
Prepared from tert-butylamine (12.6 mL, 120 mmol) using general method L to give a white 
solid (4.51 g, 89%); Rf 0.69 (5% MeOH/CH2Cl2); M.p. 151 °C dec.; IR (CHCl3 Ȟmax/cmí 
3401, 2939, 1737, 1435, 1403, 1143; 1H NMR (400.1 MHz, CDCl3įH 7.11 (s, 1H, NHBoc), 
5.03 (s, 1H, NHC(CH3)3)), 1.50 (s, 9H, COOC(CH3)3), 1.36 (s, 9H, NHC(CH3)3); 13C NMR 
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(100.6 MHz, CDCl3įC 150.2 (C), 83.5 (C), 55.0 (C), 29.4 (CH3), 28.1 (CH3); HRMS (ESI 
Positive) calcd. for C9H20N2O4S, [M+Na] 275.1036, found 275.1042; Anal. Calc. for 
C9H20N2O4S: C, 42.84; H, 7.99; N, 11.10%. Found: C, 42.62; H, 7.97; N, 11.05%. 
 
tert-Butyl N-phenylsulfamoylcarbamate 4.10e 
 
Prepared from aniline (10.9 mL, 120 mmol) using general method L to give a white solid (4.37 
g, 80%). 
Prepared from aniline (1.82 mL, 20 mmol) using general method M to afford the product as a 
cream crystalline solid (4.23 g, 78%). 
Rf 0.67 (10% MeOH/CH2Cl2); M.p. 140 °C dec.; IR (CHCl3 Ȟmax/cmí 3395, 1739, 1432, 
1145; 1H NMR (400.1 MHz, CDCl3įH 7.38-7.34 (m, 2H, CHaryl), 7.28-7.23 (m, 3H, CHaryl), 
7.15 (br s, 1H, NHBoc), 7.01 (br s, 1H, NHC(CH3)3), 1.45 (s, 9H, C(CH3)3); 13C NMR (100.6 
MHz, CDCl3 įC 149.9 (C), 135.8 (C), 129.5 (CH), 126.6 (CH), 122.9 (CH), 84.2 (C), 27.9 
(CH3); HRMS (ESI Positive) calcd. for C11H16N2O4S, [M+Na] 295.0723, found 295.0720; 
Anal. Calc. for C11H16N2O4S: C, 48.52; H, 5.92; N, 10.29%. Found: C, 48.13; H, 5.84; N, 
10.26%. These data were consistent with literature values.[248] 
 
(R)-tert-Butyl N-(1-phenylethyl)sulfamoylcarbamate (R)-4.10g 
 
Prepared from (R)-1-methylbenzylamine (2.54 mL, 20 mmol) using general method M to give 
a white solid (3.29 g, 55%); Rf 0.66 (5% MeOH/CH2Cl2); M.p. 142 °C dec.; >Į@D = +1.8 (c = 
1.11, CHCl3); IR (CHCl3 Ȟmax/cmí 3399, 2984, 1738, 1433, 1145; 1H NMR (400.1 MHz, 
CDCl3įH 7.37-7.26 (m, 5H, CHaryl), 7.13 (s, 1H, NHBoc), 5.55 (d, J = 7.2 Hz, 1H, NHCH), 
4.61-4.54 (m, 1H, NHCH), 1.53 (d, J = 6.8 Hz, 3H, CHCH3), 1.39 (s, 9H, C(CH3)3); 13C NMR 
(100.6 MHz, CDCl3įC 149.9 (C), 141.6 (C), 128.8 (CH), 127.9 (CH), 126.2 (CH), 83.5 (C), 
54.5 (CH), 27.9 (CH3), 23.1 (CH3); HRMS (ESI Positive) calcd. for C13H20N2O4S, [M+Na] 
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323.1036, found 323.1022; Anal. Calc. for C13H20N2O4S: C, 51.98; H, 6.71; N, 9.33%. Found: 
C, 51.97; H, 6.73; N, 9.23%. 
 
(S)-tert-Butyl N-(1-phenylethyl)sulfamoylcarbamate (S)-4.10g 
 
Prepared from (S)-1-methylbenzylamine (2.58 mL, 20 mmol) using general method M to give 
a white solid (3.50 g, 58%). Analytical data as for (R)-4.10g except; >Į@D   í c = 0.99, 
CHCl3). 
 
N-Methylsulfamide 4.4a 
 
Prepared from 4.10a (16.7 g, 79.5 mmol) using general method N, purified by column 
chromatography (5% MeOH/CH2Cl2) to give the product as a white crystalline solid (7.28 g, 
83%); Rf 0.24 (10:1 CH2Cl2:MeOH); M.p. 63-64 °C; lit. 63-65 °C;[312] IR (CHCl3Ȟmax/cmí 
3446, 3396, 3351, 1403, 1344, 1162; 1H NMR (400.1 MHz, acetone-d6 įH 5.81 (br s, 2H, 
NH2), 5.51 (br s, 1H, NHCH3), 2.71 (d, J = 5.2 Hz, 3H, NHCH3); 13C NMR (100.6 MHz, 
methanol-d4 įC 29.6 (CH3); HRMS (EI) calcd. for CH6N2O2S, [M+] 110.0150, found 
110.0150; Anal. Calc. for CH6N2O2S: C, 10.91; H, 5.49; N, 25.44%. Found: C, 10.97; H, 5.36; 
N, 25.16%. These data were consistent with literature values.[312,313] 
 
N-Ethylsulfamide 4.4b 
 
Prepared from 4.10b (2.0 g, 8.92 mmol) using general method N, purified by column 
chromatography (10% MeOH/CH2Cl2) to give the product as a white crystalline solid (1.10 g, 
99%); Rf 0.12 (5% MeOH/CH2Cl2); IR QHDWȞmax/cmí 3285, 2983, 1561, 1428, 1326, 1159, 
954; 1H NMR (400.1 MHz, DMSO-d6įH 6.42 (br s, 3H, NH2 and NHCH2), 2.90 (q, J = 7.3 
Hz, 2H, NHCH2CH3), 1.06 (t, J = 7.4 Hz, 3H, NHCH2CH3); 13C NMR (100.6 MHz, DMSO-
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d6įC 37.4 (CH2), 14.7 (CH3); HRMS (ESI Positive) calcd. for C2H8N2O2S, [M+Na] 147.0199, 
found 147.0198. These data were consistent with literature values.[314] 
 
N-iso-Propylsulfamide 4.4c 
 
Prepared from 4.10c (1.95 g, 8.17 mmol) using general method N, purified by column 
chromatography (5% MeOH/CH2Cl2) to give the product as a pale yellow oil (788 mg, 70%); 
Rf 0.26 (5% MeOH/CH2Cl2); IR (CHCl3Ȟmax/cmí 3433, 3386, 3345, 3297, 2977, 1550, 1343, 
1141, 1006, 910; 1H NMR (400.1 MHz, CDCl3 įH 4.87 (br s, 3H, NH2 and NHCH), 3.62 
(septet, J = 6.5 Hz, 1H, NHCH), 1.24 (d, J = 6.4 Hz, 6H, CH(CH3)2); 13C NMR (100.6 MHz, 
CDCl3 įC 46.5 (CH), 23.5 (CH3); HRMS (EI) calcd. for C3H10N2O2S, [M-Me+] 123.0223, 
found 123.0228; This compound is reported in the literature but no analytical data are 
quoted.[315] 
 
N-tert-Butylsulfamide 4.4d[316] 
 
Prepared from 4.10d (9.94 g, 39.4 mmol) using general method N, no chromatography 
required to give a colourless crystalline solid (5.70 g, 95%); Rf 0.16 (5% MeOH/CH2Cl2); M.p. 
52-54 °C; lit. 57-59 °C;[316] IR (CHCl3 Ȟmax/cmí 3386, 2979, 1416, 1337, 1151, 996; 1H 
NMR (400.1 MHz, CDCl3įH 6.40 (br s, 2H, NH2), 6.30 (br s, 1H, NHC(CH3)3), 1.24 (s, 9H, 
C(CH3)3); 13C NMR (100.6 MHz, CDCl3 įC 52.3 (C), 29.6 (CH3); HRMS (EI) calcd. for 
C4H12N2O2S, [M-Me+] 137.0379, found 137.0383. These data were consistent with literature 
values.[316,317] 
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N-Phenylsulfamide 4.4e[318] 
 
Prepared from 4.10e (4.32 g, 15.5 mmol) using general method N, purified by column 
chromatography (5% MeOH/CH2Cl2) to give the product as a light brown solid (2.12 g, 
79%);.Rf 0.22 (5% MeOH/CH2Cl2); M.p. 105-107 °C; lit. 108.5-109.5 °C;[318] IR (CHCl3) 
Ȟmax/cmí 3350, 1412, 1164; 1H NMR (400.1 MHz, DMSO-d6įH 9.46 (s, 1H, NHPh), 7.28-
7.23 (m, 2H, CHaryl), 7.17-7.14 (m, 2H, CHaryl), 7.06 (br s, 2H, NH2) 6.96 (tt, J = 7.2, 1.1 Hz, 
1H, CHaryl); 13C NMR (100.6 MHz, DMSO-d6įC 139.5 (C), 128.7 (CH), 121.8 (CH), 117.9 
(CH); HRMS (EI) calcd. for C6H8N2O2S, [M+] 172.0301, found 172.0305. These data were 
consistent with literature values.[318] 
 
N-Benzylsulfamide 4.4f[319] 
 
Following the procedure of Kohn et al.[243] a solution of benzylamine (5.47 mL, 50 mmol) and 
sulfamide (4.81 g, 50 mmol) in H2O (50 mL) was stirred at reflux for 5 h. The resulting 
suspension was allowed to cool with stirring. The white solid was collected by filtration, 
washed with H2O and dried on the pump (6.10 g, 66%). Rf 0.34 (1:1 pet. ether:EtOAc); M.p. 
103-105 °C; lit. 104-105 °C;[319] IR (CHCl3 Ȟmax/cmí 3348, 1414, 1349, 1162; 1H NMR 
(400.1 MHz, DMSO-d6įH 7.36-7.30 (m, 4H, CHaryl), 7.26-7.22 (m, 1H, CHaryl), 7.03 (t, J = 
6.4 Hz, 1H, NHCH2), 6.61 (s, 2H, NH2), 4.07 (d, J = 6.4 Hz, 2H, NHCH2Ph); 13C NMR (100.6 
MHz, CDCl3 įC 138.7 (C), 128.1 (CH), 127.6 (CH), 126.9 (CH), 46.1 (CH2); HRMS (ESI 
Positive) calcd. for C7H10N2O2S, [M+Na] 209.0355, found 209.0364. These data were 
consistent with literature values.[319] 
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(R)-N-(1-Phenylethyl)sulfamide (R)-4.4g 
 
Prepared from (R)-4.10g (1.39 g, 4.63 mmol) using general method N, purified by column 
chromatography (2:1 pet. ether:EtOAc) to give a colourless oil (1.59 g, 80%); Rf 0.11 (2:1 pet. 
ether:EtOAc); >Į@D = +19.1 (c = 1.22, CHCl3); IR /LTXLGILOPȞmax/cmí 3283, 1603, 1495, 
1455, 1331, 1163, 967; 1H NMR (400.1 MHz, CDCl3įH 7.36-7.24 (m, 5H, CHaryl), 5.23 (br d, 
J = 5.6 Hz, 1H, NHCH), 4.59-4.53 (m, 3H, NH2 and NHCH), 1.50 (d, J = 6.4 Hz, 3H, 
CHCH3); 13C NMR (100.6 MHz, CDCl3įC 142.5 (C), 128.8 (CH), 127.7 (CH), 126.3 (CH), 
54.0 (CH), 23.3 (CH3); HRMS (ESI Positive) calcd. for C8H12N2O2S, [M+H] 223.0512, found 
223.0523. These data were consistent with literature values.[317] 
 
(S)-N-(1-Phenylethyl)sulfamide (S)-4.4g 
 
Prepared from (S)-4.4g (1.50 g, 5.00 mmol) using general method N, purified by column 
chromatography (2:1 pet. ether:EtOAc) to give a colourless oil (1.59 g, 73%); Analytical data 
as for (R)-4.4g except; >Į@D  íc = 1.26, CHCl3). 
 
N-Methyl-N'-[phenylmethylidene]sulfamide 4.1aa 
 
Prepared from 4.4a (3.30 g, 30 mmol) and benzaldehyde (3.37 mL, 33 mmol) using general 
method O, trituration with hexanes gave the product as a cream solid (5.09 g, 86%); Rf 0.19 
(4:1 pet. ether:EtOAc); M.p. 127-130 °C; IR (CHCl3Ȟmax/cmí 3386, 1610, 1578, 1336, 1161, 
842; 1H NMR (400.1 MHz, CDCl3įH 8.93 (s, 1H, N=CH), 7.96-7.93 (m, 2H, CHaryl), 7.64 (tt, 
J = 1.6, 7.4 Hz, 1H, CHaryl), 7.55-7.51 (m, 2H, CHaryl), 4.42 (d, J = 5.2 Hz, 1H, NHCH3), 2.84 
(d, J = 5.2 Hz, 3H, NHCH3); 13C NMR (100.6 MHz, CDCl3įC 170.0 (CH), 134.6 (CH), 132.3 
(C), 130.9 (CH), 129.2 (CH), 29.9 (CH3); HRMS (ESI Positive) calcd. for C8H10N2O2S, 
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[M+Na] 221.0355, found 221.0359; Anal. Calc. for C8H10N2O2S: C, 48.47; H, 5.08; N, 
14.13%. Found: C, 48.28; H, 5.14; N, 13.99%. 
 
N-Methyl-N'-[4-chlorophenylmethylidene]sulfamide 4.1ba 
 
Prepared from 4.4a (1.10 g, 10 mmol) and 4-chlorobenzaldehyde (1.55 g, 11 mmol) using 
general method O, purified by column chromatography (2:1 pet. ether:EtOAc) to give a white 
solid (1.60 g, 67%); Rf 0.23 (2:1 pet. ether:EtOAc); M.p. 135-137 °C; IR (CHCl3Ȟmax/cmí 
3388, 1611, 1594, 1338, 1162, 842; 1H NMR (400.1 MHz, CDCl3įH 8.88 (s, 1H, N=CH), 
7.88 (dt, J = 8.4, 2.3 Hz, 2H, CHaryl), 7.50 (dt, J = 8.4, 2.2 Hz, 2H, CHaryl), 4.44 (br q, J = 5.2 
Hz, 1H, NH), 2.84 (q, J = 5.2 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3įC 168.5 (CH), 
141.1 (C), 132.0 (CH), 130.8 (C), 129.6 (CH), 29.9 (CH3); HRMS (ESI Positive) calcd. for 
C8H9N2O2S, [M+Na] 254.9965, found 254.9974; Anal. Calc. for C8H9N2O2S: C, 41.29; H, 
3.90; N, 12.04%. Found: C, 41.24; H, 3.86; N, 11.82%. 
 
N-Methyl-N'-[2-methylphenylmethylidene]sulfamide 4.1ae 
 
Prepared from 4.4a (552 mg, 5 mmol) and o-tolualdehyde (0.64 mL, 5.5 mmol) using general 
method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give a white solid 
(665 mg, 63%); Rf 0.10 (4:1 pet. ether:EtOAc); M.p. 124-127 °C; IR (CHCl3Ȟmax/cmí 3389, 
1611, 1593, 1403, 1355, 1161, 843; 1H NMR (400.1 MHz, CDCl3įH 9.23 (s, 1H, N=CH), 
8.03 (dd, J = 8.0, 1.2 Hz, 1H, CHaryl), 7.50 (td, J = 7.4, 1.3 Hz, 1H, CHaryl), 7.34-7.28 (m, 2H, 
CHaryl), 4.38 (q, J  = 5.2 Hz, 1H, NHCH3), 2.84 (d, J = 5.6 Hz, 3H, NHCH3), 2.62 (s, 3H, 
ArCH3); 13C NMR (100.6 MHz, CDCl3įC 168.5 (CH), 141.8 (C), 134.2 (CH), 131.6 (CH), 
130.3 (C), 130.2 (CH), 126.6 (CH), 29.9 (CH3), 19.7 (CH3); HRMS (ESI Positive) calcd. for 
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C9H12N2O2S, [M+Na] 235.0512, found 235.0505; Anal. Calc. for C9H12N2O2S: C, 50.92; H, 
5.70; N, 13.20%. Found: C, 50.70; H, 5.64; N, 13.16%. 
 
N-Methyl-N'-[4-methoxyphenylmethylidene]sulfamide 4.1af 
 
Prepared from 4.4a (551 mg, 5 mmol) and p-DQLVDOGHK\GHȝ/PPROXVLQJJHQHUDO
method O, purified by column chromatography (2:1 pet. ether:EtOAc) to give a white solid 
(743 mg, 65%); Rf 0.15 (2:1 pet. ether:EtOAc); M.p. 114-116 °C; IR (CHCl3Ȟmax/cmí3386, 
1599, 1569, 1514, 1333, 1263, 1157, 840; 1H NMR (400.1 MHz, CDCl3 įH 8.84 (s, 1H, 
N=CH), 7.89 (dt, J = 9.2, 2.3 Hz, 2H, CHaryl), 7.00 (dt, J = 8.8, 2.0 Hz, 2H, CHaryl), 4.39 (q, J = 
5.3 Hz, 1H, NHCH3), 3.90 (s, 3H, OCH3), 2.81 (d, J = 5.6 Hz, 3H, NHCH3); 13C NMR (125.8 
MHz, CDCl3įC 169.2 (CH), 165.0 (C), 133.3 (CH), 125.0 (C), 114.7 (CH), 55.7 (CH3), 29.9 
(CH3); HRMS (ESI Positive) calcd. for C9H12N2O3S, [M+Na] 251.0461, found 251.0460; 
Anal. Calc. for C9H12N2O3S: C, 47.35; H, 5.30; N, 12.27%. Found: C, 47.11; H, 5.27; N, 
12.29%. 
 
N-Ethyl-N'-[phenylmethylidene]sulfamide 4.1ba 
 
Prepared from 4.4b (1.99 g, 16 mmol) and benzaldehyde (1.80 g, 17.7 mmol) using general 
method O, to give a cream solid which was triturated with hexanes to give the product as a 
white solid (2.93 g, 86%); Rf 0.23 (4:1 pet. ether:EtOAc); M.p. 76-80 °C; IR (CHCl3) 
Ȟmax/cmí 3380, 2985, 1611, 1337, 1160, 863; 1H NMR (400.1 MHz, CDCl3įH 8.92 (s, 1H, 
N=CH), 7.95-7.92 (m, 2H, CHaryl), 7.63 (tt, J = 7.4, 1.5 Hz, 1H, CHaryl), 7.54-7.50 (m, 2H, 
CHaryl), 4.41 (t, J = 5.8 Hz, 1H, NHCH2CH3), 3.22 (dq, J = 7.2, 6.0 Hz, 2H, NHCH2CH3), 1.24 
(t, J = 7.4 Hz, 3H, CH2CH3); 13C NMR (100.6 MHz, CDCl3įC 169.4 (CH), 134.5 (CH), 132.4 
(C), 130.9 (CH), 129.2 (CH), 38.9 (CH2), 15.3 (CH3); HRMS (ESI Positive) calcd. for 
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C9H12N2O2S, [M+Na] 235.0512, found 235.0523; Anal. Calc. for C9H12N2O2S: C, 50.92; H, 
5.70; N, 13.20%. Found: C, 50.68; H, 5.72; N, 13.02%. 
 
N-iso-Propyl-N'-[phenylmethylidene]sulfamide 4.1ca 
 
Prepared from 4.4c PJPPRODQGEHQ]DOGHK\GHȝ/PPROXVLQJJHQHUDO
method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give a white 
crystalline solid (859 mg, 90%); Rf 0.20 (4:1 pet. ether:EtOAc); M.p. 52-55 °C; IR (CHCl3) 
Ȟmax/cmí 3380, 2978, 1611, 1577, 1341, 1159, 1003; 1H NMR (400.1 MHz, CDCl3įH 8.92 
(s, 1H, N=CH), 7.94-7.91 (m, 2H, CHaryl),  7.63 (tt, J = 7.6, 1.6 Hz, 1H, CHaryl), 7.53-7.49 (m, 
2H, CHaryl), 4.44 (d, J = 8.0 Hz, 1H, NHCH(CH3)2), (doublet of septets, J = 7.6, 6.4 Hz, 1H, 
NHCH(CH3)2), 1.26 (d, J = 6.4 Hz, 6H, CH(CH3)2); 13C NMR (100.6 MHz, CDCl3įC 168.6 
(CH), 134.4 (CH), 132.5 (C), 130.8 (CH), 129.1 (CH), 47.1 (CH), 23.9 (CH3); HRMS (ESI 
Positive) calcd. for C10H14N2O2S, [M+Na] 249.0668, found 249.0666. 
 
N-tert-Butyl-N'-[phenylmethylidene]sulfamide 4.1da 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and benzaldehyde (0.84 mL, 8.25 mmol) using general 
method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give a white solid 
(1.49 g, 83%); Rf 0.33 (4:1 pet. ether:EtOAc); M.p. 103-106 °C; IR (CHCl3Ȟmax/cmí 3386, 
2980, 1613, 1576, 1391, 1333, 1150, 998, 864; 1H NMR (400.1 MHz, CDCl3įH 8.92 (s, 1H, 
N=CH), 7.93-7.91 (m, 2H, CHaryl), 7.62 (tt, J = 7.4, 1.5 Hz, 1H, CHaryl), 7.53-7.49 (m, 2H, 
CHaryl), 4.50 (s, 1H, NHC(CH3)3)), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 
167.8 (CH), 134.2 (CH), 132.7 (C), 130.7 (CH), 129.1 (CH), 55.0 (C), 30.2 (CH3); HRMS 
(ESI Positive) calcd. for C11H16N2O2S, [M+Na] 263.0825, found 263.0815; Anal. Calc. for 
C11H16N2O2S: C, 54.98; H, 6.71; N, 11.66%. Found: C, 54.82; H, 6.68; N, 11.71%. 
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N-tert-Butyl-N'-[4-fluorophenylmethylidene]sulfamide 4.1db 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and 4-fluorobenzaldehyde (0.88 ml, 8.25 mmol) using 
general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to afford 
product as a cream solid (1.15 g, 59%); Rf 0.31 (4:1 pet. ether:EtOAc); M.p. 103-105 °C; IR 
(CHCl3 Ȟmax/cmí 3386, 2939, 1601, 1510, 1333, 1242, 1149, 999; 1H NMR (400.1 MHz, 
CDCl3įH 8.88 (s, 1H, N=CH), 7.96-7.91 (m, 2H, CHaryl), 7.22-7.17 (m, 2H, CHaryl), 4.63 (s, 
1H, NHC(CH3)3)), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 166.4 (C, d, 1JCF 
= 256 Hz), 166.3 (CH), 133.1 (CH, d, 3JCF = 10.2 Hz), 129.0 (C), 116.6 (CH, d, 2JCF = 21.8 
Hz), 55.0 (C), 30.1 (CH3); 19F NMR (376.5 MHz, CDCl3įF íHRMS (ESI Positive) 
calcd. for C11H15FN2O2S, [M+Na] 281.0730, found 281.0724; Anal. Calc. for C11H15FN2O2S: 
C, 51.15; H, 5.85; N, 10.84%. Found: C, 51.10; H, 5.85; N, 10.84%. 
 
N-tert-Butyl-N'-[4-chlorophenylmethylidene]sulfamide 4.1dc 
 
Prepared from 4.4d (1.40 g, 9.2 mmol) and 4-chlorobenzaldehyde (1.42 g, 10.1 mmol) using 
general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give the 
product as a white solid (1.21 g, 85%); Rf 0.32 (4:1 pet. ether:EtOAc); M.p. 111-114 °C; IR 
(CHCl3 Ȟmax/cmí 3386, 2980, 1614, 1595, 1334, 1150, 999, 868; 1H NMR (400.1 MHz, 
CDCl3įH 8.87 (s, 1H, N=CH), 7.85 (dt, J = 8.4, 2.1 Hz, 2H, CHaryl), 7.49 (dt, J = 8.4, 2.0 Hz, 
2H, CHaryl),  4.46 (s, 1H, NHC(CH3)3)), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) 
įC 166.4 (CH), 140.7 (C), 131.8 (CH), 131.1 (C), 129.6 (CH), 55.1 (C), 30.2 (CH3); HRMS 
(ESI Positive) calcd. for C11H15ClN2O2S, [M+Na] 297.0435, found 297.0441; Anal. Calc. for 
C11H15ClN2O2S: C, 48.08; H, 5.50; N, 10.20%. Found: C, 48.05; H, 5.48; N, 10.21%. 
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N-tert-Butyl-N'-[4-methylphenylmethylidene]sulfamide 4.1dd 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and p-tolualdehyde (0.98 ml, 8.25 mmol) using general 
method O, purified by column chromatography (4:1 pet. ether:EtOAc) to afford product as a 
cream solid (1.69 g, 88%); Rf 0.39 (4:1 pet. ether:EtOAc); M.p. 131-134 °C; IR (CHCl3) 
Ȟmax/cmí 3386, 2979, 1603, 1569, 1332, 1148, 998, 872; 1H NMR (400.1 MHz, CDCl3 įH 
8.87 (s, 1H, N=CH), 7.81 (d, J = 8.0 Hz, 2H, CHaryl), 7.31 (d, J = 8.0 Hz, 2H, CHaryl), 4.38 (br 
s, 1H, NHC(CH3)3)), 2.45 (s, 3H, ArCH3), 1.38 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, 
CDCl3įC 167.7 (CH), 145.5 (C), 130.8 (CH), 130.1 (C), 129.9 (CH), 54.9 (C), 30.1 (CH3), 
21.9 (CH3);  HRMS (ESI Positive) calcd. for C12H18N2O2S, [M+Na] 277.0981, found 
277.0982; Anal. Calc. for C12H18N2O2S: C, 56.67; H, 7.13; N, 11.01%. Found: C, 56.70; H, 
7.13; N, 10.92%. 
 
N-tert-Butyl-N'-[3-methylphenylmethylidene]sulfamide 4.1dh 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and m-tolualdehyde (0.97 mL, 8.25 mmol) using 
general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give a cream 
solid (1.44 g, 76%); Rf 0.26 (4:1 pet. ether:EtOAc); M.p. 85-88 °C; IR (CHCl3 Ȟmax/cmí 
3386, 2937, 1583, 1391, 1333, 1149, 997; 1H NMR (400.1 MHz, CDCl3 įH 8.88 (s, 1H, 
N=CH), 7.73-7.69 (m, 2H, CHaryl), 7.44-7.37 (m, 2H, CHaryl), 4.51 (br s, 1H, NH), 2.42 (s, 3H, 
ArCH3), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3 įC 168.1 (CH), 139.0 (C), 
135.2 (CH), 132.6 (C), 130.9 (CH), 129.0 (CH), 128.2 (CH), 55.0 (C), 30.2 (CH3), 21.2 (CH3);  
HRMS (ESI Positive) calcd. for C12H18N2O2S, [M+H] 277.0981, found 277.0989; Anal. Calc. 
for C12H18N2O2S: C, 56.67; H, 7.13; N, 11.01%. Found: C, 56.58; H, 7.13; N, 11.01%. 
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N-tert-Butyl-N'-[3-methoxyphenylmethylidene]sulfamide 4.1dk 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and 3-methoxybenzaldehyde (1.00 ml, 8.25 mmol) 
using general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to afford 
product as a cream solid (1.80 g, 89%); Rf 0.26 (4:1 pet. ether:EtOAc); M.p. 90-93 °C; IR 
(CHCl3Ȟmax/cmí 3386, 2941. 1581, 1333, 1150, 998, 869; 1H NMR (400.1 MHz, CDCl3įH 
8.87 (s, 1H, N=CH), 7.48-7.39 (m, 3H, CHaryl), 7.16 (ddd, J = 8.0, 2.8, 1.6 Hz, 1H, CHaryl), 
4.57 (br s, 1H, NHC(CH3)3)), 3.87 (s, 3H, OCH3), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 
MHz, CDCl3įC 167.8 (CH), 160.1 (C), 134.0 (C), 130.1 (CH), 124.4 (CH), 121.1 (CH), 113.4 
(CH), 55.5 (CH3), 55.0 (C), 30.1 (CH3); HRMS (ESI Positive) calcd. for C12H18N2O3S, 
[M+Na] 293.0930, found 293.0927; Anal. Calc. for C12H18N2O3S: C, 53.31; H, 6.71; N, 
10.36%. Found: C, 53.26; H, 6.67; N, 10.24%. 
 
N-tert-Butyl-N'-[4-(trifluoromethyl)phenylmethylidene]sulfamide 4.1dl 
 
Prepared from 4.4d (1.14 g, 7.5 mmol) and 4-(trifluoromethyl)benzaldehyde (1.13 mL, 8.25 
mmol) using general method O, purified by column chromatography (2:1 pet. ether:EtOAc) to 
give the product as a yellow solid (1.93 g, 84%); Rf 0.27 (4:1 pet. ether:EtOAc); M.p. 103-106 
°C; IR (CHCl3Ȟmax/cmí 3386, 2980, 1619, 1324, 1175, 1151, 1000; 1H NMR (400.1 MHz, 
CDCl3 įH 8.96 (s, 1H, N=CH), 8.04 (d, J = 8.0 Hz, 2H, CHaryl), 7.77 (d, J = 8.0 Hz, 2H, 
CHaryl), 4.68 (s, 1H, NHC(CH3)3), 1.40 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 
166.1 (CH), 135.7 (C), 135.3 (C, q, 2JCF = 32.8 Hz), 130.7 (CH), 126.1 (CH, q, 3JCF = 3.8 Hz), 
123.4 (C, q, 1JCF = 271 Hz), 55.2 (C), 30.1 (CH3); 19F NMR (376.5 MHz, CDCl3įF í
HRMS (ESI Positive) calcd. for C12H15F3N2O2S, [M+Na] 331.0699, found 331.0689; Anal. 
Calc. for C12H15F3N2O2S: C, 46.75; H, 4.90; N, 9.09%. Found: C, 46.70; H, 4.88; N, 8.97%. 
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N-Phenyl-N'-[phenylmethylidene]sulfamide 4.1ea 
 
Prepared from 4.4e (941 mg, 5.5 mmol) and benzaldehyde (0.61 ml, 6.0 mmol) using general 
method O, purified by column chromatography (4:1 pet. ether:EtOAc) to give the product as a 
cream solid (1.21 g, 85%); Rf 0.16 (4:1 pet. ether:EtOAc); M.p. 112-114 °C; IR (CHCl3) 
Ȟmax/cmí 3363, 3263, 3045, 1600, 1349, 1160, 932; 1H NMR (400.1 MHz, CDCl3įH 8.83 (s, 
1H, N=CH), 7.85-7.83 (m, 2H, CHaryl), 7.59 (tt, J = 7.4, 1.4 Hz, 1H, CHaryl), 7.45 (t, J = 7.6 Hz, 
2H, CHaryl), 7.32-7.24 (m, 4H, CHaryl), 7.16-7.12 (m, 1H, CHaryl), 6.98 (s, 1H, NHPh); 13C 
NMR (100.6 MHz, CDCl3 įC 170.7 (CH), 136.3 (C), 134.8 (CH), 132.0 (C), 131.1 (CH), 
129.3 (CH), 129.1 (CH), 125.5 (CH), 121.9 (CH); HRMS (ESI Positive) calcd. for 
C13H12N2O2S, [M+Na] 283.0512, found 283.0512; Anal. Calc. for C13H12N2O2S: C, 59.98; H, 
4.65; N, 10.76%. Found: C, 59.90; H, 4.61; N, 10.76%. 
 
N-Benzyl-N'-[phenylmethylidene]sulfamide 4.1fa 
 
Prepared from 4.4f (2.12 g, 11.4 mmol) and benzaldehyde (1.28 mL, 12.5 mmol) using general 
method O, to give a cream solid which was triturated with hexanes to give the product as a 
white solid (2.05 g, 65%); Rf 0.66 (1:1 pet. ether:EtOAc); M.p. 101-103 °C; IR (CHCl3) 
Ȟmax/cmí 3383, 3045, 1611, 1575, 1341, 1158; 1H NMR (400.1 MHz, CDCl3įH 8.89 (s, 1H, 
N=CH), 7.90-7.88 (m, 2H, CHaryl), 7.64 (tt, J = 7.4, 1.5 Hz, 1H, CHaryl), 7.54-7.49 (m, 2H, 
CHaryl), 7.37-7.23 (m, 5H, CHaryl), 4.71 (t, J = 6.0 Hz, 1H, NHCH2), 4.36 (d, J = 6.0 Hz, 2H, 
NHCH2Ph); 13C NMR (100.6 MHz, CDCl3įC 169.6 (CH), 136.2 (C), 134.5 (CH), 132.2 (C), 
130.9 (CH), 129.0 (CH), 128.6 (CH), 128.0 (CH), 127.9 (CH), 47.9 (CH2); HRMS (ESI 
Positive) calcd. for C14H14N2O2S, [M+Na] 297.0668, found 297.0664; Anal. Calc. for 
C14H14N2O2S: C, 61.29; H, 5.14; N, 10.21%. Found: C, 61.00; H, 5.15; N, 10.10%. 
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(R)-N-(1-Phenylethyl)-N'-[phenylmethylidene]sulfamide (R)-4.1ga 
 
Prepared from (R)-4.4g (1.24 g, 6.17 mmol) and benzaldehyde (0.69 ml, 6.79 mmol) using 
general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to afford 
product as a light yellow oil (1.49 g, 83%); Rf 0.19 (4:1 pet. ether:EtOAc); >Į@D = +11.8 (c = 
1.67, CHCl3); IR (CHCl3 Ȟmax/cmí 3279, 2979, 1610, 1574, 1332, 1156; 1H NMR (400.1 
MHz, CDCl3įH 8.65 (s, 1H, N=CH), 7.73-7.70 (m, 2H, CHaryl), 7.58 (tt, J = 7.4, 1.5 Hz, 1H, 
CHaryl), 7.46-7.42 (m, 2H, CHaryl), 7.31-7.28 (m, 2H, CHaryl), 7.24-7.19 (m, 2H, CHaryl), 7.10 
(tt, J = 7.4, 1.5 Hz, 1H, CHaryl), 5.00 (d, J = 7.6 Hz, 1H, NHCH), 4.66 (quintet, J = 7.2 Hz, 1H, 
NHCH), 1.58 (d, J = 6.8 Hz, 3H, CHCH3); 13C NMR (100.6 MHz, CDCl3 įC 168.9 (CH), 
141.6 (C), 134.3 (CH), 132.3 (C), 130.7 (CH), 128.9 (CH), 128.6 (CH), 127.6 (CH), 126.3 
(CH), 54.4 (CH), 23.4 (CH3); HRMS (ESI Positive) calcd. for C15H16N2O2S, [M+Na] 
311.0825, found 311.0815.  
 
(S)-N-(1-Phenylethyl)-N'-[phenylmethylidene]sulfamide (S)-4.1ga 
 
Prepared from (S)-4.4g (1.45 g, 7.25 mmol) and benzaldehyde (0.81 ml, 7.97 mmol) using 
general method O, purified by column chromatography (4:1 pet. ether:EtOAc) to afford 
product as a light yellow oil (1.86 g, 89%). Analytical data as for (R)-4.1ga except: >Į@D = 
íc = 1.36, CHCl3). 
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N-Methyl-N¶-diphenylmethylsulfonamide 4.2aaa 
 
Prepared from 4.1aa (496 mg, 2.5 mmol) using general method P, purification by column 
chromatography (2:1 pet. ether:EtOAc) gave the product as a white crystalline solid (652 mg, 
94%); Rf 0.25 (2:1 pet. ether:EtOAc); M.p. 131-133 °C; IR (CHCl3 Ȟmax/cmí 3393, 3012, 
1409, 1329, 1154, 1028; 1H NMR (400.1 MHz, acetone-d6įH 7.45-7.42 (m, 4H, CHaryl), 7.36-
7.31 (m, 4H, CHaryl), 7.25 (tt, J = 7.2, 1.5 Hz, 2H, CHaryl), 6.84 (br d, J = 8.4 Hz, 1H, NHCH), 
5.68 (br q, J = 5.2 Hz, 1H, NHCH3), 5.61 (d, J = 9.2 Hz, 1H, NHCH), 2.39 (d, J = 5.2 Hz, 3H, 
NHCH3); 13C NMR (100.6 MHz, acetone-d6 įC 143.6 (C), 129.3 (CH), 128.4 (CH), 120.1 
(CH), 61.8 (CH), 29.1 (CH3); HRMS (ESI Positive) calcd. for C14H16N2O2S, [M+Na] 
299.0825, found 299.0820; Anal. Calc. for C14H16N2O2S: C, 60.85; H, 5.84; N, 10.14%. Found: 
C, 60.87; H, 5.84; N, 10.08%. 
 
N-Methyl-N¶-(4-chlorophenyl)(phenyl)methylsulfonamide (±)-4.2aac 
 
Prepared from 4.1aa (198.2 mg, 1.0 mmol) using general method Q, purification by column 
chromatography (2:1 pet. ether:EtOAc) gave the product as a white solid (306.0 mg, 98%); Rf 
0.16 (2:1 pet. ether:EtOAc); M.p. 126-128 °C; IR (CHCl3Ȟmax/cmí 3393, 1491, 1411, 1331, 
1154, 1091; 1H NMR (400.1 MHz, CDCl3įH 7.38-7.26 (m, 9H, CHaryl), 5.59 (d, J = 6.4 Hz, 
1H, NHCH), 4.96 (d, J = 6.8 Hz, 1H, NHCH), 3.93 (br q, J = 4.4 Hz, 1H, NHCH3), 2.47 (d, J = 
4.8 Hz, 3H, NHCH3); 13C NMR (100.6 MHz, CDCl3įC 140.5 (C), 139.4 (C), 133.7 (C), 128.9 
(CH), 128.8 (CH), 128.7 (CH), 128.2 (CH), 127.3 (CH), 60.8 (CH), 29.1 (CH3); HRMS (ESI 
Positive) calcd. for C14H15ClN2O2S, [M+Na] 333.0435, found 333.0429; Anal. Calc. for 
C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01%. Found: C, 54.09; H, 4.85; N, 8.81%; HPLC 
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Daicel Chiralpak OD-H, 90:10 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 17.8 
min, (R)-enantiomer tR = 22.1 min. 
 
N-Methyl-N¶-(R)-(4-chlorophenyl)(phenyl)methylsulfonamide (R)-4.2aac 
 
Prepared from 4.1aa (99 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) gave the product as a white solid (101 mg, 65%). 
Analytical data as for (±)-4.2aac except; >Į@D = +1.8 (c = 1.15, CHCl3, for 86% ee material). 
 
N-Methyl-N¶-(2-methylphenyl)(phenyl)methylsulfonamide (±)-4.2aae 
 
Prepared from 4.1ae (159 mg, 0.75 mmol) using general method P, purified by column 
chromatography (2:1 pet. ether:EtOAc) to give a white solid (186 mg, 85%); Rf 0.38 (2:1 pet. 
ether:EtOAc); M.p. 91-93 °C; IR (CHCl3Ȟmax/cmí 3393, 1408, 1328, 1153; 1H NMR (400.1 
MHz, CDCl3įH 7.44-7.41 (dd, J = 7.6, 1.2 Hz, 1H, CHaryl), 7.35-7.16 (m, 8H, CHaryl), 5.84 (d, 
J = 6.0 Hz, 1H, NHCH), 4.82 (br d, J = 6.0 Hz, 1H, NHCH), 3.78 (q, J = 5.1 Hz, 1H, NHCH3), 
2.49 (d, J = 5.6 Hz, 3H, NHCH3), 2.30 (s, 3H, ArCH3); 13C NMR (100.6 MHz, CDCl3 įC 
140.2 (C), 138.8 (C), 135.7 (C), 130.9 (CH), 128.7 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 
126.6 (CH), 126.3 (CH), 58.1 (CH), 29.1 (CH3), 19.5 (CH3); HRMS (ESI Positive) calcd. for 
C15H18N2O2S, [M+H] 313.0981, found 313.0977; Anal. Calc. for C15H18N2O2S: C, 62.04; H, 
6.25; N, 9.65%. Found: C, 61.82; H, 6.25; N, 9.61%. 
 
  
 223 
N-Ethyl-N¶-(4-chlorophenyl)(phenyl)methylsulfonamide (±)-4.2bac 
 
Prepared from 4.1ba (424.5 mg, 2.0 mmol) using general method Q, purification by column 
chromatography (4:1 pet. ether:EtOAc) gave the product as a white solid (480.1 mg, 74%); Rf 
0.23 (4:1 pet. ether:EtOAc); M.p. 72-75 °C; IR (CHCl3 Ȟmax/cmí 3385, 3012, 1491, 1417, 
1329, 1153; 1H NMR (400.1 MHz, CDCl3įH 7.38-7.26 (m, 9H, CHaryl), 5.60 (d, J = 6.8 Hz, 
1H, NHCH), 4.87 (d, J = 6.0 Hz, 1H, NHCH), 3.80 (t, J = 5.8 Hz, 1H, NHCH2CH3), 2.93-2.79 
(m, 2H, NHCH2CH3), 0.94 (t, J = 7.2 Hz, 3H, CH2CH3); 13C NMR (100.6 MHz, CDCl3įC 
140.6 (C), 139.6 (C), 133.6 (C), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.1 (CH), 127.3 (CH), 
61.0 (CH), 38.0 (CH2), 14.5 (CH3); HRMS (ESI Positive) calcd. for C15H17ClN2O2S, [M+Na] 
347.0591, found 347.0591; Anal. Calc. for C15H17ClN2O2S: C, 55.46; H, 5.28; N, 8.62%. 
Found: C, 55.53; H, 5.31; N, 8.50%; HPLC: Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 
mL/min; 200 nm; (S)-enantiomer tR = 25.1 min, (R)-enantiomer tR = 33.0 min. 
 
N-Ethyl-N¶-(R)-(4-chlorophenyl)(phenyl)methylsulfonamide (R)-4.2bac 
 
Prepared from 4.1ba (106 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a yellow oil (81 mg, 50%). Analytical data as 
for (±)-4.2bac except; >Į@D = +0.6 (c = 1.27, CHCl3, for 87% ee material). 
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N-iso-Propyl-N¶-(4-chlorophenyl)(phenyl)methylsulfonamide (±)-4.2cac 
 
Prepared from 4.1ca (226 mg, 1.0 mmol) using general method Q, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (293 mg, 86%); Rf 0.30 (4:1 pet. 
ether:EtOAc); M.p. 142-145 °C; IR (CHCl3Ȟmax/cmí 3384, 1491, 1417, 1333, 1139, 1005; 
1H NMR (400.1 MHz, CDCl3 įH 7.38-7.26 (m, 9H, CHaryl), 5.60 (d, J = 6.8 Hz, 1H, 
NHCH(Aryl)2), 4.85 (d, J = 6.4 Hz, 1H, NHCH(Aryl)2), 3.84 (d, J = 7.6 Hz, 1H, 
NHCH(CH3)2), 3.43-3.31 (m, 1H, NHCH(CH3)2), 1.00 (d, J = 6.4 Hz, 3H, CH(CHĮ)(CH3)), 
0.97 (d, J = 6.4 Hz, 3H, CH(CHȕ)(CH3)); 13C NMR (100.6 MHz, CDCl3įC 140.8 (C), 139.8 
(C), 133.6 (C), 128.9 (CH), 128.84 (CH), 128.79 (CH), 128.0 (CH), 127.3 (CH), 60.7 (CH), 
46.2 (CH), 23.5 (CH3), 23.4 (CH3); HRMS (ESI Positive) calcd. for C16H19ClN2O2S, [M+Na] 
361.0748, found 361.0728; Anal. Calc. for C16H19ClN2O2S: C, 56.71; H, 5.65; N, 8.27%. 
Found: C, 56.66; H, 5.63; N, 8.24%; HPLC: Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 
mL/min; 200 nm; (S)-enantiomer tR = 26.0 min, (R)-enantiomer tR = 32.1 min. 
 
N-iso-Propyl-N¶-(R)-(4-chlorophenyl)(phenyl)methylsulfonamide (R)-4.2cac 
 
Prepared from 4.1ca (113 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a light yellow solid (47.5 mg, 28%). Analytical 
data as for (±)-4.2cac except; >Į@D = +1.6 (c = 1.04, CHCl3, for 86% ee material). 
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N-tert-Butyl-N¶-diphenylmethylsulfonamide 4.2daa 
 
Synthesised as meso-3.96 following the procedure of Borghese et al.,[222] using 4.30 (245 mg, 
PPRODQGDPLQRGLSKHQ\OPHWKDQHȝ/PPRO:RUNXSJDYHDZKLWHVROLG
mg, 86%); Rf 0.26 (4:1 pet. ether:EtOAc); M.p. 140-143 °C; IR (CHCl3Ȟmax/cmí3383, 3011, 
1391, 1321, 1144, 991; 1H NMR (400.1 MHz, CDCl3įH 7.37-7.27 (m, 10H, CHaryl), 5.63 (d, 
J = 6.4 Hz, 1H, CHNH), 4.78 (d, J = 6.4 Hz, 1H, CHNH), 3.85 (s, 1H, NHC(CH3)3), 1.17 (s, 
9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 141.2 (C), 128.7 (CH), 127.8 (CH), 127.5 
(CH), 61.7 (CH), 54.3 (C), 29.6 (CH3); HRMS (ESI Positive) calcd. for C17H22N2O2S, [M+Na] 
341.1294, found 341.1289; Anal. Calc. for C17H22N2O2S: C, 64.12; H, 6.96; N, 8.80%. Found: 
C, 63.99; H, 6.95; N, 8.79%. 
 
N-tert-Butyl-N¶-(4-chlorophenyl)(phenyl)methylsulfonamide (±)-4.2dac 
 
Prepared from 4.1da (206 mg, 0.75 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (230 mg, 93%); Rf 0.29 (4:1 pet. 
ether:EtOAc); M.p. 157-159 °C; IR (CHCl3 Ȟmax/cmí 3383, 2980, 1491, 1324, 1145; 1H 
NMR (400.1 MHz, CDCl3įH 7.36-7.26 (m, 9H, CHaryl), 5.59 (d, J = 6.8 Hz, 1H, NHCH), 4.85 
(d, J = 6.4 Hz, 1H, NHCH), 4.02 (s, 1H, NHC(CH3)3), 1.18 (s, 9H, C(CH3)3); 13C NMR (100.6 
MHz, CDCl3įC 140.9 (C), 140.0 (C), 133.2 (C), 128.8 (CH), 128.7 (CH), 128.6 (CH), 127.8 
(CH), 127.4 (CH), 60.8 (CH), 54.2 (C), 29.5 (CH3); HRMS (ESI Positive) calcd. for 
C17H21ClN2O2S, [M+Na] 375.0904, found 375.0916; Anal. Calc. for C17H21ClN2O2S: C, 57.86; 
H, 6.00; N, 7.94%. Found: C, 57.63; H, 6.02; N, 7.77%; HPLC: Daicel Chiralpak OD-H, 95:5 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 22.2 min, (R)-enantiomer tR = 30.1 
min. 
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N-tert-Butyl-N¶-(R)-(4-chlorophenyl)(phenyl)methylsulfonamide (R)-4.2dac 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (147 mg, 83%). Analytical data as 
for (±)-4.2dac except: >Į@D = +0.7 (c = 1.11, CHCl3, for 86% ee material). 
 
N-tert-Butyl-N¶-(S)-(4-chlorophenyl)(phenyl)methylsulfonamide (S)-4.2dac 
 
Prepared from 4.1dc (137.4 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (156.8 mg, 89%). Analytical data 
as for (±)-4.2dac except: >Į@D  íc = 1.09, CHCl3, for 81% ee material). 
 
N-tert-Butyl-N¶-(4-methylphenyl)(phenyl)methylsulfonamide (±)-4.2dad 
 
Prepared from 4.1dd (127 mg, 0.5 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (148 mg, 89%); Rf 0.33 (4:1 pet. 
ether:EtOAc); M.p. 147-149 °C; IR (CHCl3Ȟmax/cmí 3384, 3011, 1321, 1144, 990; 1H NMR 
(400.1 MHz, CDCl3 įH 7.34-7.32 (m, 4H, CHaryl), 7.30-7.25 (m, 1H, CHaryl), 7.22-7.20 (m, 
2H, CHaryl), 7.15-7.13 (m, 2H, CHaryl), 5.59 (d, J = 6.4 Hz, 1H, NHCH), 4.74 (d, J = 6.4 Hz, 
1H, NHCH), 3.84 (br s, 1H, NHC(CH3)3), 2.33 (s, 3H, ArCH3), 1.17 (s, 9H, C(CH3)3); 13C 
NMR (100.6 MHz, CDCl3įC 141.4 (C), 138.3 (C), 137.5 (C), 129.4 (CH), 128.7 (CH), 127.6 
(CH), 127.5 (CH), 127.4 (CH), 61.5 (CH), 54.3 (C), 29.6 (CH3), 21.0 (CH3); HRMS (ESI 
 227 
Positive) calcd. for C18H24N2O2S, [M+Na] 355.1451, found 355.1450; Anal. Calc. for 
C18H24N2O2S: C, 65.05; H, 7.28; N, 8.43%. Found: C, 64.98; H, 7.30; N, 8.20%; HPLC: 
Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 21.1 
min, (R)-enantiomer tR = 26.1 min. 
 
N-tert-Butyl-N¶-(R)-(4-methylphenyl)(phenyl)methylsulfonamide (R)-4.2dad 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a cream solid (119 mg, 71%). Analytical data 
as for (±)-4.2dad except; >Į@D = +3.9 (c = 0.99, solvent, for 95% ee material). 
 
N-tert-Butyl-N¶-(3-methylphenyl)(phenyl)methylsulfonamide (±)-4.2dah 
 
Prepared from 4.1dh (127 mg, 0.5 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (155 mg, 93%); Rf 0.30 (4:1 pet. 
ether:EtOAc); M.p. 90-93 °C; IR (CHCl3Ȟmax/cmí 3384, 2978, 1391, 1324, 1144, 990; 1H 
NMR (400.1 MHz, CDCl3įH 7.34-7.19 (m, 6H, CHaryl), 7.14-7.06 (m, 3H, CHaryl), 5.57 (d, J 
= 6.8 Hz, 1H, CHNH), 4.91 (d, J = 6.4 Hz, 1H, CHNH), 4.05 (s, 1H, NHC(CH3)3), 2.32 (s, 3H, 
ArCH3), 1.15 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 141.4 (C), 141.2 (C), 138.3 
(C), 128.60 (CH), 128.55 (CH), 128.4 (CH), 128.2 (CH), 127.6 (CH), 127.5 (CH), 124.5 (CH), 
61.6 (CH), 54.2 (C), 29.5 (CH3), 21.4 (CH3); HRMS (ESI Positive) calcd. for C18H24N2O2S, 
[M+Na] 355.1451, found 355.1450; Anal. Calc. for C18H24N2O2S: C, 65.03; H, 7.28; N, 8.43%. 
Found: C, 65.03; H, 7.28; N, 8.41%; HPLC: Daicel Chiralpak AD, 95:5 hexanes:iPrOH; 1.0 
mL/min; 200 nm; (S)-enantiomer tR = 26.3 min, (R)-enantiomer tR = 35.6 min. 
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N-tert-Butyl-N¶-(R)-(3-methylphenyl)(phenyl)methylsulfonamide (R)-4.2dah 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (59 mg, 35%). Analytical data as 
for (±)-4.2dah except; >Į@D = +1.12 (c = 1.1, CHCl3, for 76% ee material). 
 
N-tert-Butyl-N¶-(S)-(3-methylphenyl)(phenyl)methylsulfonamide (S)-4.2dah 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (89 mg, 54%). Analytical data as 
for (±)-4.2dah except; >Į@D  íc = 1.10, CHCl3, for 85% ee material). 
 
N-tert-Butyl-N¶-(3-methoxyphenyl)(phenyl)methylsulfonamide (±)-4.2dak 
 
Prepared from 4.1dk (135.2 mg, 0.5 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (145 mg, 83%); Rf 0.28 (4:1 pet. 
ether:EtOAc); M.p. 100-103 °C; IR (CHCl3Ȟmax/cmí 3383, 2969, 1600, 1321, 1240, 1042; 
1H NMR (400.1 MHz, CDCl3įH 7.34-7.32 (m, 6H, CHaryl), 6.92-6.88 (m, 2H, CHaryl), 6.82-
6.80 (m, 1H, CHaryl), 5.59 (d, J = 6.4 Hz, 1H, NHCH), 4.80 (d, J = 6.8 Hz, 1H, NHCH), 3.91 
(br s, 1H, NHC(CH3)3), 3.78 (s, 3H, OCH3), 1.18 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, 
CDCl3įC 159.8 (C), 142.9 (C), 141.2 (C), 129.7 (CH), 128.6 (CH), 127.6 (CH), 127.5 (CH), 
119.8 (CH), 113.4 (CH), 112.9 (CH), 61.6 (CH), 55.2 (CH3), 54.2 (C), 29.5 (CH3); HRMS 
(ESI Positive) calcd. for C18H24N2O3S, [M+Na] 371.1400, found 371.1390; Anal. Calc. for 
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C18H24N2O3S: C, 62.04; H, 6.94; N, 8.04%. Found: C, 61.90; H, 6.91; N, 8.06%; HPLC: 
Daicel Chiralpak AD, 95:5 hexanes:iPrOH; 0.5 mL/min; 200 nm; (S)-enantiomer tR = 95.6 min, 
(R)-enantiomer tR = 104.0 min. 
 
N-tert-Butyl-N¶-(R)-(3-methoxyphenyl)(phenyl)methylsulfonamide (R)-4.2dak 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (158 mg, 91%). Analytical data as 
for (±)-4.2dak except; >Į@D  íc = 1.26, CHCl3, for 97% ee material). 
 
N-tert-Butyl-N¶-(S)-(3-methoxyphenyl)(phenyl)methylsulfonamide (S)-4.2dak 
 
Prepared from 4.1dk (135 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (59.3 mg, 34%). Analytical data 
as for (±)-4.2dak except: >Į@D = +1.1 (c = 1.02, CHCl3, for 86% ee material). 
 
N-tert-Butyl-N¶-(4-fluorophenyl)(phenyl)methylsulfonamide (±)-4.2dab 
 
Prepared from 4.1db (129 mg, 0.5 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (147 mg, 87%); Rf 0.25 (4:1 pet. 
ether:EtOAc); M.p. 133-135 °C; IR (CHCl3Ȟmax/cmí 3383, 2980, 1606, 1510, 1322, 1144, 
991; 1H NMR (400.1 MHz, CDCl3įH 7.36-7.26 (m, 7H, CHaryl), 7.04-6.98 (m, 2H, CHaryl), 
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5.60 (d, J = 6.8 Hz, 1H, NHCH), 4.89 (d, J = 6.8 Hz, 1H, NHCH), 4.05 (s, 1H, NHC(CH3)3), 
1.17 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 162.1 (C, d, 1JCF = 246 Hz), 141.1 
(C), 137.1 (C, d, 4JCF = 2.9 Hz), 129.2 (CH, d, 3JCF = 8.8 Hz), 128.8 (CH), 127.9 (CH), 127.4 
(CH), 115.5 (CH, d, 2JCF = 20.3 Hz), 61.0 (CH), 54.4 (C), 29.5 (CH3); 19F NMR (376.5 MHz, 
CDCl3įF íHRMS (ESI Positive) calcd. for C17H21FN2O2S, [M+Na] 359.1200, found 
359.1197; Anal. Calc. for C17H21FN2O2S: C, 60.69; H, 6.29; N, 8.33%. Found: C, 60.58; H, 
6.26; N, 8.22%; HPLC: Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; 
(S)-enantiomer tR = 20.1 min, (R)-enantiomer tR = 25.2 min. 
 
N-tert-Butyl-N¶-(R)-(4-fluorophenyl)(phenyl)methylsulfonamide (R)-4.2dab 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (151 mg, 90%). Analytical data as 
for (±)-4.2dab except: >Į@D = +0.5 (c = 0.97, CHCl3, for 95% ee material). 
 
N-tert-Butyl-N¶-(S)-(4-fluorophenyl)(phenyl)methylsulfonamide (S)-4.2dab 
 
Prepared from 4.1db (129.2 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (69 mg, 41%). Analytical data as 
for (±)-4.2dab except: >Į@D  íc = 1.04, CHCl3, for 80% ee material). 
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N-tert-Butyl-N¶-(4-trifluoromethylphenyl)(phenyl)methylsulfonamide (±)-4.2dal 
 
Prepared from 4.1dl (154 g, 0.5 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (167 mg, 87%); Rf 0.13 (4:1 pet. 
ether:EtOAc); M.p. 140-143 °C; IR (CHCl3Ȟmax/cmí 3382, 2979, 1421, 1326, 1169, 1144, 
991; 1H NMR (400.1 MHz, CDCl3įH 7.60 (d, J = 8.0 Hz, 2H, CHaryl), 7.49 (d, J = 8.8 Hz, 
2H, CHaryl), 7.40-7.28 (m, 5H, CHaryl), 5.67 (d, J = 6.4 Hz, 1H, CHNH), 4.83 (d, J = 6.8 Hz, 
1H, CHNH), 3.98 (s, 1H. NHC(CH3)3), 1.19 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) 
įC 145.3 (C), 140.6 (C), 129.8 (C, q, 2JCF = 32 Hz), 128.9 (CH), 128.2 (CH), 127.8 (CH), 127.5 
(CH), 125.5 (CH, q, 3JCF = 3.6 Hz), 124.0 (C, q, 1JCF = 271 Hz), 61.2 (CH), 54.4 (C), 29.5 
(CH3); 19F NMR (376.5 MHz, CDCl3 įF í HRMS (ESI Positive) calcd. for 
C18H21F3N2O2S, [M+Na] 409.1168, found 409.1167; Anal. Calc. for C18H21F3N2O2S: C, 55.95; 
H, 5.48; N, 7.25%. Found: C, 55.95; H, 5.47; N, 7.12%; HPLC: Daicel Chiralpak OD-H, 95:5 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 13.6 min, (R)-enantiomer tR = 22.1 
min. 
 
N-tert-Butyl-N¶-(R)-(4-trifluoromethylphenyl)(phenyl)methylsulfonamide (R)-4.2dal 
 
Prepared from 4.1da (120 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (162 mg, 84%). Analytical data as 
for (±)-4.2dal except: >Į@D  íc = 1.35, CHCl3, for 98% ee material). 
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N-tert-Butyl-N¶-(S)-(4-trifluoromethylphenyl)(phenyl)methylsulfonamide (S)-4.2dal 
 
Prepared from 4.1dl (154 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a white solid (137 mg, 71%). Analytical data as 
for (±)-4.2dal except: >Į@D = +2.7 (c = 1.43, CHCl3, for 78% ee material). 
 
N-Phenyl-N¶-(4-chloromethylphenyl)(phenyl)methylsulfonamide (±)-4.2eac 
 
Prepared from 4.1ea (260 mg, 1.0 mmol) using general method Q, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (360 mg, 96%); Rf 0.24 (4:1 
pet. ether:EtOAc); M.p. 131-133 °C; IR (CHCl3Ȟmax/cmí 3388, 1602, 1495, 1155, 954; 1H 
NMR (400.1 MHz, CDCl3įH 7.21-7.12 (m, 7H, CHaryl), 7.08-7.03 (m, 5H, CHaryl), 6.89-6.86 
(m, 2H, CHaryl), 6.82 (br s, 1H, NHPh), 5.57 (d, J = 7.6 Hz, 1H, CHNH), 5.39 (d, J = 6.8 Hz, 
1H, CHNH); 13C NMR (100.6 MHz, CDCl3 įC 139.8 (C), 138.7 (C), 136.7 (C), 133.5 (C), 
129.2 (CH), 128.71 (CH), 128.67 (CH), 128.6 (CH), 127.9 (CH), 127.2 (CH), 124.1 (CH), 
119.1 (CH), 60.9 (CH); HRMS (ESI Positive) calcd. for C19H17ClN2O2S, [M+Na] 395.0591, 
found 395.0599; Anal. Calc. for C19H17ClN2O2S: C, 61.20; H, 4.60; N, 7.51%. Found: C, 
61.21; H, 4.54; N, 7.43%; HPLC: Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 mL/min; 
200 nm; (S)-enantiomer tR = 29.6 min, (R)-enantiomer tR = 35.6 min. 
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N-Phenyl-N¶-(R)-(4-chloromethylphenyl)(phenyl)methylsulfonamide (R)-4.2eac 
 
Prepared from 4.1ea (130 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (120 mg, 64%). Analytical data 
as for (±)-4.2eac except: >Į@D  íc = 1.15, CHCl3, for 90% ee material). 
 
N-Benzyl-N¶-(4-chloromethylphenyl)(phenyl)methylsulfonamide (±)-4.2fac 
 
Prepared from 4.1fa (110 mg, 0.4 mmol) using general method P, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a cream solid (155 mg, 100%). Rf 0.24 (4:1 pet. 
ether:EtOAc); M.p. 133-135 °C; IR (CHCl3 Ȟmax/cmí 3380, 1492, 1418, 1336, 1153; 1H 
NMR (400.1 MHz, CDCl3įH 7.38-7.26 (m, 12H, CHaryl), 7.04-7.02 (m, 2H, CHaryl), 5.64 (d, J 
= 6.4 Hz, 1H, NHCH), 4.90 (d, J = 6.4 Hz, 1H, NHCH), 4.13 (t, J = 5.8 Hz, 1H, NHCH2), 
4.02-3.93 (m, 2H, NHCH2); 13C NMR (100.6 MHz, CDCl3įC 140.5 (C), 139.4 (C), 135.9 (C), 
133.8 (C), 129.0 (CH), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.2 (CH), 128.0 (CH), 127.9 
(CH), 127.3 (CH), 60.9 (CH), 47.3 (CH2); HRMS (ESI Positive) calcd. for C20H19ClN2O2S, 
[M+Na] 409.0748, found 409.0747; Anal. Calc. for C20H19ClN2O2S: C, 62.09; H, 4.95; N, 
7.24%. Found: C, 62.07; H, 4.95; N, 6.86%; HPLC Daicel Chiralpak OD-H, 95:5 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tR = 21.5 min, (R)-enantiomer tR = 32.9 
min. 
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N-Benzyl-N¶-(R)-(4-chloromethylphenyl)(phenyl)methylsulfonamide (R)-4.2fac 
 
Prepared from 4.1fa (137.2 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a cream solid (118 mg, 61%). Analytical data 
as for (±)-4.2fac except: >Į@D = +3.4 (c = 1.10, CHCl3, for 88% ee material). 
 
N-(R)-(1-phenylethyl)-N¶-(4-chloromethylphenyl)(phenyl)methylsulfonamide (R,±)-4.2gac 
 
Prepared from (R)-4.1ga (288.4 mg, 1.0 mmol) using general method Q, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (351.9 mg, 88%); Rf 0.27 (4:1 
pet. ether:EtOAc); >Į@D = +8.1 (c = 0.91, CHCl3); IR (CHCl3 Ȟmax/cmí 3383, 1492, 1419, 
1330, 1155, 1091, 968; 1H NMR (400.1 MHz, CDCl3įH PL[WXUHRIĮ-diastereoisomer and 
ȕ-diastereoisomer 7.33-7.05 (m, 28H, CHĮȕDU\O), 5.49 (app t, J = 7.0 Hz, 2H, NHCHĮȕ(Ar)2), 
4.97 (d, J = 6.8 Hz, 1H, NHĮCH(Ar)2), 4.88 (d, J = 6.8 Hz, 1H, NHȕCH(Ar)2), 4.62 (d, J = 6.4 
Hz, 1H, NHĮCHMePh), 4.50 (d, J = 6.8 Hz, 1H, NHȕCHMePh), 4.43-4.35 (m, 2H, 
NHCHĮȕMePh), 1.33 (d, J = 7.2 Hz, 3H, CHȕ), 1.30 (d, J = 6.8 Hz, 3H, CHĮ); 13C NMR 
(100.6 MHz, CDCl3įC Į-diastereoisomer: 142.6 (C), 140.8 (C), 139.5 (C), 133.4 (C), 128.83 
(CH), 128.75 (CH), 128.70 (CH), 128.6 (CH), 127.92 (CH), 127.62 (CH), 127.16 (CH), 125.9 
(CH), 60.7 (CH), 53.8 (CH), 23.7 (CH3ȕ-diastereoisomer: 142.5 (C), 140.6 (C), 139.8 (C), 
133.5 (C), 128.83 (CH), 128.75 (CH), 128.68 (CH), 128.6 (CH), 127.89 (CH), 127.59 (CH), 
127.21 (CH), 126.0 (CH), 60.8 (CH), 53.9 (CH), 23.6 (CH3); HRMS (ESI Positive) calcd. for 
C21H21ClN2O2S, [M+Na] 423.0904, found 423.0915. 
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N-(R)-(1-phenylethyl)-N¶-(R)-(4-chloromethylphenyl)(phenyl)methylsulfonamide (R,R)-
4.2gac 
 
Prepared from (R)-4.1ga (144.2 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (116.5 mg, 58%). Analytical 
data as for (R,±)-4.2gac Į-diastereoisomer) except: >Į@D = +7.8 (c = 1.12, CHCl3, for 83% ee 
material measured on acetamide). 
 
N-(S)-(1-phenylethyl)-N¶-(4-chloromethylphenyl)(phenyl)methylsulfonamide (S,±)-4.2gac 
 
Prepared from (S)-4.1ga (288.4 mg, 1.0 mmol) using general method Q, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (146.1 mg, 36%). Analytical 
data as for (R,±)-4.2gac except: >Į@D  í c = 0.90, CHCl3); IR (CHCl3Ȟmax/cmí 3383, 
1492, 1420, 1330, 1155, 968. 
 
N-(S)-(1-phenylethyl)-N¶-(R)-(4-chloromethylphenyl)(phenyl)methylsulfonamide (S,R)-
4.2gac 
 
Prepared from (S)-4.1ga (144.2 mg, 0.5 mmol) using general method R, purified by column 
chromatography (4:1 pet. ether:EtOAc) to give a colourless oil (146.1 mg, 36%). Analytical 
data as for (R,±)-4.2gac ȕ-diastereoisomer) except: >Į@D  íc = 1.07, CHCl3, for 85% ee 
material measured on acetamide). 
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(4-Chlorophenyl)(phenyl)methanol 3.117c[320] 
 
A flame-dried Schlenk was charged with 4-chlorobenzaldehyde (141 mg, 1.0 mmol) was THF 
(10 mL) and cooled to 0 °C. Phenylmagnesium bromide (2.0 M in THF, 1 mL, 2.0 mmol) was 
added dropwise with stirring. The solution was stirred overnight and allowed to warm to rt. 
The reaction mixture was then quenched with sat. NH4Cl solution (20 mL), extracted with Et2O 
(2 × 20 mL), the organics were dried (Na2SO4) and concentrated to a colourless oil. This was 
purified by column chromatography (9:1 pet. ether:EtOAc) to afford the product as a 
colourless oil (162 mg, 74%). Rf 0.09 (9:1 pet. ether:EtOAc); IR (CHCl3 Ȟmax/cmí 3603, 
3011, 1490, 1090, 1014; 1H NMR (400.1 MHz, CDCl3įH 7.34-7.25 (m, 9H, CHaryl), 5.80 (d, 
J = 3.6 Hz, 1H, CHOH), 2.25 (d, J = 3.6 Hz, 1H, CHOH); 13C NMR (100.6 MHz, CDCl3įC 
143.3 (C), 142.1 (C), 133.1 (C), 128.52 (CH), 128.47 (CH), 127.8 (CH), 127.7 (CH), 126.4 
(CH), 75.4 (CH); HRMS (EI) calcd. for C13H11ClO, [M+] 218.0493, found 218.0488; HPLC: 
Daicel Chiralpak AD, 95:5 hexanes:iPrOH; 0.5 mL/min; 200 nm; (R)-enantiomer tR = 36.0 
min, (S)-enantiomer tR = 39.6 min. These data were consistent with literature values.[320] 
 
N-(tert-Butyl)-2-oxo-1,3-oxazolidine-3-sulfonamide 4.30 
 
Synthesised as (R)-3.98 following the procedure of Borghese et al.,[222] using tert-butylamine 
(578 µL, 5.5 mmol) to give the product as a white solid (896 mg, 81%); M.p. 134-137 °C; IR 
(CHCl3Ȟmax/cmí 3545, 3366, 2982, 1772, 1392, 1361, 1167; 1H NMR (400.1 MHz, CDCl3) 
įH 5.52 (br s, 1H, NHC(CH3)3), 4.44-4.40 (m, 2H, NCH2CH2O), 4.08-4.04 (m, 2H, 
NCH2CH2O), 1.37 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 153.4 (C), 62.4 (CH2), 
55.6 (C), 44.5 (CH2), 29.4 (CH3); HRMS (ESI Positive) calcd. for C7H14N2O4S, [M+Na] 
245.0566, found 245.0574; Anal. Calc. for C7H14N2O4S: C, 37.83; H, 6.36; N, 12.60%. Found: 
C, 37.69; H, 6.27; N, 12.46%. These data were consistent with literature values.[321] 
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N,N-Dimethyl-N¶-diphenylmethylsulfonamide 3.123 
 
Synthesised as meso-3.96 following the procedure of Borghese et al.,[222] using 3.119a (160 
PJPPROGLPHWK\ODPLQHK\GURFKORULGHPJPPRODQGWULHWK\ODPLQHȝ/
2.19 mmol). Work up gave a colourless oil which was purified using column chromatography 
(4:1 pet. ether:EtOAc) to give the product as a white solid (83.0 mg, 59%); Rf 0.15 (4:1 pet. 
ether:EtOAc); M.p. 111-114 °C; IR (CHCl3Ȟmax/cmí 3390, 3011, 1454, 1331, 1148, 961; 1H 
NMR (400.1 MHz, CDCl3įH 7.35-7.23 (m, 10H, CHaryl), 5.61 (d, J = 6.8 Hz, 1H, CHNH), 
5.18 (d, J = 7.2 Hz, 1H, CHNH), 2.53 (s, 6H, N(CH3)2); 13C NMR (100.6 MHz, CDCl3įC 
141.3 (C), 128.6 (CH), 127.6 (CH), 127.3 (CH), 61.5 (CH), 36.5 (CH3); HRMS (ESI Positive) 
calcd. for C15H18N2O2S, [M+Na] 313.0981, found 313.0979; Anal. Calc. for C15H18N2O2S: C, 
62.04; H, 6.25; N, 9.65%. Found: C, 61.89; H, 6.23; N, 9.61%. 
 
N-(Furan-2-ylmethylene)-4-methylbenzenesulfonamide 5.28[322] 
 
A suspension of p-toluenesulfonamide (3.42 g, 20 mmol), 2-furaldehyde (1.66 mL, 20mmol) in 
tetraethoxysilane (4.9 mL) was stirred a 160 °C for 4 h in a flask fitted with a short distillation 
kit. Allowed to cool, then diluted with Et2O (20 mL). The resulting brown solid was collected 
by filtration, washed with cold Et2O (20 mL) and recrystallised from EtOAc/hexanes to afford 
the product as a brown crystalline solid (2.37 g, 47%); Rf 0.51 (1:1 hexanes:EtOAc); M.p. 99-
101 °C (EtOAc/hexanes); lit. 100.7-102.8 °C;[322] IR (CHCl3 Ȟmax/cmí 1607, 1466, 1323, 
1161, 1090, 823; 1H NMR (400.1 MHz, CDCl3įH 8.80 (s, 1H, N=CH), 7.87 (d, J = 8.4 Hz, 
2H, CHaryl), 7.73 (m, 1H, CHaryl), 7.34-7.31 (m, 3H, CHaryl), 6.63 (dd, J = 3.6, 1.7 Hz, 1H, 
CHaryl), 2.42 (s, 3H, ArCH3); 13C NMR (100.6 MHz, CDCl3įC 155.6 (CH), 149.7 (CH), 149.0 
(C), 144.5 (C), 135.1 (C), 129.7 (CH), 128.0 (CH), 124.6 (CH), 113.7 (CH), 21.6 (CH3); 
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HRMS (ESI Positive) calcd. for C12H11NO3S, [M+Na] 272.0352, found 272.0348; These data 
were consistent with literature values.[322] 
 
N-(Furan-2-ylmethyl)-4-methylbenzenesulfonamide 5.30 
 
Sodium borohydride (112 mg, 3 mmol) was added to a suspension of 5.28 (249 mg, 1 mmol) in 
methanol (25 mL) at 0 °C. The suspension was stirred at rt for 16 h then concentrated in vacuo. 
The residue was partitioned between CH2Cl2 (20 mL) and 2 M HCl (2 × 20 mL). The organics 
were washed with H2O (20 mL), dried (Na2SO4) and concentrated to a cream solid (203 mg, 
81%); Rf 0.60 (1:1 pet. ether:EtOAc); M.p. 112-114 °C; lit. 111-112 °C;[323] IR (CHCl3) 
Ȟmax/cmí 3387, 1410, 1334, 1161, 1119; 1H NMR (400.1 MHz, CDCl3įH 7.72 (dt, J = 8.3, 
1.9 Hz, 2H, CHaryl), 7.30-7.27 (m, 2H, CHaryl), 7.25 (dd, J = 1.9, 0.8 Hz, 1H, CHaryl), 6.22 (dd, J 
= 3.2, 1.9 Hz, 1H, CHaryl), 6.10-6.09 (m, 1H, CHaryl), 4.82 (t, J = 5.8 Hz, 1H, NHCH2), 4.18 (d, 
J = 6.0 Hz, 2H, NHCH2), 2.42 (s, 3H, CH3);13C NMR (100.6 MHz, CDCl3 įC 149.5 (C), 
143.5 (C), 142.5 (CH), 136.8 (C), 129.6 (CH), 127.1 (CH), 110.4 (CH), 108.2 (CH), 40.1 
(CH2), 21.5 (CH3); HRMS (ESI Positive) calcd. for C12H13NO3S, [M+Na] 274.0508, found 
274.0507; These data were consistent with literature values.[324] 
 
2-(2-Bromophenyl)-1,3-dioxolane 5.39[325] 
 
A suspension of 2-bromobenzaldehyde (11.7 mL, 0.1 mol), ethylene glycol (6.7 mL, 0.12 mol) 
and p-toluenesulfonic acid monohydrate (190 mg, 1 mmol) in toluene (60 mL) was stirred at 
reflux with a Dean-Stark trap overnight. The reaction mixture was allowed to cool, and then 
poured into a stirred sat. NaHCO3 solution (150 mL). This was then extracted with MTBE (3 × 
100 mL). The combined organic extracts were dried (MgSO4), concentrated to a yellow oil and 
purified by distillation under reduced pressure (102-104 °C, 0.69-0.71 mmHg) to give a light 
yellow oil (19.6 g, 86%). Rf 0.55 (1:1 pet. ether:EtOAc); B.p. 102-104 °C, 0.69-0.71 mmHg; 
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lit. 98 °C, 0.1 mmHg;[325] IR OLTXLGILOPȞmax/cmí 3424, 2955, 2888, 1697, 1389, 1211, 1091, 
757; 1H NMR (400.1 MHz, CDCl3įH 7.60 (dd, J = 8.0, 1.6 Hz, 1H, CHaryl), 7.56 (dd, J = 8.0, 
1.2 Hz, 1H, CHaryl), 7.33 (app. t, J = 7.6 Hz, 1H, CHaryl), 7.21 (td, J = 7.6, 1.6 Hz, 1H, CHaryl), 
6.10 (s, 1H, OCHO), 4.19-4.03 (m, 4H, -O(CH2)2O-); 13C NMR (100.6 MHz, CDCl3įC 136.5 
(C), 132.8 (CH), 130.5 (CH), 127.7 (CH), 127.3 (CH), 122.8 (C), 102.5 (CH), 65.3 (CH2); 
HRMS (EI) calcd. for C9H9BrO2, [M+] 227.9780, found 227.9789. This data was consistent 
with literature values.[325] 
 
(3-(2-(1,3-Dioxolan-2-yl)phenyl)prop-1-yn-1-yl)trimethylsilane 5.40[326] 
 
Prepared according to the procedure of Knobloch et al.[326] an oven dried flask was charged 
with 2-(2-bromophenyl)-1,3-dioxolane 5.39 (8.25 g, 36 mmol) and THF (200 mL) and cooled 
to ±60 °C. n-Butyllithium (2.5 M in hexanes, 17.3 mL, 43.2 mmol) was added dropwise, and 
the solution was stirred at ±60 °C for 2 h, became a light orange suspension. Magnesium 
bromide (7.29 g, 39.6 mmol) was suspended in Et2O (40 mL) and stirred vigorously at rt for 
1.5 h, the resulting biphasic mixture was added dropwise to the reaction mixture at ±55 °C. The 
reaction mixture was stirred at rt for 1.5 h. 3-Bromo-1-propynyltrimethylsilane (7.06 mL, 43.2 
mmol) was added and stirred at reflux for 2 h. The yellow solution was allowed to cool and 
poured into a 1:1 mixture of sat. NH4Cl solution and H2O (200 mL) with stirring. The mixture 
was separated and the aqueous layer washed with MTBE (100 mL). The combined organic 
extracts were dried (MgSO4) and concentrated to a yellow oil which was then purified by 
column chromatography (9:1 hexanes:EtOAc) to afford the product as a yellow oil (7.16 g, 
76%). Rf 0.34 (9:1 pet. ether:EtOAc); IR /LTXLGILOPȞmax/cmí3417, 2959, 2891, 2176, 1251, 
1077, 844, 759; 1H NMR (400.1 MHz, CDCl3įH 7.59-7.57 (m, 1H, CHaryl), 7.53 (dd, J = 7.4, 
1.4 Hz, 1H, CHaryl), 7.36 (td, J = 7.4, 1.5 Hz, 1H, CHaryl), 7.27-7.24 (m, 1H, CHaryl), 5.98 (s, 
1H, -OCHO-), 4.13-4.01 (m, 4H, -O(CH2)2O-), 3.82 (s, 2H, CH2&Ł&V+6L&+3)3); 
13C NMR (100.6 MHz, CDCl3įC 134.9 (C), 134.6 (C), 129.3 (CH), 128.8 (CH), 126.6 (CH), 
126.2 (CH), 103.9 (C), 101.9 (CH), 87.3 (C), 65.1 (CH2), 23.1 (CH2) 0.05 (CH3); HRMS (ESI 
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Positive) calcd. for C15H20O2Si, [M+Na] 283.1125, found 283.1120. This compound is 
reported in the literature but no analytical data are quoted.[326]  
 
N,N'-Dibenzylsulfamide 5.31[327] 
 
Sodium borohydride (56.1 mg, 1.5 mmol) was added to a stirred solution of 4.1fa (137.2 mg, 
0.5 mmol) in MeOH (25 mL) at 0 °C. The solution was stirred for 6 h and allowed to warm to 
rt. The colourless solution was concentrated to a white solid, this was taken up in CH2Cl2 (25 
mL) and washed with 1 M HCl (2 × 25 mL). The organics were washed with H2O (20 mL), 
dried (MgSO4) and concentrated to a white solid (123 mg, 89%); Rf 0.54 (2:1 pet. 
ether:EtOAc); M.p. 177-180 °C; lit. 181-183 °C;[327] IR (CHCl3Ȟmax/cmí 3381, 3271, 1455, 
1415, 1327, 1151; 1H NMR (400.1 MHz, DMSO-d6 įH 7.45 (t, J = 6.4 Hz, 2H, NHCH2), 
7.33-7.32 (m, 8H, CHaryl), 7.29-7.23 (m, 2H, CHaryl), 4.02 (d, J = 6.4 Hz, 4H, NHCH2); 13C 
NMR (100.6 MHz, DMSO-d6įC 138.4 (C), 128.2 (CH), 127.7 (CH), 127.0 (CH), 45.9 (CH2); 
HRMS (ESI Positive) calcd. for C14H16N2O2S, [M+Na] 299.0825, found 299.0815. These data 
were consistent with literature values.[327] 
 
2-(Prop-2-yn-1-yl)benzaldehyde 5.41 
 
A solution of (3-(2-(1,3-dioxolan-2-yl)phenyl)prop-1-yn-1-yl)trimethylsilane 5.40 (2.0 g, 7.68 
mmol) and K2CO3 (53.1 mg, 0.38 mmol) in MeOH (50 mL) was stirred at reflux for 90 min. 
The reaction mixture was diluted with H2O (50 mL) and washed with EtOAc (2 × 50 mL). The 
organics were dried (MgSO4) and concentrated to a yellow oil (1.35 g). The oil was taken up in 
acetone (24 mL) and H2O (20 mL) and p-toluenesulfonic acid monohydrate (68.2 mg, 0.36 
mmol) was added. The solution was stirred at reflux for 45 min. The resulting yellow solution 
was poured into sat. NaHCO3 solution (100 mL) and extracted with MTBE (2 × 50 mL). The 
organics were dried (MgSO4) and concentrated to a yellow oil. Purified by column 
chromatography (19:1 hexanes:EtOAc) to give a light yellow oil (737 mg, 72%). Rf 0.40 (4:1 
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hexanes:EtOAc); 1H NMR (400.1 MHz, CDCl3įH 10.20 (s, 1H, CHO), 7.81 (dd, J = 7.6, 1,2 
Hz, 1H, CHaryl), 7.74 (d, J = 7.6 Hz, 1H, CHaryl), 7.59 (td, J = 7.5, 1.3 Hz, 1H, CHaryl), 7.45 (t, J 
= 7.4 Hz, 1H, CHaryl), 4.08 (d, J = 2.8 Hz, 2H, CH2), 2.26 (t, J  +]+&Ł&+13C NMR 
(100.6 MHz, CDCl3 įC 192.8 (CH), 137.8 (C), 134.0 (CH), 133.9 (CH), 133.1 (C), 129.8 
(CH), 127.3 (CH), 81.1 (C), 71.7 (CH), 22.6 (CH2). These data were consistent with literature 
values.[328] 
 
N-benzyl-N'-[2-(prop-2-yn-1-yl)phenylmethylidene]sulfamide 5.42 
 
Prepared from N-benzylsulfamide 4.4f (373 mg, 2.0 mmol) and 5.41 (317 mg, 2.2 mmol) using 
general method K refluxed for 2.5 h, work up gave a yellow oil which was purified using 
column chromatography (4:1 hexanes:EtOAc) to give the product as a white solid (445 mg, 
65%); Rf 0.13 (4:1 hexanes:EtOAc); M.p. 99-100 °C; IR (CHCl3Ȟmax/cmí 3377, 3307, 1611, 
1593, 1570, 1414, 1382, 1158; 1H NMR (400.1 MHz, CDCl3įH 9.16 (s, 1H, N=CH), 7.92 
(dd, J = 7.8, 1.4 Hz, 1H, CHaryl), 7.66 (br d, J = 7.2 Hz, 1H, CHaryl), 7.59 (td, J = 7.5, 1.5 Hz, 
1H, CHaryl), 7.42 (br t, J = 7.6 Hz, 1H, CHaryl), 7.36-7.24 (m, 5H, CHaryl), 4.76 (t, J = 6.0 Hz, 
1H, NHCH2), 4.36 (d, J = 6.4 Hz, 2H, NHCH2), 3.92 (d, J = 2.8 Hz, 2H, CH2&Ł&+WJ 
 +]+&Ł&+ 13C NMR (100.6 MHz, CDCl3įC 168.1 (CH), 139.1 (C), 136.1 (C), 
134.2 (CH), 132.1 (CH), 130.0 (CH), 129.6 (C), 128.6 (CH), 128.0 (CH), 127.8 (CH), 127.5 
(CH), 80.8 (C), 72.1 (CH), 47.7 (CH2), 23.1 (CH2); HRMS (ESI Positive) calcd. for 
C17H16N2O2S, [M+H] 335.0826, found 335.0825; Anal. Calc. for C17H16N2O2S: C, 65.36; H, 
5.16; N, 8.97%. Found: C, 65.06; H, 5.18; N, 8.97%. 
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